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UK	 health	 policy	 places	 digital	 technology	 developments	 at	 the	 heart	 of	
plans	to	improve	health,	increase	access	and	reduce	cost.	Electronic	health	
(eHealth)	and	mobile	health,	offer	opportunities	 to	 revolutionise	 the	way	
services	 for	 sexually	 transmitted	 infections	 (STIs)	 are	 delivered.	
Developments	 include	 point-of-care	 and	 self-tests,	 and	 online	 treatment	
through	eHealth	clinics.	Such	innovations	offer	potential	benefits	including	












• Focus	 groups	 with	 young	 people	 aged	 16-24	 to	 elicit	 views	 on	
attributes	which	are	important	in	STI	services	
• Expert	groups	to	provide	a	policy/	service	perspective		











The	 DCE	 found	 that	 test	 accuracy,	 followed	 by	 time	 to	 result	 were	 the	
strongest	attributes	influencing	preferences.		
	
The	 economic	 evaluation	 identified	 that	 online	 care	 is	 cost	 saving	
compared	 with	 existing	 practice	 however	 further	 work	 is	 required	 to	
understand	the	impact	on	health	outcomes.		
	























































































































































































































































































































































































































































































“One	 of	 the	 greatest	 opportunities	 of	 the	 21st	 century	 is	 the	 potential	 to	
safely	 harness	 the	 power	 of	 the	 technology	 revolution,	 which	 has	







and	 that	whilst	 the	developing	world	 is	 subject	 to	 the	greatest	burden	of	




(STI)	 in	 England,	 the	 European	 Union	 (EU)	 and	 the	 USA,	 with	 rates	 of	
reported	diagnoses	continuing	to	increase	(ECDC,	2014).	In	England	young	
people	 aged	 15-24	 account	 for	 61%	 of	 chlamydia	 cases	 (Public	 Health	
England,	 2016b).	 Whilst	 easy	 to	 treat	 with	 a	 single	 dose	 antibiotic,	 it	 is	
largely	asymptomatic	and	can	result	in	serious	long	term	consequences	for	
women	 in	 particular,	 including	 pelvic	 inflammatory	 disease	 (PID),	 ectopic	
pregnancy	and	infertility	(WHO,	2012).	The	resultant	complications	present	








Advancements	 in	 technology,	 particularly	 electronic	 health	 (eHealth)	 and	
mobile	health	(mHealth),	have	already	opened	up	a	wide	range	of	options	
to	revolutionise	the	way	that	aspects	of	STI	testing	and	treatment	services	
are	delivered.	 These	 include	 the	development	of	 point-of-care	 (POC)	 and	
self-tests,	and	online	treatment	pathways	either	through	eHealth	clinics	or	
smartphone	applications	 (apps).	 Such	 innovations	may	offer	 a	number	of	
potential	 benefits	 for	 service	 delivery	 including	 increased	 testing	 uptake,	
higher	treatment	rates	and	reduced	disease	transmission.		
	
This	 thesis	 presents	 the	 doctoral	 research	 undertaken	 to	 inform	 the	
understanding	 of	 young	 people’s	 preferences	 for	 new	 STI	 testing	 and	
treatment	services	and	the	costs	and	consequences	of	the	introduction	of	




Chlamydia	 Trachomatis	 is	 the	 most	 commonly	 diagnosed	 STI	 in	
England	 (PHE,	 2016a).	 Whilst	 genital	 chlamydia	 trachomatis	 is	 the	
most	 frequently	 diagnosed,	 	 pharyngeal	 and	 rectal	 infections	 also	
occur.	 For	 the	 purposes	 of	 this	 thesis,	 chlamydia	 and	 chlamdial	
infection	 refer	 to	 genital	 chlamydia	 trachomatis	 only.	 Within	
mainstream	 sexual	 health	 services	 in	 England	 over	 434,000	 new	
diagnoses	of	STIs	were	made	 in	2015,	46%	 (200,288)	of	 these	were	
chlamydia	(Public	Health	England,	2016b).	Young	people	aged	15-24	
experience	 the	 highest	 rates	 of	 STI	 diagnosis	 with	 61%	 of	 all	
chlamydia	 diagnoses	 made	 in	 2015	 in	 this	 age	 range	 (ibid.).	 STI	










and	 13%	 of	 males	 within	 the	 target	 age	 range	 were	 tested	 for	
chlamydia	(ibid.).	The	Public	Health	Outcomes	Framework	(PHOF)	for	
England	 has	 a	 specific	 target	 for	 Chlamydia	 diagnosis	 within	 the	
central	 objective	 to	 protect	 population	 health,	 with	 a	 target	
detection	rate	of	2,300	per	100,000	population	within	the	15-24	age	
range	(Department	of	Health,	2013c).	In	2015	only	20%	of	upper	tier	
local	 authorities	 (LA)	 achieved	 this	 target	 (Public	 Health	 England,	




with	 chlamydia	 are	 limited.	 The	most	 recent	work	 by	Development	
Economics	 refreshes	 the	 approach	 taken	 by	 the	 North	West	 Public	
Health	 Observatory	 in	 2005.	 This	 reflects	 2011	 data	 and	 estimates	
the	 direct	 medical	 costs	 per	 identified	 case	 of	 chlamydia	 to	 be	
£796.87	 (£176.86	 million	 annualised	 amount)	 (Development	
Economics,	2013).	Detailed	scenario	estimation	was	included	in	their	
report,	 which	 demonstrated	 that	 if	 growth	 in	 detection	 rate	
continued	 at	 2002-2011	 levels	 and	 access	 to	 services	 continued	 on	
the	same	basis,	 the	annual	direct	medical	cost	 for	 the	 treatment	of	
chlamydia	 in	 2015	 would	 be	 £249.8	 million	 and	 2020	 would	 be	
£387.4	million	(ibid.).		
	
As	 outlined	 briefly	 above,	 new	 digital	 technologies	 may	 have	 the	
potential	 to	 increase	 testing	 coverage	 and	 treatment	 rates	 and	
therefore	 reduce	 disease	 transmission	 particularly	within	 the	 16-24	
age	 range.	 Data	 on	 internet	 usage	 published	 by	 the	 Office	 for	
National	Statistics	 (ONS)	 supports	 this,	demonstrating	high	 levels	of	
accessibility	to	the	required	base	technology:	
		 32	
• Internet	 access	 is	 now	 available	 in	 89%	 of	 households	 with	
99%	 of	 households	 with	 children	 having	 an	 internet	
connection,	
• 75%	 of	 the	 adult	 population	 now	 report	 accessing	 the	
internet	via	a	mobile	device	such	as	a	smartphone	or	tablet,	
however	 this	 percentage	 is	 much	 higher	 in	 the	 16-24	 age	
range	at	97%,		








delivery	 of	 healthcare	 services:	 “the	 consumer	 experience	 of	 care	
services	 remains	 much	 as	 it	 was	 before	 the	 mobile	 phone	 and	




Low	 uptake	 of	 chlamydia	 testing	 services	 as	 outlined	 previously	
represents	both	an	individual	and	population	health	problem.	As	well	
as	the	financial	costs	of	diagnosing	and	treating	chlamydial	infection,	







These	 can	 include	 tangible	 service	 properties	 such	 as	 location	 of	
service,	 and	 personal	 factors	 including	 the	 stigma	 associated	 with	
attendance,	embarrassment	and	fear	of	being	recognised	or	privacy	
concerns	 (Booth	et	 al.,	 2013,	 Friedman	and	Bloodgood,	 2013,	Balfe	




of	 the	 only	 open	 access	 diagnostic	 services	 available	 within	 the	
National	Health	Service	(NHS),	that	 is,	 the	 individual	can	 initiate	the	
test	without	a	referral	from	a	healthcare	professional.	There	is	a	key	
question	 as	 to	 the	 role	of	 new	 technology	 in	 the	delivery	of	 sexual	
health	 services,	 particularly	 in	 the	 use	 of	 remote	 care	 pathways1	
which	 both	 the	 development	 of	 self-tests	 and	 eHealth/mHealth	
solutions	 form	 part	 of	 -	 will	 they	 increase	 uptake	 of	 testing	 and	
treatment	by	young	people	 for	 chlamydia	 infections	and	are	 they	a	
cost-effective	way	of	delivering	a	health	service?	There	are	currently	
no	published	studies	that	explore	young	people’s	preferences	for	the	
use	 of	 a	 remote	 clinical	 pathway	 involving	 self-testing	 and	 online	





in	 2016	 is	 low.	 At	 the	 time	 of	 writing	 this	 thesis	 there	 are	 no	
smartphone	diagnostic	apps	made	available	by	the	NHS	for	patients	
to	 use	 and	 the	 NHS	 apps	 library	 has	 been	 withdrawn,	 removing	









The	 aim	 of	 this	 research	 was	 to	 explore	 the	 costs	 and	 benefits	 of	
integrated	 online	 chlamydia	 testing	 and	 treatment	 within	 an	 early	
health	 technology	 assessment	 (eHTA)	 framework.	 The	 research	
undertaken	had	the	following	objectives:	
	
• To	 assess	 which	 attributes	 influence	 young	 people’s	
preferences	for	the	testing	and	treatment	of	chlamydia	and	





benefits	 of	 implementing	 a	 fully	 remote,	 integrated	 online	
pathway	including	self-testing.	
	
Consideration	 is	 given	 to	 the	 limitations	 of	 the	 work	 and	 its	




























There	 are	 two	 separate	 technologies	within	 the	 fully	 integrated	 pathway	
which	are	at	different	stages	of	development	–	the	online	chlamydia	care	
pathway	 (OCCP)	 and	 the	 self-test.	 The	 key	 terms	 in	 relation	 to	 the	




The	 following	 chapter	 (Chapter	 2)	 provides	 more	 detailed	
background	to	a	number	of	the	key	issues	introduced	in	section	1.1.	
Chapter	3	outlines	the	theoretical	framework	for	Health	Technology	
Assessment	 (HTA)	 and	 eHTA,	 considering	 the	 current	 stage	 of	
technology	 development.	 It	 also	 presents	 the	methods	 selected	 to	
address	 the	 research	 objectives	 and	 summarises	 the	 scope	 of	
research	undertaken	as	part	of	this	doctoral	research.	
	
Chapter	 4	 presents	 current	 research	 evidence	 on	 individuals’	
preferences	 for	 accessing	 testing	 and	 treatment	 services	 for	 STIs,	
including	 the	 service	 attributes	 which	might	 influence	 preferences.	
Chapter	 5	 presents	 the	 findings	 of	 qualitative	 research	 including	
focus	 groups	 and	 expert	 groups	 undertaken	 to	 develop	 the	 main	
themes	 and,	 from	 them,	 identify	 the	 attributes	 and	 levels	 for	




Chapter	 7	 explores	 the	 costs	 associated	with	 the	OCCP	 exploratory	
study	and	presents	the	outcome	of	the	costing	study	including	a	cost	
analysis	of	the	OCCP	and	review	of	intermediate	outcomes.	Chapter	
8	 builds	 on	 this,	 extending	 the	 work	 into	 an	 economic	 model	 to	

















An	 analysis	 of	 the	 evolution	 of	 eHealth	 and	 mHealth	 is	 given,	 set	
within	the	framework	of	policy	and	practice	of	healthcare	in	England	
and	learning	from	international	developments.	Next,	a	review	of	key	
aspects	 of	 sexual	 health	 services	 in	 England	 is	 presented,	 including	
both	 the	 general	 policy	 position	 for	 sexual	 health	 services,	 with	 a	
specific	 focus	on	chlamydia	where	appropriate,	drawing	out	current	




From	 the	 initial	 creation	 of	 the	 concept	 of	 the	 world	 wide	 web	 in	
1989	 to	 an	 estimated	 3.2	 billion	 users	 world-wide	 in	 2015	 (BBC,	
2015),	 the	 internet	 creates	 opportunities	 for	 open	 access	 to	
information	 and	 services	 in	 ways	 that	 were	 previously	 unfeasible,	
through	 other	 communications	 media.	 The	 transition	 to	 digital	
mobile	networks	in	the	early	1990s,	enabled	an	expansion	of	service	








growth	 of	 mobile	 phone	 use	 for	 data	 services	 such	 as	 email	 and	
internet	 services	 (Fiordelli	 et	 al.,	 2013).	 A	 further	 addition	 to	
smartphone	services	 is	 the	 ‘app’	–	 software	designed	 specifically	 to	
run	 on	 a	 device	 such	 as	 a	 mobile	 phone.	 Estimates	 in	 June	 2016	
suggest	that	1.5	million	apps	are	available	in	the	Apple	app	store	and	
since	 its	 launch	 in	 2008	 130	 billion	 downloads	 have	 been	 made	
(Statistica,	2016a).	Whilst	Apple	led	the	field,	apps	are	now	available	
on	 other	 smartphone	 operating	 systems.	 Google	 Play,	 which	 is	 the	
leading	 app	 store	 for	 android	 (an	 alternative	 operating	 system	 to	




the	 data	 introduced	 in	 Chapter	 1,	 data	 from	 the	 Office	 of	
Communications	 (OFCOM)	 which	 regulates	 the	 communications	
market	in	the	UK,	identified	that	at	the	end	of	2015	there	were	91.5	
million	 active	 mobile	 phone	 subscriptions	 (OFCOM,	 2016).	 The	
quarterly	‘Technology	Tracker’	trends	survey	published	by	Ipsos	Mori	
identified	that	in	quarter	2	of	2016:	
• internet	 access	 across	 gender	 and	 socioeconomic	 status	 for	
15-24	 year	 olds	 is	 consistently	 high,	 with	 the	 lowest	 access	
rate	 in	females	aged	15-24,	socioeconomic	status	D	and	E	at	
96%	
• smartphone	 ownership	 across	 gender	 and	 socioeconomic	
status	is	also	high	with	94%	of	males	and	95%	of	females	aged	
15-24	 owning	 a	 smartphone.	 The	 lowest	 rates	 of	 ownership	









for	 the	 analysis	 of	 test	 results),	 websites	 optimised	 for	 use	 on	 a	






a	 number	 of	 published	 studies	 which	 demonstrate	 a	 preference	
among	 patients	 and	 citizens	 for	 the	 use	 of	 the	 internet	 to	 source	
information	about	health	conditions.	A	literature	review	published	in	
2011	 by	 the	 European	 Centre	 for	 Disease	 Prevention	 and	 Control	
(ECDC)	found	that	use	for	this	purpose	was	growing	rapidly	amongst	
patients,	 carers,	 and	 their	 friends	 and	 relatives,	 with	 women	 and	




This	 section	 considers	 the	key	 concepts	and	definitions	used	 in	 this	
thesis	 in	 greater	 depth.	 It	 is	 recognised	 that	 due	 to	 the	 relative	







within	 the	delivery	of	healthcare.	The	common	overarching	 term	 in	
use	in	most	current	policy	documents	is	‘digital	health’,	although	no	
consistent	definition	 is	offered	within	 these.	One	definition,	offered	
by	 Kostkova	 is	 “the	 use	 of	 information	 and	 communications	
technologies	 to	 improve	 human	 health,	 healthcare	 services,	 and	
wellness	 for	 individuals	 and	across	 populations”	 (Kostkova,	 2015:1).	




care	 services,	 where	 distance	 is	 a	 critical	 factor,	 by	 all	 health	 care	
professionals	using	 information	and	communication	technologies	for	
the	 exchange	 of	 valid	 information	 for	 diagnosis,	 treatment	 and	





It	 is	 recognised	 that	 there	 are	 similarities	 in	 the	 use	 of	 the	 terms	
telemedicine	and	telehealth,	with	van	Dyk	noting	that	delivery	over	a	
distance	 is	 a	 common	 feature	 of	 both	 telemedicine	 and	 telehealth	
(van	 Dyk,	 2014),	 and	 Bashshur	 and	 colleagues	 suggested	 that	
“conceptually,	 telemedicine	 is	 to	 telehealth	 what	 medicine	 is	 to	
health”	(Bashshur	et	al.,	2011:487).	A	white	paper	by	Wragge	and	Co	
draws	out	 a	 key	distinction	 in	 the	use	of	 the	 terms	 suggesting	 that	
telemedicine	 is	 used	 to	 describe	 “the	 provision	 of	 a	 regulated	
healthcare	service”	 (Wragge	&	Co	and	ECH	Alliance,	2014:10)	whilst	
telehealth	refers	to	the	remote	monitoring	of	physiological	data.	This	




The	 definition	 of	 telecare	 offered	 by	 the	 Telecare	 Services	
Association	 is	 “support	 and	 assistance	 provided	 at	 a	 distance	 using	
information	 and	 communication	 technology.	 It	 is	 the	 continuous,	
automatic	 and	 remote	monitoring	 of	 users	 by	means	 of	 sensors	 to	
enable	 them	to	continue	 living	 in	 their	own	home,	while	minimising	
risks…”	(Telecare	Services	Association,	2015).	
	
Deloitte	 UK	 offer	 a	 definition	 of	 connected	 health	 as	 “connected	
health	 or	 technology	 enabled	 care	 (TEC)	 is	 the	 collective	 term	 for	
telecare,	 telehealth,	 telemedicine,	 mHealth,	 digital	 health	 and	
eHealth	services.	TEC	involves	the	convergence	of	health	technology,	
digital,	 media	 and	 mobile	 telecommunications	 and	 is	 increasingly	
seen	 as	 an	 integral	 part	 of	 the	 solution	 to	many	 of	 the	 challenges	
facing	 the	 health,	 social	 care	 and	 wellness	 sectors,	 especially	 in	




with	 eHealth	 first	 being	 discussed	 in	 the	 late	 1990s	 and	 mHealth	













































The	 founding	 definition	 of	 eHealth	 was	 proposed	 by	 Eysenbach	 as	
“an	emerging	 field	 in	 the	 intersection	of	medical	 informatics,	 public	
health	 and	 business,	 referring	 to	 health	 services	 and	 information	
delivered	or	enhanced	through	the	internet	and	related	technologies.	
In	 a	 broader	 sense,	 the	 term	 characterises	 not	 only	 a	 technical	
development,	but	also	a	state-of-mind,	a	way	of	thinking,	an	attitude	
and	 a	 commitment	 for	 networked,	 global	 thinking,	 to	 improve	




Organisation	 (WHO)	 recognised	 the	 absence	 of	 a	 standardised	
definition	 of	mHealth,	 choosing	 to	 define	 it	 as	 “Medical	 and	 public	
health	practice	supported	by	mobile	devices,	such	as	mobile	phones,	
patient	 monitoring	 devices,	 personal	 digital	 assistants	 (PDAs)	 and	






MHealth	 is	 closely	 aligned	 with	 other	 health	 technologies,	
particularly	 eHealth	 and	 telemedicine	 with	 the	 mobile	 device	
enabling	existing	 technologies	 to	be	utilised	 in	 a	different	way,	 e.g.	
remote	 monitoring,	 as	 well	 as	 extending	 the	 scope	 of	 technology	
available	for	use,	as	illustrated	in	table	2.1.	The	pace	of	change	in	the	
development	 of	 mobile	 technologies	 has	 presented	 significant	
opportunities	 for	 the	 growth	 of	 mHealth	 initiatives,	 making	 the	




NHS	 health	 policy	 has	 incorporated	 these	 technological	 advances.	
The	publication	in	1998	of	‘Information	for	Health	–	An	Information	
Strategy	 for	 the	 Modern	 NHS	 1998-2005’	 set	 out	 a	 commitment	
from	the	Department	of	Health	to	delivering,	amongst	other	things	
“lifelong	 electronic	 health	 records	 for	 every	 person	 in	 the	
country…fast	and	convenient	public	access	to	information	and	care	









general	practice	and	hospitals	 (Department	of	Health,	2000).	 	 The	
plan	 included	 reference	 to	 a	 vision	 where	 self-care	 and	 self-
management	 would	 be	 facilitated	 through	 the	 NHS	 Direct	
telephone	and	 internet	site,	and	 information	technology	would	be	
used	to	enable	patients	to	email	or	phone	GPs	and	practice	nurses	




From	 a	 policy	 perspective,	 over	 the	 period	 2000-2010,	 the	 focus	
remained	 on	 the	 integration	 of	 systems	 through	 the	 work	 of	
Connecting	 for	Health	 (CfH)	 in	delivering	 the	National	 Programme	
for	 IT	 (NPfIT).	 This	 included	 the	development	and	 implementation	
of	 systems	 linking	 both	 primary	 and	 secondary	 care	 including	 the	
NHS	 Care	 Records	 Service,	 Choose	 and	 Book	 and	 the	 Electronic	











media	as	part	of	 their	daily	 lives,	 the	ability	 to	use	email	 for	non-
confidential	 communications,	 or	 to	 have	 a	 remote	 consultation	






‘Digital	 First’	 in	 2012	 which	 aimed	 to	 “make	 available	 the	 digital	
means	 (channels,	 content,	 services)	 for	 the	 general	 public	 to	
manage	 their	 healthcare	 digitally	 wherever	 possible	 and	 provide	
the	mechanisms	and	support	that	ensure	they	can	migrate	to	these	
digital	channels	as	their	preferred	manner	to	engage”	(Department	
of	 Health,	 2012:3).	 	 Ten	 high	 impact	 digital	 initiatives	 were	 cited	
which	 incorporated	 the	 use	 of	 eHealth	 and	 mHealth	 solutions,	






During	 this	 period,	 digital	 health	 initiatives	 also	 began	 to	 spread	
into	service	and	condition	specific	policies,	 including	sexual	health,	
to	 be	 outlined	 further	 in	 section	 2.4.1.	 These	 were	 incorporated	
into	 healthcare	 contracting	 arrangements	 through	 service	
specifications,	enhanced	services	and	commissioning	for	quality	and	
innovation	 schemes	 (CQUINs).	 The	 NHS	 five	 year	 forward	 view,	
published	 by	 NHS	 England	 in	 2014,	 also	 gave	 a	 commitment	 to	
expanding	the	use	of	digital	technology	in	the	NHS	recognising	the	
role	of	 a	 range	of	eHealth	and	mHealth	 solutions	 including	health	
apps,	 online	 GP	 appointments	 and	 patients	 having	 full	 access	 to	
their	electronic	health	record	(NHS	England,	2014).	The	subsequent	
National	 Information	 Board	 (NIB)	 report	 published	 later	 that	 year	
built	on	 this	 commitment	outlining	 the	practical	 arrangements	 for	





The	 adoption	 of	 telemedicine,	 eHealth	 and	 mHealth	 at	 a	 system	
level	within	the	NHS	and	other	health	systems	has	proved	to	be	a	
challenge	 with	 limited	 evaluation	 of	 cost-effectiveness.	 A	 2011	
WHO	 global	 survey	 was	 the	 first	 to	 comprehensively	 identify	
barriers	 to	adoption	of	mHealth	by	health	systems	 internationally.	
Competing	 priorities	 within	 the	 health	 system	 were	 identified	 as	
the	most	significant	barrier	to	the	adoption	of	mHealth	(52%),	with	
lack	 of	 knowledge	 about	 how	 mHealth	 can	 be	 utilised	 and	 its	








been	 adopted	 fairly	 consistently	 across	 the	NHS,	 for	 example	 text	
message	 appointment	 reminders,	 the	 adoption	 of	 eHealth	 and	
mHealth	 has	 followed	 a	 path	 of	 small	 scale,	 localised,	 initiatives	
with	minimal	structured	evaluation,	this	 is	not	dissimilar	to	that	of	
other	 nations	 (ibid.).	 Sustained	 adoption	 has	 been	 heavily	
influenced	 by	 clinicians	 with	 for	 example,	 access	 to	 choose	 and	
book,	 the	 system	 for	 booking	 online	 hospital	 appointments,	
reducing	when	the	 financial	 incentive	 for	GP	practice	participation	
ceased.	 The	 Whole	 System	 Demonstrator	 (WSD)	 project	 was	 the	
largest	 randomised	 control	 trial	 (RCT)	 undertaken	 in	 England	
designed	to	explore	the	costs	and	benefits	of	using	telehealth	and	
telecare	 alongside	 the	 standard	 interventions.	 The	 trial	 covered	
patients	in	three	areas	with	one	or	more	of	the	following	conditions	
–	chronic	obstructive	pulmonary	disease,	heart	failure	or	diabetes,	
and	 considered	 the	 effect	 of	 telehealth	 on	 access	 to	 primary,	
secondary	and	 social	 care	 services.	 The	 cost	effectiveness	analysis	
identified	that	telehealth	was	unlikely	to	be	cost-effective	where	it	





conditions	 indicates	 that	widespread	adoption	 is	minimal.	The	NIB	
report	published	in	2014	acknowledged	that,	despite	commitments	
given	 over	 the	 previous	 years	 in	 national	 policy,	 from	 a	 patient	
perspective	 “the	 consumer	 experience	 of	 care	 services	 remains	
much	as	 it	was	before	the	mobile	phone	and	the	 internet	became	
commonplace.	 For	 care	 professionals,	 from	 social	 workers	 to	
doctors	 and	 nurses,	 the	 arrival	 of	 the	 digital	 age	 has	 often	 been	
experienced	 not	 as	 a	 force	 for	 good	 but	 rather	 as	 an	 intrusive	






clinics.	 This	 returned	 a	 high	 proportion	 of	 results	 in	 the	 top	 100	
relating	 to	either	general	practice,	mental	health	or	 sexual	health.		
In	general	practice,	since	2013,	there	are	increasing	examples	of	the	
use	 of	 e-consultation,	 in	 part	 driven	 by	 opportunities	 through	
initiatives	such	as	the	Prime	Minister’s	Challenge	Fund	(PMCF).	An	
evaluation	of	 the	use	of	e-consultation	 in	primary	care	 found	 that	
60%	 of	 e-consultations	 were	 closed	 remotely,	 80%	 of	 e-
consultations	 that	 required	 a	 call	 back	 were	 closed	 remotely	 and	
18%	of	users	who	had	planned	to	book	a	face-to-face	appointment	
did	not	require	one	(The	Hurley	Group,	2014).	A	second	area	where	
an	 online	 service	 presence	 has	 been	 adopted	 is	 mental	 health	
services,	with	services	such	as	Big	White	Wall	leading	the	way	with	










effectiveness.	 The	 library	 was	 widely	 criticised	 with	 significant	
concerns	raised	regarding	data	privacy;	89%	of	apps	that	sent	data	
to	online	services	and	66%	of	apps	 that	sent	personal	 information	







There	 is	 considerable	 evidence	 in	 grey	 literature	 of	 a	 growing	
eHealth/	mHealth	market,	that	is	products	and/or	services	targeted	
directly	 to	 the	 patient	 or	 general	 public,	 or	 products	 in	 an	 early	
stage	of	development	which	are	not	at	the	clinical	trial	stage.	A	grey	
literature	 search	 using	 Google	 was	 undertaken	 following	 the	
principles	 outlined	 in	 the	 Canadian	 Agency	 for	 Drugs	 and	
Technologies	 in	 Health	 (CADTH)	 checklist	 for	 grey	 literature	
(CADTH,	2013).	 This	 approach	was	 selected	 to	 focus	on	 trade	and	
technology	 websites	 as	 the	 pace	 of	 technology	 development	 far	
outstrips	 the	 time	 lag	 for	publishing	 journal	articles.	The	objective	











to	 minimise	 overlap	 in	 search	 results.	 The	 searches	 were	
undertaken	 on	 14	 February	 2016.	 The	 top	 100	 results	 returned	
were	 reviewed	 to	 identify	 their	 content,	 as	 recommended	 by	
CADTH	(2013)	and	are	summarised	into	themes	as	follows:		
• health	 apps	 –	 links	 to	 app	 stores,	 news	 articles	 from	
mainstream	news	websites,	blogs	and	news	articles	on	trade	
websites,	 app	 review	 websites	 (reviews	 by	 users),	
government	 and	 health	 service	 websites	 principally	




news	 articles	 on	 smartphone	 diagnostics	 for	 health,	 press	
releases	 and	 websites	 for	 companies	 and	 research	
organisations	developing	smartphone	diagnostics,	
• online	 clinics	 health	 –	 private	 providers	 of	 online	 clinics	 in	
the	UK	and	USA,	NHS	service	websites	offering	online	clinic	
booking,	 news	 articles	 about	 online	 health	 clinics	 from	UK	
and	USA.	
	
The	 top	 100	 results	 from	 the	 smartphone	 diagnostics	 healthcare	
Google	search	(excluding	blogs	and	other	commentaries)	identified	
the	following	diagnostics	in	varying	stages	of	development:	
• Colorimetrix	 –	 app	 developed	 by	 Cambridge	 University	 to	




and	 enables	 the	 diagnosis	 of	 eye	 conditions	 including	
glaucoma,	 macular	 degeneration	 and	 diabetic	 retinopathy	
(Peek	Vision,	2015)	
• QPoC	 –	 point	 of	 care	 platform	 which	 can	 analyse	 DNA	 in	




• ELISA	 Platform	 –	 platform	 which	 links	 to	 a	 smartphone	
which	 can	 interpret	 Enzyme	 Linked	 Immunosorbent	Assays	
(ELISA)	including	HIV,	West	Nile	virus	and	hepatitis	B	(UCLA,	
2015)	






• Smartphone	 based	 diagnostic	 for	 preeclampsia	 –	 journal	
abstract	 summarising	 the	effectiveness	of	 an	app	 for	using	
the	Congo	Red	Dot	test	to	diagnose	preeclampsia	(Jonas	et	
al.,	2015)	
• MobiUS	 Scanner	 –	 ultrasound	 scanner	 that	 plugs	 into	 a	
smartphone	 to	 enable	 phone	 to	 be	 used	 as	 an	 ultrasound	
device	(MobiSante,	2015).	
	





Considering	 patients	 as	 consumers,	 there	 are	 a	 large	 number	 of	
health	 and	 wellness	 apps	 available	 in	 the	 Apple	 and	 Google	 Play	
App	 Stores.	 Xu	 and	 Liu	 created	 a	 central	 health	 related	 app	
repository	in	2015	using	apps	from	the	Apple	App	store	and	Google	
Play	 store	 in	 the	 USA,	 China,	 Japan,	 Brazil	 and	 Russia	 and	
systematically	 analysed	 them	 to	 evaluate	 their	 strengths	 and	
weaknesses	(Xu	and	Liu,	2015).	Despite	estimates	being	as	high	as	
100,000	 medical	 and	 fitness	 apps,	 their	 analysis	 concluded	 that	
there	are	only	21,121	unique	 (not	duplicated)	medical	apps	 in	 the	




wearables	 such	 as	watches,	 and	 connected	 devices	 such	 as	 blood	
pressure	monitors	 that	 increase	 the	 ‘medical	 functionality’	 of	 the	
smartphone.	 These	 have	 primarily	 been	 targeted	 at	 individual	
consumers	 rather	 than	 featuring	 as	 a	 part	 of	 health	 services.	
		 54	
However,	 looking	 to	 the	 American	 healthcare	 system,	 Price	
Waterhouse	Coopers	(PWC)	have	predicted	2016	will	see	a	growth	
in	the	use	of	such	devices.	“Connected	otoscopes,	activity	trackers,	
scales,	 health	 apps,	 algorithm-based	 symptom	 checkers	 and	 on-
demand	e-visits	are	being	offered	directly	to	consumers.	Clinicians	
are	sending	patients	with	chronic	conditions	home	with	connected	
pacemakers,	 ECG	 monitors,	 glucose	 trackers	 and	 other	 remote	
monitoring	devices.”	(Price	Waterhouse	Coopers,	2015).		
	
The	 impact	 of	 this	 type	 of	 technology	 adoption	 was	 in	 part	
measured	 through	 the	WSD	 RCT	 in	 England,	 however	 as	 the	 trial	
commenced	 in	 2008,	 much	 of	 the	 technology	 piloted	 has	 been	
superseded.	 Of	 the	 smartphone-based	 diagnostics	 and	 eHealth	
solutions	 reviewed,	 so	 far	 none	 has	 attempted	 to	 integrate	
diagnosis	 and	 treatment	 for	 infectious	 diseases.	 In	 addition,	 no	
apps	 have	 been	 identified	 that	 prescribe	 a	 prescription	 only	
medicine	without	 the	 input	 of	 a	 clinician.	 There	 are	 a	 number	 of	
websites	that	enable	access	to	prescribed	medicine	without	a	face-
to-face	 consultation	 for	 example	 Dr	 Thom	 however,	 every	




Alongside	 the	 changing	 digital	 context	 there	 have	 been	 several	
changes	in	the	organisation	and	delivery	of	sexual	health	services	in	
England.	 The	 following	 sections	 introduce	 the	 policy	 and	
commissioning	 context	 for	 sexual	 health	 services,	 and	 the	
epidemiology,	clinical	management	and	pathways	for	the	testing	and	





The	 first	 strategy	 for	 sexual	 health	 and	 HIV	 in	 England	 was	
published	 in	 2001	 against	 a	 national	 backdrop	 of	 increasing	 STI	
rates,	 high	 rates	 of	 unplanned	 pregnancies	 and	 attendances	 at	
Genito-Urinary	Medicine	(GUM)	clinics	doubling	in	the	preceding	10	
years	 (Department	 of	 Health,	 2001).	 The	 strategy	 reflected	 the	





• improve	 health,	 sexual	 health	 and	wellbeing”	 (Department	
of	Health,	2001:12).	
		
Together	 with	 its	 implementation	 plan,	 published	 the	 following	
year,	priorities	for	action	included:	
• placing	 a	 focus	 on	 prevention	 and	 health	 promotion,	
ensuring	that	 information	 is	available	for	people	to	be	able	
to	make	informed	decisions,	
• modernising	 service	 delivery	 to	 enable	 more	 choice	 for	
people	wanting	to	access	sexual	health	services	through	the	
identification	 of	 commissioning	 leads	 for	 sexual	 health,	
creation	 of	 clinical	 networks	 for	 sexual	 health	 and	 piloting	
new	models	of	delivery	e.g.	one-stop	shops,	
• structuring	 sexual	 health	 services	 within	 local	 health	
economies	into	the	three	service	levels	(basic,	intermediate	
and	specialist)	that	are	still	used	today,	





The	 implementation	of	 this	 strategy	and	 the	 issues	 arising	 from	 it	
can	 be	 charted	 through	 the	 Health	 Select	 Committee	 Reports	 on	
sexual	 health	 and	 HIV/	 AIDS	 and	 the	 government’s	 response	 to	
them.	The	Health	Select	Committee	report	published	in	2003	stated	
that	 “nothing	 in	 the	evidence	we	have	 received	 convinces	us	 that	
sexual	 health	 is	 yet	 accorded	 the	 priority	 it	 deserves…	 Despite	 a	
considerable	 investment	by	 the	government	 in	 targets	 to	 improve	
access	to	care	and	to	improve	health,	sexual	health	is	an	area	which	
seems	 to	 have	 fallen	 completely	 through	 the	 net…	We	 therefore	
recommend	that	the	Government	takes	urgent	steps	to	ensure	that	
access	 to	 high-quality	 sexual	 health	 services	 is	 prioritised	 and	
resourced.”	 (House	 of	 Commons.	 	 Select	 Committee	 on	 Health,	
2003:93).	
	
The	 government	 response	 to	 this	 in	 the	 areas	 of	 STI	 testing	 and	
treatment	included:	
• the	continued	roll	out	of	the	NCSP	to	an	additional	10	areas,	
• additional	 investment	 in	 Genito-Urinary	 Medicine	 (GUM)	
services	to	increase	capacity	and	reduce	waiting	times,	
• the	introduction	of	the	GUM	48-hour	access	targets,	




The	 2005	 report	 of	 the	 Health	 Select	 Committee	 which	 explored	
developments	 in	 Sexual	 Health	 and	 HIV/	 AIDS	 policy	 applauded	
Government	 investment	 and	 action	 in	 terms	 of	 waiting	 times	





• failure	 of	 Primary	 Care	 Trusts	 (PCTs)	 to	 ensure	 additional	
government	 funding	 for	 sexual	 health	 services	 is	 actually	
being	spent	on	sexual	health	services,	
• inadequate	 access	 to	 chlamydia	 screening	 for	 high	 risk	




• an	 additional	 £300	 million	 investment	 in	 sexual	 health	
services	to	ensure	that	GUM	services	could	achieve	the	48-
hour	access	target	by	March	2008,	
• accelerating	 the	 roll	 out	 of	 the	 NCSP	 so	 that	 100%	 of	
England	was	covered	by	March	2007,	
• further	investment	to	support	the	migration	of	laboratories	





Framework	 for	 Sexual	Health	 Improvement	 in	 England	 in	 2013,	 in	
readiness	 for	 the	 devolution	 of	 public	 health	 commissioning	
budgets	 to	 local	 authorities	 later	 that	 year.	 This	 stressed	 the	
importance	 of	 access	 to	 services	 and	 reducing	 STI	 rates	 as	 key	
objectives	 in	achieving	the	ambition	to	“improve	the	sexual	health	
of	 the	 whole	 population”	 (Department	 of	 Health,	 2013b:10).	 It	
recognised	 the	 role	 that	 technology	could	have	 in	 supporting	 self-
care	for	sexual	health	and	future	developments	that	would	impact	















in	 England	 (ibid).	 The	 target	detection	 rate	 is	 2,300	diagnoses	per	
100,000	population	as	this	is	the	rate	determined	by	mathematical	
modelling	 to	 achieve	 a	 reduction	 in	 chlamydia	 prevalence	
(Department	of	Health,	2016b).	
	
The	 NCSP	 featured	 heavily	 within	 the	 2013	 framework	 to	 reduce	
rates	of	STIs	stating	that	in	taking	the	programme	forward	in	terms	
of	service	delivery	there	should	be	a	focus	on:	
• “integrating	 screening	 into	 wider	 sexual	 health	 service	
provision	 and	 increasing	 screening	 in	 primary	 care,	
particularly	general	practice;	
• restricting	 outreach	 screening	 to	 those	 young	 people	 with	
limited	access	to	sexual	health	services;	
• expanding	 internet	 testing	 services,	 which	 are	 particularly	
attractive	to	young	men;	
• promoting	 annual	 screening	 for	 young	 people	 (and	







As	 noted	 by	 the	 Health	 Select	 Committee	 2003	 report,	 the	 first	
national	 strategy	 for	 sexual	 health	 and	 HIV	 placed	 considerable	
emphasis	 on	 PCTs,	 the	 then	 commissioners	 of	 services,	 to	
implement	 the	 strategy.	 To	 support	 implementation	 the	
Department	 of	 Health	 and	 NCSP	 issued	 several	 best	 practice	
documents	for	PCTs	to	assist	with	their	implementation	of	the	new	
service	 requirements	 through	 commissioning	 arrangements.	





changes	 came	 into	 effect	 on	 1	 April	 2013	 and	 the	 responsibilities	
are	summarised	in	table	2.2.	This	has	produced	a	fragmentation	in	
the	delivery	of	services,	most	notably	a	split	in	responsibility	for	the	











































new	 technologies	 into	 chlamydia	 testing	and	 treatment	pathways.	
One	 of	 the	 key	 challenges	 in	 achieving	 a	 reduction	 in	 chlamydial	
infection	 is	 the	 lack	 of	 symptoms.	 In	many	 cases	 people	 infected	
with	 chlamydia	 remain	asymptomatic,	 in	others	 symptoms	appear	
weeks	 or	 months	 after	 infection	 (FPA,	 2013).	 It	 is	 estimated	 that	
70%-80%	 of	 young	 people	 with	 chlamydia	 will	 be	 asymptomatic	




different	 elements	 of	 the	 transmission	 dynamic.	 For	 example,	
increasing	 the	 use	 of	 condoms	 will	 reduce	 the	 likelihood	 of	
infection,	 targeted	 health	 promotion	 initiatives	 and	 partner	
notification	may	also	impact	on	the	rate	of	change	of	partners,	and	
increasing	 testing	 within	 the	 population	 will	 contribute	 to	 a	
reduction	 in	 the	 duration	 of	 infectiousness.	 For	 chlamydia	 in	
England	 the	NCSP	 has	 a	 key	 role	 to	 play	 in	 reducing	 transmission	
through	its	aim	to	screen	16-24	year	olds	annually	or	on	change	of	
partner	 (Public	 Health	 England,	 2016b).	 Introduced	 in	 2003,	 the	
NCSP	 is	 fundamentally	 different	 to	 all	 the	 other	 screening	
programmes	 in	operation	 for	 adults	because	 it	 is	 screening	 for	 an	
infectious	disease.		
	
It	 is	 also	 an	 opportunistic	 rather	 than	 population	 based	 screening	
programme	 meaning	 its	 target	 population	 are	 not	 invited	 to	
participate	 in	 screening	 directly	 through	 a	 recall	 programme.	 As	
well	 as	 securing	 a	 reduction	 in	 the	 prevalence	 of	 chlamydia,	 its	
objectives	 include	 informing	 sexually	 active	 under	 25	 year	 olds	











population,	 although	 the	 number	 of	 diagnoses	 made	 is	 still	




captured	 for	 chlamydia	 tests	 aligned	 to	 the	 15-24	 age	 range	
separately.	 The	 headline	 data	 shows	 that	 in	 2015	 1,538,819	 tests	
were	undertaken	 in	 the	15-24	population,	with	a	 total	 of	 129,022	
positive	tests	(Public	Health	England,	2016b).	Assuming	one	test	per	











Performance	 against	 the	 PHOF	 chlamydia	 detection	 rate	 indicator	
has	also	steadily	declined	over	the	 last	 three	years	as	summarised	
in	 table	 2.3.	 This	 deterioration	 in	 performance	 has	 been	
consistently	 attributed	 to	 the	 relationship	 between	 testing	
coverage	 and	 diagnosis	 rate	 (Public	 Health	 England,	 2016b).	














The	detection	 rate	per	 100,000	population	 remains	highest	 in	 the	
under	25	population.	The	highest	rate	is	within	the	20-24	age	range	
for	 both	 men	 and	 women	 with	 a	 detection	 rate	 of	 1,693.8	 per	
100,000	for	men	and	2,557.0	per	100,000	for	women	(Public	Health	
England,	 2016d).	 There	 is	 an	 even	 more	 marked	 difference	 in	
detection	 rates	between	men	and	women	 in	 the	15-19	 age	 range	
with	 the	 female	 detection	 rate	 per	 100,000	 significantly	 higher	 at	




females	 (ibid.).	 Information	 regarding	 the	 ethnic	 origin	 of	 the	
population	 who	 tested	 positive	 is	 limited	 with	 34%	 of	 diagnoses	
made	 in	 2015	having	 an	ethnic	 origin	 as	 ‘unknown’;	 although	 this	
was	 an	 improvement	 on	 previous	 years	 (Public	 Health	 England,	





Information	collected	as	part	of	 the	NCSP	 for	 the	15-24	age-range	
shows	variation	between	regions	in	testing	for	chlamydia	from	19%	
in	the	West	Midlands	and	East	of	England	to	27%	in	London	(Public	
Health	 England,	 2016b).	 This	 data	 shows	 that	 despite	 the	 aims	 of	
the	NCSP,	testing	uptake	to	the	desired	levels	is	not	being	achieved.	
In	developing	new	technology	 ‘will	people	use	 it?’	 is	an	 important	
consideration	 for	 both	 technology	 developers	 to	 optimise	 their	




limited.	Whilst	 PHE	 collect	 data	 on	 the	population	 tested	 and	 the	
positive	 test	 results	 this	does	not	equate	 to	prevalence	within	 the	
overall	 population.	 Mathematical	 modelling	 has	 identified	 that	 a	
detection	 rate	 of	 2,300	 per	 100,000	 population	 is	 required	 to	
deliver	 to	 a	 sustained	 reduction	 in	 chlamydia	 prevalence	
(Department	of	Health,	2016b)	which	is	the	rationale	for	the	PHOF	




1.1%	 in	women	 (Sonnenberg	 et	 al.,	 2013).	 This	was	 higher	within	
the	20-24	age-range	in	men	and	the	18-19	age	range	in	women	with	
estimated	 prevalence	 of	 3.4%	 and	 4.7%	 respectively	 (ibid).	
Prevalence	 is	 an	 important	 factor	 in	 estimating	 test	 performance	






Service	 delivery	 pathways	 for	 the	 testing	 and	 treatment	 of	
chlamydia	currently	vary	from	locality	to	locality	depending	on	the	
models	commissioned	by	the	LA	and	can	involve	single	or	multiple	
service	 providers.	 Examples	 of	 pathway	 options	 for	 chlamydia	
testing	 and	 treatment	 are	 shown	 on	 in	 figure	 2.1,	 including	GUM	
clinic,	 GP,	 Contraceptive	 and	 Sexual	 Health	 (CaSH)	 and	 NCSP	
internet	 testing.	 The	proposed	 fully	 integrated	 remote	pathway	 is	
also	illustrated	alongside	this.		The	pathways	illustrated	are	for	the	
testing	 and	 treatment	 of	 asymptomatic	 patients.	 These	 pathways	
have	 been	 examined	 as	 part	 of	 the	 costing	 study	 and	 the	 two	
selected	as	comparator	pathways	are	outlined	further	in	Chapter	7.		
They	have	been	broken	down	 into	 six	 stages	 to	 ease	 comparison,	












A	 number	 of	 organisations	 are	 involved	 in	 determining	 standards	
and	 practice	 for	 chlamydia	 testing.	 Standards	 for	 microbiology	
investigations	 are	 published	 by	 PHE	 in	 association	 with	 the	 Royal	
College	 of	 Pathologists	 and	 other	 professional	 bodies,	 and	 testing	
guidelines	for	chlamydia	are	published	by	the	British	Association	of	
Sexual	Health	and	HIV	(BASHH)	(BASHH,	2010).	The	Medicines	and	
Healthcare	 Products	 Regulatory	 Agency	 (MHRA)	 also	 play	 an	
indirect	 role	 in	 the	 approval	 of	 products	 in	 line	 with	 the	 In	 Vitro	
Diagnostic	(IVD)	Medical	Devices	Directive	(MHRA,	2006).	It	appears	
that	 the	 majority	 of	 STI	 tests	 within	 the	 UK	 are	 analysed	 in	 a	
laboratory	setting.	NAATs	are	the	standard	required	by	the	NHS	for	
testing	 for	 chlamydia	 because	 they	 are	 recognised	 to	 have	 higher	




types,	 the	 recommended	 type	 for	 women	 is	 a	 vaginal	 or	
endocervical	 swab	 and	 men	 first	 catch	 urine	 or	 urethral	 swab	
(BASHH,	 2010,	 Public	 Health	 England,	 2014c).	 It	 is	 a	 requirement	
that	 the	 test	 must	 deliver	 a	 Positive	 Predictive	 Value	 (PPV)	 of	







STI	 testing	 was	 traditionally	 associated	 with	 clinician-collected	
samples	 however	 the	 development	 of	 NAATs	 testing	 has	 enabled	
patients	to	provide	their	own	samples	for	the	testing	of	chlamydia	
and	 gonorrhoea.	 Studies	 have	 shown	 that	 the	 performance	 of	
NAATs	on	self-collected	urine,	urethral	or	vaginal	swabs	 is	at	 least	
comparable	with	 clinician-collected	 samples	 (Graseck	 et	 al.,	 2011,	
Sexton	et	al.,	2013,	Hocking	et	al.,	2013).	
	
Advances	 in	 technology	have	 also	 enabled	 testing	 to	move	out	 of	
the	 laboratory	 and	 closer	 to	 the	 patient.	 A	 systematic	 review	 of	
studies	 published	 between	 2010	 and	 2015	 identified	 10	 POCT	 for	
chlamydia,	 with	 the	 authors	 identifying	 two	 tests	 –	 the	 ‘Cepheid	
GeneXpert’	 and	 ‘aQcare	 Chlamydia	 TRF	 kit’	 with	 a	 PPV	 of	 above	






and	 Drug	 Administration	 (FDA)	 approval	 for	 their	 GeneXpert	
combined	chlamydia	and	gonorrhoea	test	(Cepheid,	2013).	The	FDA	
categorised	 this	 test	 as	 a	 ‘test	 of	 moderate	 complexity’	 which	
meant	 it	 could	 be	 used	 in	 the	 USA	 within	 a	 hospital	 setting,	
however	 it	did	not	meet	the	requirements	of	a	 ‘waived	test’	–	“so	
simple	and	accurate	as	to	render	the	likelihood	of	erroneous	results	
by	 the	 user	 negligible”	 (Cepheid,	 2013:240).	 This	 is	 currently	 the	
only	NAAT	POCT	 for	 chlamydia	 approved	by	 the	 FDA,	 comparable	
data	 for	 the	MHRA	 is	 not	 publicly	 available	 on	 their	website.	 The	
test	operates	on	the	same	principle	as	laboratory	based	testing	but	




Advances	 in	 microfluidic	 technologies	 have	 seen	 initial	 proof	 of	
concept	 for	a	number	of	 lab-on-a-chip	 technologies	 in	other	areas	
such	as	hospital	acquired	infection,	tuberculosis	and	HIV	(Niemz	et	
al.,	2011).	However,	it	is	recognised	that	NAATs	are	one	of	the	most	
challenging	 tests	 for	 this	 type	 of	 development	 “due	 to	 additional	
steps	required	for	sample	pre-treatment	(e.g.	cell	sorting,	isolation,	






tests	 available,	 for	 example,	 Accunon	 Diagnostics	 Ltd	 offer	 home	
testing	 kits	 that	 deliver	 results	 in	 15	 minutes	 for	 diagnosing	
Chlamydia,	 Gonorrhoea,	 Hepatitis	 B,	 Hepatitis	 C	 and	 Syphilis,	
however	 these	 test	 kits	 are	 antibody	 (EIA)	 tests	 (Accunon	
Diagnostics	 Ltd,	 2013).	 As	 highlighted	 previously	 the	 performance	
of	EIA	tests	is	inferior	to	NAAT	tests	and	there	are	no	EIA	tests	that	
















48-hour	 access	 target.	 	 Furthermore,	 an	 online	 search	 in	 2015	
identified	 a	 number	 of	 NHS	 providers	 offering	 some	 additional	
aspect	of	online	sexual	health	services.	These	included	appointment	
booking,	 online	 triage	 (directing	 to	 the	 most	 appropriate	 service	
e.g.	 http://www.icash.nhs.uk)	 and	 online	 clinics	 (via	 instant	
message	e.g.	https://www.sexualhealthvirtualclinic.co.uk).		
	
As	 highlighted	 in	 section	 2.4.5	 there	 are	 currently	 no	 self-tests	
(stage	2	in	figure	2.1)	available	for	chlamydia	which	have	a	suitable	
accuracy.	 There	 is	 however	 a	 self-test	 option	 available	 for	HIV.	 In	
April	 2014,	 regulations	were	 relaxed	 to	 allow	 the	 sale	of	HIV	 self-
test	 kits	 in	 England.	 There	 is	 currently	 one	 CE	 marked	 self-test	
available,	 the	 Biosure	 HIV	 self-test	 (National	 AIDS	 Trust,	 2015).	




many	 localities	 use	 an	 online	 service	 for	 chlamydia	 (and	 in	 some	
cases	 gonorrhoea)	 testing	 for	 the	 16-24-year-old	 population.	
Services	 such	 as	 freetest.me	 and	 checkurself.org.uk	 enable	 online	
ordering	 of	 a	 test	 kit	 for	 self-sampling	 and	 provide	 a	 freepost	
envelope	 for	 the	 sample	 to	be	 sent	 to	 the	 laboratory	 for	analysis.	
Freetest.me	 also	 provides	 an	 online	 results	 notification	 service.	








health	 service	 provision	 in	mainstream	 sexual	 health	 services.	 For	
example,	checkurself	launched	a	new	service	in	2016	for	a	number	
of	London	boroughs	which	includes	over	25s	and	a	broader	range	of	




provision	 in	 the	 private	 healthcare	 sector,	 with	 several	 online	
pharmacies	 including	 Lloyds,	 Boots	 and	 Superdrug	 offering	 online	
testing	 and	 treatment	 (stages	 1-5,	 figure	 2.1).	 For	 stages	 1	 and	2,	
the	 online	 testing	 component	 operates	 the	 same	 model	 as	
checkurself	 and	 freetest.me	 and	 for	 stage	 3,	 results	 are	 made	
available	 online.	 The	 treatment	 component	 (stage	 4)	 is	 offered	
differently	to	the	NCSP	internet	testing	services,	with	patients	able	
to	 complete	 an	 online	 form	 to	 secure	 treatment	 for	 chlamydia,	
gonorrhoea,	 herpes	 and	 genital	 warts	 which	 is	 reviewed	 by	 a	 GP	
(Lloyds	 Pharmacy,	 2016).	 In	 2015,	 private	 sector	 online	 sexual	
health	 treatment	 services	 came	 under	 heavy	 criticism	 for	 the	
prescription	 of	 oral	 antibiotics	 for	 the	 treatment	 of	 gonorrhoea	
(Kirkland,	 2015,	 BASHH,	 2011).	 Oral	 treatment	may	 be	 ineffective	
due	 to	 antimicrobial	 resistance	 and	 sub-optimal	 when	 compared	
with	 the	 national	 treatment	 guidelines	 for	 gonorrhoea	 (BASHH,	
2011,	Kirkland,	2015).	Whilst	this	is	occurring	in	the	private	sector,	
there	 is	 no	 evidence	 of	 this	 occurring	 in	 the	 treatment	 of	
gonorrhoea	in	mainstream	sexual	health	services.	
	
There	 are	 limited	 examples	 of	 the	 use	 of	 POCT	 in	 mainstream	
sexual	health	services	for	chlamydia	(services	A,B	&	C	in	figure	2.1).	
A	published	service	evaluation	of	the	use	of	the	Cepheid	GeneXpert	











stage	 of	 the	 pathway	 Hislop	 and	 colleagues	 have	 explored	 the	
impact	of	introducing	EIA	POCT	into	family	planning	settings	in	the	
UK	 and	 concluded	 that	 this	 is	 not	 presently	 clinically	 or	 cost-
effective	 (Hislop	 et	 al.,	 2010).	 This	 is	 in	 contrast	 to	 Turner	 and	
colleagues	 who	 find	 that	 the	 new	 generation	 NAAT	 POCT	 are	
potentially	 cost	 saving	 with	 a	 small	 increase	 in	 QALYs	 and	 major	
outcomes	 averted	 (Turner	 et	 al.,	 2014).	 The	 primary	 difference	
between	the	 two	studies	 is	 the	performance	characteristics	of	 the	
tests	considered,	the	EIA	POCT	considered	by	Hislop	and	colleagues	
has	 a	 considerably	 lower	 sensitivity	 and	 specificity	 than	 the	NAAT	
POCT	considered	by	Turner	and	colleagues.		
	
To	 illustrate	 another	 potential	 impact	 of	 test	 performance	
characteristics	 on	 the	 cost-effectiveness	 of	 chlamydia	 testing,	 Gift	
and	colleagues	explored	the	‘rapid	test	paradox’	using	a	scenario	in	
which	 laboratory	 tests	 have	 greater	 sensitivity	 than	 rapid	 tests	
however	the	loss	to	follow	up	is	greater.	Their	findings	suggest	that	
if	 there	 is	a	 loss	 to	 follow	up	of	greater	 than	35%,	a	 less	 sensitive	
rapid	 test	 (63%	 v’s	 94%)	 would	 lead	 to	 the	 treatment	 of	 more	








based	 testing	 and	 found	 the	 internet	 based	 strategy	 to	 be	 cost-
effective	 (Huang	 et	 al.,	 2011).	 Two	 studies	 have	 been	 identified	
considering	 the	use	of	 the	 internet	 in	a	 full	 chlamydia	 testing	and	
treatment	 pathway,	 the	 UK	 based	 study	 concluding	 the	 pathway	
piloted	 is	 not	 clinically	 or	 cost	 effective	 compared	 to	 the	 existing	
NCSP	 pathway	 (Bracebridge	 et	 al.,	 2012),	 and	 an	 American	 based	
study	 operating	 a	 similar	 pathway	 concluding	 that	 it	 has	 the	
potential	to	be	a	cost-effective	alternative	to	clinic	based	screening	
(Spielberg	et	al.,	2014).	Neither	of	 these	studies	however	consider	
an	 eHealth	 solution	 which	 enables	 the	 prescribing	 of	 chlamydia	
treatment	without	the	involvement	of	a	prescriber.		
	
Two	 systematic	 reviews	 of	 the	 cost-effectiveness	 of	 chlamydia	
screening	 have	 both	 concluded	 that	 chlamydia	 screening	 is	 cost-
effective.	One	covering	the	period	1990-2000	(Honey	et	al.,	2002),	
and	 one	 covering	 the	 period	 until	 August	 2004	 (Roberts	 et	 al.,	
2006).	Subsequent	to	this	review,	the	European	Centre	for	Disease	
Prevention	 and	 Control	 (ECDC)	 published	 a	 comprehensive	
literature	review	examining	chlamydia	control	in	Europe.	As	part	of	
this	 literature	 review,	 they	 updated	 the	 Roberts	 and	 colleagues	
review	 to	 February	 2012.	 This	 update	 identified	 a	 further	 10	











are	 constantly	 new	 products	 for	 evaluation,	 which	 set	 against	 the	
time	 constraints	 of	 traditional	 approaches	 to	 clinical	 and	 economic	
evaluation	are	the	most	likely	reason	there	is	an	absence	of	a	strong	
evidence	 base	 upon	 which	 the	 NHS	 and	 other	 health	 systems	 can	
take	 decisions	 to	 commission	 eHealth	 and	 mHealth	 technologies.	
However,	 this	 lack	 of	 evidence	 base	must	 be	 balanced	 against	 the	









are	 recognised	 future	developments	 that	will	 have	a	 key	 impact	on	













Within	 the	 context	 of	 current	 healthcare	 policy,	 availability	 of	
products	 and	 service	 delivery	 models	 for	 chlamydia	 testing	 and	
treatment	there	are	two	important	considerations	identified	for	this	









“There	 are	 two	 key	 gaps	 in	 the	 translation	 of	 health	 research	 into	
improvements	 in	 practice	 that	 generate	 health	 and	 economic	
benefits:	 translating	 ideas	 from	 basic	 and	 clinical	 research	 into	 the	
development	 of	 new	 products	 and	 approaches	 to	 treatment	 of	
disease	 and	 illness;	 and	 implementing	 those	 new	 products	 and	
approaches	into	clinical	practice”	(Cooksey,	2006:35).	
	
The	 purpose	 of	 this	 chapter	 is	 to	 outline	 the	 overarching	methods	
and	approach	used	to	address	the	research	objectives:	
• To	 assess	 which	 attributes	 influence	 young	 people’s	
preferences	for	the	testing	and	treatment	of	chlamydia	and	to	
explore	 their	 implications	 for	 the	 development	 of	 sexual	
health	services	in	England,		
• To	explore	 the	 likely	 costs	of	 implementing	online	 chlamydia	
treatment	in	mainstream	sexual	health	services	in	England,	
• To	develop	an	economic	model	 to	assess	 the	 likely	costs	and	





research	 undertaken.	 Several	 methods	 were	 used	 in	 this	 doctoral	
research	 including	 literature	 reviews,	 focus	 and	 expert	 groups,	
cognitive	 testing,	 discrete	 choice	 experiment,	 interviews,	 pathway	






As	 an	 NHS	 manager,	 undertaking	 research	 that	 will	 add	 to	 the	









“interventions	 with	 several	 interacting	 components”	 (Medical	
Research	Council,	2008:6).	They	further	outline	the	issues	associated	
with	 evaluating	 this	 type	 of	 intervention	 as	 being	 “the	 difficulty	 of	
standardising	 the	 design	 and	 delivery	 of	 interventions,	 their	
sensitivity	 to	 features	 of	 the	 local	 context,	 the	 organisational	 and	
logistical	 difficult	 of	 applying	 experimental	 methods	 to	 service	 or	
policy	 change,	 and	 the	 length	 and	 complexity	 of	 the	 causal	 chains	
linking	 intervention	 with	 outcome”	 (ibid.).	 This	 research	 was	
conducted	within	 the	 context	of	 the	 framework	of	HTA,	 specifically	
eHTA.	Whilst	 not	 conducting	 a	 full	 eHTA,	 the	 research	 focused	 on	
two	elements	to	inform	an	eHTA	–	a	DCE	to	measure	young	people’s	
preferences	(to	 inform	likely	uptake)	and	early	economic	evaluation	





A	 number	 of	 individual	 pieces	 of	 research	 were	 undertaken	 which	
came	together	to	inform	both	the	DCE	and	the	economic	evaluation,	
including	 a	 link	 between	 the	 two	 where	 the	 probabilities	 derived	
from	the	DCE	results	were	used	 to	 inform	sensitivity	analysis	 in	 the	
economic	 evaluation.	 To	 guide	 the	 reader	 through	 the	 following	
sections,	 a	 summary	of	 the	 research	undertaken	by	 the	author	and	
presented	in	this	thesis	is	outlined	in	table	3.1.	This	doctoral	research	
was	 undertaken	 as	 part	 of	 a	 UKCRC	 strategic	 grant	 aimed	 at	








































































The	 remainder	 of	 this	 chapter	 presents	 the	 background	 to	 the	
theoretical	 framework	 for	 the	 consideration	 of	 the	 research	





diagnostics,	 procedures	 or	 other	 interventions,	 and	 its	 impact	 on	
clinical	 care	 pathways	 is	 desirable	 prior	 to	 large-scale	
implementation	 within	 the	 NHS	 to	 minimise	 the	 associated	 risk.	
Szczepura	 and	Kankaanpää	 recognise	 that	HTA	has	 the	potential	 to	
address	 the	 translational	 research	 deficit	 identified	 by	 Cooksey	 in	
that	 it	 presents	 an	 opportunity	 to	 “look	 before	 you	 leap”	 into	
widespread	 implementation	 of	 a	 new	 technology	 within	 a	 health	
service	(Szczepura	and	Kankaanpää,	1996:5).	
	
eHTA	 recognises	 the	 value	 of	 an	 assessment	 of	 the	 likely	 costs	 for	
technology	developers	in	particular	(Pietzsch	and	Paté-Cornell,	2008).	
An	 insight	 into	 the	 cost	 impact	 of	 the	 implementation	 of	 the	
technology	to	the	healthcare	system	can	inform	future	development	
and	 likely	 issues	 to	 be	 addressed	 to	 achieve	 adoption.	 This	 section	
sets	 out	 the	 background	 to	 HTA,	 giving	 context	 to	 the	 research	
included	in	this	doctoral	thesis.		
	
HTA	 is	 “the	 systematic	 process	 by	 which	 the	 direct	 and	 indirect	
consequences	of	a	particular	technology	are	assessed;	it	is	concerned	
with	evaluating	the	safety,	effectiveness,	and	cost-effectiveness,	and	
(where	 appropriate)	 the	 social,	 ethical	 and	 legal	 impact	 of	 a	
technology”	 (Szczepura	 and	 Kankaanpää,	 1999:4-5).	 EUnetHTA,	 a	
network	of	European	HTA	agencies,	cites	the	aim	of	HTA	as	being	“to	
inform	 the	 formulation	 of	 safe,	 effective,	 health	 policies	 that	 are	
patient	 focused	 and	 seek	 to	 achieve	 best	 value”	 (EUnetHTA,	
2015a:e1).		
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Goodman	extends	 this,	acknowledging	 that	 there	are	many	reasons	
that	HTAs	are	undertaken	including	to	advise	or	inform:		
• whether	 a	 technology	 should	 be	 approved	 by	 a	 regulatory	
agency	or	adopted	by	a	health	care	system	e.g.	whether	the	
NHS	should	fund,	
• guideline	 development	 on	 the	 use	 of	 a	 technology	 within	
clinical	practice,	









• Project-oriented	–	to	adopt	a	 local	 focus	e.g.	to	consider	the	
adoption	of	a	technology	by	a	particular	organisation	(ibid.).		
	
Within	 the	 context	 of	 these	 orientations	 the	 most	 commonly	
recognised	 application	 of	 HTA	 is	 the	 technology	 oriented	 approach	
undertaken	by	HTA	agencies.		
	
The	 definition	 outlined	 by	 EUnetHTA	 offers	 some	 insight	 into	 the	







“May	 involve	 the	 investigation	 of	 one	 or	more	 properties,	














































































In	 England,	 the	 National	 Institute	 of	 Health	 and	 Care	 Excellence	
(NICE)	 carries	 out	 evaluation	 of	 the	 key	 innovative	 or	 high	 impact	








It	 is	 a	 requirement	 for	 commissioners	 in	 England	 to	 comply	 with	
recommendations	made	in	respect	of	drugs	and	devices	through	the	
TA	 and	HST	 programmes	within	 three	months	 of	 recommendation.	
However,	 the	 recommendations	of	all	other	 technology	assessment	
programmes	 are	 advisory	 only	 at	 the	moment,	 that	 is	 the	 decision	
rests	with	 the	 commissioner,	 be	 that	 NHSE,	 CCGs	 or	 the	 LA	 (ibid.).	
Regardless	of	 the	decision	 taken	 in	 respect	of	 a	new	 technology	by	
commissioners,	 individual	 clinical	 practice	 of	 medical	 staff	 is	 a	
significant	factor	in	medical	technology	uptake.		
	
Diagnostic	 technology	evaluation	 is	undertaken	 through	 the	DAP	or	
MTEP.	 To	 date	 no	 evaluation	 of	 an	 eHealth	 or	mHealth	 technology	
has	been	considered	by	NICE.	Work	is	ongoing	between	a	number	of	
agencies	 including	 NICE,	 PHE,	 NHS	 England	 and	 NHS	 Digital	 on	 the	
processes	and	methods	for	the	evaluation	of	apps	(Osipenko,	2016).	
	
Whilst	 it	 is	 recognised	 that	 the	 theory	 that	 NICE	 technology	
assessments	 will	 act	 as	 “filters	 for	 new	 technology	 and	 then	 as	
catalysts	 for	adoption”	 (Liddell	et	al.,	2008:viii)	 there	are	 limitations	
due	to	NICE’s	capacity	to	evaluate	only	a	limited	number	of	products.	





are	 not	 subject	 to	 mandatory	 funding	 (MTEP/DAP/IP	
recommendations)	 and	 for	 the	 many	 technologies	 that	 are	 not	
assessed	by	NICE.	
	
For	 healthcare	 commissioning	 organisations	 the	 approach	 taken	 is	
normally	 set	 out	 within	 policies	 on	 in	 year	 service	 developments	
which	 restrict	 how	 new	 service	 developments	 are	 adopted,	 for	
example,	 NHS	 England’s	 Policy	 on	 ‘in	 year’	 service	 developments	
(NHS	 England,	 2013)	 and	 Clinical	 Priorities	 Advisory	 Group	 (NHS	
England,	2016).	Within	local	authorities	commissioning	decisions	are	




through	 the	 business	 case	 process,	 whereby	 directorate	 teams	
develop	 a	 business	 case	 which	 identifies	 the	 costs,	 benefits	 and	
service	 delivery	 implications	 of	 the	 adoption	 of	 a	 new	 technology.	









In	 terms	 of	 the	 OCCP	 (pathway	 E,	 stage	 3	 onwards	 in	 figure	 2.1),	
whilst	 there	 are	well-established	 programmes	 for	 the	 evaluation	 of	
pharmaceutical	 products,	 and	 to	 a	much	 lesser	 extent	 devices	 and	
diagnostics,	health	technology	assessment	and	economic	evaluation	
of	 online	 provision	 (eHealth	 and	 mHealth	 initiatives)	 is	 largely	
untested	(Tate	et	al.,	2009,	Free	et	al.,	2013a).		
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This	 view	 is	 reinforced	 by	 the	 WHO	 who	 identify	 that	 the	
implementation	 of	mHealth	 is	 taking	 place	 through	 localised,	 small	










The	 principal	 differences	 between	 the	MAST	model	 and	 the	 EUnet	
HTA	model	 are	 a	 reduction	 in	 the	 number	 of	 domains	 through	 the	
consolidation	 of	 the	 health	 problem	 and	 technology	 characteristics	
into	one	component,	and	the	rationalisation	of	the	ethical,	social	and	
legal	aspects	 into	another.	 	A	 ‘patient	perspectives’	 component	has	
been	added,	noting	that	this	was	a	specific	request	resulting	from	the	
stakeholder	 work,	 driven	 by	 a	 belief	 that	 the	 model	 required	






Unlike	 HTA,	 there	 is	 no	 standard	 definition	 offered	 within	 the	
literature	 for	 eHTA.	 Pietzsch	 and	 Paté-Cornell	 identify	 the	 aim	 of	
eHTA	 as	 being	 the	 same	 as	 HTA,	 only	 it	 is	 an	 assessment	 of	 the	
likelihood	of	the	safety,	effectiveness	and	cost-effectiveness	of	a	new	
technology	 (Pietzsch	 and	 Paté-Cornell,	 2008).	 Literature	 on	 the	
methods	 and	 practice	 of	 eHTA	has	 emerged	 in	 recent	 years,	 borne	
out	 of	 the	 recognition	 of	 the	 uncertainty	 faced	 by	 developers	 in	
waiting	 for	 regulatory	 approval.	 Pietzsch	 and	 Paté-Cornell	 highlight	
that	this	uncertainty	could	be	reduced	by	undertaking	eHTA	“at	the	




















































Ijzerman	 and	 Steuten	 (2011)	 break	 this	 down	 further,	 proposing	
three	 stages	 of	 HTA	 within	 the	 four	 stages	 of	 the	 product	
development	 lifecycle	–	very	eHTA,	eHTA	and	HTA	 (figure	3.3).	This	
has	rarely	been	seen	in	practice	 in	published	literature,	for	example	
Dong	and	Buxton’s	early	 assessment	of	 the	 likely	 cost-effectiveness	
of	 computer-assisted	 total	 knee	 replacement	 (Dong	 and	 Buxton,	
2006),	 O’Prinsen	 and	 colleagues	 consideration	 of	 a	 new	 medical	





Cosh	and	colleagues	 identified	a	decision	 framework	 for	 companies	
considering	 investing	 in	new	medical	technology	(Cosh	et	al.,	2007).	
This	 includes	 strategic	 consideration,	 clinical	 problem	 definition,	
headroom	 analysis,	 return-on-investment	 analysis	 and	 further	







The	 evolution	 of	HTA	 and	 economic	 evaluation	 is	 centred	 primarily	
on	 the	 evaluation	 of	 drugs	 rather	 than	 devices	 or	 other	 health	
technologies	 such	as	 telemedicine,	 eHealth	or	mHealth	 (Tate	et	 al.,	
2009,	Free	et	al.,	2013).	Pecchia	and	Craven	identify	a	number	of	key	
factors	which	impact	on	HTA	that	differ	between	the	drug	and	device	




iterative	 economic	 evaluation	 approach	 in	 the	 development	 of	 an	
e/mHealth	 intervention,	 there	 is	 some	 evidence	 of	 the	 adoption	 of	
this	 approach	 in	 respect	 of	 biomedical	 devices.	 Considering	 the	
differences	highlighted,	eHealth	and	mHealth	technologies	with	their	
constantly	evolving	product	and	‘user	dependent	efficacy’	are	much	




of	 eHealth	 and	 mHealth.	 A	 review	 of	 the	 cost-effectiveness	 of	
internet	interventions	published	in	2009	concluded	that	“whilst	there	




systematic	 review	 of	 literature	 on	 the	 cost-effectiveness	 of	
telemedicine,	 eHealth	 and	mHealth	 systems	 found	 that	 there	were	




An	 earlier	 scoping	 review	 undertaken	 as	 part	 of	 this	 doctoral	
research	 (not	 included	 in	 the	 thesis)	 in	 2013	 to	 identify	 whether	
eHealth/mHealth	 initiatives	for	diagnosis,	treatment	and	monitoring	
are	 cost	 effective	 identified	 only	 three	 economic	 evaluations,	








identify	 five	principal	 approaches	 to	 the	measurement	of	 costs	 and	
consequences	 in	economic	evaluation,	noting	 that	 in	all	 cases	 costs	
are	 valued	 as	 monetary	 units,	 however	 the	 identification	 and	
measurement	 of	 consequences	 is	 different,	 depending	 on	 the	
approach.	The	authors	acknowledge	the	growth	of	a	further	form	of	
economic	evaluation	-	cost-consequence	analysis	which	 is	a	 form	of	










































































































The	 primary	 form	 of	 economic	 evaluation	 adopted	 by	 NICE	 in	 its	
HTA	 programmes	 is	 CUA,	 with	 the	 main	 technology	 appraisal	
programmes	all	 incorporating	this	approach,	with	the	exception	of	





(figure	 3.3),	 when	 the	 technology	 is	 sufficiently	 developed	 to	 be	
adopted	by	 the	NHS,	 Sculpher	and	colleagues	had	earlier	outlined	
the	 benefits	 of	 adopting	 an	 iterative	 approach	 to	 economic	
evaluation	which	 can	 also	 be	 aligned	 to	 earlier	 stages	 of	 product	
development.	They	argue	that	“just	as	clinical	evaluation	progresses	
through	 various	 stages,	 with	 the	 choice	 of	 research	 method	






























3	 Clinical	Research	 Mainstream	HTA	 Close	to	Widespread	
Diffusion	
















of	 techniques	 used	 in	 early	 economic	 evaluation	 including	 early	
economic	modelling,	Bayesian	decision	theory,	value	of	information	
analysis	 and	 clinical	 trial	 simulation.	 However,	 of	 the	 83	 papers	
included	 in	 their	 review,	 70%	were	 early	 economic	 evaluations	 of	
drugs	and	30%	were	other	interventions	including	“surgery,	imaging	
or	 novel	 products	 of	 systems”	 (Hartz	 and	 John,	 2008:469).	 It	 is	





For	 medical	 devices,	 Girling	 and	 colleagues	 have	 developed	 a	
framework	 to	 undertake	 early	 economic	 evaluation	 (Girling	 et	 al.,	
2010).	 	 They	 used	 a	 two-stage	 model	 based	 on	 the	 product	





the	 key	 difference	 between	 the	 two	 stages	 in	 the	 model	 is	 the	
consideration	 of	 different	 forms	 of	 uncertainty:	 developmental	
uncertainty	“those	aspects	of	product	design	and	performance	that	
will	 be	 resolved	 during	 the	 development	 phase”	 (Girling	 et	 al.,	
2010:586),	 and	 post-market	 uncertainty	 “those	 aspects	 of	
commercial	 performance	 that	 will	 not	 be	 resolved	 in	 time	 to	
influence	the	decision	to	launch	the	product	into	the	marketplace”	





entry	 point	 (ibid.),	 however	 Vallejo-Torres	 highlight	 its	 successful	




Considering	 the	 technologies	 included	 in	 the	 fully	 remote	 online	
pathway	 (Pathway	 E	 in	 figure	 2.1)	 against	 the	 stages	 outlined	 in	
table	3.5,	they	are	currently	at	different	stages	of	development:	
• Self-test	–	The	self-test	is	at	a	very	early	development	stage.	
Techniques	 for	 the	 component	 elements	 of	 self-tests	 are	








to	 inform	 the	 selection	 of	methods	 for	 considering	 the	 costs	 and	






The	 methods	 finally	 selected	 reflect	 the	 stage	 of	 technology	
development,	 and	 specific	methodological	 issues	 identified	 in	 the	
consideration	of	the	costs	and	benefits	of	asymptomatic	chlamydia	
testing	 and	 treatment.	 There	 are	 two	 linked	 pieces	 of	 research	
presented	in	this	thesis,	firstly	a	preliminary	evaluation	of	the	costs	
and	 outcomes	 for	 the	 delivery	 of	 an	 OCCP	 which	 is	 presented	 in	
Chapter	7.		
	
This	 included	 some	data	 from	an	exploratory	 study	undertaken	 in	
London	 by	 the	 eSTI2	 consortium.	 Secondly,	 Chapter	 8	 outlines	 an	
economic	model	 for	 a	 fully	 remote	 online	 pathway	 (Pathway	 E	 in	






Methods	 for	 costing	 health	 services	 and	 their	 strengths	 and	





two	 further	steps	prior	 to	commencing	costing	 that	have	a	critical	
role	to	play	in	setting	the	perspective	of	the	costing	and	framing	the	
service	to	enable	the	accurate	identification	of	costs.	Their	five	step	







costs	 to	 be	 included	 in	 the	 economic	 model	 and	 to	 ensure	 that	
costs	are	 reflective	of	 current	 service	delivery	models.	Drummond	
and	 colleagues	 identify	 a	 scale	 of	 precision	 to	 healthcare	 costing	
from	average	daily	cost	 to	micro-costing	 (Drummond	et	al.,	2005),	













A	 pragmatic	 approach	 was	 adopted	 to	 costing	 the	 OCCP	 and	
comparator	pathways,	in	line	with	the	type	of	economic	evaluation	
for	 stage	 II	 of	 technology	development	 identified	by	 Sculpher	 and	
colleagues.	 They	 recognise	 that	 in	 respect	 of	 the	 identification	 of	
costs	there	is	greater	access	to	“individual	patient	data	on	the	costs	
and	 outcomes	 of	 the	 new	 technology”	 however	 that	 “stage	 II	




Careful	 consideration	was	 given	 to	 the	 selection	 of	 the	 economic	
model	 used	 to	 assess	 the	 likely	 costs	 and	 benefits	 of	 a	 fully	
integrated	online	testing	and	treatment	service	for	chlamydia.	The	
use	 of	 static	 versus	 dynamic	 models	 in	 considering	 the	 cost-
effectiveness	 of	 interventions	 for	 infectious	 diseases	 is	 widely	
debated.	 A	 literature	 review	 was	 undertaken,	 and	 the	 result	
presented	 in	 section	 7.4.4.	 This	 identified	 that,	 for	 evaluating	 the	
cost-effectiveness	 of	 chlamydia	 testing	 and	 treatment,	 both	 types	
of	models	are	in	us:	static	models	(Althaus	et	al.,	2014,	Hislop	et	al.,	
2010,	Turner	et	al.,	2011,	Turner	et	al.,	2014)	and	dynamic	models	
(Adams	 et	 al.,	 2007,	 Looker	 et	 al.,	 2015,	 Low	 et	 al.,	 2007).	 A	
separate	 published	 literature	 review	 exploring	 the	 cost-
effectiveness	 of	 chlamydia	 screening	 identified	 that	 six	 out	 of	 ten	





model	 developer	 rather	 than	 the	 policy	 maker	 to	 determine	 the	
type	of	model	being	used,	and	“advocate	the	use	of	simple	models	
that	 still	 accurately	 reflect	 disease	 progression	 and	 health	 care	
delivery	 to	 the	 extent	 needed	 by	 a	 given	 decision	 problem”	
(Brennan	et	al.,	2006:1307).			
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This	 view	 is	 supported	 by	 Pitman	 and	 colleagues	 who	 note	 that	
dynamic	models	 are	 important	when	 the	 intervention	 impacts	 on	
the	 transmission	 of	 the	 disease,	 however	 they	 suggest	 that	 static	
models	 are	 acceptable	 where	 “their	 projections	 suggest	 that	 an	
intervention	 is	 cost-effective	 and	 dynamic	 effects	 would	 further	
enhance	 this”	 (Pitman	 et	 al.,	 2012:829),	 proposing	 the	 use	 of	
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Roberts	 concluded	 that	 in	 order	 to	 avoid	 misleading	 results,	
transmission	dynamic	models	should	be	used	to	evaluate	the	cost-
effectiveness	of	chlamydia	screening	programmes.	To	illustrate	the	
difference	between	 the	 static	 and	dynamic	modelling	approaches,	
Roberts	 created	 three	 models,	 two	 static	 and	 one	 transmission	
dynamic	 to	 compare	 the	 cost-effectiveness	 of	 non-selective	
proactive	 screening,	 with	 no	 organised	 screening	 (Roberts,	 2008).	
This	 identified	base	case	results	 from	the	three	models	as	follows:	
Static	 1	 -	 £8,474	 per	 major	 outcome	 averted	 (MOA),	 Static	 2	 -	
£13,344	 per	 MOA	 and	 Dynamic	 -	 £19,300	 per	 MOA.	 Roberts	
explains	 the	 difference	 in	 results	 as	 being	 attributable	 to	 the	
comparator	 option	 not	 being	 the	 same	 –	 the	 static	models	 had	 a	
comparator	of	no	screening,	whereas	the	dynamic	model	assumed	
a	background	level	of	opportunistic	screening,	plus	the	difference	in	
approach	 to	 the	 application	 of	 discounting	 between	 static	 and	
dynamic	models	(ibid.).		
	
Whilst	 it	 is	 recognised	 that	 dynamic	models	 are	 superior	 to	 static	
models	 for	 modelling	 infectious	 diseases	 (Barton	 et	 al.,	 2004,	
Roberts,	 2008)	 it	 also	 recognised	 that	 they	 are	 more	 complex,	
costlier	 and	 time	 consuming	 to	 develop.	 In	 the	 present	 study,	 a	
decision	analytic	model	was	selected	for	the	following	reasons:	
• This	 is	 an	 early	 stage	 evaluation	 of	 a	 new	 technology	 and	
therefore	 the	objective	 is	 to	demonstrate	 the	 likely	 impact	
on	 costs	 and	 outcomes	 to	 inform	 future	 research	 and	
development		
• Data	 for	 parametrising	 a	model	 about	 the	 new	 technology	
are	somewhat	limited,	with	no	data	on	self-testing	(Stages	1	
and	2	in	pathway	E,	figure	2.1)	and	some	initial	exploratory	




• It	 is	 not	 yet	 known	 how	 the	 availability	 of	 self-tests	 may	
influence	sexual	behaviours,	risk	taking	and	testing	patterns,	
all	 of	 which	 would	 be	 material	 considerations	 within	 a	
dynamic	 model	 to	 inform	 parameters	 such	 as	 partner	
change	rate.		
	
In	 terms	 of	 quantifying	 benefits,	 Drummond	 and	 colleagues	
categorise	outcomes	into	intermediate	and	final,	with	intermediate	
outcomes	 representing	 a	 measure	 which	 indicates	 a	 change	 in	
health	outcome	e.g.	improvement	in	CD4	count	(a	measure	of	how	
well	 the	 immune	 system	 is	working	 in	patients	with	HIV)	 versus	a	
final	 outcome	 e.g.	 survival	 or	 health	 related	 quality	 of	 life	
(Drummond	 et	 al.,	 2015).	 	 Process	 measures	 may	 also	 be	 an	
important	consideration	in	the	evaluation	of	a	complex	intervention	
(Moore	et	al.,	2015).	Process	measures	typically	 include	aspects	 in	
relation	 to	 “service	 organisation,	 delivery	 and	 use”	 (Bowling,	
2009:11).	 Use,	 i.e.	 testing	 and	 treatment	 uptake,	 are	 key	





which	 enables	 comparison	 of	 outcomes	 between	 different	 health	
care	 interventions	 (Gray	 et	 al.,	 2011).	 QALYs	 are	 calculated	 by	
multiplying	 the	health	state	outcome	 (represented	on	a	scale	of	1	
for	 perfect	 health	 to	 0	 which	 is	 death)	 by	 the	 time	 spent	 in	 that	










effectiveness	 of	 chlamydia	 screening	 is	 inappropriate	 because	
“undiagnosed	 asymptomatic	 chlamydia	 infections	 do	 not	 affect	
quality	of	 life.	The	complications	of	chlamydia	are	also	rarely	fatal.	
The	impact	of	chlamydia	is	therefore	mainly	through	morbidity	and	








study	 (ibid.).	 The	 reviewers	 highlight	 methodological	 concerns	
associated	with	 valuing	 short-term	 health	 states	 for	 chlamydia	 as	




Jackson	 and	 colleagues	 argue	 that	 further	 research	 is	 required	 to	
enable	more	robust	health	state	measurements	to	enable	economic	
evaluations	for	chlamydia	screening	to	be	conducted	in	accordance	
with	NICE	standards	 (ibid.).	 	Owing	 to	 the	concerns	highlighted	by	
the	 ECDC	 and	 Jackson	 and	 colleagues,	 a	 proxy	measure	 of	 health	
outcomes	 (health	complications	of	untreated	chlamydia)	has	been	











economic	 model,	 recognising	 the	 early	 stage	 of	 technology	







A	 key	 feature	 of	 early	 economic	 evaluation	 is	 that	 it	 is	 indicative	
rather	than	definitive	and	significant	parameter	uncertainty	is	one	of	
the	main	 reasons	 for	 this	 (Sculpher	 et	 al.,	 1997).	 The	 aim	 of	 early	
economic	evaluation	is	to	provide	an	indication	of	the	likely	costs	and	
benefits	 of	 a	 new	 technology	 and	 to	 identify	 areas	 for	 further	
consideration	 for	 technology	 developers.	 Therefore,	 sensitivity	
analysis	 has	 been	 undertaken	 as	 part	 of	 both	 the	 costing	 study	
presented	 in	 Chapter	 7	 and	 the	 economic	 modelling	 in	 Chapter	 8.	
Reference	was	made	 to	both	 the	NICE	MTEP	methods	 guide	 (NICE,	
2011)	 and	 the	 ISPOR	 good	 research	 practices	 for	 parameter	
estimation	 and	 uncertainty	 (Briggs	 et	 al.,	 2012)	 to	 inform	 the	
selection	of	 the	methods.	One	way	sensitivity	analysis	was	 selected	






Detailed	 information	 on	 the	 methods	 for	 the	 development	 and	





clinician,	 they	 are	 therefore	 directly	 dependent	 on	 individuals’	
preferences.	 Probabilities	 of	 uptake	 are	 key	 parameters	 within	 the	
economic	model	and	early	insight	into	the	attributes	which	are	most	
influential	 in	 determining	whether	 individuals	would	 use	 a	 new	 STI	
self-test	 and	 treatment	 pathway	 will	 therefore	 be	 helpful	 in	
informing	 product	 development	 and	 the	 assumptions	 used	 in	 any	
later	economic	modelling.	 	 It	 is	also	recognised	that	“aligning	health	
care	policy	with	patient	preferences	could	improve	the	effectiveness	
of	 health	 care	 interventions	 by	 improving	 adoption	 of,	 satisfaction	




preference	 elicitation	 in	 this	 study.	 A	 summary	 of	 the	 techniques	























































HTA	 recognises	 that	 patient	 preferences	 must	 be	 taken	 into	
consideration,	 reflecting	 the	 importance	 of	 acceptability	 of	 a	 new	
technology	 (Drummond	 et	 al.,	 2013).	 From	 the	 list	 of	 methods	
identified	 for	 capturing	 patient	 preferences	 Ryan	 and	 colleagues	
concluded	that	there	is	no	single	method	which	is	best,	but	highlight	
that	 “conjoint-based	methods	 (including	 ranking,	 rating	and	 choice-
based),	willingness	to	pay,	standard	gamble	and	time	trade-off	of	the	
quantitative	 techniques	 and	 one-to-one	 interviews,	 focus	 groups,	
Delphi	 technique	and	 citizens’	 juries	of	 the	qualitative	methods	are	
recommended”	(Ryan	et	al.,	2001:iv).		
	
More	 recently,	 Drummond	 and	 colleagues	 also	 point	 to	 the	 lack	 of	
methodological	consensus	on	how	to	incorporate	patients’	views	into	
the	HTA	process	and	called	 for	 the	development	of	methods	 in	 this	
area	 (Drummond	 et	 al.,	 2013).	 They	 propose	 the	 use	 of	 systematic	
reviews	 of	 primary	 and	 secondary	 evidence	 on	 patients’	
perspectives.		
	
Choice	 based	 methods	 are	 recognised	 as	 being	 acceptable	 to	
participants	“on	 the	basis	 that	 they	present	 them	with	 the	 types	of	
decisions	they	face	on	a	daily	basis.	It	is	this	argument	that	has	led	to	
the	choice	based	technique	being	preferred	over	ranking	and	rating	
approaches”	 (Ryan	 et	 al.,	 2001:31).	 However,	 the	 same	 review’s	
conclusions	 note	 that	 that	 choice-based	 methods	 require	 further	
exploration,	 rather	 than	 give	 an	 explicit	 recommendation	 for	 their	
use	 as	 a	 quantitative	 preference	 elicitation	 method.	 Since	 the	









and	 product	 development	 (Bridges,	 2003),	 with	 Hall	 and	 colleagues	
highlighting	 their	 benefit	 when	 evaluating	 “new	 products	 and	







an	 intervention”	 (Bridges	 et	 al.,	 2011:404)	 which	 include	
contingent	valuation	and	willingness	to	pay	methods.	
		
Focusing	 specifically	 on	 the	definitions	 of	 the	 first	 category,	 Carson	
and	 Louviere	 (2011)	 point	 to	 inconsistency	 in	 the	 use	 of	 language	
with	 terms	 such	 as	 conjoint	 analysis	 and	DCE	used	 interchangeably	
(Carson	 and	 Louviere,	 2011).	 They	 define	 the	 origins	 of	 conjoint	
analysis	 within	 the	 marketing	 field,	 defining	 it	 as	 a	 term	 used	 to	
“refer	 to	 the	 specific	method	 of	 eliciting	 preferences	 derived	 from	
conjoint	 measurement”	 (Carson	 and	 Louviere,	 2011:5).	 In	 contrast	
they	 highlight	 that	 DCEs	 have	 a	 theoretical	 basis	 in	 random	 utility	
theory	 and	 define	 them	 as	 “	 a	 general	 preference	 elicitation	
approach	 that	asks	agents	 to	make	choice[s]	between	 two	or	more	
discrete	alternatives	where	at	least	one	attribute	of	the	alternative	is	
systematically	 varied	 across	 respondents	 in	 such	 a	 way	 that	






methods	 in	 health	 care	 evaluation	 over	 cost-effectiveness	 analysis.	
These	include	the	ability	of	stated	preference	methods	to	focus	on	all	




these	 methods	 can	 add	 value	 where	 population	 uptake	 is	 key	 to	
achieving	 cost-effectiveness	 through	 offering	 insight	 into	 attributes	
which	 the	 population	 value	 other	 than	 health	 outcomes,	 e.g.	
convenience,	waiting	times	(Hall	et	al.,	2004,	Ryan,	2004).		
	
Bryan	 and	Dolan	 (2004)	 consider	 some	of	 the	disadvantages	 to	 the	
use	 of	 DCEs	 in	 particular	 in	 evaluating	 health	 care,	 they	 identify	 a	
range	of	limitations	including:		


























A	 DCE	 is	 a	 prospective	 mixed	 methods	 study	 that	 comprises	 a	
number	 of	 stages;	 the	 stages	 identified	 by	 Ryan	 and	 colleagues	




























This	 approach	 is	 defined	 as	 an	 exploratory	 sequential	 mixed	
methods	 design	 by	 Cresswell	 who	 highlights	 it	 as	 an	 approach	
which	 is	 helpful	 for	 the	 development	 of	 a	 quantitative	 survey	






The	 use	 of	 a	 qualitative	 data	 collection	 stage	 for	 the	 selection	 of	
attributes	 and	 levels	 has	 varied	over	 time	with	 a	 recent	 literature	
review	of	the	use	of	DCEs	in	healthcare	identifying	that	qualitative	
methods	were	used	to	inform	attribute	selection	in	69%	of	studies	




The	 literature	 review	 did	 not	 indicate	 how	 included	 studies	
identified	 attributes	 and	 levels	 if	 not	 using	 qualitative	 methods,	
however,	Bridges	and	colleagues	have	 listed	potential	methods	as	
“literature	review	and	other	evidence	on	the	impact	of	the	disease	
and	 the	 nature	 of	 the	 health	 technology	 being	 assessed.	
Consultation	 with	 clinical	 experts,	 qualitative	 research	 or	 other	
preliminary	studies	can	provide	the	basis	for	identifying	the	full	set	
of	 attributes	 (and	 even	possible	 attribute	 levels)	 that	 characterize	
the	 profiles	 to	 be	 evaluated”	 (Bridges	 et	 al.,	 2011:405-406).	 The	












Qualitative	 research	 with	 young	 people	 was	 identified	 to	 be	
essential	 in	 the	 identification	 of	 attributes	 and	 levels	 in	 this	
research	with	 a	 second	 stage	 review	with	 experts	 because	 of	 the	
number	of	potential	attributes	and	levels	that	could	be	included.	In	
considering	 which	 qualitative	 research	 method	 was	 most	
appropriate	 to	 inform	 the	 selection	 of	 attributes	 for	 the	 DCE,	 a	
number	 of	 factors	 were	 taken	 into	 consideration	 as	 described	
below.	These	 included	the	topic	(STI	testing),	the	target	age	group	
for	 participation	 in	 the	 research	 (young	 people	 aged	 16-24)	 and	





identification	 and	 selection	 of	 attributes	 and	 levels,	 Ryan	 and	
colleagues	 (2008)	 single	 out	 focus	 groups	 as	 being	 particularly	
helpful	 in	DCEs	 to	 inform	the	 identification	of	attributes,	attribute	
levels	 and	 interaction	 effects	 (Ryan	 et	 al.,	 2008).	 Coast	 and	
colleagues	 explored	 the	 use	 of	 two	 methods	 in	 attribute	
development	(interviews	or	focus	groups)	and	concluded	that	there	





Qualitative	 research	 methods	 literature	 was	 explored	 to	
understand	whether	there	were	any	notable	benefits	in	the	use	of	a	
particular	 method	 in	 undertaking	 research	 with	 the	 selected	 age	
range.	However,	there	were	no	findings	from	this	which	supported	
the	selection	of	one	method	over	another	based	on	age.	Kirk	noted	
in	 her	 literature	 review	 exploring	 methodological	 issues	 in	
conducting	 qualitative	 research	 with	 young	 people	 and	 children	
that	there	are	more	similarities	in	undertaking	qualitative	research	
with	 young	 people	 compared	 with	 adults	 than	 there	 are	
differences.	 The	 main	 differences	 relate	 to	 psychological	
development	 -	 the	 differing	 perspectives	 on	 the	 world,	 cognitive	
development	 and	 ability	 to	 communicate,	 and	 adaptation	 of	
methods	to	enable	participation	(Kirk,	2007).	
	
In	 undertaking	 qualitative	 research	 with	 young	 people	 Millward	
notes	that	there	has	been	considerable	interest	in	the	use	of	focus	
groups	to	elicit	views	from	this	population,	stating	that	the	interest	
is	 “mainly	 derived	 from	 the	potential	 of	 focus	 groups	 to	 generate	




In	 considering	 whether	 focus	 groups	 were	 the	 most	 appropriate	
method	 to	 use	 for	 DCE	 attribute	 development	 it	 was	 noted	 that	
focus	 groups	 are	 commonly	 used	 as	 a	 first	 step	 in	 general	
questionnaire	 development	 (Millward,	 2012),	 for	 exploring	







people	 to	 “explore	 and	 clarify	 their	 views”	 (Kitzinger,	 1995:299),	
reflect	 on	 the	 views	 of	 others	 and	 consider	 their	 own	 position	
further	 (Finch	 et	 al.,	 2014),	 and	 the	 method	 unsurprisingly	
encourages	 dialogue	 which	 questions,	 as	 it	 is	 highly	 unlikely	 that	
everyone	in	the	group	will	be	in	agreement	initially	(Barbour,	2007).	






the	 area	 of	 sexual	 health	 and	 HIV	 (Barbour,	 2007,	 Barbour	 and	
Kitzinger,	 1999).	 Therefore,	 taking	 into	 consideration	 the	 benefits	
outlined	above,	 focus	groups	were	selected	over	 interviews	as	the	
method	 of	 qualitative	 research	 to	 support	 attribute	 development	
and	selection.		
	
To	 inform	the	selection	of	attributes	and	 levels	 for	 the	DCE,	 three	


























From	 the	 initial	 background	 knowledge	 acquired	 through	 the	
mapping	 of	 clinical	 pathways	 it	was	 apparent	 that	 the	 breadth	 of	
potential	 attributes	 which	 could	 be	 included	 in	 the	 DCE	 far	
outweighed	what	 is	was	 feasible	 to	 include	 in	 the	DCE	 taking	 into	
account	 both	 product	 and	 service	 characteristics.	 Therefore,	
considerable	 importance	was	placed	on	the	selection	of	attributes	
and	levels	to	minimise	the	risks	associated,	principally	respondents	



























The	 detailed	methods	 for	 the	DCE	 questionnaire	 design	 stage	 are	
outlined	further	in	section	6.2.	A	generic	main	effects	questionnaire	
design	 was	 chosen	 to	 understand	 the	 component	 attributes	 of	
importance	 to	 young	 people.	 The	 questionnaire	 was	 constructed	
using	 a	 pairwise	 choice	 with	 opt	 out	 to	 reduce	 the	 risk	 of	 social	
desirability	 bias,	 using	 full	 profiles,	 that	 is,	 including	 all	 attributes	
being	 considered	 in	 the	 study.	 Cognitive	 testing	was	used	 to	pilot	
the	questionnaire	to	evaluate	the	cognitive	burden	of	questionnaire	
























Informed	 consent	 was	 recorded	 for	 all	 focus	 group,	 cognitive	
interview	and	costing	 study	participants.	A	 statement	of	 consent	
was	 included	 at	 the	 start	 of	 the	online	DCE	questionnaire	which	
made	it	clear	that	by	continuing	participants	were	consenting	for	







research	 covered	 by	 the	 clinical	 trials	 regulations	 a	 minor	 is	
defined	as	someone	under	the	age	of	16	and	“where	common	law	
applies	–	all	 situations	not	 covered	by	 the	Regulations	–	 the	 law	
states	that	the	age	of	majority	is	18.	Whilst	not	considered	to	have	
fully	reached	adulthood,	young	people	between	the	age	of	16	and	




age	 16	 and	 they	 can	 choose	 to	 access	 NHS	 STI	 testing	 and	
treatment	 services	 (including	 ordering	 postal	 chlamydia	 testing	
kits	 from	 the	 NCSP)	 without	 their	 parents	 being	 informed	 or	
requiring	their	consent.	As	the	research	involved	talking	to	16-18	
year	 olds	 about	 their	 preferences	 for	 STI	 testing	 and	 treatment	
services,	 and	 within	 the	 context	 of	 the	MRC	 guidance,	 parental	




For	 participants	 in	 the	 focus	 groups	 and	 cognitive	 testing	
interviews	 the	only	potential	 risk	 identified	was	 that	participants	
may	 regard	 the	 topic	 of	 STI	 testing	 and	 treatment	 to	 be	
embarrassing	 or	 sensitive.	 Participants	were	made	 aware	 of	 the	
topic	 in	advance	and	that	discussion	centred	on	the	attributes	of	
testing	 and	 treatment	 services,	 and	 what	 may	 influence	 their	
decision	to	use	them.	Participants	were	also	reminded	during	the	
introduction	 to	 the	 focus	group	and	 interviews	 that	 if	 they	were	
not	 comfortable	with	 answering	 a	question	or	 taking	part	 in	 the	









Participants	 in	 the	 focus	 groups	 and	 cognitive	 interviews	 were	
offered	 a	 £10	 shopping	 voucher	 in	 recognition	 of	 their	 time	
commitment.	 Participants	 in	 the	 final	 online	 DCE	 were	 offered	
reimbursement	in	accordance	with	the	predefined	criteria	used	by	
Youthsight	of	1	point	(equivalent	to	£1)	for	completion	of	a	survey	
of	 up	 to	 20	 minutes	 in	 length.	 Points	 are	 then	 exchanged	 for	
Amazon	Vouchers.	No	participant	in	the	costing	study	was	offered	






in	 this	 thesis.	Whilst	 the	methods	 used	 for	 undertaking	HTA	 at	 the	
end	of	the	technology	development	process	(at	the	point	of	market	
access)	 are	 well	 defined	 and	 utilised	 by	 agencies	 such	 as	 NICE,	
published	 research	 on	 the	 methods	 and	 application	 of	 eHTA	 are	
limited,	particularly	in	respect	of	telemedicine,	eHealth	and	mHealth.		
It	 is	 important	 to	 recognise	 that	 the	 research	 presented	 addresses	
some,	 but	 not	 all	 aspects	 of	 eHTA,	 with	 the	 safety	 and	 clinical	





The	 technology	being	considered	 in	 this	 thesis	has	been	 situated	 in	




of	 eHTA.	 As	 outlined,	 both	 the	 DCE	 and	 economic	 evaluation	 are	
comprised	of	a	number	of	component	pieces	of	 research	which	are	
presented	in	the	following	chapters,	each	chapter	includes	a	detailed	
outline	of	 the	methods	 selected	and	 the	 justification	of	 the	choices	
made.	 The	 next	 chapter,	 Chapter	 4,	 introduces	 the	 two	 literature	
reviews	 undertaken	 to	 understand	 patient	 preferences	 for	 and	
























This	 chapter	 describes	 two	 separate	 literature	 reviews	 that	 were	
undertaken	 to	 inform	 the	 DCE	 study	 design	 and	 the	 selection	 of	 a	
‘long	list’	of	potential	attributes	for	the	DCE:	
i. a	review	of	the	use	of	stated	preference	studies	for	STI	testing	
and	 treatment	 services	 adopting	 a	 systematic	 review	
approach	






of	 the	 proposed	 DCE	 and	 to	 explore	 evidence	 on	 which	 attributes	
influence	 patient	 and	 clinician	 preferences	 for	 the	 testing	 and	
treatment	of	STIs.	The	desired	outcomes	would	both	contribute	to	a	
‘long	list’	of	potential	attributes	and	inform	the	development	of	the	
planned	 DCE.	 The	 objective	 of	 the	 second	 literature	 review	was	 to	
identify	which	factors	influence	individuals’	decisions	to	access	testing	




Consideration	 was	 given	 to	 the	 methods	 for	 undertaking	 the	
literature	 reviews	using	Grant	&	Booth’s	 typology	of	 reviews	 (Grant	
and	Booth,	2009).	For	the	first	review	a	systematic	review	approach	
was	 adopted,	 which	 conformed	 to	 the	 methods	 outlined	 in	 the	




For	 the	 second	 review	 a	 scoping	 review	 was	 undertaken.	 This	 is	
defined	 by	 Grant	 and	 Booth	 as	 “a	 preliminary	 assessment	 of	 the	
potential	 size	 and	 scope	 of	 available	 research	 literature.	 It	 aims	 to	
identify	the	nature	and	extent	of	research	evidence	(usually	including	
ongoing	research)”	(Grant	and	Booth,	2009:101).	A	weakness	of	this	
approach	 is	that	 it	does	not	 include	an	assessment	of	the	quality	of	
studies	which	may	lead	to	bias,	however	since	the	aim	of	this	second	
review	was	to	add	to	the	‘long	list’	of	potential	attributes,	the	quality	
















Quality	 assessment	 was	 undertaken	 for	 the	 first	 review	 only,	
recognising	 the	 aim	 was	 to	 learn	 from	 the	 application	 of	 stated	
preference	methods	 to	 inform	 the	 design	 and	 development	 of	 the	







review	 was	 to	 identify	 and	 appraise	 published	 studies	 exploring	







products	 (e.g.	 tests,	 drugs,	 condoms,	 microbicides)	 and	
services	 (e.g.	 screening	 and	 screening	 programmes,	 and	
service	providers	e.g.	GPs,	CaSH	clinics	and	GUM	clinics);	






• from	 outside	 of	 the	 OECD	 High	 Income	 Countries	 (see	
Appendix	5	for	list);	
• not	 related	 to	 the	 diagnosis	 or	 treatment	 of	 STIs	 (e.g.	
vaccinations).		
	
The	 review	 was	 registered	 in	 the	 International	 Register	 of	








were	 re-run	 in	 April	 2015	 to	 search	 for	 any	 studies	 meeting	 the	

















applicable)	 are	 summarised	 in	 table	 4.1.	 	 Search	 terms	 were	
identified	from	books	and	published	research	outlining	methods	for	
DCEs	(Ryan	et	al.,	2008,	McIntosh	et	al.,	2010,	Lancsar	and	Louviere,	
2008,	 Bridges	 et	 al.,	 2011,	 Clark	 et	 al.,	 2014).	 Searches	 were	














































An	 example	 search	 strategy	 from	 Medline	 is	 included	 in	
Appendix	 6.	 Individual	 STIs	 (e.g.	 Chlamydia)	 were	 not	




The	 results	 were	 imported	 into	 Endnote	 x6	 for	 Mac	 and	





removed	 in	Endnote	 leaving	4,345	for	 initial	 review.	The	titles	and	
abstracts	were	reviewed	for	each	exclusion	criterion	in	turn;	leaving	
a	total	of	10	studies	that	met	the	inclusion	criteria.	Bibliographies	of	
the	 included	 papers	 were	 then	 reviewed	 and	 this	 identified	 a	
further	two	studies	which	met	the	 inclusion	criteria	 (Phillips	et	al.,	
2002,	Ryan	and	Watson,	2009),	 taking	the	total	number	of	studies	
included	 to	 12.	 A	 second	 reviewer	 confirmed	 that	 all	 studies	met	























The	 data	 extraction	 form	 was	 designed	 to	 take	 into	 account	 the	
review	 question.	 It	 captured	 key	 study	 characteristics	 and	 the	
quality	 requirements.	 Recognising	 the	 benefits	 of	 electronic	 data	
capture	 “Use	 of	 an	 electronic	 form	 has	 the	 added	 advantage	 of	
being	able	to	combine	data	extraction	and	data	entry	into	one	step,	
and	 to	 facilitate	data	analysis	and	 the	production	of	 results	 tables	
for	 the	 final	 report”	 (Centre	 for	 Reviews	 and	 Dissemination,	
2009:Section	 1.3.3).	 The	 data	 extraction	 form	 is	 included	 in	
Appendix	7.	These	forms	were	reproduced	in	Excel	for	Mac	2011	to	




In	 total	 12	 studies	 met	 the	 inclusion	 criteria;	 six	 focusing	 on	 STI	
testing	 (general	 STI	 testing,	 HIV	 testing	 and	 chlamydia	 screening),	
four	 exploring	 preferences	 for	 STI	 treatment	 (HIV	 and	 genital	
herpes)	 and	 two	 exploring	 preferences	 for	 an	 intervention	 to	
prevent	the	transmission	of	STIs	(microbicide	development).	These	
are	 summarised	within	 the	 context	 of	 a	 sexual	 health	 pathway	 in	
figure	 4.2.	 Of	 studies	 included:	 11	 focused	 on	 the	 patient/service	
user	 perspective	 and	 one	 explored	 a	 clinician	 perspective;	 eight	
focused	 on	 existing	 services/	 treatments	 and	 four	 explored	 the	





rather	 than	 reporting	 the	 study	 findings	 themselves	 –	 adaptive	
conjoint	 analysis	 (Beusterien	 et	 al.,	 2005),	 and	 comparison	 of	

































































































































































groups	 included.	Not	unsurprisingly	 given	 the	 focus	of	 the	 studies	
there	is	a	spread	in	the	type	of	characteristics	considered:	






• Medication	 Characteristics	 and	 Side	 Effects	 (Beusterien	 et	
al.,	2005,	Scalone	et	al.,	2011,	Hauber	et	al.,	2009).		
	
It	 should	 be	 noted	 that	 of	 the	 studies	 included,	 Llewellyn	 et	 al	
(2013)	used	the	questionnaire	developed	by	Miners	et	al	(2012)	 in	
their	 study	 (and	 acknowledge	 this),	 and	 the	 attributes	 and	 levels	






There	has	 been	 some	debate	over	 the	use	of	 a	 ‘cost’	 attribute	 to	
assess	willingness-to-pay	 (WTP)	 in	 conjoint	analysis,	particularly	 in	
countries	 like	 the	 UK	 where	 healthcare	 is	 free	 at	 the	 point	 of	
delivery.	 	 Clark	 and	 colleagues	 noted	 that	 the	 “proportion	 of	DCE	
studies	using	either	a	‘per	WTP’	or	a	‘monetary	welfare	measure’	as	





Of	 the	 four	 identified	 studies	 undertaken	 solely	 in	 the	 UK,	 two	
included	 a	 cost	 attribute	 (Ryan	 and	Watson,	 2009,	Watson	 et	 al.,	
2009)	 and	 two	 studies	 excluded	 a	 cost	 attribute	 (Llewellyn	 et	 al.,	
2013,	Miners	et	al.,	2012).	Miners	and	colleagues	highlighted	that	a	
cost	 attribute	 was	 excluded	 because	 “strong	 objections	 to	 the	
notion	of	‘cost’	in	the	context	of	STI	testing	were	raised	in	most	of	
the	 focus	 groups”	 (Miners	 et	 al.,	 2012:511).	 Ryan	 and	 Watson’s	
paper	compared	the	use	of	payment	card	contingent	valuation	and	
a	DCE	to	elicit	WTP	data	from	the	same	sample,	whilst	Watson	and	
colleagues	 paper	 included	 cost	 of	 screening	 as	 one	 of	 the	 five	
attributes	in	their	DCE.	Neither	reported	concerns	over	inclusion	of	
a	cost	attribute	within	their	papers,	however	neither	indicated	that	































































































































































































































































No	 reporting	 checklist	 was	 identified	 which	 was	 suitable	 for	
assessing	 the	 reporting	 of	 stated	 preference	 studies.	 	 Literature	
reviews	 of	 DCEs	 in	 health	 economics	 (Ryan	 and	 Gerard,	 2003,	 de	
Bekker-Grob	 et	 al.,	 2010,	 Clark	 et	 al.,	 2014)	 centred	 primarily	 on	
three	key	aspects:	experimental	design,	estimation	procedures	and	
validity	 because	 of	 the	 ongoing	 methodological	 debate	 in	 these	
areas	 (de	Bekker-Grob	et	al.,	2010).	These	 literature	 reviews	were	
helpful	 in	 understanding	 advances	 in	 the	 methodology	 and	
utilisation	 of	 DCEs	 over	 time	 but	 did	 not	 offer	 insight	 into	 the	
quality	or	recommend	good	practice	for	reporting	of	studies.		
	
The	 International	 Society	 for	 Pharmacoeconomics	 and	 Outcomes	
Research	(ISPOR),	recognised	the	benefit	that	a	“structure	to	guide	
the	 development,	 analysis	 and	 publication	 of	 conjoint	 analyses	 in	
health	care	studies”	would	offer,	established	a	task	force	to	explore	
good	research	practices	for	conjoint	analysis	 (Bridges	et	al.,	2011).	
The	 intent	of	 the	checklist	produced	was	 to	offer	a	view	on	 ‘good	
research	 practice’	 rather	 than	 define	 best	 practice	 (ibid.).	 A	 pilot	
evaluation	 of	 the	 ISPOR	 checklist	 on	 articles	 published	 between	
1980	 and	 2008	 found	 that	 studies	 generally	 reported	 less	 than	
suggested	by	the	checklist,	in	particular	in	the	areas	of	methods	to	




present	 review,	 reference	 was	 made	 to	 the	 EQUATOR	 network	
‘Library	 of	 Health	 Research	 Reporting’	 (EQUATOR	Network,	 2014)	
and	the	Critical	Appraisal	Skills	Programme	(CASP)	(Critical	Appraisal	
Skills	 Programme,	 2014).	 The	 ISPOR	 checklist	was	 selected	 as	 it	 is	






adequately	 considered	 in	 the	 study	 design	 and	 development.	 In	
utilising	 the	 checklist	 consideration	 was	 given	 to	 the	 30	 sub-
questions	 under	 the	 10	 items	 on	 the	 checklist	 because	 of	 the	
breadth	of	good	practice	cited	under	each	heading	on	the	checklist,	
to	identify	whether	there	were	common	themes	at	a	lower	level.	A	





always	presented	 in	 the	 form	of	a	 testable	hypothesis.	However,	
in	all	cases	the	question	enabled	a	hypothesis	to	be	deduced.		
	
The	 context	 of	 the	 study	 was	 clear	 and	 the	 study	 perspective	
described	 (for	 example	 patient	 or	 healthcare	 professionals’	
perspective)	 in	 11	 of	 the	 12	 included	 studies.	 However,	 the	





The	majority	 of	 the	 studies	 (nine	 out	 of	 twelve)	 provided	 some	
information	 on	 the	 approach	 used	 to	 identify	 the	 attributes	
included	 in	 the	 study.	Methods	 used	 included	 literature	 review,	





2005,	 Hauber	 et	 al.,	 2009,	 Llewellyn	 et	 al.,	 2013,	 Miners	 et	 al.,	
2012,	 Phillips	 et	 al.,	 2002,	 Tanner	 et	 al.,	 2008,	 Young	Holt	 et	 al,	
2006)	 undertook	 qualitative	 research	 with	 users	 to	 inform	 the	
development	of	 their	questionnaire.	 It	 should	be	noted	 that	one	
study	(Llewellyn	et	al.,	2013)	included	no	information	on	attribute	




and	 five	 introduced	 a	 hypothetical	 element,	 for	 example,	
extended	 service	 offer	 (Albus	 et	 al.,	 2005,),	 POCT	 parameters	




The	 numbers	 of	 attributes	 and	 levels	 varied	 significantly	 across	
the	studies.	The	range	in	the	number	of	attributes	was	from	three	
to	 twelve,	 with	 five	 of	 the	 studies	 having	 six	 attributes.	 The	
number	 of	 levels	 within	 each	 attribute	 again	 varied	 significantly	
with	 the	 range	 being	 two	 to	 nine.	 Good	 practice	 (Bridges	 et	 al.,	
2011)	suggests	 that	 the	 inclusion	and	exclusion	of	attributes	and	
levels	should	be	clearly	justified.	In	the	studies	reviewed	there	was	










These	 sections	 of	 the	 checklist	 cover	 aspects	 that	 centre	 on	 the	
justification	of	the	experimental	design	including	whether	a	full	or	
partial	 profile	 was	 selected,	 the	 number	 of	 profiles	 included	 in	
each	 task,	 whether	 an	 opt-out	 option	 was	 considered	 and	
whether	 the	 number	 of	 conjoint	 tasks	 included	was	 appropriate	




In	 all	 studies	 limited	 information	 was	 provided	 on	 these	 topic	
areas	 with	 only,	 for	 example,	 three	 studies	 (Albus	 et	 al.,	 2005,	
Phillips	 et	 al.,	 2002,	 Young	 Holt	 et	 al.,	 2006)	 providing	 a	 full	
justification	of	the	number	of	attributes	and	profiles	 in	each	task	
and	only	 three	 studies	 (Llewellyn	et	al.,	2013,	Ryan	and	Watson,	




was	 limited	with	only	 two	studies	 (Miners	et	al.,	2012,	Ryan	and	
Watson,	 2009)	 discussing	 this	 issue	 in	 detail,	 although	 a	 further	
four	made	 a	 brief	 reference	 to	 experimental	 design.	 Half	 of	 the	
studies	reported	consideration	of	the	number	of	conjoint	tasks	to	
be	 included	 in	 the	 study.	 Of	 the	 DCEs	 included,	 all	 used	 paired	
choice	 with	 two	 providing	 an	 opt	 out	 to	 take	 account	 of	 a	
participant	preferring	a	no	test/	no	treatment	option	(Llewellyn	et	
al.,	 2013,	 Scalone	 et	 al.,	 2011).	 The	 number	 of	 choice	 questions	
ranged	from	nine	to	24.	Of	the	twelve	studies	reviewed:	
• three	used	 rating	 scales	 (Albus	et	al.,	2005,	Tanner	et	al.,	
2008,	Young	Holt	et	al.,	2006),	










In	 respect	 of	 preference	 elicitation	 very	 little	 information	 was	
provided	in	articles	on	the	motivation	and	explanation,	elicitation	
format	 or	 qualifying	 questions,	 and	 where	 reported	 this	 only	
covered	part	of	the	conjoint	analysis	checklist	sub-question.		As	a	
result	 it	 is	 difficult	 to	 comment	on	how	 studies	 addressed	 these	
aspects.	In	section	10,	the	checklist	points	to	the	option	available	
(in	 most	 cases)	 of	 publishing	 the	 questionnaire	 on	 the	 journal’s	
website	 as	 supplementary	 data	 (Bridges	 et	 al.,	 2011);	 of	 the	




All	 studies	 recognised	 the	 importance	 of	 eliciting	 socio-
demographic	and	health	status	information	to	enable	exploration	
of	 preferences	based	on	 these	 criteria.	All	 of	 the	 studies	 (where	
the	 study	 included	 both	 sexes)	 except	 one	 (Beusterien	 et	 al.,	
2005)	 considered	 gender	 a	 key	 demographic.	Of	 the	 five	 studies	
which	 explored	 STI	 testing	 with	 service	 users	 (Llewellyn	 et	 al.,	
2013,	Miners	et	al.,	2012,	Phillips	et	al.,	2002,	Ryan	and	Watson,	
2009,	Watson	 et	 al.,	 2009)	 two	 studies	 considered	 previous	 STI	
testing	 history	 (Llewellyn	 et	 al.,	 2013,	 Miners	 et	 al.,	 2012)	 and	





With	 respect	 to	 the	 provision	 of	 contextual	 information	 to	
respondents	to	ensure	that	they	have	a	consistent	understanding	
of	 the	 attributes	 and	 levels	 within	 the	 tasks,	 very	 limited	
information	was	provided,	with	only	one	study	(Young	Holt	et	al.,	
2006)	providing	sufficient	information	about	this	within	the	article	
to	 enable	 assessment	 against	 the	 checklist	 criteria.	 Similarly,	
limited	 information	 was	 provided	 on	 the	 level	 of	 burden	 of	 the	
data	 collection	 instrument	 with	 the	 published	 information	




In	 terms	 of	 data	 collection,	 five	 of	 the	 studies	 reported	 some	
justification	of	the	sampling	strategy	and	inclusion	criteria.	Sample	
size	 is	 perhaps	 the	 element	 of	 the	 sample	 recruitment	 strategy	
which	 is	 worthiest	 of	 discussion	 within	 this	 section.	 All	 papers	
reported	 their	 sample	 size,	 and	 the	majority	 commented	on	 the	
basis	 for	 including/	 excluding	 returned	 questionnaires	 e.g.	
incomplete	 responses	 (Albus	 et	 al.,	 2005,	 Hsieh	 et	 al.,	 2011,	
Phillips	 et	 al.,	 2002),	 illogical	 responses	 (Miners	 et	 al.,	 2012,	
Beusterien	 et	 al.,	 2005),	 identical	 ratings	 for	 all	 profiles	 (Young	




The	 good	 practice	 checklist	 cites	 Orme’s	 recommendation	 of	
“sample	sizes	of	at	least	300	with	a	minimum	of	200	respondents	
per	group	for	subgroup	analysis”	(Bridges	et	al.,	2011:409).	On	this	
basis	 it	 can	 be	 seen	 that	 only	 a	 third	 of	 the	 studies	 exceed	 the	
suggested	 minimum	 number	 of	 responses	 (Miners	 et	 al.,	 2012,	




In	addition,	 it	 should	be	noted	 that	all	 studies	used	convenience	
samples,	and	of	the	nine	studies	based	on	patients/	service	users	
only	 two	 studies	 incorporated	 people	 without	 the	 condition	 or	




used	 across	 the	 12	 studies	 with	 one	 study	 using	 face-to-face	
completion	with	trained	interviewer	(Young	Holt	et	al.,	2006),	five	
completion	of	paper	based	questionnaires	in	waiting	rooms	(Albus	
et	 al.,	 2005,	 Miners	 et	 al.,	 2012,	 Phillips	 et	 al.,	 2002,	 Ryan	 and	











Across	 the	 12	 studies,	 all	 reported	 the	 characteristics	 of	 the	
respondent	sample,	although	consideration	of	the	generalizability	
of	 results	was	more	 limited.	Due	 to	 the	methods	used	 to	 recruit	
participants,	none	had	information	on	people	who	had	declined	to	






undertaken	on	 the	 sample	population.	 In	one,	 logistic	 regression	
was	used	to	assess	whether	there	were	any	statistically	significant	
differences	 between	 demographic	 groups	 which	 predicted	
completeness	of	response	(Miners	et	al.,	2012)	and	in	the	other	a	
Kruskal-Wallis	 test	 was	 used	 to	 assess	 significant	 differences	
between	 the	 “characteristics	 of	 the	 full	 and	 reduced	 samples”	
(Ryan	and	Watson,	2009:394).	
	
The	majority	of	 studies	 (nine	out	of	 twelve)	 reported	 the	 checks	
undertaken	on	 validity,	with	more	 than	one	 check	being	used	 in	
some	cases.	Checks	included:	
• Face	 validity	 of	 the	 results/	 Consistency	 with	 theoretical	
predictions	(Beusterien	et	al.,	2005,	Llewellyn	et	al.,	2013,	
Miners	 et	 al.,	 2012,	 Phillips	 et	 al.,	 2002,	 Scalone	 et	 al.,	
2011),		
• Percentage	 of	 questions	 answered	 illogically/	 consistency	
check	 (Beusterien	 et	 al.,	 2005,	 Llewellyn	 et	 al.,	 2013,	
Miners	et	al.,	2012,	Phillips	et	al	2002,	Ryan	and	Watson,	
2009,	Young	Holt	et	al.,	2006),		






offering	 the	participants	an	option	of	 screening	 reflecting	one	of	







coding	 was	 used	 for	 variables,	 with	 three	 using	 effects	 coding	
(Phillips	et	al.,	2002,	Ryan	and	Watson,	2009,	Watson	et	al.,	2009),	





















































































































































Although	 Bridges	 and	 colleagues	 provide	 a	 brief	 summary	 of	
models	that	can	be	used	in	conjoint	analysis	(Bridges	et	al.,	2011),	
they	 do	 not	 offer	 an	 opinion	 on	 a	 preferred	model	 for	 different	
scenarios.	 This	 has	 been	 considered	 in	more	 detail	 by	 Ryan	 and	
colleagues	 who	 outlined	 the	 strengths	 and	 weaknesses	 of	
different	model	types	and	suggested	binary	probit	or	logit	models	
for	 binary	 choice	 and	 paired	 choice	 questionnaires,	 and	
multinomial	 logit	 model	 for	 scenarios	 involving	 three	 or	 more	
choices	(Ryan	et	al.,	2008).	For	the	studies	included	in	the	present	
review,	 where	 a	 model	 was	 specified	 in	 the	 article	 these	 were	





Beusterien	 et	 al.,	 2005,	 Hsieh	 et	 al.,	 2011,	 Tanner	 et	 al.,	 2008)	
either	 did	 not	 clearly	 report	 their	 results	 or	 the	 statistical	
uncertainty	 associated	 with	 results.	 All	 studies	 presented	
conclusions	 supported	 by	 evidence	 and	 the	 majority	 situated	
these	 within	 the	 context	 of	 existing	 published	 findings.	 All	
discussed	the	limitations	of	their	study	and	all	but	two	(Beusterien	






The	 final	 area	of	 the	 checklist	 relates	 to	 the	presentation	of	 the	




articles	between	 journals,	 in	particular	 those	published	 in	health	
economic	 journals	 (Beusterien	 et	 al.,	 2005,	 Ryan	 and	 Watson,	
2009,	 Watson	 et	 al.,	 2009)	 compared	 with	 specialist	 clinical	
journals,	 however	 the	 summary	 of	 the	 assessment	 against	 the	
checklist	 (Appendix	 8)	 did	 not	 identify	 any	 pattern	 of	 reporting	
specific	 to	 health	 economic	 journals	 compared	 with	 specialist	




The	 checklist	 also	 highlights	 that	 “a	 reviewer	 cannot	 provide	 a	
meaningful	review	of	a	conjoint	analysis	paper	without	seeing	the	
format	 and	 framing	 of	 the	 questions	 that	 generated	 the	 data.”	
(Bridges	et	al.,	2011:411).	As	highlighted	only	 two	studies	 (Hsieh	
et	al.,	2011,	Scalone	et	al.,	2011)	 included	the	questionnaire	as	a	













• Selection	 of	 attributes	 and	 levels	 –	 a	 priority	 for	 the	 DCE	
being	 developed	 is	 that	 it	 considers	 the	 impact	 of	 new	
technology	on	existing	service	pathways,	that	 is,	action	can	
be	taken	as	a	result	of	the	findings	to	improve	services;	
• Sampling	 strategy	 –	 to	 reflect	 the	 point	 highlighted	 above,	
to	realise	the	economic	and	public	health	benefit,	a	primary	





owing	 to	 the	 lack	 of	 information	 in	 articles,	 however,	 to	
minimise	 the	 risks	 associated	 with	 assumptions	 regarding	
potential	attributes	not	 included	 in	the	DCE	 is	one	which	 is	
essential.	
	
The	 studies	 reviewed	 varied	 in	 the	 degree	 to	 which	 they	 were	
applicable	to	all	stages	of	a	model	of	fully	remote	online	provision	
(Pathway	 E,	 figure	 2.1).	 Of	 the	 studies	 identified,	 only	 one	
considered	self-testing	 (Phillips	et	al.,	2002).	This	 is	self-testing	 for	
HIV,	 an	 incurable	 STI,	 which	 may	 in	 turn	 be	 an	 attribute	 which	











screening	 at	 home	 “decreases	 the	 general	 preference	 for	
screening”	(Watson	et	al.,	2009:622).	Two	studies	(Llewellyn	et	al.,	
2013,	 Miners	 et	 al.,	 2012)	 explored	 preference	 for	 testing	 within	
the	 context	 of	 current	 STI	 services	 but	 did	 not	 incorporate	
hypothetical	 scenarios	 based	 on	 new	 technology	 e.g.	 POCT,	 self-
testing	or	treatment	availability	via	an	eHealth/mHealth	solution.		
	
Whilst	 Phillips	 and	 colleagues	 identified	 that	 “instant	 home	 tests	
would	become	at	least	as	preferred	as	the	baseline	scenario	(public	
clinic	 tests)	 if	 they	were	highly	 accurate	 and	 cost	 $10”	 (Phillips	 et	
al.,	 2002:1697),	 no	 studies	 were	 identified	 which	 explored	
preferences	 for	 testing	 for	 STIs	 incorporating	 the	 potential	 new	




study	 (Llewellyn	 et	 al.,	 2013)	 sought	 to	 include	 non-service	 users	
within	 the	 sample,	 all	 other	 samples	 were	 drawn	 from	 people	
known	to	have	the	condition,	current	service	users	or	attendees	for	
other	 linked	 services	e.g.	 family	planning.	This	 is	 significant	within	
the	 context	 of	 new	 technology	 development	 for	 asymptomatic	
pathways	 where	 the	 economic	 and	 public	 health	 benefit	 may,	 in	





Applying	 the	 ISPOR	 good	 practice	 checklist	 as	 a	 mechanism	 for	
assessing	 the	 quality	within	 the	 reporting	 of	 the	 conjoint	 analysis	
provided	 a	 useful	 framework	 for	 exploring	 the	 strengths	 and	




of	 conjoint	 analysis	 studies	 for	 colorectal	 cancer	 screening	 which	
applied	 the	 ISPOR	 checklist	 as	 a	 framework	 for	 reviewing	 the	
studies	(Ghanouni	et	al.,	2013).	
	
Finally,	 the	 findings	 from	 the	 literature	 review	 also	 point	 to	 a	
number	of	potential	attributes	(table	4.4)	to	be	included	in	the	‘long	
list’	 for	 the	discrete	choice	experiment	 including	 test	performance	
characteristics,	time	to	result,	range	of	STIs	tested	for	and	location	








As	 outlined	 in	 section	 4.1	 the	 objective	 of	 the	 second	 literature	
review	 was	 to	 identify	 which	 factors	 might	 influence	 individuals’	
decisions	 to	 access	 testing	 and	 treatment	 services	 for	 STIs.	 The	









Attributes	 can	 be	 defined	 as	 the	 product	 specific	 features	 that	 are	
evaluated	 in	 the	 DCE	 and	 levels	 are	 the	 variation	 within	 each	
attribute	 (Szeinbach	 et	 al.,	 2011).	 Attributes	 are	 comprised	 of	 a	
number	 of	 levels	 (e.g.	 for	 time	 to	 result,	 the	 levels	 would	 be	 a	
selection	 of	 times	 to	 result).	 Levels	 must	 be	 “plausible,	 actionable	
and	capable	of	being	traded”	(Ryan,	1999:445).	Ryan	and	colleagues	
note	 that	 there	 are	 no	 specific	 rules	 for	 determining	 the	 attributes	
and	levels	included	in	a	DCE,	defining	a	good	experiment	as	one	“that	
has	a	sufficiently	rich	set	of	attributes	and	choice	contexts,	together	
with	 enough	 variation	 in	 the	 attribute	 levels	 necessary	 to	 produce	
meaningful	 behavioural	 responses	 in	 the	 context	 of	 the	 strategies	
under	study”	(Ryan	et	al	2008:17).	
	





• What	 are	 the	 advantages	 and	 disadvantages	 of	 different	
qualitative	methods	for	developing	attributes?	






in	 determining	 the	 inclusion	 and	 exclusion	 criteria	 for	 this	 second	




• any	 study	 which	 indicates	 individuals’	 preferences	 or	
acceptability	of	STI	testing	and/	or	treatment	services	
• studies	published	between	Jan	2004-Sept	2014	
• conference	 abstracts,	 where	 the	 abstract	 enabled	 the	
extraction	of	information	on	study	focus	and	key	findings.		
	
The	date	 range	 for	 the	 literature	 review	was	 selected	 to	 limit	 the	
volume	of	results	identified	to	the	last	10	years.	This	recognised	the	
fact	 that	 the	 previous	 literature	 review	 only	 identified	 one	 stated	
preference	 study	 which	 met	 the	 inclusion	 criteria	 pre-2004,	 and	







• from	 outside	 of	 the	 OECD	 High	 Income	 Country	 List	 (see	
Appendix	5)	
		 156	
• not	 related	 directly	 to	 testing	 and/	 or	 treatment	 provision	
e.g.	drug	characteristics,	health	promotion	interventions		
• not	 offering	 a	 perspective	 provided	 by	 service	 user/	
potential	service	user	e.g.	clinician	
• focused	on	non-mainstream	service	provision	e.g.	STI	testing	
in	 A&E,	 dedicated	 service	 provision	 for	 specific	 high	 risk	










Individual	 STIs	 (e.g.	 Chlamydia)	 were	 not	 included	 in	 the	 search	
strategy,	 as	 it	 was	 determined	 that	 attributes	 and	 levels	 could	




with	 the	 databases	 selected	 being	 those	 which	 had	 generated	 a	
high	return	rate	of	relevant	articles	in	the	first	literature	review	and	









The	 initial	 search	 identified	 8,057	 records	 and	 1,057	 duplicates	
were	removed	in	Endnote	leaving	6,959	for	initial	review.	The	titles	
and	abstracts	were	reviewed	by	a	single	reviewer	for	each	exclusion	
criterion	 in	turn;	 leaving	a	total	of	135	studies	 for	 full	 text	 review.	
Three	papers	were	excluded	at	 this	 stage,	 resulting	 in	132	 studies	
identified.	 Given	 the	 volume	 of	 papers	 meeting	 the	 inclusion	
criteria	 a	 bibliographic	 search	 of	 included	 studies	 was	 not	
undertaken.	 The	 search	 results	 are	 presented	 in	 the	 PRISMA	



















































• Parameter	 1	 -	 population	 studied	 –	 service	 users,	 general	
population,	unclear,	
• Parameter	2	-	whether	the	study	considered	HIV	only,	
• Parameter	 3	 -	 whether	 the	 study	 focused	 on	 product	 or	
service	 characteristics,	 or	 values	 beliefs,	 perceptions	 and	
behaviours,	
• Parameter	 4	 -	 whether	 the	 study	 focused	 on	 a	 single	
product	 or	 characteristic	 or	whether	 it	 encompassed	more	
than	one	aspect	of	the	pathway	in	figure	2.1,	
























Finally,	 using	 the	 information	 extracted,	 potential	 attributes	 or	
factors	informing	attributes	were	drawn	out	from	the	literature.		
	
The	 data	 was	 extracted	 into	 an	 Excel	 spreadsheet	 for	 analysis.	 A	
review	of	 the	quality	 of	 the	papers,	 examination	of	 bias	 and	data	
analysis	 was	 not	 undertaken	 as	 the	 outcome	 of	 this	 would	 not	
change	the	identification	of	potential	attributes	for	inclusion	in	the	
DCE.	A	 summary	of	all	 included	studies	which	 shows:	 study	 focus,	




Of	 132	 papers	 reviewed,	 broadly	 equal	 numbers	 (57	 versus	 62)	
were	 classified	 under	 Parameter	 1	 as	 service	 users	 and	 general	
population	 respectively	 (43%	 versus	 47%).	 In	 13	 studies	 the	





service	 characteristics,	 whilst	 30%	 focused	 on	 values,	 beliefs,	
perceptions	 and	 behaviours	 relating	 to	 accessing	 sexual	 health	
services,	 but	 did	 not	 report	 specifically	 on	 product	 or	 service	
characteristics.	 Four	 of	 the	 93	 focused	 on	 product	 and	 service	
characteristics	 also	 included	 some	 findings	 in	 respect	 of	 values,	
beliefs,	perceptions	and	behaviours	(Parameter	3).		
	
Of	 the	 93	 studies	 reporting	 on	 acceptability	 or	 preferences	 for	
product	 or	 service	 characteristics,	 77	 studies	 (83%)	 focused	 on	 a	





























Whilst	a	number	of	 the	 studies	 identified	 include	 the	 introduction	
of	a	new	technology	(Parameter	5)	including	use	of	some	aspects	of	
eHealth	and	mHealth	these	did	not	reflect	all	the	core	features	of	a	
fully	 integrated	 online	 pathway,	 particularly	 online	 treatment	
consultation.	 In	 respect	 of	 remote	 self-testing,	 reviewing	 the	 22	
studies	which	considered	sampling	methods	for	STIs	other	than	HIV,	





Analysis	 of	 the	 93	 studies	 which	 focused	 on	 product	 or	 services	
characteristics	shows	that	17	(18%)	focused	on	some	aspect	of	self-
sampling,	 12	 (13%)	 on	 POCT	 and	 nine	 (10%)	 on	 aspects	 of	 self-
testing,	see	table	4.8.	A	total	of	17	(18%)	focused	on	test	 location.	
Only	 six	 (6%)	 focused	on	 the	 next	 stage	 in	 the	 pathway	 shown	 in	
figure	 2.1,	 results	 notification.	 The	 consultation	 method	 and	





































Table	 4.10	 provides	 more	 details	 on	 the	 findings	 of	 studies	
considering	 a	 preference	 for	 testing	 location.	 These	 included	 the	
studies	 considering	 preferences	 for	 where	 the	 test	 itself	 was	
undertaken.	In	respect	of	where	the	test	kit	was	collected	from,	one	
study	 explored	 this	 for	 young	men,	 identifying	 that	 the	 preferred	
collection	points	were	GUM,	GP	practice	and	pharmacy	 (Saunders	
et	al	2012)	which	reflects	the	findings	of	Wayal	and	colleagues	who	
found	 that	 MSM	 preferred	 testing	 kits	 to	 be	 made	 available	 in	
medical	locations	rather	than	‘social’	locations	(Wayal	et	al.,	2011).	
Other	 studies	 have	established	 the	 acceptability	 of	 internet-based	
access	 to	 testing	 i.e.	ordering	 the	 test	online	 (Gaydos	et	al.,	2006,	

















































Balfe	 and	 colleagues	 identified	 four	 reasons	 why	 young	 people	
choose	to	test	for	STIs	-	a	‘transitional	moment’	e.g.	ceasing	to	use	
condoms	with	a	partner,	unprotected	sex,	symptoms	of	an	STI,	or	if	
a	 requirement	 of	 their	 employment	 (Balfe	 and	 Brugha,	 2009).	
Equally,	 many	 of	 the	 included	 studies	 which	 focused	 on	 values,	
beliefs,	 perceptions	 and	 behaviours	 identified	 key	 reasons	 why	































































































cited	 reason	 was	 privacy,	 confidentiality	 or	 anonymity	 concerns,	
identified	 in	 24	 studies	 (56%).	 This	 was	 followed	 by	 access	 and	
convenience	of	services,	cited	by	10	of	the	43	studies	(23%),	stigma,	




The	 findings	of	 both	 literature	 reviews,	 along	with	other	 key	data	
sources	 including	 clinical	 guidelines	 and	 test	 performance	 data,	
were	mapped	 to	 the	 key	 stages	 in	 the	 STI	 testing	 and	 treatment	
pathway	 shown	 in	 figure	 2.1.	 In	 considering	 the	 inclusion	 of	
potential	attributes	 in	this	 list	the	following	selection	criteria	were	
used.	Attributes	were	 included	 in	 the	 list	 of	 potential	 attributes	 if	
they	were:	
• From	 the	 stated	 preference	 studies	 literature	 review,	
directly	 related	 to	 the	 provision	 of	 testing	 and	 treatment	
services	for	STIs	in	England	







• Could	 be	 inferred	 from	 the	 studies	 considering	 values,	
beliefs,	 perceptions	 e.g.	 stigma	 associated	 with	 testing	 for	
STIs.	 Location	 of	 testing	 and	 how	 you	 access	 a	 healthcare	
































































being	 assessed,	 expert	 opinion,	 qualitative	 research	 and	 other	
preliminary	 studies	 as	 the	 primary	 sources	 for	 attribute	
identification.	 The	 value	 of	 the	 qualitative	 research	 process	 in	 DCE	
questionnaire	design	is	summarised	by	KlØjgaard	and	colleagues	who	
recognised	 that	 their	 phased	 approach	 to	 qualitative	 research	
(incorporating	 a	 number	 of	 qualitative	 techniques)	 in	 attribute	 and	
level	 selection	and	questionnaire	design	had	a	direct	 impact	on	 the	




Whilst	 the	 importance	 of	 qualitative	 research	 in	 DCE	 questionnaire	










The	publication	of	 information	 regarding	 the	 selection	of	 attributes	
and	levels	is	problematic	with	little	or	no	information	being	published	
as	 part	 of	 the	 reporting	 of	 a	 DCE	 (ibid).	 A	 recent	 review	 of	 DCE	
studies	 in	 health	 economics	 found	 a	 decrease	 in	 the	 use	 of	
qualitative	 methods	 for	 attributes	 selection	 in	 studies	 published	
during	2001-2008	 (69%)	 to	51%	 in	 studies	published	between	2009	
and	2012.		
	
Conversely	 the	use	of	 qualitative	methods	 to	 inform	 level	 selection	
increased	between	 the	 two	periods	 from	33%	 for	 studies	published	
during	 2001-2008	 to	 40%	 for	 studies	 published	 between	 2009	 and	
2012	 (Clark	 et	 al.,	 2014).	 This	 makes	 it	 difficult	 for	 the	 reader	 to	
consider	the	implications	of	the	selection	of	attributes	and	levels	on	
the	 interpretation	 and	 limitations	 of	 the	 DCE	 study	 (Coast	 and	





what	 is	 important	 in	 the	 context	 of	 the	 policy/	 service	 perspective	
and	the	perspective	of	the	respondent	(Bridges	et	al.,	2011,	Lancsar	
and	 Louviere,	 2008).	 It	 is	 suggested	 that	 “the	 eventual	 balance	 of	
these	competing	objectives	must	be	guided	by	the	research	question	
and	the	study	perspective”	(Bridges	et	al.,	2011:405).	It	is	recognised	
that	 it	 is	 not	 always	 possible	 to	 include	 all	 relevant	 attributes	 and	
levels	 within	 the	 DCE	 and	 Lancsar	 and	 Louviere	 suggest	 that	 DCEs	
need	 to	 both	 capture	 sufficient	 relevant	 attributes	 to	 avoid	
respondents	 making	 assumptions	 regarding	 missing	 attributes	 of	
importance	 and	 that	 levels	 are	 sufficiently	 different	 to	 avoid	












used	 in	 the	DCE.	 This	 includes	 the	 use	 of	 focus	 groups	 to	 seek	 the	
views	of	young	people	on	the	‘long	list’,	and	exploring	the	findings	of	
these	 with	 expert	 groups	 to	 incorporate	 the	 policy	 and	 service	





























outlines	 the	 rationale	 for	 the	 use	 of	 focus	 groups	 to	 inform	 the	
development	 of	 the	 DCE,	 presenting	 the	 research	 undertaken	 to	
inform	 the	 selection	 of	 attributes	 from	 the	 ‘long	 list’	 identified	 in	
Chapter	 4,	 and	 identification	 of	 levels	 through	 the	 use	 of	 focus	
groups,	 expert	 groups	 and	 evidence	 synthesis.	 This	 chapter	 is	
structured	into	four	parts:	first,	the	focus	group	research	undertaken	
with	 young	 people	 is	 presented.	 This	 includes	 the	 detail	 of	 the	
methods	used,	how	the	 focus	groups	were	conducted	and	analysed	
and	 the	 findings	 from	 this	 research.	 Second,	 the	 findings	 from	 the	
focus	 groups	 are	 used	 to	 inform	 the	 development	 of	 the	 expert	
groups	 which	 follow	 in	 this	 chapter.	 Third,	 the	 synthesis	 of	 the	
findings	 from	 the	 focus	 groups	 and	 expert	 groups	 to	 finalise	 the	
selection	 of	 attributes	 and	 levels	 is	 presented.	 Finally,	 the	 chapter	










• To	 identify	 which	 the	 themes	 and	 factors	 young	 people	








o Rationale	 for	 trading	 between	 factors	 and	
prioritisation	






















1	 6	 4F,	2M	 16-17	 Existing	Group	
2	 5	 3F,	2M	 17-18	 Existing	Group	
3	 3	 3M	 18-24	 Self-selected	










phase	 of	 the	 research.	 The	 convenience	 sampling	 approach	 is	
defined	 as	 selection	 based	 on	 who	 is	 available,	 they	 self-select	
into	the	sample.	Whilst	it	is	recognised	that	the	main	limitation	of	
this	approach	is	the	impact	on	the	validity	(Finch	et	al.,	2014)	and	




principal	 criteria	of	 relevance	within	 the	16-24	age	 range.	Whilst	
research	 does	 suggest	 there	 are	 differences	 in	 preferences	
between	demographic	groups	for	different	testing	and	treatment	
services	(Iles	&	Oakeshott,	2005,	Lorimer	et	al.,	2009)	there	is	also	
evidence	 that	 other	 factors	 may	 be	 more	 significant	 such	 as	
relationship	 status	 (Balfe	 and	 Brugha,	 2009).	 The	 population	 of	
interest	for	this	research	was	the	16-24	age	range	since	this	is	the	
population	 with	 the	 highest	 rates	 of	 diagnosis	 of	 STIs	 (PHE,	
2016b);	 the	 greatest	 frequency	 of	 change	 of	 partner	 (Mercer	 et	









to	 align	 the	 language	 and	 content	 to	 ensure	 relevance	 to	 the	
‘target’	population	age	range,	in	order	to	pitch	the	content	of	the	
focus	group	at	an	appropriate	level.	Websites	were	reviewed	that	




Respect	 Yourself	 (the	 Warwickshire	 relationships	 and	 sex	
education	website)	and	Brook	(a	national	charity	with	a	focus	on	
sexual	 health	 services	 for	 under	 25s).	 Market	 analysis	 data	 was	
reviewed	 to	 identify	 the	 most	 commonly	 used	 technology	 and	




When	 planning	 the	 focus	 groups,	 time	was	 allowed	 before	 each	
focus	group	began	to	enable	participants	to	review	the	participant	
information	 leaflet,	 formally	 consent	 to	 take	 part,	 and	 for	 the	
volunteers	 to	 complete	 the	 demographic	 information.	 The	
introduction	 was	 planned	 to	 be	 brief,	 thanking	 participants	 for	
their	 input,	outlining	 the	purpose	of	 the	 focus	group	and	setting	
out	the	ground	rules	for	participation.	These	included:	












for	 the	 focus	group.	This	was	because	 in	designing	the	questions	
there	 was	 a	 logical	 flow	 through	 the	 vignettes	 into	 the	 later	
questions	 and	 related	 exercise	 and	 it	 was	 believed	 that	 the	
vignettes	 would	 offer	 an	 easy	 route	 into	 the	 topic.	 The	 scene	
setting	 drew	 on	 the	 views	 of	 a	 small	 number	 of	 clinical	 staff	
working	 in	 sexual	 health	 services	 in	 London,	 based	 on	 their	
experience	 of	 what	 prompts	 young	 people	 to	 attend	 clinic.	
References	were	made	to	Facebook	specifically	because	this	was	
proportionately	 the	 most	 used	 social	 networking	 site	 (Ipsos	
MediaCT,	2015).			
	
In	 developing	 the	 focus	 group	 topic	 guide	 a	 key	 point	 was	
identifying	 the	 questions	 to	 use.	 Recognising	 the	 need	 for	
questions	 to	 be	 open-ended,	 and	 structured	 in	 such	 a	 way	 that	
participants	would	be	willing	to	respond	to	them	(Barbour,	2007),	
careful	 consideration	 was	 given	 as	 to	 how	 to	 link	 them	 to	 the	
vignettes	 and	 frame	 their	 content	 with	 the	 other	 connecting	
dialogue.		
	
To	 make	 sure	 that	 the	 vignettes	 were	 credible	 and	 authentic	
(O'Dell	 et	 al.,	 2012),	 prior	 consultation	 was	 undertaken	 with	 a	
small	group	of	clinical	staff	working	on	the	related	eSTI2	research	
project.	 This	 included	 two	 GUM	 consultants,	 a	 research	 nurse	
working	in	the	field	and	a	sexual	health	advisor.	An	afternoon	was	
spent	talking	through	the	plans	including	the	number	of	vignettes	
and	 the	 degree	 of	 detail	 required.	 Following	 this	 the	 author	
drafted	 three	 vignettes	 –	 one	 describing	 a	 GUM	 clinical	 care	
pathway,	 one	 describing	 an	 NCSP	 internet	 testing	 pathway	 and	





animation	 developed	 by	 another	 eSTI2	 researcher	 used	 as	 an	
introduction	 to	 the	 human	 computer	 interaction	 focus	 groups.	
The	 other	 two	 were	 developed	 based	 on	 what	 happens	 to	
someone	if	they	choose	to	test	at	a	sexual	health	clinic,	or	through	




the	 small	 group	 of	 clinical	 staff	 for	 review.	 The	 vignettes	 were	
then	amended	taking	 into	account	this	 feedback.	 It	 is	 recognised	
that	 it	 is	 important	 for	 vignettes	 to	 be	 “easily	 followed	 and	
understood,	 and	 are	 internally	 consistent	 and	 not	 too	 complex”	
(Barter	 and	 Renold,	 2000:314).	 Thus,	 care	 was	 taken	 to	 ensure	
that	the	vignettes	were	written	impersonally,	as	a	walk-through	of	
what	would	happen	if	a	participant	chose	that	route	to	test	for	an	
STI,	 rather	 than	 to	 shape	 them	 around	 a	 hypothetical	 person.	 It	






or	 videos.	 The	 reason	 for	 this	 was	 two-fold,	 firstly	 the	 level	 of	
detail	did	not	lend	itself	to	flip	charts	or	storyboards,	and	secondly	













The	 first	 vignette	 is	 longer	 in	 length	 since	 it	 contains	 additional	
information	which	 is	referred	to	 in	vignettes	two	and	three,	thus	




Following	 the	 introduction,	 all	 participants	 were	 asked	 to	 give	
their	name	and	to	confirm	that	they	understood	the	ground	rules.	
The	 topic	 guide	 for	 the	 first	 focus	 group	 acknowledged	 that	 this	
was	a	pre-existing	group	therefore	individual	introductions	would	
not	be	necessary.	 The	 topic	 guide	was	adapted	 for	 the	 final	 two	
focus	groups	as	participants	selected	themselves	by	responding	to	
an	 online	 advert.	 It	 was	 decided	 to	 amend	 the	 introductory	
section	slightly	to	ask	participants	to	introduce	themselves	to	the	
group	as	part	of	the	confirmation	process.	A	broader	introductory	








opening	 by	 asking	 if	 there	was	 anything	 to	 ask	 about	what	 they	
had	been	 told.	 It	was	 important	 to	 check	 comprehension	 at	 this	
stage	 since	 it	 was	 anticipated	 that	 the	 majority	 of	 participants	
would	not	 have	previously	 used	 sexual	 health	 services.	 The	next	
question	 asked	 about	 each	 vignette	 was	 ‘can	 you	 think	 of	 the	
things	 in	 the	 example	 that	might	make	 a	 difference	 to	whether	
you	decided	to	use	 this	 service?	What	do	you	particularly	 like	or	




The	 second	 part	 of	 the	 focus	 group	 centred	 on	 exploring	 these	
factors	 in	 more	 detail	 using	 a	 further	 three	 questions,	 again	 to	
draw	 out	 the	most	 important	 ones.	 It	 started	 with	 a	 paragraph	
which	 asked	 participants	 to	 reflect	 and	 compare	 the	 factors,	 to	
think	 about	 whether	 there	 was	 one	 particular	 thing	 about	 an	
option	 that	 makes	 it	 more	 attractive	 than	 another,	 or	 to	 think	
about	if	there	were	things	that	would	be	important	which	haven’t	
been	 covered	 by	 the	 examples	 talked	 through.	 Two	 explicit	
questions	were	 asked	 about	what	 the	most	 important	 factors	 in	
making	 a	 choice	 about	which	 service	 to	 use	were	 and	why,	 and	












The	 questions	 were	 written	 to	 be	 open	 ended	 and	 in	 language	
appropriate	 to	 the	 participants	 as	 is	 identified	 good	 practice	 for	
focus	groups	 (Millward,	2012,	Krueger	and	Casey,	2000).	For	 this	
part	 of	 the	 focus	 group,	 cards	with	 factors	 on	were	 prepared	 in	
advance	 and	 held	 by	 the	 facilitator.	 These	 cards	were	 based	 on	
the	 factors	 identified	 in	 the	 vignettes,	 and	 other	 known	 factors	
from	 the	 literature	 review	 which	 were	 not	 included	 in	 the	




was	 selected	 because	 task	 based	 activities	 can	 stimulate	
discussion	 in	 focus	 groups	 in	 a	 way	 that	 asking	 open	 ended	
questions	cannot	(Krueger	and	Casey,	2000).	The	exercise	was	not	
intended	to	be	a	formal	ranking	exercise.	The	task	was	modelled	
in	 the	 style	 of	 an	 X-Factor	 results	 show	 (reality	 TV	 show)	 with	
participants	asked	to	work	as	a	group	with	the	cards	used	during	
the	 second	 stage	of	 the	 focus	group	eliminating	one	 factor	 from	
the	bottom	two	each	time	to	get	ultimately	get	to	a	‘winner’.	The	
X-Factor	was	 chosen	as	 it	was	 the	highest	 rated	UK	 talent	 series	
within	the	16-34	age	range	(Freemantle	Media	UK,	2014)	and	was	





The	 topic	 guide	 ended	with	 thanking	 participants	 for	 their	 time,	
setting	 it	 in	 the	 context	 of	 what	 will	 happen	 next	 and	 how	 the	
outputs	will	 be	 used,	 and	 offering	 them	 the	 opportunity	 to	 add	
anything	else	before	the	group	concluded.	The	guide	was	written	
as	a	full	script	to	act	as	an	aide	memoir	for	the	facilitator	however	
it	 was	 planned	 only	 to	 read	 the	 ground	 rules	 and	 vignettes	
verbatim.	 The	 topic	 guide	was	 reviewed	by	 the	PhD	 supervisors,	
and	tested	informally	on	research	colleagues	who	have	experience	
of	 working	 with	 young	 people	 to	 check	 comprehension	 and	






of	 these	 data	 are	 lost	 in	 the	 absence	 of	 appropriate	methods	 of	
analysis”	(Frankland	and	Bloor,	1999:144-5).	
	
Thematic	 analysis	was	 selected	 as	 the	 core	 approach	 to	 analyse	
the	 focus	 group	 data	 recognising	 that	 this	 is	 one	 of	 the	 three	
‘main	methods’	 for	analysing	 focus	group	data	 (Silverman,	2014)	
and	is	the	method	most	closely	aligned	to	that	used	to	design	the	
focus	 group.	 In	 managing	 and	 analysing	 the	 data	 the	 process	
outlined	 in	 the	 figure	 5.1	 was	 adopted	 to	 ensure	 the	 effective	
management	 and	 analysis	 of	 the	 focus	 group	 data.	 This	 was	





Both	 Saldana	 and	 Morgan	 recognise	 the	 need	 to	 ensure	 that	
coding	 and	 analysis	 are	 appropriate	 for	 and	 aligned	 to	 the	
research	 question	 and	 the	 information	 requirements	 of	 the	
project	 (Morgan,	 1997,	 Saldana,	 2013).	 In	 taking	 forward	 the	
preliminary	 coding	 undertaken	 on	 the	 hard	 copy	 transcripts,	
consideration	 was	 given	 to	 the	 coding	 approach	 that	 would	 be	
applied	 and	 its	 impact	 on	 the	 analysis.	 The	 specific	 purpose	 of	























Descriptive	 coding	was	 used	 to	 focus	 on	 specific	 properties	 that	
were	discussed	in	respect	of	the	tests	and	services.	Many	of	these	





Emotion	 coding	 and	 values	 coding	 were	 used	 to	 capture	 the	
participants’	beliefs,	feelings	and	perceptions	on	their	views	of	the	
specific	attributes	and	properties.	Saldana	draws	attention	to	the	
importance	 of	 coding	 both	 values	 and	 emotions	 in	 research	 as	
participants’	 actions	 and	 views	 cannot	 be	 separated	 from	 one	
another.	 “Since	emotions	are	a	universal	human	experience,	our	


















In	 order	 to	 identify	 ways	 to	 access	 the	 population,	 a	 group	 of	
experienced	 researchers	 in	 the	 field,	 based	 at	 the	 Studies	 in	
Adolescent	 Sexual	 Health	 (SASH)	 Group	 at	 Coventry	 University,	
were	 approached	 for	 additional	 advice	 into	what	worked	well	 for	
them	 when	 gaining	 access	 to	 young	 people	 to	 participate	 in	
research.	Their	suggestions	included	targeting	the	education	sector	
(sixth	 form,	 further	 education	 colleges	 and	 universities)	 and	 the	
voluntary	sector	(youth	projects	and	the	youth	organisations).	
	
Recognising	 the	 reliance	 on	 participants	 choosing	 to	 opt	 in,	
approaches	were	made	in	a	staged	way	to	enable	the	management	
of	 recruitment	 to	 ensure	 a	 spread	 of	 responses	 across	 the	 age	










Initial	 contact	 was	 made	 with	 organisations	 working	 with	 the	
younger	end	of	the	age	range	including	schools	with	sixth	forms	and	
youth	organisations.	A	 standard	cover	 letter,	 along	with	a	 copy	of	





Once	 the	 first	 two	 focus	 groups	were	 undertaken,	 the	 participant	
demographic	 information	was	 reviewed	which	 confirmed	 that	 the	
majority	 of	 participants	 were	 aged	 16-17,	 therefore	 subsequent	
organisations	targeted	enabled	the	recruitment	of	participants	over	
the	age	of	18,	including	further	education	colleges	and	universities.	




to	 one	 another	 in	 advance)	 and	 considering	 the	 methodological	
literature	 on	 this	 topic	 the	 author	 decided,	 if	 possible,	 to	 seek	
participants	who	were	not	 part	 of	 a	 pre-existing	 group	 to	 explore	
whether	this	was	significant	in	the	findings.		
	
The	 recruitment	 of	 participants	 through	 organisations	 addressed	
some	 of	 the	 key	 issues	 with	 group	 composition,	 particularly	 by	
recruiting	through	organisations	where	young	people	already	share	





than	 originally	 anticipated,	 with	 difficulties	 in	 securing	 access	 to	
relevant	people	following	the	 initial	contact	 letter	by	telephone	or	
by	 email.	 Non-response	 was	 a	 greater	 issue	 than	 negative	
responses.	The	 initial	group	to	engage	was	a	youth	organisation,	a	
pre-existing	group	of	young	people	who	meet	fortnightly.	Members	
of	 the	 youth	 organisation	were	 identified	 as	 predominantly	 16-17	
years	 old	 and	 female	 during	 the	 initial	 organisation	 of	 the	 group.	
The	final	two	focus	groups	were	recruited	by	online	advertising	at	a	
university.	 Participants	 opted	 into	 both	 focus	 groups,	 the	 youth	





organising	 a	 focus	 group	 –	 timing,	 venue,	 ‘hosting’	 the	 group,	
observers	and	co-moderators	and	 recording	 (Finch	et	al.,	2014).	 It	








their	 time.	 A	 record	 of	 the	 voucher	 distribution	 was	 kept	 for	
research	 audit	 and	 to	 meet	 current	 institutional	 financial	
regulations.		
	
Given	 the	 amount	 of	 information	 being	 imparted,	 accompanying	
written	materials	were	developed	for	participants.	These	were:	
• A	printed	summary	slide	of	each	of	the	three	vignettes,	
• A	 comparative	 table,	 drawing	 out	 the	 key	 features	 of	 the	
pathway,	and	what	happens	in	each	of	the	three	vignettes.		
	
The	 written	 materials	 were	 on	 the	 table	 ready	 for	 each	 of	 the	
participants	at	the	start	of	the	focus	group.		
	
The	author	was	 the	 facilitator	 for	 all	 four	 focus	 groups.	 The	 room	
was	organised	so	that	seating	was	in	a	circle	and	the	facilitator	sat	
with	 the	group	as	part	of	 the	 circle.	 The	 focus	 groups	were	audio	
recorded	 using	MP3	 equipment.	 All	 equipment	was	 tested	 before	
each	 focus	 group	 then	 placed	 centrally	 within	 the	 group	 to	





approximately	 32,500	words	 and	 83	 pages	 of	 data	 for	 qualitative	
analysis.	
	
In	 total	 there	were	21	participants	across	 the	 four	 focus	groups,	a	




































process	 provided	 an	 important	 key	 part	 of	 data	 familiarisation	
stage.	 All	 focus	 group	 data	 was	 transcribed	 by	 the	 author,	 thus	
providing	 a	 valuable	 opportunity	 to	 listen	 to	 the	 recordings	 first	
hand,	 and	 therefore	 becoming	more	 familiar	with	 the	 contents	 in	
preparation	 for	 the	 main	 analysis.	 Notes	 on	 non-verbal	






excluding	 the	 introduction	 and	 conclusion	 given	 by	 the	 facilitator,	
and	 the	 use	 of	 vignettes	 read	 out	 to	 all	 four	 focus	 groups.	 Notes	
were	made	in	the	transcripts	for	any	other	aspects	of	the	recording	
e.g.	 laughter,	 non-verbal	 communication	 noted	 by	 the	 researcher	




all	 the	 recordings	 and	 annotating	 any	 corrections	 needed	 in	 hard	
copy,	 prior	 to	 updating	 the	 electronic	 copy.	 This	 review	 process	











and	 observational	 statements	 separately	 to	 distinguish	 between	
points	of	 clarification	and	views	on	potential	 factors.	 	An	 iterative	
approach	 was	 adopted,	 reviewing	 each	 focus	 group	 transcript	 in	
order.	 On	 completion	 of	 each	 focus	 group	 transcript	 review,	 the	
outputs	were	entered	into	Mindjet	MindManager.	This	enabled	the	











This	 structure	 was	 then	 input	 into	 NVivo	 10	 for	 Mac	 (QSR	






initial	 codes	made	 on	 the	 hard	 copy	which	were	 used	 to	 develop	
the	 draft	 coding	 framework.	 This	 provided	 the	 opportunity	 to	
identify	 areas	 coded	 differently	 and	 then	 to	 consider	 the	 reasons	
for	 this.	 One	 important	 point	 to	 note	 is	 that	 the	 ranking	 exercise	
undertaken	 at	 the	 end	 of	 the	 focus	 group	 to	 stimulate	 discussion	
was	 coded	 in	 a	 slightly	 different	 way	 to	 the	 main	 focus	 groups.	
Specifically,	coding	focused	on	statements	made	by	the	participants	












• Rationalisation	 of	 codes	 where	 grouping	 could	 be	 made	
without	loss	of	fidelity;	
• Realignment	of	sub-codes	within	coding	framework;	

















































Data	 summaries	 in	 conjunction	 with	 matrix	 coding	 queries	 were	
used	 to	 structure	 the	 analysis.	 Starting	 initially	 with	 the	 factors	




• variation	 within	 and	 between	 groups	 in	 their	 views	 of	 a	
particular	sub-theme,	




This	 enabled	 the	 findings	 to	 be	 grouped	 into	 three	 overarching	
categories	for	further	exploration,	outlined	in	detail	in	section	5.2.6.	
Participant	 questions	 was	 established	 as	 a	 separate	 theme	
recognising	their	potential	contribution	to	the	development	of	the	
background	 and	 introductory	 information	 for	 the	 DCE,	 as	 well	 as	
identifying	potential	 attributes	 and	 levels.	 The	discussion	 seeks	 to	
build	 on	 this,	 offering	 explanation	 for	 the	 linkages	 found	 and	
exploring	the	impact	of	the	use	of	the	focus	group	method	including	






coding	 the	 focus	 groups	 as	 outlined	 in	 table	 5.5.	 The	 categories	
build	 on	 each	 other	 but	 are	 presented	 in	 this	 section	 in	 order	 of	
frequency.	 Firstly,	 exploring	 the	 individual	 product/	 service	
characteristics	 of	 sexual	 health	 services	 and	 whether	 the	 focus	
group	participants	considered	them	important	and	how	they	traded	
between	 them.	 The	 second	 category	 built	 on	 this	 and	 considered	
the	 impact	 of	 values,	 beliefs,	 perceptions	 and	 emotions	 in	 the	
participants’	 consideration	of	 importance	–	whether	 there	was	an	
indicator	 as	 to	 what	 drives	 their	 view	 on	 importance.	 The	 final	




(codes)	 are	highlighted	 in	bold	 and	 italics,	with	 supporting	quotes	







Time	 to	 result	 was	 the	 most	 consistently	 discussed	 sub-theme	
across	 all	 four	 focus	 groups.	 The	 vignettes	 presented	 three	
pathway	options	with	time	to	result	at	15	minutes,	7	days	and	14	
days.	The	view	across	all	 four	groups	was	generally	consistent	 in	





“I	 think	 what	 I	 like	 about	 this	 because	 I’ve	 been	 going	 on	 about	 it	 is	
timing,	 I	mean	15	minutes	 compared	 to	14	days	and	7	days	 like	 I’ll	 be	
more	likely	to	use	that	service	because	you	get	it	in	…”	FG2,	Male,	17	
	
However,	 this	 was	 by	 no	 means	 universal	 with	 one	 participant	
equating	time	to	result	with	accuracy,	indicating	a	preference	for	a	
longer	waiting	time:	

















Consideration	 of	 trade-offs	 for	 time	 to	 result	were	 highlighted	 by	
participants,	 particularly	 test	 accuracy,	 range	 of	 tests	 and	
knowledge	of	the	HCP:	
	





those	14	days	or	 those	15	minutes	but	 I’d	 rather	 it	be	15	minutes,	erm	





that	 is	 going	 to	 be	 telling	 you	 has	 more	 knowledge	 surely…”	 FG1,	
Female,	Age	16	or	17	
	
“Although	 it’s	 more	 convenient	 considering	 the	 fact	 you	 get	 to	 do	
everything	over	the	Internet	and	if	that	takes	seven	days	and	this	takes	
14	 days	 from	 your	 home	 it’s	 always	more	 convenient	 and	 it	 saves	 you	















These	 findings	 are	 in	 line	 with	 findings	 from	 other	 published	
studies	which	 recognise	 that	 reduced	waiting	 time	enhances	 the	
acceptability	 of	 a	 service	 e.g.	 self-management	 within	 a	 GUM	
clinic	 (Baraitser	 et	 al.,	 2011,	 Fernando	 and	 Thompson,	 2013,	
Martin	 et	 al.,	 2013),	 within	 mainstream	 sexual	 health	 services	 -	




Reduced	 time	 to	 result	has	been	 found	 to	be	both	an	 important	
factor	 in	 acceptability	 of	 HIV	 testing	 in	 community	 locations	
(Guenter	 et	 al.,	 2008)	 and	 HIV	 testing	 in	 general	 (Peralta	 et	 al.,	
2007,	 Tomnay	 et	 al.,	 2014,	 Turner	 et	 al.,	 2013),	 although	 other	
research	has	found	that	in	the	case	of	rapid	testing	for	HIV	time	is	
preferable	 to	 enable	 an	 individual	 to	 come	 to	 terms	 with	 the	
impact	of	the	result	outcome	(Cohall	et	al.,	2010).		
	
Test	 accuracy	 also	 featured	 consistently	 in	 the	 discussion	 as	 an	
important	 factor	 for	young	people.	On	reflection,	 this	 sub-theme	
stands	out	because	it	was	introduced	into	the	discussion	by	young	




















“I	 think	 it’s	 not	 really	 something	 that	 you	 can	 have	 that	 isn’t	 accurate	
because	 it’s	 like	 obviously	 a	 lot	 of	 the	 time	 you	 don’t	 recognise	 the	












Consideration	 was	 given	 to	 what	 accuracy	 means	 in	 terms	 of	
results,	 this	 was	 expressed	 by	 participants	 in	 terms	 of	 false	
negatives	 and	 false	 positives.	 Concerns	 erred	 slightly	 more	
towards	 false	negatives,	 i.e.	being	 told	 that	 you	do	not	have	 the	
disease	when	you	actually	do:	
	
“Well	 the	 reverse	 of	 that	 as	well	 as	 if	 it	 comes	 back	 negative	 and	 you	
actually	have	one…”	FG1,	Male,	17	
	














or	gonorrhoea,	and	 then	 they	 just	go	 to	 the	doctors	and	 this	would	be	
pointless…”	FG2,	Male,	17	
	









Participants	 highlighted	 their	 ways	 of	 compensating	 for	 accuracy	
concerns	 through	multiple	 testing	 and	 testing	 through	more	 than	
one	 route.	 In	 their	 comments,	 there	 was	 a	 clear	 underlying	
perception	 that	 the	 self-test	 would	 be	 less	 accurate	 than	 a	 test	
undertaken	at	a	clinic:	














Again,	 the	 desire	 for	 an	 accurate	 test	 result	 among	 individuals	
considering	 testing	 for	 STIs	 had	 been	 identified	 in	 other	 peer	
reviewed	research,	although	the	number	of	studies	exploring	this	








all	 four	 focus	groups.	Participants’	 lack	of	prior	knowledge	about	
STIs	 was	 a	 common	 sub-theme	 in	 discussing	 the	 range	 of	 tests,	
particularly	whether	they	would	be	experiencing	symptoms:	
“Yeah	 definitely	 if	 you	 don’t	 know	 what	 you	 had	 and	 you	 had	 no	




“I	 think	 what	 you’re	 getting	 tested	 for	 cos	 even	 though	 those	 two	 do	










“Yet	 people	might	 interpret	 that	 as	 they’re	 the	only	 two	 you	 could	get	
because	there	are	some	people	who	might	actually	think	wow	these	are	
the	only	 two	which	 I	 could	get	because	 I	 couldn’t,	 they	might	not	even	
bother	 to	 test	 for	 anything	 else	 just	 because	 that’s	 negative…”	 FG2,	
Female,	17	
	
“I	 think	 the	choice	here	 is	not	much,	you	 just	get	 tested	 for	 just	 two	of	
the	 STIs	 so	 that	 again	 is	 something	 that	 has	 to	 be	 taken	 into	
consideration	you	may	have	something	else”	FG3,	Male,	24	
	
Peace	 of	 mind	 (reassurance)	 was	 identified	 as	 being	 the	
overarching	reason	for	participants’	preference	for	more	tests:	
“…I’d	 be	 very	 conscious	 of	 if	 I’m	 not	 getting	 tested	 for	 certain	 things”	
FG2,	Male,	17	
	
“…	 but	 then	 you	 have	 two	 out	 of	 so	many	 that	 haven’t	 been	 tested,	 I	










Range	of	 tests	was	 identified	as	an	attribute	 in	both	Miners	and	
colleagues	 and	 Llewellyn	 and	 colleagues	 DCE	 exploring	 user	
preferences	for	testing	for	STIs.	They	 identified	participants	were	






such	 that	 the	 range	of	STIs	 tested	 for	 in	a	GUM	clinic	are	a	core	
four	 (Chlamydia,	 Gonorrhoea,	 HIV	 and	 Syphilis),	 and	 any	 further	
tests	 undertaken	 are	 selected	based	on	 the	 risk	 exposure	of	 the	
patient	 (BASHH,	 2006).	 The	 qualitative	 research	 undertaken	 by	
Llewellyn	 and	 colleagues	 to	 enable	 the	 development	 of	 the	 DCE	
highlights	the	range	of	tests	offered	as	being	a	factor	in	choosing	
to	attend	a	GUM	clinic	 rather	 than	a	GP	 (Llewellyn	et	 al.,	 2012).	
This	was	also	borne	out	in	a	study	by	Hambly	and	Luzzi	exploring	
patient	preferences	 for	GUM	or	GP	based	sexual	health	services.	





Peace	 of	 mind	 (reassurance)	 was	 also	 reflected	 in	 considering	
access	to	a	healthcare	professional:	
“I	 think	 a	 disadvantage	 of	 this	 one	 would	 be	 that	 like	 medical	
reassurance	 because	 you’re	 not	 really	 in	 contact	 with	 a	 medical	
professional	so…”	FG1,	Female,	age	16	or	17	
	







“I	 think	 if	 for	 me	 it’s	 more	 comfortable	 to	 get	 professional	 walk	 you	
through	the	processes	and	and	to	give	you	kind	of	psychological	support	
























Participants	 provided	 insight	 into	 access	 to	 a	 healthcare	
professional	generally	within	the	pathway,	access	to	a	health	care	





In	 respect	of	sample	collection	method	 the	 input	of	an	HCP	 into	
taking	 the	 sample	 was	 not	 considered	 important	 with	 one	
reference	to	HCP	input	being	beneficial:	
	
“…	 so	 there’s	 less	 privacy	 but	 maybe	 they	 know	 what	 they’re	 doing	




This	 is	 borne	 out	 by	 the	majority	 of	 published	 studies	 that	 have	
found	 self-sampling	 and/	 or	 self-testing	 to	 be	 acceptable	 in	
asymptomatic	patients	as	summarised	in	table	4.9.	
	
Whereas	 being	 able	 to	 access	 a	 healthcare	 professional	 when	














including	 Bilardi	 and	 colleagues	 who	 found	 that	 HIV	 self-testing	
would	 be	 valuable	 but	 could	 not	 replace	 existing	 testing	 routes	
due	to	the	lack	of	professional	expertise	and	support	(Bilardi	et	al.,	
2013),	 and	 Greacen	 and	 colleagues	 who	 found	 that	 those	 not	
interested	 in	HIV	self-testing	cited	not	wanting	to	be	alone	when	
getting	results	as	a	limiting	factor	(Greacen	et	al.,	2013).	Prost	et	al	
(2007)	 found	 that	 post-test	 support	 was	 a	 limiting	 factor	 in	
outreach	 for	 HIV	 rapid	 testing.	 In	 considering	 more	 general	 STI	
testing	support	for	individual’s	receiving	a	positive	result	has	been	
identified	 as	 a	 concern	 for	 the	 acceptability	 of	 internet	 based	




Despite	 the	 desire	 to	 have	 access	 to	 a	 healthcare	 professional	
when	they	got	their	results	how	they	were	notified	of	their	results	





















Considerable	 research	 has	 been	 undertaken	 on	 patient	
preferences	 for	 results	 notification	 for	 STIs,	 this	 has	 found	 that	
people	 want	 to	 be	 notified	 of	 all	 results	 (including	 negatives)	
rather	than	just	positives	(Brown	et	al.,	2008,	Miners	et	al.,	2012,	
Patel	 et	 al.,	 2006),	 and	 generally	 prefer	 a	 remote	 notification	
method	 such	 as	 text	 for	 negative	 results	 and	 in	 person	method	




A	 number	 of	 studies	 have	 looked	 at	 preference	 for	method	 and	
results	 (based	 on	 the	 number	 of	 studies)	 have	 identified	 a	













“I	 couldn’t	 take	 anyone	 seriously	 if	 I	 was	 on	 my	 bed	 [with	 someone]	
telling	me	I’ve	got	HIV”	FG1,	Male,	17	
	




you’re	 talking	 to	 a	 real	 person,	 anything	 that	we’re	 agreeing	here	 it	 is	
nice	to	talk	to	a	real	person”	FG3,	Male,	18	
	
This	 is	 in	contrast	 to	a	small	number	of	specific	studies	exploring	
telemedicine	 options	 within	 sexual	 health	 services	 for	 young	
people.	Garrett	and	colleagues	found	that	young	people	preferred	
in	 person	 consultation	 (85%),	 compared	with	 63%	 for	 telephone	
consultation	 and	 29%	 video	 consultation	 (Garrett	 et	 al.,	 2011).	
This	 view	was	different	 in	a	 subsequent	 study	considering	young	
people	 in	 rural	 locations	 who	 identified	 that	 telephone	




Within	 the	 context	 of	 access	 to	 a	 healthcare	 professional	 two	
other	 related	 attributes	 were	 discussed	 knowledge	 of	 the	
healthcare	professional	(specialist	knowledge	of	STIs)	and	type	of	
healthcare	 professional	 (e.g.	 doctor,	 nurse	 or	 pharmacist).	 The	




positive	 result	 and	 the	person	 you	go	 to	 see	has	 rather	 vague	or	 basic	
knowledge…”	FG1,	Male,	16	
	










reflected	 in	 the	 impact	of	 views	on	 trust	 in	 the	NHS.	 In	effect,	 it	











Although	 the	 views	 were	 mixed	 on	 type	 of	 healthcare	
professional,	 when	 it	 came	 to	 the	 group	 ranking	 task,	 type	 of	





“…specialist	 would	 always	 be	 better	 but	 then	 again	 erm	 it’s	 not	 a	 big	
deal	I	don’t	think”	FG3,	Male,	24	
	
“I	 would	 prefer	 a	 doctor	 compared	 to	 a	 nurse	 I	 think	 they	 are	 more	




of	 healthcare	 professional,	 Baker	 and	 colleagues	 found	 that	
patients	were	 comfortable	 consulting	with	 GPs	 on	 STIs,	 and	 this	
increased	 if	 the	GP	had	a	 specialist	 qualification	 in	 sexual	 health	
and	reduced	if	they	knew	the	GP	socially	(Baker	et	al.,	2013)	whilst	





the	most	 important	 factors	 identified	 by	 patients	 in	 considering	
their	 preferences	 for	 GUM	 services	 compared	 with	 GP	 services	
(Hambly	 and	 Luzzi	 2006),	 a	 view	 supported	 by	 the	 findings	 of	
Miners	 and	 colleagues	 and	 Llewellyn	 and	 colleagues	 who	 found	
that	 ‘perceived	 expertise’	 was	 a	 key	 preference	 expressed	 by	
people	when	choosing	between	GUM	and	GP	services	(Miners	et	





was	 one	 of	 the	 least	 valued	 aspects	 of	 sexual	 health	 services	
(Hitchings	et	al	2009).		
	
Through	 the	 focus	 group	 discussions	 an	 overlap	 between	 the	
location	of	treatment	(outlined	 in	the	vignettes	as	completion	of	

























No	 studies	 are	 thought	 to	 have	 published	 results	 specifically	
exploring	preferences	for	where	people	attend	for	treatment	once	
they	 have	 had	 a	 positive	 test	 result	 or	 how	 they	 access	 a	
healthcare	 professional	 for	 treatment	 outside	 of	 the	 studies	
exploring	 preferences	 for	 accessing	 sexual	 health	 services	 in	
general	terms	outlined	previously.		
	
Location	of	 test	 (e.g.	 self-test	at	home,	 self-sample	at	home	and	
send	 away	 for	 analysis,	 attend	GP	 practice,	 attend	 sexual	 health	
clinic)	 was	 discussed	 and	 was	 seemed	 to	 be	 considered	 an	
attribute	 of	 lower	 importance	 through	 the	 discussions	 than	
location	 of	 treatment,	 however	 through	 completing	 the	 ranking	
exercise	 as	 a	 group	 this	 was	 reversed.	 Within	 these	 discussions	
participants	 focused	 more	 on	 location	 of	 test	 as	 being	 the	
collection	point	for	the	test	e.g.	shops	or	ordering	online,	with	the	
actual	 location	 that	 the	 test	 was	 undertaken	 garnering	 more	
discussion	in	connection	with	sample	collection	method:	
	





up	 you	 know	 the	 test	 product	 that	 everyone	 would	 see	 what	 I’m	 you	
know,	what	I’m	buying”	FG4,	Female,	21	
	
Discussion	 took	 place	 within	 Focus	 Group	 2	 about	 the	 need	 to	
make	STI	 testing	kits	more	widely	available	 to	 reduce	 the	stigma	
associated	 with	 testing	 including	 suggestions	 of	 schools,	 youth	
centres	and	public	toilets:	
	














Finally,	how	 you	 tell	 your	 partners	was	 considered	 by	 the	 focus	
group	participants	as	being	of	lower	importance	than	the	majority	
of	 other	 attributes	 in	 the	 discussions	 and	 it	 was	 ranked	 in	 the	
lower	 half	 of	 factors	 in	 the	 ranking	 exercise.	 The	 discussions	
highlighted	 mixed	 views	 on	 partner	 notification	 ranging	 from	
participants	 expressing	 a	 view	 that	 they	 should	 not	 be	 told	 via	
text,	indicating	a	preference	for	telling	partners	face-to-face:	
	



















Whereas	 other	 participants	 acknowledged	 a	 preference	 for	 a	
clinician	to	notify	their	partners	for	them:	
“I	 quite	 like	 the	 part	 where	 the	 doctor	 will	 tell…	 notify	 your	 partner	





have	to	 tell	your	partners	yourself	but	 in	 the	previous	scenario	you	can	
help	from	the	advisors”	FG4,	Female,	age	unknown.	
	
Apoola	 and	 colleagues	 identified	 that	 preferences	 for	 partner	








e-card	 compared	 to	 direct	 notification	 (Kerani	 et	 al.,	 2013),	 and	
Shivasankar	 and	 colleagues	 noted	 a	 preference	 for	 traditional	
partner	referral	(Shivasankar	et	al.,	2008).		
	
Gursahaney	 and	 colleagues	 found	 that	 patient	 delivered	 partner	
notification	 was	 more	 successful	 where	 people	 were	 in	
established	 relationships	 (Gursahaney	 et	 al.,	 2011),	 a	 view	





This	 completes	 the	 summary	 of	 the	 findings	 into	 participants’	
views	on	product/	service	characteristics	introduced	into	the	focus	
groups	by	the	 facilitator,	either	 through	the	vignettes	or	 through	
the	 subsequent	 group	questions.	Of	 note	 is	 that	 participants	 did	
introduce	two	factors	themselves	that	had	not	been	identified	by	
the	 facilitator	 prior	 to	 running	 the	 focus	 groups	 –	 data	 security	
and	staff	attitude.		
	
Data	 Security	 and	 aspects	 of	 it	 such	 as	 data	 sharing	 with	 other	
health	 services,	 and	 security	 on	 smartphones	 was	 raised	 by	
participants	 in	 all	 four	 focus	 groups.	 The	 issues	 ranged	 from	 the	
security	of	the	app/eHealth	clinic	itself:	






to	 be	 confidential	 your	 friends	 might	 see	 it	 or	 something	 and…”	 FG4,	
Female,	age	unknown	
	










“I	 think	 when	 someone	 don’t	 want	 other	 people	 to	 know	 about	 them	
going	 to	 see	 the	 clinic	 they	 won’t	 do	 it	 online,	 just	 everything’s	 got	 a	




Three	 studies	 identified	 in	 the	 literature	 review	 identified	
















she	was	worried	 that	 she	 had	 an	 STI,	 erm	 and	 like	 the	woman	 at	 the	
counter	was	 like	 ‘oh	 is	 this	 for	 you’	 and	 she	made	 like	 really	 sarcastic	
comments	and	that	really	puts	people	off	like,	I	think	people	who	work	in	





Staff	 attitude,	 for	 example,	 friendliness	 and	 empathy,	 has	 been	
identified	 as	 important	 in	 a	 number	 of	 studies	 (see,	 for	 example,	
Hambly	 and	 Luzzi	 (2006);	 Ingram	 and	 Salmon	 (2007);	 and	 Knapp	
and	Anaya	(2010)).	Staff	gender	was	also	identified	as	an	important	





product/	 service	 characteristics,	 their	 preference	was	 considered	
in	 the	 context	 of	 their	 broader	 statements	 and	 the	 group	
discussion.	 This	broadly	 fell	 into	 two	 themes	 related	 to	 impact	–	
emotions,	beliefs	and	perceptions	(the	emotional	impact)	and	the	
tangible	impact	of	testing	(the	user	impact)	Again,	a	matrix	coding	
query	 was	 used	 to	 map	 frequency	 of	 codes	 falling	 into	 these	
themes.	Starting	with	the	emotional	impact	theme,	worry	was	the	
emotion	mentioned	most	 frequently	 for	 making	 a	 choice	 in	 the	























to	go	a	clinic	whereas	 if	 you	don’t	and	you’re	 just	worried	 the	 internet	
one	might	make	more	sense…”	FG3,	Male,	18	
	





a	 particular	 product/	 service	 characteristic	 but	 was	 viewed	 by	
participants	 as	 a	 significant	 consideration	 in	 making	 a	 choice	 to	
use	a	service:	
“But	 then	 you	 could	 argue	 if	 you’re	 having	 it	 ordered	 to	 your	 house	
somebody	 might	 not	 like	 that	 because	 if	 someone	 else	 like	 sees	 it,	
whatever	then…	FG1,	Female,	17	
	
“you	can	get	privacy	as	well,	 like	 I	 said	before,	 if	 you	are	going	 into	a,	
walking	 into	 a	 clinic	 you	 might	 not	 want	 someone	 to	 see	 you,	 some	
people	 don’t	 like,	 feel	 like	 awkward,	 the	 might	 not	 want	 to	 speak	 to	
anyone	 about,	 like	 a	 nurse	 or	 a	 doctor	 so	 they	 might	 rather	 do	 it	
themselves”	FG2,	Female,	17	
	
“…	 you	 get	 to	 kind	 of	 do	 everything	 almost	 anonymously	 like	 over	 the	
internet	 you	 kind	 of	 feel	 that	 you’re	 anonymous	 so	 you	 kind	 of	 get	 to,	
you	 don’t	 talk	 to	 another	 human	 being	 about	 it	 or	whatever	 until	 you	







which	 makes	 it	 all	 the	 sense	 but	 then	 again	 when	 you’re	 talking	 to	
someone,	when	you’re	talking	erm	talking	to	someone	personally…	and	
you’re	 sure	 the	 information	 will	 be	 confidential	 I	 think	 it	 always	 feels	







perception	 of	 others.	 Coding	 for	 embarrassment	 included	
consideration	of	situations	described	by	participants	as	awkward,	

















“I	 can	 see	 how	 this	 could	 be	 very	 advantageous	 for	 people	 who	 are	
























































of	 convenience	 featured	 in	 Focus	 Groups	 1	 and	 2	 it	 was	 only	
explicitly	discussed	 in	Focus	Groups	3	and	4.	This	may	be	due	 to	
the	age	of	 the	participants	with	 the	 first	 two	 focus	groups	being	
comprised	 of	 16	 and	 17	 year	 olds,	 and	 3	 and	 4	 18-23	 year	 olds.	















like	 you	 have	 to	 go	 speak	 to	 the	 professional…”	 FG4,	 Female,	 age	
unknown	
	
“I	 find	 the	 internet	 testing	 is	 like	 convenient	 because	 you	 can	 do	
yourself…”	FG4,	Female,	19	
	
Convenience	was	also	discussed	 in	respect	of	 location	to	a	 lesser	
extent:	













Little	 or	 no	 consideration	 was	 given	 to	 personal	 cost	 by	 the	












The	 third	 and	 final	 category	 relates	 to	 the	 questions	 asked	 by	
participants	in	order	to	inform	their	thoughts	and	decisions	as	part	




















The	 categories	 build	 on	 each	 other,	 starting	 with	 participant	
questions,	 to	 inform	 understanding	 and	 assessment	 of	 user	







The	 final	 data	 obtained	 from	 the	 focus	 group	 was	 a	 ranking	
exercise	 of	 the	 long	 list	 of	 potential	 product/	 service	
characteristics.	As	outlined	in	more	detail	above	in	section	5.2.2.4,	
the	decision	to	include	this	was	as	an	enabler	for	discussion	on	the	
importance	 of	 characteristics.	 The	 level	 of	 engagement	 in	 the	
earlier	focus	group	questions	was	not	anticipated	when	designing	
them,	 which	 in	 part	 made	 this	 question	 less	 important	 as	
participants	 had	 outlined	 their	 views	 extensively	 in	 response	 to	
earlier	 questions.	 This	 in	 itself	 also	 made	 for	 much	 quicker	









FG1	 FG2	 FG3	 FG4	 Total	
1.	 Range	of	STIs	 3	 2	 1	 3	 9	
2.	 How	long	it	takes	to	get	
result	
1	 3	 5	 5	 14	
3.	 Sample	Collection	
Method	
7	 1	 3	 8	 19	
4.	 Accuracy	 6	 6	 7	 1	 20	
4.	 Access	to	HCP	(Result	&	
Treatment)	
4	 5	 2	 9	 20	
6.	 Treatment	Consultation	
Method	
5	 4	 9	 4	 22	
7.	 Knowledge	of	HCP	 2	 12	 11	 2	 27	
8.	 Where	you	do	the	test	 11	 8	 6	 6	 31	
9.	 How	you	tell	partners	 10	 7	 8	 7	 32	
9.	 Where	you	go	to	get	
treatment	
8	 10	 4	 10	 32	
11.	 Type	of	HCP	 9	 11	 10	 12	 42	









organising	 themselves	 to	 answer	 the	 question	 and	 how	 they	
selected	the	final	order.	FG1	and	FG3	had	a	clearly	identified	order	
of	 selection,	 with	 the	 exception	 of	 FG1	 where,	 on	 analysing	 the	
recording	afterwards,	it	was	not	clear	on	the	order	of	the	third	and	
fourth	 most	 important	 characteristic.	 FG2	 grouped	 the	
characteristics	 into	three	groups	–	a	bottom	four,	middle	four	and	












information.	 The	 themes	 identified	 from	 the	 thematic	 analysis	 of	
the	 data	 provided	 an	 innovative	 method	 of	 supporting	 the	 DCE	
development	 incorporating	 the	 respondent	 perspective	 on	 a	
number	of	levels:	
• Providing	insight	into	young	people’s	knowledge	of	STIs	and	




to	 get	 treatment	 both	 in	 terms	 of	 attributes	 and	 potential	
levels.		





the	 technological	advances	 that	are	 feasible	 in	 the	next	3-5	years.	
These	 include	 self-testing	 via	 a	mobile	 phone,	 online	 consultation	
for	chlamydia	and	an	alternative	method	of	partner	notification.	 It	
also	 provides	 this	 within	 the	 context	 of	 a	 whole	 STI	 testing	 and	
treatment	 pathway	 as	 opposed	 to	 the	 current	 published	 studies	





undertaken	 with	 young	 people,	 rather	 than	 ‘service	 users’,	
including	 providing	 views	 from	 the	 broader	 population	 who	 have	
not	 previously	 used	 STI	 testing	 services.	 This	 is	 particularly	
important	 given	 that	 uptake	 by	 young	 people	 is	 the	 key	 factor	 in	
diagnosing	 and	 treating	 STIs	 for	 reducing	 transmission	 rates	 and	
preventing	long	term	complications.		
	
The	 findings	 of	 the	 focus	 group	 study	 support	 the	 overall	 general	
direction	 proposed	 in	 both	 general	 health	 policy	 and	 the	 national	
strategy	 for	 sexual	 health	 that	 seek	 to	 incorporate	 technological	
advances	 into	service	delivery,	this	was	demonstrated	through	the	
expression	 of	 support	 for	 remote	 testing	 options.	 However,	 the	
focus	 groups	 did	 not	 wholly	 embrace	 all	 of	 the	 options,	 most	




first	 is	 that	 convenience	 sampling	 was	 used	 to	 recruit	 the	 focus	
group	participants.	The	impact	that	this	might	have	on	the	validity	
and	 generalizability	 and	 the	 steps	 taken	 to	 limit	 this	 impact	 have	
been	described	in	section	5.2.2.	The	second	is	that	only	the	author	
was	 present	 in	 the	 focus	 groups	 and	 her	 primary	 focus	 was	 the	
facilitation	of	the	group.	Whilst	 it	was	 important	 for	the	author	to	
demonstrate	 her	 competence	 as	 a	 researcher	 and	 no	 verbal	
communication	was	lost	owing	to	the	focus	groups	being	recorded,	






However,	 the	 opportunity	 to	 capture	 this	 fully	 was	 not	 possible.	
Reflecting	 on	 the	 non-verbal	 communication	 observed	 it	 is	 not	
believed	that	a	detailed	recording	of	the	non-verbal	communication	
would	 have	 affected	 the	 findings	 however,	 its	 incorporation	 may	




focus	 groups	 with	 participants	 who	 were	 not	 known	 to	 one	
another,	provided	the	researcher	with	an	opportunity	to	experience	
and	consider	the	juxtaposed	views	of	Krueger	and	Kitzinger	on	the	




analysis	 and	 the	 consequences	 for	 external	 validity	 (Freeman,	
2006).	 This	 is	 in	 contrast	 with	 Kitzinger’s	 view	 that	 pre-existing	
groups	offer	 a	 valid	way	 to	explore	 topics	 “friends	and	 colleagues	
can	 relate	 to	 each	 other’s	 comments	 to	 incidents	 in	 their	 shared	
daily	 lives.	 They	 may	 challenge	 each	 other	 on	 contradictions	
between	 what	 they	 profess	 to	 believe	 and	 how	 they	 actually	
behave”	(Kitzinger,	1995:300).	
	





Within	 the	 pre-existing	 groups	 there	 was	 ‘banter’	 between	
participants	and	they	would	pick	up	on	comments	made	by	others	
and	 continue	 to	 the	 point	 or	 offer	 a	 different	 point	 of	 view.	 The	
discussion	 became	 more	 tangential	 than	 the	 self-selected	 groups	
with	 the	 facilitator	needing	 to	 redirect	back	onto	 topic	on	a	 small	
number	 of	 occasions.	 Within	 the	 self-selected	 groups	 the	




This	 impacted	 on	 the	 role	 of	 the	 facilitator	 greatly	 in	 terms	 of	
providing	 the	 acknowledgement	 and/	 or	 feedback	 to	 the	 group	
participants.	This	contrasted	with	the	experience	in	the	pre-existing	
groups	 where	 the	 facilitator	 felt	 much	more	 pulled	 by	 the	 group	
into	 their	 discussions	 as	 they	 actively	 sought	 to	 engage	 the	
facilitator	in	their	discussions	on	a	number	of	occasions.	Reflecting	
on	 the	 process,	whilst	 very	 different,	 both	 types	 of	 group	 yielded	
significant	 information	 on	 the	 participants’	 views	 of	 sexual	 health	
services.	
	
This	 section	 reported	 on	 the	 methods	 used	 and	 results	 obtained	
from	 the	 focus	 groups.	 The	 main	 themes	 have	 been	 set	 out	 and	
discussed	 in	 relation	 to	 young	 people’s	 view	 of	 different	 ways	 of	
accessing	 sexual	 health	 services	 for	 the	 testing	 and	 treatment	 of	
STIs.	The	next	section	takes	forward	the	selection	of	attributes	and	







respondent	and	what	 is	 relevant	 to	 the	particular	policy	or	decision	
making	environment”	is	identified	by	Bridges	and	colleagues	as	a	key	
consideration	in	the	identification	of	attributes	(Bridges	et	al.,	2011).	







• The	potential	 attributes	met	best	 practice	 requirements	 as	
defined	by	 ISPOR	Conjoint	Analysis	working	 group	 (Bridges	




o Whether	 attributes	 are	 related	 to	 one	 another”	
(Bridges	et	al.,	2011:406);	
• Any	key	attributes	omitted	that	may	lead	response	bias;	






Consideration	 was	 given	 to	 the	 range	 of	 methods	 available	 for	
seeking	 expert	 opinion	 including	 consensus	 methods	 such	 as	 the	
Delphi	 technique	 and	 nominal	 group	 technique	 (Bowling,	 2009).	
However,	 following	 discussions	 with	 supervisors	 	 the	 author	
determined	that	running	the	expert	group	as	a	 focus	group	would	
best	deliver	the	objectives	by	enabling	discussion	around	a	series	of	
key	 questions	 “in	 a	 focused	 discussion	 to	 help	 understand	 the	
topic”	(Krueger,	1994:10).		
	





• The	 research	 undertaken	 to	 date	 and	 findings	 (literature	
review	&	focus	groups),	
• Proposed	 attributes	 based	 on	 focus	 group	 findings	 and	
rationale	for	selection	and	de-selection,	
• Proposed	 levels	 based	 on	 focus	 group	 findings	 and	
literature.	
	











health	 clinicians	 and	 nurses,	 an	 epidemiologist	 and	 qualitative	
sexual	health	researcher,	two	issues	were	identified	that	warranted	
further	consideration:	
• The	 technical	 components	 of	 the	 test	 were	 key	 attributes	










interaction)	 from	 eSTI2	 focused	 specifically	 on	 the	 test	
related	attributes;	
• Test	 developers	 (microbiology)	 from	 eSTI2	 focused	
specifically	on	test	related	attributes;	
• Sexual	 health	 researchers	 and	 clinicians	 affiliated	 with	 the	




In	 all	 cases	 the	 groups	 were	 run	 at	 locations	 convenient	 to	 the	
participants.	The	data	provided	by	the	expert	groups	was	noted	by	
the	 facilitator	 against	 the	 attributes	 discussed	 and	 a	 summary	 of	





The	 key	 issues	 raised	 by	 each	 of	 the	 expert	 groups	 were	
summarised	 by	 attribute	 using	 a	 matrix.	 The	 expert	 groups	 were	
not	 recorded,	 fully	 transcribed	 or	 analysed	 thematically	 as	 their	







discussed	 with	 the	 focus	 groups.	 It	 should	 be	 noted	 that	 not	 all	
attributes	were	commented	on	by	all	expert	groups,	this	was	driven	


















































































































































































































Reflecting	 on	 the	 need	 to	 balance	 what	 is	 important	 to	 young	
people	and	 the	policy/	decision	making	context	 the	expert	groups	
have	 introduced	 some	 different	 perspectives	 on	 a	 number	 of	
attributes.	 	 The	 range	 of	 tests	 undertaken	 is	 the	most	 significant	
difference	 between	 the	 focus	 groups	 with	 young	 people	 and	 the	
expert	 groups.	 	 The	 focus	 groups	 indicated	 that	 there	 is	 a	 strong	
desire	 to	 be	 tested	 for	 ‘everything’	 whereas	 the	 expert	 groups	
indicated	that	this	will	never	happen.	This	is	clinically	driven	in	that	
the	 range	of	 tests	 requested	by	 clinicians	 is	determined	according	





the	DCE.	Given	 the	 variation	between	 STIs	 from	chlamydia,	which	
once	 diagnosed	 is	 treatable	with	 a	 single	 course	 of	 antibiotics,	 to	
HIV,	which	 is	currently	 incurable,	participants	 in	the	expert	groups	
believed	 that	 this	 may	 be	 a	 significant	 factor	 in	 which	 levels	
individuals	 express	 preferences	 for,	 for	 example	 the	 method	 by	
which	 they	 get	 their	 results	 –	 phone,	 email,	 text	 or	 face-to-face.	
Whilst	 this	was	not	explicitly	discussed	 in	any	of	 the	 focus	groups	
there	was	some	evidence	of	participants	considering	this:	
“I	 think	 what	 you’re	 getting	 tested	 for	 cos	 even	 though	 those	 two	 do	












was	 a	difference	between	 the	 views	of	 the	 young	people	 and	 the	
expert	groups.	Whilst	the	young	people	generally	regarded	how	you	
access	a	healthcare	professional	as	an	attribute	of	importance,	the	
expert	 groups	 highlighted	 alternative	 access	 methods	 e.g.	




Finally,	 the	 expert	 groups	 introduced	 consideration	 of	 a	 new	
attribute	 –	 how	 you	 get	 your	 antibiotic.	 Within	 the	 focus	 groups	
with	young	people,	where	you	go	to	get	treatment	was	considered	
e.g.	 GP,	 pharmacy	 etc.,	 but	 not	 how	 you	 get	 your	 antibiotic	 e.g.	
collect	 from	 pharmacy	 or	 by	 post.	 Whilst	 this	 was	 not	 identified	
through	the	literature	reviews	undertaken	to	inform	the	long	list	of	
potential	 attributes,	 immediately	 prior	 to	 the	 expert	 groups	 it	
became	 a	 national	 media	 topic	 in	 England	 due	 to	 online	 sexual	
health	 services	 in	 the	 private	 sector	 offering	 sub-optimal	 (oral	
antibiotic)	 treatment	 for	 gonorrhoea.	 However,	 the	 use	 of	 postal	
treatment	for	chlamydia	is	feasible	and	safe,	given	that	it	is	a	single	
dose	 oral	 antibiotic.	 Therefore,	 to	 address	 the	 issue	 of	 overlap	
within	the	‘how	you	get	treatment	for	chlamydia’	attribute	the	first	
expert	 group	 proposed	 that	 exploring	 this	 as	 a	 separate	 attribute	








The	 purpose	 of	 the	 focus	 and	 expert	 groups	 was	 to	 inform	 the	
selection	 of	 attributes	 and	 levels	 for	 the	 DCE.	 As	 highlighted	 in	
section	 3.5.1	 there	 are	 a	 number	 of	 key	 considerations	 that	
determine	 selection.	 Achieving	 a	 balance	 between	 attributes	 of	
importance	to	the	study	population	and	attributes	which	will	deliver	
impact	 to	 services	 and	 technology	 developers	 was	 the	 key	
consideration	 in	 selection.	 This	 led	 to	 the	 decision	 that	 a	 formal	
ranking	 or	 consensus	 method	 should	 not	 be	 used	 with	 either	 the	
focus	 or	 expert	 groups	 as	 a	 combined	 view	 of	 both	 was	 required.	
Instead,	 the	approach	adopted	was	a	narrative	synthesis	developed	












































• Current/	 known	 future	 technology	 development	 –	 derived	
from	expert	groups	and	background	literature,	
• DCE	requirements	for	the	selection	of	attributes	and	levels	–	
ISPOR	 good	 practice	 checklist	 (Bridges	 et	 al.,	 2011),	 other	




In	order	 to	 synthesise	 the	data	a	matrix	was	 created	 summarising	
the	 key	 considerations	 against	 the	 checklist	 criteria.	 The	 detail	
underpinning	 the	matrix	 has	 been	 articulated	 in	 other	 sections	 of	
the	thesis	and	therefore	is	not	replicated	in	full	in	this	section:	

































































































Once	 created,	 the	 preliminary	 data	 synthesis	 matrices	 were	
reviewed	 several	 times	 and	 a	 number	 of	 issues	 and	 themes	
emerged	 from	 this	 process	 that	 were	 of	 particular	 significance	 in	
the	selection	of	the	attributes	and	levels:	







the	author	assessed	 the	original	 long	 list	of	attributes	used	within	
the	 focus	 groups,	 and	 the	 additional	 ones	 identified	 by	 the	 focus	




and	merged,	 and	whether/	 how	 they	 should	be	 incorporated	 into	
















Sample	collection	method	 ~	 û	 ü	 ü	
FG	participants	linked	closely	with	‘where	you	do	the	test’	
attribute.	Not	viable	as	individual	attribute	due	to	overlap.	








Time	to	result	 ü	 û	 ü	 ü	
Considerable	discussion	within	FGs,	particularly	
willingness	to	trade	for	other	attributes.	




Results	notification	 û	 û	 ü	 ~	
Consistently	identified	as	not	important	how	FG	
participants	get	results	as	long	as	they	get	them.		
Access	to	an	HCP	when	you	get	your	result	 ü	 ü	 ü	 û	 	
Treatment	consultation	method	 ~	 ü	 ü	 ü	
FG	participants	overlapped	with	‘where	you	go	to	get	
treatment’	not	viable	as	individual	attribute.	














Partner	notification	method	 û	 û	 ü	 ~	 Experts	felt	although	important	health	issue,	area	subject	
to	significant	research	already.	Minimal	discussion	within	
FGs.	














Data	Security	 ü	 ü	 ü	 ü	
Importance	recognised	however	minimum	standard	for	
NHS	services	specified.	Including	in	DCE	won’t	add	value.	









Pope	 and	 colleagues	 identify	 that	 in	 reflecting	 critically	 on	 the	
synthesis	process	this	should	include	consideration	of	the:	
	
	“methods	 used	 (especially	 focusing	 on	 the	 limitations	 and	 their	
influence	 on	 the	 results);	 evidence	 used	 (quality,	 validity,	
generalizability)	–	with	emphasis	on	the	possible	sources	of	bias	and	








the	 results	 of	 the	 synthesis	 there	 are	 evidently	 a	 number	 of	
tensions	 in	 from	 the	 perspective	 of	 young	 people	 and	 the	 policy/	
service	 perspectives	 articulated	 by	 the	 expert	 groups.	 The	 main	
source	of	potential	bias	 is	notably	on	 the	 side	of	 the	experts	who	
have	 an	 interest	 professionally	 in	 the	 development	 of	 the	 new	
technology	and/	or	the	configuration	of	services,	although	there	is	a	
broader	evidence	base	that	can	be	drawn	on	from	published	policy	
and	 service	 data	 to	 contribute	 to	 this	 perspective.	 	 The	 young	
people	participating	 in	the	focus	groups	offered	their	views	within	
the	structure	of	a	focus	group	designed	with	questions	to	stimulate	








service	 leads	 on	 pathway	 redesign,	 therefore	 in	 making	 the	 final	
selection,	 the	 incorporation	 of	 attributes	 and	 levels	 which	 are	
realistic	and	meaningful	to	young	people,	but	within	the	bounds	of	
possibility	 for	 delivery	 within	 mainstream	 sexual	 health	 services	
was	 critical	 to	 the	 decision	 making.	 This	 is	 borne	 out	 in	 the	






































The	 rationale	 for	 the	non-selection	of	 attributes	 is	 summarised	as	
follows:	
• Range	 of	 tests	 –	 the	 concerns	 regarding	 the	 variance	 in	
preferences	 based	 on	 the	 STI	 being	 considered	 by	 the	
respondent	was	the	primary	reason	for	narrowing	down	the	
scope	 of	 the	 DCE	 to	 focus	 on	 one	 STI.	 Chlamydia	 was	






• Staff	 attitude	 and	 knowledge	 of	 HCP	 –	 no	 levels	 were	




inform	 service	 development	 given	 the	 NHS	 information	
governance	 standards	 set	 out	 the	 minimum	 acceptable	
levels	of	data	security.	
• Type	 of	 HCP	 –	 consistently	 considered	 of	 low	 importance	
relative	to	other	attributes	 in	the	focus	groups.	This	was	 in	
part	picked	up	in	the	treatment	consultation	method	as	the	







• Sample	 collection	 method	 and	 where	 you	 do	 the	 test	 –	
combined	into	one	attribute.	




not	 offer	 an	 option	 where	 access	 to	 a	 healthcare	





















































































































































Reflecting	 on	 the	 process	 undertaken	 to	 select	 the	 attributes	 and	
levels	 to	 take	 forward	 into	 the	 DCE,	 a	 key	 strength	 is	 the	 insight	
gained	from	the	qualitative	research	undertaken	with	young	people	
and	 experts	 to	 directly	 inform	 the	 selection.	 This	 is	 particularly	
relevant	as,	at	the	time	this	research	was	undertaken,	there	were	no	
published	 studies	 looking	 at	 preferences	 for	 STI	 testing	 and	
treatment	 services	 which	 incorporated	 the	 novel	 technology	 being	
developed	 by	 eSTI2	 research	 consortium.	 A	 second	 strength	 of	 the	
research	 is	 the	 rigour	 which	 has	 been	 applied	 to	 the	 selection	 of	
attributes	 and	 levels,	 employing	 a	 number	 of	 research	methods	 to	
distil	a	long	list	of	potential	attributes	into	the	final	selection	for	the	
study.	 Reflecting	 back	 on	 the	 methodological	 issues	 of	 concern	 in	
selecting	attributes	and	levels	outlined	in	section	4.1,	care	has	been	
taken	 to	 minimise	 the	 risk	 associated	 with	 not	 achieving	 an	
appropriate	balance	between	the	policy/	service	perspective	and	the	
user	perspective	by	explicitly	considering	the	breadth	of	views	in	the	
synthesis	 process.	 Attributes	 have	 developed	 from	 the	 ‘long	 list’,	
taking	 on	 board	 the	 findings	 from	 the	 focus	 groups	 with	 young	






a	 range	of	 issues	associated	with	 the	 inclusion	of	 specific	attributes	
and	levels	and	how	effectively	they	could	be	incorporated	into	a	DCE.	
One	of	 the	 key	 learning	 points	 stemmed	 from	 the	 consideration	 of	
the	 ‘range	 of	 tests’	 potential	 attribute.	 It	 was	 identified	 as	 of	
considerable	importance	by	young	people	in	the	focus	groups,	but	on	
further	exploration	with	the	expert	groups	was	highlighted	as	highly	
complex	 to	 incorporate	 into	 a	 DCE	 design	 looking	 at	 a	 detailed	
pathway.	 The	 synthesis	 process	 provided	 the	 opportunity	 to	
consolidate	 these	 views	 to	 provide	 an	 explicit	 process	 for	
selection/de-selection.		
	
As	highlighted	 in	 the	 literature	 review	presented	 in	 section	4.2,	 the	
level	of	detail	provided	on	the	selection	process	is	minimal	and	falls	
short	 of	 the	 suggested	 reporting	 checklist	 identified	 by	 Coast	 and	
colleagues	(Coast	et	al.,	2012).		
	
The	 ISPOR	 good	 practice	 checklist	 for	 conjoint	 analysis	 suggests	 a	
number	 of	 methods	 for	 the	 selection	 of	 attributes	 and	 levels	 but	
does	 not	 endorse	 one	 approach	 (Bridges	 et	 al.,	 2011).	 One	 study	
(Miners	 et	 al.,	 2012)	 published	 the	 findings	 of	 the	 focus	 groups	
undertaken	 in	order	 to	 inform	the	selection	of	attributes	and	 levels	




Exploring	more	widely,	 two	 studies	 have	 been	 identified	 publishing	
papers	 specifically	 on	 the	 process	 by	which	 a	 long	 list	 of	 attributes	
and	levels	led	to	the	final	selection	for	a	DCE.	Both	studies	are	from	
research	 in	 Malawi,	 the	 first	 (Abiiro	 et	 al.,	 2014)	 explored	
preferences	 for	 micro	 health	 insurance	 in	 Malawi.	 They	 used	 a	
literature	review	to	 inform	qualitative	data	collection	(through	both	
qualitative	 interviews	 and	 focus	 groups),	 and	 subsequently	 used	
expert	 opinion	 to	 down-select	 attributes	 and	 levels,	 followed	 by	
piloting	 of	 the	 questionnaire.	 The	 second	was	 to	 explore	Malawian	
women’s	 preferences	 for	 breast	 cancer	 screening	 (Kohler	 et	 al.,	
2015).	 The	 process	 adopted	 initially	 was	 similar	 to	 the	 approach	
taken	 in	 this	 research	 –	 literature	 reviews	 to	 inform	 a	 long	 list	 of	
potential	attributes,	the	use	of	qualitative	interviews	with	health	care	
professionals	 and	 respondents,	 however	 the	 process	 for	 final	
selection	 differed,	 with	 dialogue	 between	 researchers	 and	






This	 chapter	 has	 presented	 the	 results	 of	 the	 focus	 groups	 with	
young	 people,	 expert	 groups	 and	 evidence	 synthesis	 to	 select	 the	
attributes	 and	 levels	 for	 the	 DCE.	 The	 focus	 groups	 provided	
considerable	 insight	 into	 the	 factors	 that	 are	 important	 to	 young	
people	 when	making	 choices	 about	 testing	 and	 treatment	 for	 STIs	
and	 how	 their	 emotions,	 beliefs,	 experiences	 and	 perceptions	
influence	their	decision	making.		
	
The	 expert	 groups	 built	 on	 the	 findings	 of	 the	 focus	 groups	 and	
offered	valuable	real	world	insight	into	the	policy	and	service	context	
outlined	 in	 section	 2.4.	 This	 was	 particularly	 helpful	 in	 identifying	
direct	conflicts	between	what	young	people	consider	important	e.g.	a	
desire	 to	 be	 tested	 for	 ‘everything’	 versus	 what	 is	 good	 clinical	
practice	i.e.	the	use	of	national	clinical	guidelines	on	testing	for	STIs.	
Considering	the	outputs	of	both	the	focus	groups	and	expert	groups	
alongside	 the	 published	 policy,	 service	 and	 technology	 context	 in	 a	
narrative	 synthesis	 enabled	 the	 selection	 of	 attributes	 and	 levels	







read	 prior	 to	 completion,	 in	 particular	 capturing	 the	 key	
















The	 focus	 groups	 presented	 in	 Chapter	 5	 provided	 a	 rich	 source	 of	
data	 into	 the	 views	of	 young	people	on	what	 is	 important	 to	 them	
when	 considering	 testing	 and	 treatment	 for	 STIs	 which,	 when	




























exploring	 good	 practice	 in	 the	 application	 of	 conjoint	 analysis	 in	









Ryan	 and	 colleagues,	 and	 Bridges	 and	 colleagues	 identified	 the	
following	 methodological	 considerations	 which	 should	 be	













Choices	 can	be	 labelled	e.g.	GP,	 sexual	health	 clinics,	or	 through	
generic	labelling	e.g.	choice	A,	choice	B.	The	benefits	of	labels	are	
that	 they	 offer	 context	 and	 therefore	 potentially	 reduce	 the	
cognitive	 burden	 for	 respondents.	 However,	 the	 key	 risk	 is	 that	
respondents	focus	on	the	labels	and	do	not	give	due	consideration	
to	the	attributes	when	making	their	choice	(Ryan	et	al.,	2008).	For	
this	 survey	 a	 generic	design	has	been	 chosen.	 The	 rationale	was	
that	labels	are	most	commonly	used	where	there	is	likely	to	be	a	
strong	preference	for	a	brand,	or	when	one	of	the	objectives	is	to	
capture	market	 share	 predictions	 (Ryan	 et	 al.,	 2014).	Whilst	 the	
fully	remote	online	pathway	itself	could	be	isolated	and	treated	as	
a	 brand,	 the	 focus	 of	 the	 DCE	 is	 to	 understand	 the	 component	
attributes	of	importance	to	young	people	rather	than	the	pathway	





Main	 effects	 can	 be	 defined	 as	 the	 “effects	 of	 each	 attribute”	
whilst	 interaction	 effects	 explore	 the	 “effect	 of	 interaction	
between	two	or	more	attributes”	(Lancsar	and	Louviere,	2008:26).	
Ryan	and	colleagues	note	that	interaction	effects	are	a	significant	
constraint	 on	 the	 design,	 and	 in	 practice	 account	 for	 minimal	
variation	 in	 choices	 (Ryan	 et	 al.,	 2014).	 Studies	 exploring	 main	
effects	only	are	the	most	common	practice	within	published	DCE	
studies	in	the	health	care	context,	with	a	recent	systematic	review	




This	 increased	 to	 89%	 in	 2001-2008,	 and	 reduced	 to	 54%	 2009-
2012.	In	contrast	only	13%	of	studies	published	between	2009	and	




The	 research	 question	 explored	 in	 this	 chapter,	 namely	 ‘which	
attributes	 influence	 young	 people’s	 preferences	 for	 testing	 and	
treatment	 for	 chlamydia?’	 can	 be	 answered	 through	 a	 main	
effects	 design.	 It	 was	 decided	 to	 exclude	 interaction	 effects	
because	they	are	not	the	primary	focus	of	the	research	question,	




Ryan	 and	 colleagues	 note	 that	 that	 the	 number	 of	 levels	 per	
attribute	 depends	 on	 the	 type	 of	 attribute	 (categorical,	
continuous	or	probability)	 (Ryan	et	al.,	 2014),	whilst	Bridges	and	
colleagues	suggest	that	it	is	good	practice	to	have	no	more	than	3-
4	 levels	 per	 attribute	 (Bridges	 et	 al.,	 2011).	 Ryan	 and	 colleagues	
also	 note	 that	 from	 both	 a	 psychological	 perspective	 and	 a	
technical	 design	 perspective	 it	 is	 beneficial	 to	 use	 the	 same	
number	of	levels	for	every	attribute	(Ryan	et	al.,	2014).	
	




levels	 for	 every	 attribute	 owing	 to	 the	 variation	 between	










Full	 profiles	 comprise	 all	 of	 the	 attributes	which	 are	 included	 in	
the	 study	 whereas	 partial	 profiles	 include	 a	 subset	 only.	 It	 is	
acknowledged	 that	 it	 is	 recognised	 good	 practice	 within	
healthcare	research	to	use	full	profiles.	However,	it	is	necessary	to	
understand	whether	respondents	are	able	to	“reasonably	evaluate	
the	 full	 profiles”	 (Bridges	 et	 al.,	 2011:407).	 Alternatives	 to	 full	
profiles	include	partial	profiles,	or	full	profiles	with	overlap,	that	is,	





phase	 of	 the	 questionnaire	 development	 incorporated	 questions	
to	evaluate	the	cognitive	burden	of	questionnaire	completion	and	









• Multiple	 choice	 (more	 than	 two	 options	 to	 choose	







health	 care	 context	 on	 the	 impact	 of	 increasing	 the	 number	 of	
choices	 available	 to	 respondents	 within	 a	 task	 (Bridges	 et	 al.,	
2011).		
	




in	providing	 respondents	with	background	 information	 to	enable	
them	 to	 complete	 the	 questionnaire	 there	was	 a	 possibility	 that	
respondents	would	answer	yes	to	all	questions	in	a	binary	choice	
design.	 Social	 desirability	 bias	 has	 been	 widely	 documented	 in	
respect	 of	 surveys	 exploring	 lifestyle	 behaviours	 and	 sensitive	
topics	including	drug	misuse,	sexual	behaviour,	voting,	alcohol	and	
tobacco	 use,	 unintentional	 injuries,	 violence	 diet	 and	 physical	
activity	 (Tourangeau	 and	 Yan,	 2007,	 Brener	 et	 al.,	 2003).	 Brener	
and	 colleagues’	 literature	 review	 exploring	 factors	 affecting	 the	
validity	 of	 self-reported	 health	 risk	 behaviours	 identified	 that	




behaviours,	 a	 pairwise	 choice	 design	mitigates	 the	 risk	 of	 social	







number	 of	 options	 including	 choices	 for	 no	 treatment,	 no	
preference	or	current	treatment	(Bridges	et	al.,	2011).	They	note	
that	 they	 can	 be	 “useful,	 or	 even	 necessary,	 if	 researchers	 are	
assessing	 the	 potential	 demand	 or	 market	 share	 of	 a	 (novel)	
product”	(Bridges	et	al.,	2001:407).	Ryan	and	colleagues	note	that	
it	 “improves	 the	 behavioural	 realism	 of	 tasks”	 (Ryan	 et	 al.,	
2014:126);	 however,	 it	 can	 “decrease	 the	 cognitive	 difficulty	 of	
the	 task”	 (ibid).	 In	 the	 real	world	 the	decision	 to	 test	or	not	 test	




of	 the	 findings	 in	 a	 real-world	 context	 because	 in	 the	 real-world	
people	 will	 always	 have	 the	 choice	 to	 not	 test.	 Therefore,	 the	
decision	was	 taken	 to	 include	 an	 opt	 out	 option	 of	 ‘I	would	 not	


















A	 summary	 of	 the	 DCE	 design	 developed	 for	 this	 chapter	 against	





























The	 six	 attributes	 and	 24	 levels	 adopted	 in	 this	 study	 are	
summarised	 in	 table	 6.2.	 SAS	 9.4	was	 used	 to	 explore	 the	 design	
options.	 Using	 the	 ‘%mktruns’	 macro	 it	 was	 identified	 that	 a	 full	
factorial	 design	 (all	 possible	 combinations	 of	 attribute	 levels)	 has	
3,072	possible	 alternatives.	 This	 is	 not	manageable	 in	 practice	 for	





principles	 –	 orthogonality	 “The	 attributes	 are	 said	 to	 be	
independent	(or	orthogonal),	meaning	that	the	main	effects	of	one	
attribute	 is	not	polluted	by	 the	main	effects	of	 another	attribute”	











L1.	 Self-test	 30	mins	 2	in	100	(False	
Negative)	
Online	 Phone	 Post	to	Home	










14	Days	 	 Sexual	Health	Clinic	 Face	to	Face	 Collect	from	Sexual	
Health	Clinic	
L5.	 GP	Practice	 	 	 	 	 	




The	 output	 of	 the	 %mktruns	 macro	 identified	 that	 the	 smallest	




sets	 can	 be	 blocked	 into	 two	 questionnaires	 with	 24	 sets,	 three	
questionnaires	of	16	sets,	or	four	questionnaires	of	12	sets.	 It	was	
decided	 to	 undertake	 the	 cognitive	 testing	 based	 on	 two	





orthogonality	 because	 of	 constraints	 placed	 on	 implausible	
combinations,	 lack	of	 balance,	 or	 repetition	of	 particular	 attribute	
levels	across	a	set	of	alternatives	(overlap)”	(Johnson	et	al	2013:8).	
The	outputs	for	the	optimum	questionnaire	design	identified	in	SAS	
9.4	were	 used	 to	 compute	 the	 design	 in	 SAS	 JMP	Pro	 11.2.0.	 The	
choice	 design	 module	 within	 design	 of	 experiments	 module	 was	
used	 to	 create	 the	 questionnaire	 design.	 Thirty	 questionnaire	







outcome.	 These	 are	 important	 considerations	 in	 questionnaire	
design	 because	 of	 the	 consequences	 of	 how	 respondents	 view	
them	 when	 completing	 the	 questionnaire,	 including	
misinterpretation	or	hypothetical	bias	(Johnson	et	al.,	2013).		
		 269	
Implausible	 combinations	 are	 one	 of	 the	 reasons	 suggested	 by	
Johnson	and	colleagues	where	it	is	appropriate	to	trade	statistical	
efficiency	for	response	efficiency	(ibid.).	






• Attribute	1,	 Level	2	–	 Self-Sample	&	Post	off	 for	Analysis,	
with	Attribute	2,	Level	1	–	30	mins	










arrangements	 for	 drug	 dispensing),	 it	 is	 unlikely	 in	 reality	 that	 a	
person	attending	a	pharmacy	for	a	consultation	would	then	go	to	
a	 second	 location	 to	 get	 their	 antibiotics	 when	 they	 could	 be	
dispensed	 by	 the	 pharmacist.	 Both	 implausible	 and	 unlikely	
combinations	were	included	in	the	cognitive	testing	(pilot	phase).	



























Switching	 the	 implausible	 combinations	 as	 above	 creates	 one	









A1	 A2	 A3	 A4	 A5	 A6	
L1	 16	 24	 48	 23	 24	 24	
L2	 16	 24	 48	 25	 24	 24	
L3	 17	 24	 	 25	 24	 24	
L4	 16	 24	 	 23	 24	 24	
L5	 15	 	 	 	 	 	
L6	 16	 	 	 	 	 	




It	 did	 not	 generate	 a	 fully	 balanced	 design.	 Using	 the	 ‘Evaluate	








A1	 A2	 A3	 A4	 A5	 A6	
L1	 16	 24	 48	 23	 24	 24	
L2	 16	 23	 48	 25	 24	 24	
L3	 17	 25	 	 25	 24	 24	
L4	 16	 24	 	 23	 24	 24	
L5	 15	 	 	 	 	 	
L6	 16	 	 	 	 	 	




for	 implausible	 combinations.	 This	 is	 defined	 by	 Ryan	 and	
colleagues	 as	 “occurrence	 of	 one	 attribute	 does	 not	 depend	 on	
any	 other	 attribute”	 (Ryan	 et	 al.,	 2014:105).	 Using	 the	 ‘CORREL’	
function	in	Excel	for	Mac	2016	the	results	are	shown	in	table	6.6.	
This	 demonstrated	 that	 the	 values	 were	 close	 to	 zero	 (no	
correlation	 at	 all)	 in	 all	 cases	meaning	 that	 the	 pollution	 of	 the	
main	effects	of	one	attribute	by	another	was	minimal.		
	 A1	 A2	 A3	 A4	 A5	 A6	
A1	 1	 	 	 	 	 	
A2	 0.162	 1	 	 	 	 	
A3	 0.091	 0.075	 1	 	 	 	
A4	 0.125	 0.025	 0.007	 1	 	 	
A5	 -0.082	 -0.113	 0	 -0.017	 1	 	




level	 for	 both	 choices	 (Johnson	 et	 al	 2013).	 The	 original	 design	
generated	by	 JMP	Pro	did	not	 include	 any	overlap	within	 choice	




In	 order	 to	 minimise	 the	 effect	 of	 the	 overlap,	 the	 four	









overlap	 between	 the	 two	 questionnaires.	 The	 loss	 of	 statistical	
efficiency	has	been	accepted	in	the	interests	of	securing	response	
efficiency;	 that	 is,	 presenting	 respondents	with	 plausible	 choices	
for	 completion	 in	 the	 questionnaire.	 No	 precise	 measure	 of	
acceptability	 in	 terms	 of	 loss	 of	 statistical	 efficiency	 has	 been	
identified,	 Johnson	 and	 colleagues	 state	 that	 “designs	 that	 are	
nearly	 balanced	 and	 nearly	 orthogonal	 usually	 are	 still	 well	
identified.	 As	 long	 as	 the	 collinearity	 is	 not	 severe,	 all	 the	




Bridges	 and	 colleagues	 note	 that	 it	 is	 imperative	 to	 ensure	 that	
participants	have	 an	 appropriate	 level	 of	 information	 to	 complete	
the	 tasks	 including	background	 information	and	an	explanation	of	
attributes	and	levels	(Bridges	et	al.,	2011).	Background	information	
and	 an	 explanation	 of	 attributes	 and	 levels	 were	 developed	 and	
shared	 initially	 with	 a	 small	 group	 of	 researchers	 in	 the	 eSTI2	
research	 consortium,	 including	 two	 sexual	 health	 consultants	 to	




The	background	 information	 and	 sample	 choice	 sets	were	 subject	




Bridges	and	colleagues	note	“it	 is	 important	to	elicit	 respondent-
specific	 health	 and	 socio-demographic	 information	 to	 allow	 for	
testing	 for	 systematic	 differences	 in	 preference	 based	 on	 these	
characteristics”	(Bridges	et	al	2011:409).		
	
In	determining	 the	 range	of	 socio-demographic	characteristics	 to	
be	collected,	 consideration	was	 firstly	given	 to	which	 sub-groups	
to	analyse.	 These	were	 in	part	 limited	by	 funding	 (as	 the	overall	
sample	size	increases).	Two	sub-groups	were	selected	to	form	the	
basis	of	the	quota	sampling:	
• Age-bands	within	 the	16-24	age	 range	 -	 there	 is	evidence	
to	suggest	from	the	focus	groups	undertaken	to	inform	the	
DCE	 design	 and	 the	 uptake	 of	 the	 online	 consultation	
within	 the	 exploratory	 study	 that	 there	 may	 be	 a	
difference	 between	 the	 younger	 and	 older	 age	 groups	
within	the	16-24	age	range.	
• Gender	–	there	is	evidence	in	the	uptake	data	for	the	NCSP	
which	 shows	 a	 difference	 in	 the	 number	 of	 male	 and	
female	young	people	having	a	chlamydia	test	(PHE,	2016b).	
	
In	 addition	 to	 age	 and	 gender	 it	 was	 also	 decided	 to	 collect	
demographic	information	on	the	following	characteristics:	
• Ethnicity	(defined	by	the	ONS	dataset),	
• Region	 of	 Residence	 (defined	 by	 the	 Government	 Office	
regions),	
• Sexual	 Preference	 (Heterosexual,	 Homosexual	 (Gay/	
Lesbian)	or	Bisexual),	
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• Relationship	 Status	 (Single,	 in	 a	 relationship	 with	 one	
person,	 in	 a	 sexual	 relationship	 with	 one	 person,	 in	 a	










of	 burden	 imposed	 upon	 respondents.	 Bridges	 and	 colleagues	
note	 that	 there	 are	 a	 number	 of	 factors	 that	 can	 affect	 this,	
including:	 survey	 length,	 difficulty	 and	 incentive	 (Bridges	 et	 al	
2011).	 The	 review	 of	 published	 DCE	 studies	 by	 Clark	 and	
colleagues	 identified	 that	 between	 2009-12	 the	 majority	 of	
studies	 (62%)	 had	 between	 eight	 and	 16	 choices	 and	 the	
percentage	 with	 over	 16	 choices	 had	 remained	 stable	 at	 15%	
when	compared	with	the	previous	review	period	((2001-2008)	at	
18%	(De	Bekker-Grob	et	al.,	2010,	Clark	et	al.,	2014).	As	outlined	
in	 section	 6.2.2,	 cognitive	 testing	 was	 undertaken	 on	 a	




The	 incentive	 was	 determined	 by	 YouthSight,	 the	 company	
operating	the	research	panel	who	have	a	prescribed	structure	for	
reimbursement	 of	 participation	 as	 outlined	 in	 section	 3.7.	





Bridges	 and	 colleagues	 suggest	 that	 sample	 size	 calculations	 for	
DCEs	are	complex	and	do	not	 identify	a	 specific	method	by	which	
they	should	be	calculated	(Bridges	et	al.,	2011).	Orme	recommends	
that	 where	 sub-group	 analysis	 is	 undertaken	 there	 should	 be	 a	






	 Age	16-18	 Age	19-21	 Age	22-24	 Total	per	
Questionnaire	
Male	 100	 100	 100	 300	
Female	 100	 100	 100	 300	
Total	per	
Questionnaire	
200	 200	 200	 600	
Table	6.7	-	DCE	Sampling	Strategy	per	Questionnaire	
	
An	 online	 research	 panel	 was	 selected	 as	 the	 route	 to	 recruit	
participants	to	fulfil	the	requirements	of	the	sampling	strategy	in	a	
timely	manner	 recognising	 the	 large	 sample	 size,	 and	 the	need	 to	
gain	access	to	the	general	population	as	opposed	to	recruitment	via	
healthcare	 settings.	 Funding	was	 secured	 from	 the	 eSTI2	 research	











Demographic	 characteristics	 of	 respondents	 are	 presented	 in	
section	6.5.1.		
	
Assessment	 of	 the	 external	 validity	 of	 DCE	 data	 is	 recognised	 as	
problematic	(Lancsar	&	Louviere,	2008,	Clark	et	al.,	2014)	with	the	
true	test	of	external	validity	being	whether	stated	preference	data	
reflect	 ‘real’	 behaviour	 (revealed	 preference	 data)	 (Ryan	 et	 al.,	
2008).	 In	 studies	 such	 as	 this	 where	 new	 technology	 is	 being	
explored,	with	a	number	of	hypothetical	levels,	revealed	preference	
data	 are	 generally	 not	 available.	 A	 number	 of	 methods	 have	
therefore	 been	 identified	 for	 assessing	 the	 internal	 validity	 of	 the	
data	including:	
• Repeated	questions	(Bridges	et	al.,	2011),	





• “Checking	 if	 signs	 of	 estimated	 parameters	 are	 consistent	




In	 their	 review	 of	 recently	 published	 DCE	 studies	 in	 healthcare,	
Clark	 and	 colleagues	 identified	 that	 the	most	 commonly	 reported	
tests	 for	 validity	 are	 theoretical	 validity	 tests,	 including	 whether	





To	 assess	 the	 internal	 validity	 of	 the	 questionnaire	 an	 analysis	 of	
the	 number	 of	 responses	 for	 each	 option	 was	 undertaken.	 In	
addition,	 the	 following	 methods	 were	 selected	 and	 tested	 by	
comparing	 the	 full	 dataset	 with	 the	 dataset	 with	 the	 following	
responses	removed:	
• Repeated	 choice	 set	 –	 respondents	 provide	 the	 same	
answer	to	the	repeated	choice	set,		
• Time	 to	 complete	 questionnaire	 –	 data	 where	 responses	





Tests	 for	 internal	 consistency	 and	 rationality	 were	 not	 included	
because	 there	 is	 a	 suggestion	 that	 to	 exclude	 responses	 on	 this	
basis	may	be	an	inappropriate	imposition	of	rationality	(Clark	et	al.,	





is	 to	 use	 the	 multinomial	 logit	 (MNL)	 model	 developed	 by	
McFadden	(also	known	as	the	conditional	logit	model)	(Ryan	et	al.,	
2008,	Ryan	et	al.,	2014).	Louviere	and	colleagues	identify	the	MNL	
model	 as	 the	 core	 choice	 model	 used	 for	 the	 analysis	 of	 stated	
preference	data	in	a	variety	of	fields	including	transport,	marketing	
and	 environmental	 (Louviere	 et	 al.,	 2003).	 In	 addition,	 Clark	 and	
colleagues	 point	 to	 an	 increase	 in	 the	 use	 of	 this	 modelling	
approach	in	reported	DCE	studies	in	healthcare	from	22%	of	studies	










The	 IIA	condition	 is	 recognised	as	a	 strength	and	weakness	within	
the	MNL	approach.	Louviere	and	colleagues	state	that	“its	strength	
is	that	it	provides	a	computationally	convenient	choice	model,	and	
permits	 introduction	 and/	 or	 elimination	 of	 alternatives	 in	 choice	
sets	without	 re-estimation.	 Its	weakness	 is	 that	 the	 observed	 and	
unobserved	 attributes	 of	 utility	 may	 not	 be	 independent	 of	 one	
another,	 and/	 or	 if	 the	 unobserved	 components	 of	 utility	 are	
correlated	 among	 alternatives,	 this	 leads	 to	 biased	 utility	










for	 the	 analysis.	 Attribute	 levels	 were	 specified	 using	 dummy	
variables	 as	 it	 was	 identified	 that	 dummy	 coding	 is	 the	 most	
recognised	 approach	 within	 healthcare	 research	 (Bridges	 et	 al.,	
2011),	and	is	the	preferred	form	of	coding	where	odds	ratios	are	to	
be	 calculated	 (Ijzerman	et	 al.,	 2016).	Dummy	coding	 requires	 that	




Within	 the	 model	 the	 levels	 that	 were	 dropped	 reflect	 a	 sexual	
health	clinic	pathway;	 this	was	chosen	as	 it	 represents	one	option	
currently	available	to	young	people	to	access	chlamydia	testing.	The	
other	 NCSP	 Chlamydia	 testing	 options	 can	 be	 comprised	 of	 a	
number	of	different	combinations	of	levels	and	would	therefore	not	














The	 purpose	 of	 the	 pilot	 phase	was	 to	 test	 the	 draft	 questionnaire	
and	 associated	 background	 information.	 These	 were	 piloted	 on	
respondents	 within	 the	 sample	 age	 range	 using	 cognitive	
interviewing	methodology	 -	 drawing	 on	 both	 the	 ‘think	 aloud’	 and	
probing	paradigms	 (Beatty	 and	Willis,	 2007,	 Campanelli,	 1997).	 The	
cognitive	 interviews	 involved	 a	 one-to-one	 interview	 using	 both	
concurrent	 and	 retrospective	 probing,	 with	 probes	 scripted	 in	
advance	(ibid.).	Concurrent	probing	was	used	for	the	first	half	of	the	
questionnaire,	 with	 questions	 following	 each	 of	 the	 sections	




Retrospective	 probing	 was	 used	 for	 the	 choice	 part	 of	 the	





how	 difficult	 they	 found	 the	 questionnaire	 to	 complete.	 The	
interview	 schedule	 for	 the	 third	 round	 of	 interviews	 is	 included	 in	
Appendix	13.		
	
The	 pilot	 study	 was	 undertaken	 in	 phases.	 After	 undertaking	 the	
initial	phase,	the	results	were	reviewed	to	identify	the	revisions,	and	
then	 the	 next	 iteration	 of	 the	 questionnaire	 was	 piloted.	 A	 final	
sample	 size	 was	 not	 determined	 in	 advance	 as	 it	 was	 an	 iterative	
process,	 continuing	 until	 no	 new	 significant	 issues	 impacting	 on	
completion	of	the	questionnaire	were	being	identified	(Willis,	1999).	
Convenience	sampling	was	used	for	expediency	within	the	target	age	
range	 (16-24)	 for	 the	questionnaire.	 Participants	were	 recruited	 via	




After	 each	 phase	 the	 responses	 were	 summarised	 with	 a	 specific	
focus	on:	
• Terms	 used	 where	 the	 participant	 did	 not	 interpret	 their	
meaning	as	intended.	
• Responses	 to	 choice	 questions	 to	 determine	 whether	 any	
specific	attribute	dominated,	that	 is,	whether	the	participant	
































Although	 not	 formally	 captured	 as	 part	 of	 the	 demographic	
information,	 it	 was	 observed	 during	 the	 interviews	 that	 six	 of	 the	








the	 introduction,	 key	 terms	 and	 definitions	 used.	 However,	 it	 was	
identified	 by	 participants	 in	 round	 one	 and	 round	 two	 that	
clarification	 was	 needed	 on	 terms	 relating	 to	 Epididymitis	 and	
azithromycin.	 As	 a	 suggestion	 from	 a	 participant	 in	 round	 two	 a	
visual	 representation	 of	 the	 pathway	 was	 incorporated	 to	 aid	 in	
understanding.	 Incorporation	 of	 additional	 questions	 into	 the	 third	
round	 of	 interviews	 identified	 that	 participants	 were	 able	 to	
articulate	 what	 the	 diagrams	 meant.	 It	 was	 therefore	 decided	 to	
retain	them	in	the	final	questionnaire.		
	
In	 respect	 of	 the	 choice	 sets,	 the	 first	 round	 of	 cognitive	 testing	
revealed	that	the	difference	in	the	accuracy	levels	(2	in	100	versus	8	
in	100)	dominated	as	the	reason	for	selecting	a	choice	for	two	of	the	
three	 participants;	 therefore,	 in	 the	 second	 round,	 the	 level	 was	
reduced	to	5	 in	100.	The	reasons	for	selecting	choice	sets	 in	rounds	
two	and	three	revealed	a	range	of	factors	for	making	the	choice	from	
respondents.	Therefore,	 it	was	decided	 to	proceed	with	 the	 revised	
level	 in	 the	 final	 DCE.	 Implausible	 combinations	 were	 left	 in	 the	
choice	 sets	 in	 the	 first	 round	 of	 the	 cognitive	 testing.	 The	 third	
participant	 identified	 the	 conflict	 between	 posting	 a	 sample	 for	
analysis	and	getting	the	result	 in	two	hours	as	being	impossible	and	
therefore	they	did	not	make	that	choice.	As	a	result,	 it	was	decided	







that	 they	 felt	 sure	 of	 their	 answers,	 however,	 three	 of	 the	 nine	
participants	 indicated	that	 they	went	back	and	changed	one	or	 two	
answers	as	 they	progressed	 through	 the	questionnaire.	Participants	
indicated	 that	 they	 did	 not	 find	 it	 difficult	 to	 complete	 the	 choice	
questions,	 with	 three	 participants	 indicating	 that	 they	 found	 they	
needed	to	think	about	some	choices	 longer	than	others.	One	of	the	




sets	 ranged	 from	 four	 minutes	 46	 seconds	 to	 nine	 minutes	 56	
seconds.	 Eight	 of	 the	 nine	 participants	 answered	 the	 duplicate	 set	
correctly.	Reviewing	the	total	number	of	participants	selecting	A,	B	or	
choosing	 not	 to	 test	 showed	 that	 there	 was	 variance	 across	 the	






















































The	 questionnaire	 was	 scripted	 by	 YouthSight	 and	 test	 links	 were	
provided	 for	 review.	 A	 copy	 extracts	 from	 the	 questionnaire’s	
introduction	 and	 a	 sample	 of	 the	 choice	 sets	 are	 included	 in	
Appendix	14.	YouthSight	used	their	standard	approach	to	promoting	
the	 questionnaire	 to	 potential	 participants	 via	 email	 and	 managed	
the	participation	to	ensure	that	the	sampling	quotas	were	met.	Data	
collection	was	 paused	 after	 50	 responses	 on	 each	 questionnaire	 to	





analysis	 in	 Excel	 for	Mac	 2016	 and	 STATA13	 SE	 in	 accordance	with	












In	 total,	 1,230	 responses	 to	 the	 questionnaire	 were	 received,	 a	
further	 490	 people	 commenced	 the	 questionnaire	 but	 did	 not	
complete	it	giving	a	completion	rate	of	73%.	No	further	information	
was	available	about	 the	demographic	characteristics	of	 those	who	
did	 not	 complete	 the	 questionnaire.	 The	 breakdown	 of	 the	
demographic	characteristics	of	respondents	is	summarised	in	table	
6.11;	 where	 national	 comparative	 data	 can	 be	 identified	 this	 has	
been	included.	
	
Demographic	Characteristic	 n	 %	 National	%4	
Age	
16	 8	 1%	 10%	
17	 113	 9%	 10%	
18	 294	 24%	 11%	
19	 183	 15%	 11%	
20	 132	 11%	 11%	
21	 91	 7%	 11%	
22	 162	 13%	 11%	
23	 135	 11%	 12%	
24	 112	 9%	 12%	
Total	 1230	 100%	 99%	
Gender	
Male	 607	 49%	 51%	
Female	 623	 51%	 49%	





White	–	Irish	 7	 1%	 1%	
White	–	Gypsy	or	Irish	Traveller	 1	 0%	 0%	




















Asian/	Asian	British	–	Indian	 50	 4%	 3%	
Asian/	Asian	British	-	Pakistani	 38	 3%	 2%	
Asian/	Asian	British	-	Bangladeshi	 18	 1%	 1%	














Other	–	Arab	 5	 0%	 0%	
Other	–	Any	other	ethnic	group	 9	 1%	 1%	
I	would	prefer	not	to	say	 15	 1%	 0%	
Total	 1230	 100%	 103%	
Region	
East	Midlands	 117	 10%	 9%	
London	 225	 18%	 15%	
North	East	 74	 6%	 5%	
North	West	 123	 10%	 13%	
Eastern	 55	 4%	 10%	
South	East	 222	 18%	 16%	
South	West	 143	 12%	 10%	
West	Midlands	 144	 12%	 11%	
Yorkshire	and	The	Humber	 113	 9%	 11%	
I	would	prefer	not	to	say	 14	 1%	 0%	
Total	 1230	 100%	 100%	
Sexual	Preference	







Bisexual	(partner	of	either	sex)	 98	 8%	 	
I	would	prefer	not	to	say	 50	 4%	 	
Total	 1230	 100%	 	
Previous	STI	Test	
Yes	 393	 32%	 	
No	 790	 64%	 	
		 287	
Demographic	Characteristic	 n	 %	 National	%4	
I	would	prefer	not	to	say	 47	 4%	 	
Total	 1230	 100%	 	
Relationship	Status	













I	would	prefer	not	to	say	 29	 2%	 	
Total	 1230	 100%	 	
Table	6.11	-	Demographic	Characteristics	of	DCE	Respondents	
Comparing	 the	 DCE	 sample	 characteristics	 to	 the	 national	
population	 (England)	 characteristics	 shows	 that	 the	 gender	 and	
ethnicity	 makeup	 of	 participants	 is	 broadly	 in	 line	 with	 national	
population	 demographics.	 For	 age,	 it	 can	 be	 seen	 that	 at	 the	








In	 terms	 of	 the	 geographic	 region	 of	 participants,	 the	 sample	 is	
broadly	 in	 line	with	 the	geographic	distribution	of	16-24	year	olds	
identified	 in	 the	 ONS	Mid-Year	 Population	 Estimates	 2015	 (Office	




Two	 demographic	 characteristics	 were	 identified	 a	 priori	 in	 the	
sampling	frame	for	sub-group	analysis	–	gender	and	age	range.	The	










16-18	 415	 34%	 31%	
19-21	 406	 33%	 33%	
22-24	 409	 33%	 35%	
Gender	
Male	 607	 49%	 51%	
Female	 623	 51%	 49%	
Table	6.12	-	Demographic	Characteristics	of	Sub-Groups	for	Analysis	
	
In	addition,	a	 review	of	 the	demographic	data	 identified	 sufficient	
responses	on	each	questionnaire	to	undertake	sub-group	analysis	–	
relationship	 status	 (single	 and	 in	 a	 sexual	 relationship	 with	 one	
person),	and	whether	previously	tested	for	an	STI	(yes	or	no).	It	was	



























Reviewing	 this	 for	 the	 two	 questionnaires	 individually	 shows	 a	
slightly	higher	percentage	of	respondents	on	the	first	questionnaire	
answered	both	questions	correctly	 than	the	second	questionnaire.	











The	 published	 reviews	 of	DCE	 studies	 did	 not	 include	 information	
on	 the	 proportion	 of	 repeated	 choice	 sets	 answered	 correctly	
within	published	studies.	A	further	literature	search	to	identify	any	
publications	 containing	 information	 on	 this	 failed	 to	 identify	 any	
published	reviews	considering	this.	One	paper	within	the	review	of	
stated	 preference	 studies	 included	 in	 section	 4.2	 (Phillips	 et	 al.,	
2002)	 reported	 that	 25%	 of	 respondents	 did	 not	 answer	 the	







In	 respect	 of	 whether	 to	 include	 the	 response	 to	 the	 first	 or	 last	
question	 in	 the	dataset,	a	clear	view	has	not	been	 identified	 from	
the	literature.	There	are	two	arguments	to	be	considered:	
• Inclusion	of	the	responses	to	the	first	choice	set	–	as	people	
complete	 the	 questionnaire	 they	 become	 fatigued	 and	
therefore	 their	 response	 to	 the	 first	 question	 is	 more	
reliable	than	the	last	question,	
• Inclusion	 of	 the	 responses	 to	 the	 last	 choice	 set	 –	 at	 the	
start	 of	 the	 questionnaire	 people	 are	 unsure	 of	 the	 DCE	
tasks	and	as	they	progress	they	become	more	familiar	with	
the	choice	process	and	therefore	their	response	to	the	 last	
question	 is	 more	 reliable	 than	 their	 response	 to	 the	 first	
question.	
	
Table	 6.15	 compares	 the	 results	 from	 the	 model	 run	 on	 the	 full	
dataset	 comparing	 the	 inclusion	 of	 responses	 to	 Q1	 and	 Q25	 in	
each	questionnaire.	Levels	highlighted	in	blue	indicate	a	p-value	of	
greater	 than	 0.05	 (demonstrated	 by	 the	 CI	 for	 the	 coefficient	






data	 from	 choice	 set	 25	 (OR	 of	 1.031	 with	 a	 95%	 CI	 of	 0.981	 to	
1.085)	but	is	statistically	significant	when	using	data	from	choice	set	
1	 (OR	 of	 1.053	 with	 a	 95%	 CI	 of	 1.002	 to	 1.106).	 The	 order	 of	
strength	of	preference	within	 the	attributes	 remains	 the	 same	 for	
how	 you	 test,	 time	 to	 result,	 accuracy,	 access	 to	 a	 healthcare	
professional	and	how	you	get	your	antibiotics.	However,	there	is	a	










Given	 the	 relative	 closeness	 of	 the	 odds	 ratio	 and	 confidence	
intervals	across	 the	datasets	which	option	should	be	 selected	was	
considered.	 Clark	 and	 colleagues	 noted	 that	 60%	 of	 published	
studies	between	2009	and	2012	contained	an	internal	validity	check	
and	 this	 was	 “an	 assessment	 of	 whether	 coefficients	 appear	 to	
move	in	line	with	a	priori	expectations”	(Clark	et	al.,	2014:11).	Their	
literature	review	did	not	consider	the	use	of	repeated	questions	as	
an	 internal	 validity	 measure.	 A	 search	 of	 the	 literature	 did	 not	
identify	 any	 other	 reviews	 of	 stated	 preference	 studies	 that	




which	 question	 response	 to	 choose	 in	 respect	 of	 a	 repeated	
question	 the	 latter	option	was	 selected,	 subscribing	 to	 the	 theory	
























Self-Test	 0.498	 0.432	 0.564	 1.646	 1.540	 1.758	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	
Post	 0.308	 0.239	 0.376	 1.360	 1.270	 1.456	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	
Pharmacy	 0.116	 0.056	 0.175	 1.123	 1.057	 1.192	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	
Education/	Work	 -0.206	 -0.266	 -0.146	 0.814	 0.766	 0.864	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	
GP	Practice	 0.011	 -0.050	 0.073	 1.011	 0.951	 1.075	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.579	 0.524	 0.633	 1.784	 1.688	 1.884	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	
2	Hours	 0.340	 0.283	 0.398	 1.406	 1.328	 1.488	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.149	 -0.200	 -0.099	 0.861	 0.819	 0.906	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	
Accuracy	
2	in	100	False	Negative	 1.192	 1.157	 1.226	 3.292	 3.179	 3.409	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.185	 0.133	 0.236	 1.203	 1.142	 1.266	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	




















GP	Consultation	 0.146	 0.095	 0.197	 1.157	 1.100	 1.218	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	
Sexual	Health	Clinic	Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.058	 -0.108	 -0.008	 0.943	 0.897	 0.992	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	
Instant	Messenger	 0.020	 -0.029	 0.070	 1.020	 0.971	 1.072	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	
Email	 0.027	 -0.023	 0.076	 1.027	 0.978	 1.079	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
How	you	get	Antibiotics	
Post	to	Home	 0.038	 -0.013	 0.089	 1.039	 0.987	 1.093	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	
Post	to	Collection	Point	 0.052	 0.002	 0.101	 1.053	 1.002	 1.106	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	
Collect	from	Pharmacy	 0.091	 0.038	 0.143	 1.095	 1.039	 1.154	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	
Collect	from	Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Choice	
Option	A	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Option	B	 -0.341	 -0.381	 -0.302	 0.711	 0.683	 0.740	 -0.360	 -0.400	 -0.320	 0.698	 0.670	 0.726	























Self-Test	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	 0.507	 0.429	 0.584	 1.660	 1.535	 1.794	
Post	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	 0.333	 0.254	 0.411	 1.395	 1.290	 1.508	
Pharmacy	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	 0.124	 0.054	 0.194	 1.132	 1.056	 1.214	
Education/	Work	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	 -0.253	 -0.323	 -0.183	 0.777	 0.724	 0.833	
GP	Practice	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	 0.019	 -0.053	 0.091	 1.019	 0.948	 1.095	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	 0.573	 0.510	 0.637	 1.774	 1.665	 1.890	
2	Hours	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	 0.335	 0.268	 0.402	 1.397	 1.307	 1.494	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	 -0.148	 -0.177	 -0.236	 -0.117	 0.790	 0.889	
Accuracy	
2	in	100	False	Negative	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	 1.323	 1.282	 1.364	 3.755	 3.602	 3.913	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	


















Pharmacy	Consultation	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	 0.173	 0.112	 0.234	 1.189	 1.119	 1.264	
GP	Consultation	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	 0.179	 0.119	 0.240	 1.196	 1.126	 1.271	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	 -0.084	 -0.143	 -0.026	 0.919	 0.867	 0.975	
Instant	Messenger	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	 -0.026	 -0.084	 0.031	 0.974	 0.919	 1.032	
Email	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	 -0.005	 -0.063	 0.052	 0.995	 0.939	 1.054	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
How	you	get	Antibiotics	
Post	to	Home	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	 0.014	 -0.047	 0.075	 1.014	 0.954	 1.078	
Post	to	Collection	Point	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	 0.023	 -0.036	 0.083	 1.024	 0.964	 1.086	
Collect	from	Pharmacy	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	 0.065	 0.001	 0.128	 1.067	 1.001	 1.137	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Choice	
Option	A	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Option	B	 -0.360	 -0.400	 -0.320	 0.698	 0.670	 0.726	 -0.327	 -0.374	 -0.279	 0.721	 0.688	 0.756	




on	 the	 full	 dataset	 and	 the	 exclusion	 of	 the	 responses	 with	
different	answers	for	choice	sets	1	and	25	shows	that	whilst	there	


















The	 cognitive	 testing	 identified	 a	 range	 to	 complete	 the	
questionnaire	 of	 04:46	 to	 09:56	 minutes	 with	 a	 mean	 time	 to	
completion	 of	 07:15	 minutes.	 Recognising	 that	 the	 time	 to	
completion	was	a	timing	of	the	completion	of	the	choice	sets	only,	
a	 threshold	 of	 five	 minutes	 or	 greater	 was	 applied	 to	 the	
responses	in	the	dataset;	this	is	the	minimum	time	to	completion	
observed	 in	 the	 cognitive	 testing	 rounded	 up	 to	 the	 nearest	 full	
minute.	 The	 number	 of	 responses	 were	 then	 analysed	 and	
grouped	by	 less	than	five	minutes	and	five	minutes	or	more,	and	
whether	 the	 repeated	 question	 was	 answered	 correctly.	 This	
identified	that	76%	participants	who	took	five	minutes	or	longer	to	
complete	 the	 survey	 gave	 the	 same	 answer	 to	 the	 repeated	
































Running	 the	model	on	 the	 full	dataset	and	 the	dataset	excluding	
responses	 which	 took	 less	 than	 five	 minutes	 to	 complete	 again	























Self-Test	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	 0.542	 0.467	 0.616	 1.719	 1.595	 1.852	
Post	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	 0.344	 0.269	 0.419	 1.411	 1.309	 1.521	
Pharmacy	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	 0.168	 0.101	 0.234	 1.183	 1.106	 1.264	
Education/	Work	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	 -0.245	 -0.312	 -0.177	 0.783	 0.732	 0.837	
GP	Practice	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	 -0.008	 -0.077	 0.061	 0.992	 0.925	 1.062	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	 0.642	 0.581	 0.703	 1.900	 1.788	 2.019	
2	Hours	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	 0.372	 0.308	 0.436	 1.451	 1.361	 1.547	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	 -0.147	 -0.204	 -0.091	 0.863	 0.816	 0.913	
Accuracy	
2	in	100	False	Negative	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	 1.308	 1.269	 1.348	 3.700	 3.556	 3.850	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	 0.217	 0.159	 0.276	 1.243	 1.172	 1.318	
Pharmacy	Consultation	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	 0.160	 0.102	 0.219	 1.174	 1.108	 1.245	
GP	Consultation	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	 0.171	 0.113	 0.229	 1.187	 1.120	 1.258	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	 -0.042	 -0.098	 0.014	 0.959	 0.906	 1.014	
Instant	Messenger	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	 0.043	 -0.013	 0.098	 1.044	 0.987	 1.103	
Email	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	 0.042	 -0.013	 0.097	 1.043	 0.987	 1.102	



















Post	to	Home	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	 0.001	 -0.057	 0.060	 1.001	 0.944	 1.062	
Post	to	Collection	Point	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	 0.013	 -0.044	 0.070	 1.013	 0.957	 1.072	
Collect	from	Pharmacy	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	 0.085	 0.024	 0.145	 1.089	 1.025	 1.157	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Choice	
Option	A	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Option	B	 -0.360	 -0.400	 -0.320	 0.698	 0.670	 0.726	 -0.368	 -0.413	 -0.323	 0.692	 0.662	 0.724	


















To	 understand	 this	 further,	 analysis	 was	 undertaken	 on	 the	
distribution	 of	 the	 levels	 between	 option	 A	 and	 option	 B	 to	
ascertain	whether	using	attributes	with	known	logical	choices	(e.g.	
shorter	 time	 to	 result,	 higher	 accuracy)	 it	 would	 have	 been	





















































was	 concluded	 that	 a	 higher	 proportion	 of	 respondents	 would	

































Self-Test	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	 0.501	 0.433	 0.568	 1.650	 1.542	 1.765	
Post	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	 0.320	 0.252	 0.387	 1.377	 1.287	 1.473	
Pharmacy	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	 0.152	 0.092	 0.212	 1.164	 1.096	 1.236	
Education/	Work	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	 -0.202	 -0.262	 -0.141	 0.817	 0.769	 0.868	
GP	Practice	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	 0.027	 -0.035	 0.089	 1.027	 0.965	 1.093	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	 0.612	 0.558	 0.667	 1.845	 1.746	 1.949	
2	Hours	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	 0.350	 0.292	 0.408	 1.419	 1.339	 1.503	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	 -0.145	 -0.196	 -0.094	 0.865	 0.822	 0.910	
Accuracy	
2	in	100	False	Negative	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	 1.205	 1.170	 1.241	 3.338	 3.221	 3.460	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	 0.200	 0.147	 0.253	 1.222	 1.159	 1.288	
Pharmacy	Consultation	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	 0.159	 0.106	 0.211	 1.172	 1.112	 1.235	
GP	Consultation	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	 0.174	 0.122	 0.227	 1.190	 1.130	 1.254	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	 -0.046	 -0.097	 0.004	 0.955	 0.908	 1.004	
Instant	Messenger	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	 0.029	 -0.021	 0.079	 1.029	 0.979	 1.082	
Email	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	 0.050	 0.000	 0.100	 1.051	 1.000	 1.105	



















Post	to	Home	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	 0.012	 -0.041	 0.065	 1.012	 0.960	 1.067	
Post	to	Collection	Point	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	 0.035	 -0.016	 0.086	 1.036	 0.984	 1.090	
Collect	from	Pharmacy	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	 0.076	 0.021	 0.131	 1.079	 1.022	 1.139	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Choice	
Option	A	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Option	B	 -0.360	 -0.400	 -0.320	 0.698	 0.670	 0.726	 -0.368	 -0.409	 -0.327	 0.692	 0.664	 0.721	











To	 summarise,	 the	 four	 options	 considered	 to	 test	 the	 internal	
validity	of	the	data	presented	in	the	previous	sections	showed	that	
in	 comparison	 to	 the	 full	 dataset	 all	 yielded	 very	 similar	
coefficients	 and	 odds	 ratios	 with	 no	 change	 in	 the	 order	 of	 the	
strength	 of	 preference	 for	 a	 level	 within	 each	 attribute.	 On	 this	





from	 their	 panel	 of	 approximately	 108,500	 young	 people	 within	
the	 target	 age	 range	 (YouthSight,	 2014).	 Their	 analytics	 data	
showed	 that	 an	 additional	 460	 people	 started	 but	 did	 not	
complete	 the	 survey.	 No	 further	 information	 is	 available	 on	 the	































Very	Good	 19	 12%	 9%	
Good	 47	 10%	 22%	
Average	 75	 19%	 36%	
Poor	 53	 45%	 25%	




Total	 211	 17%	 100%	
Table	6.24	-	Breakdown	of	Qualitative	Feedback	by	Response	Category	
This	 indicates	 that	 the	 majority	 of	 participants	 (83%)	 found	 the	
questionnaire	average/	satisfactory	to	complete.	This	is	reassuring	
within	the	context	of	the	sample	population,	i.e.	a	population	who	
have	 signed	 up	 to	 a	 panel	 to	 complete	 online	 surveys.	 The	
qualitative	 feedback	 was	 explored	 through	 a	 simple	 thematic	
analysis	to	draw	out	the	learning	points.	Looking	at	the	frequency	
of	comments,	repetition	was	the	issue	cited	most	frequently	with	
79	 of	 the	 211	 commenting	 indicated	 that	 they	 found	 the	
questionnaire	 repetitive;	 this	 varied	 in	 degrees	 from	 “very	
repetitive”	to	“thorough	but	quite	repetitive”.	Nineteen	of	the	211	






Tables	 6.27-6.32	 present	 the	 results	 from	 the	 DCE	 for	 the	 full	
dataset	and	 the	subgroups	analysed	as	both	coefficients	and	odds	
ratios	(OR),	along	with	the	95%	confidence	intervals	(CI).	The	odds	
ratios	 are	 used	 throughout	 this	 section	 when	 discussing	 the	
findings,	 however	 the	 coefficients	 will	 be	 used	 in	 section	 6.6	 for	
exploring	 the	 findings	 within	 the	 context	 of	 pathways	 and	
probabilities	of	uptake.		Levels	highlighted	in	blue	indicate	a	p-value	
of	 greater	 than	 0.05	 (demonstrated	 by	 the	 CI	 for	 the	 coefficient	




Looking	 across	 all	 attributes	 and	 levels	 participants	 expressed	 the	
strongest	 preference	 for	 accuracy	 of	 the	 test	 result	 (OR	 3.242).	
Accuracy	was	expressed	as	the	likelihood	of	a	false	negative	result.	
This	 point	 links	 to	 the	 findings	 of	 the	 focus	 groups	 that	
demonstrated	 a	 lack	 of	 understanding	 that	 tests	 are	 not	 ‘100%	
accurate’.	 Considering	 accuracy	 across	 the	 subgroups	 analysed,	
there	are	notable	differences	in	the	strength	of	preference	between	
males	 and	 females	 (OR	 2.950	 and	 3.570	 respectively),	 and	 those	
who	 have	 previously	 tested	 and	 not	 tested	 (OR	 2.999	 and	 3.482	
respectively).	Possible	reasons	for	this	include	the	consequences	for	
males	 personally	 are	 not	 as	 severe	 as	 they	 are	 for	 women	 as	
evidenced	in	the	background	literature	for	participants,	or	that	they	
would	manage	 the	 consequences	 of	 a	 false	 result	 differently.	 For	









across	 all	 sub-groups,	 with	 results	 consistent	 with	 the	 logical	
expectation	that	people	would	prefer	a	shorter	waiting	time	than	a	
longer	 one.	 Comparing	 ORs	 between	 sub-groups	 showed	 no	
substantial	differences,	with	the	exception	of	age	where	the	19-21	
year	olds	showed	a	stronger	preference	for	30	minutes	and	2	hours	






preference	 for	 self-testing	 (OR	 1.618)	 and	 testing	 via	 an	 outreach	
services	 in	 an	 educational/	 work	 setting	 was	 the	 least	 preferred	
option	 (OR	 0.821).	 Postal	 testing	 was	 the	 second	 strongest	
preference	across	all	sub-groups	(OR	1.358).	For	testing	via	a	sexual	




have	 not	 (OR	 1.101).	 Taking	 a	 sample	 to	 a	 pharmacy	 for	 analysis	
was	preferable	to	attending	a	sexual	health	clinic	for	all	subgroups	





testing	 and	postal	 testing)	 compared	with	 those	 that	 do	 (taking	 a	
sample	 to	 a	 pharmacy,	 an	 outreach	 clinic	 at	 place	 of	 education/	




• Females	 had	 a	 stronger	 preference	 for	 the	 more	 remote	
testing	 options	 (self-test,	 OR	 1.693,	 postal	 test,	 OR	 1.411)	
than	males	(OR	1.549	and	1.308	respectively).	
• The	older	 age	 range	 (22-24)	 had	 a	 stronger	 preference	 for	
self-testing	 (OR	 1.895)	 compared	 with	 the	 younger	 age	
groups,	(16-18	OR	1.664,	19-21	OR	1.346).	
• For	 those	 in	 a	 relationship	 with	 one	 sexual	 partner	 there	
was	 a	 stronger	 preference	 for	 self-testing	 (OR	 1.711)	
compared	with	those	who	were	single	(OR	1.632).	However,	
those	who	were	single	had	a	stronger	preference	for	taking	
a	 sample	 to	 a	 pharmacy	 (OR	 1.220)	 than	 those	 in	 a	
relationship	with	one	partner	(OR	1.109).	
• The	largest	difference	in	the	strength	of	preferences	was	in	
the	 subgroup	 who	 had	 previously	 tested	 for	 an	 STI	
compared	 with	 those	 that	 had	 not.	 Those	 that	 had	 not	
previously	 tested	 for	 an	 STI	 had	 a	 greater	 preference	 for	
remote	 testing	 options	 (self-test	 OR	 1.678,	 postal	 test	 OR	
1.465)	than	those	that	had	previously	tested	(OR	1.524	and	
OR	1.178	 respectively),	and	also	had	a	 stronger	preference	
for	 taking	 a	 sample	 to	 a	 pharmacy	 for	 analysis	 (OR	 1.277)	
than	 those	 who	 had	 previously	 tested	 (OR	 0.945	 not	
statistically	significant).	
	
Again,	 the	 preference	 for	 a	 remote	 (from	 a	 sexual	 health	 clinic)	
pathway	 can	 be	 seen	 in	 the	 preference	 for	 consultation	 method	
following	a	positive	test	result	via	an	online	consultation	(OR	1.212),	
followed	 by	 treatment	 via	 general	 practice	 (OR	 1.183)	 and	
treatment	via	pharmacy	(OR	1.158)	in	the	full	dataset.	However,	at	
the	 subgroup	 level	 there	 was	 more	 variation	 in	 the	 order	 of	
preference	for	this	attribute	than	any	other	in	the	survey,	with	the	








































The	 differences	 in	 the	 strength	 of	 preference	 suggest	 that	 some	
subgroups	 have	 a	 preference	 for	 a	 consultation	 method	 which	
involves	 contact	 with	 a	 healthcare	 professional	 rather	 than	 an	
online	pathway	where	 contact	 is	only	made	 if	 there	 is	 a	problem.	
This	in	part	reflects	the	focus	group	findings	where	the	focus	groups	





Whilst	 there	 is	 a	 statistically	 significant	 preference	 for	 all	
consultation	methods	when	 compared	with	 a	 sexual	 health	 clinic,	
the	 full	dataset	showed	that	 for	method	of	access	 to	a	healthcare	
professional	 there	 was	 no	 statistically	 significant	 preference	 for	
instant	 messenger	 or	 email	 access	 compared	 to	 accessing	 a	
healthcare	 professional	 face-to-face.	 Telephone	 access	 to	 a	
healthcare	professional	was	the	 least	preferred	option	(OR	0.949),	
which	 is	a	statistically	significant	result,	 indicating	a	preference	for	
face-to-face	 access	 compared	 with	 phone	 access.	 Examining	 this	
attribute	 at	 subgroup	 level	 shows	 no	 statistically	 significant	
preference	for	method	of	access	over	another	with	the	exception	of	
instant	 messaging	 within	 the	 16-18	 age	 group	 (OR	 1.108),	 and	
phone	(OR	0.902)	within	the	19-21	age	group.	
	
The	 final	 attribute	 ‘how	 you	 get	 your	 antibiotics’	 showed	 a	
statistically	 significant	 preference	 for	 collection	 from	 a	 pharmacy	
within	 the	 full	 dataset	 compared	 with	 collection	 from	 a	 sexual	
health	 clinic	 (OR	 1.075).	 There	 was	 a	 preference	 for	 posting	 to	
home	 or	 a	 collection	 point	 (OR	 1.011	 and	OR	 1.031	 respectively),	
however	 this	was	not	 statistically	 significant	when	 compared	with	
collection	 from	 a	 sexual	 health	 clinic.	 At	 a	 subgroup	 level,	 there	
were	 very	 few	 statistically	 significant	 preferences	 being	 limited	 to	
collection	from	a	pharmacy	for	females	(OR	1.087),	19-21	year	olds	
(OR	 1.106)	 and	 people	who	 have	 not	 previously	 tested	 for	 an	 STI	













Self-Test	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	
Post	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	
Pharmacy	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	
Education/	Work	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	
GP	Practice	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	
2	Hours	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	
7	Days	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	
Accuracy	
2	in	100	False	Negative	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	
Pharmacy	Consultation	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	
GP	Consultation	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	
Sexual	Health	Clinic	Consultation	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	
Instant	Messenger	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	
Email	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	










Post	to	Home	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	
Post	to	Collection	Point	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	
Collect	from	Pharmacy	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	





















Self-Test	 0.438	 0.344	 0.531	 1.549	 1.410	 1.701	 0.526	 0.432	 0.620	 1.693	 1.541	 1.860	
Post	 0.269	 0.174	 0.363	 1.308	 1.190	 1.438	 0.344	 0.250	 0.439	 1.411	 1.284	 1.551	
Pharmacy	 0.123	 0.039	 0.208	 1.131	 1.040	 1.231	 0.165	 0.081	 0.249	 1.180	 1.085	 1.283	
Education/	Work	 -0.084	 -0.169	 0.001	 0.919	 0.845	 1.001	 -0.310	 -0.395	 -0.225	 0.733	 0.674	 0.798	
GP	Practice	 0.048	 -0.039	 0.135	 1.049	 0.962	 1.145	 -0.010	 -0.097	 0.077	 0.990	 0.908	 1.080	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.603	 0.527	 0.680	 1.828	 1.694	 1.973	 0.580	 0.503	 0.656	 1.786	 1.654	 1.928	
2	Hours	 0.311	 0.230	 0.392	 1.365	 1.259	 1.479	 0.366	 0.285	 0.447	 1.442	 1.329	 1.563	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.170	 -0.241	 -0.098	 0.844	 0.786	 0.906	 -0.127	 -0.198	 -0.056	 0.881	 0.820	 0.945	
Accuracy	
2	in	100	False	Negative	 1.082	 1.032	 1.132	 2.951	 2.807	 3.101	 1.273	 1.223	 1.322	 3.570	 3.396	 3.753	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.171	 0.097	 0.245	 1.187	 1.102	 1.278	 0.214	 0.140	 0.288	 1.239	 1.151	 1.334	
Pharmacy	Consultation	 0.100	 0.027	 0.173	 1.106	 1.028	 1.189	 0.194	 0.121	 0.268	 1.215	 1.129	 1.307	
GP	Consultation	 0.159	 0.085	 0.232	 1.172	 1.089	 1.262	 0.178	 0.104	 0.251	 1.194	 1.110	 1.285	
Sexual	Health	Clinic	Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.065	 -0.136	 0.005	 0.937	 0.873	 1.005	 -0.039	 -0.110	 0.032	 0.962	 0.896	 1.032	
Instant	Messenger	 -0.006	 -0.076	 0.063	 0.994	 0.927	 1.065	 0.060	 -0.010	 0.130	 1.062	 0.990	 1.139	
Email	 0.033	 -0.036	 0.103	 1.034	 0.965	 1.108	 0.060	 -0.009	 0.130	 1.062	 0.991	 1.139	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
How	you	get	Antibiotics	
Post	to	Home	 -0.004	 -0.078	 0.070	 0.996	 0.925	 1.072	 0.027	 -0.046	 0.101	 1.028	 0.955	 1.106	
Post	to	Collection	Point	 0.079	 0.007	 0.151	 1.082	 1.007	 1.163	 -0.017	 -0.089	 0.055	 0.983	 0.915	 1.056	
Collect	from	Pharmacy	 0.062	 -0.014	 0.138	 1.064	 0.986	 1.149	 0.083	 0.007	 0.160	 1.087	 1.007	 1.173	










































Self-Test	 0.509	 0.395	 0.623	 1.664	 1.485	 1.865	 0.297	 0.182	 0.412	 1.346	 1.200	 1.510	 0.639	 0.523	 0.755	 1.895	 1.687	 2.128	
Post	 0.390	 0.275	 0.505	 1.477	 1.316	 1.657	 0.129	 0.013	 0.245	 1.138	 1.013	 1.277	 0.397	 0.281	 0.513	 1.487	 1.324	 1.670	
Pharmacy	 0.239	 0.137	 0.342	 1.270	 1.147	 1.408	 0.021	 -0.082	 0.124	 1.021	 0.921	 1.132	 0.170	 0.067	 0.273	 1.185	 1.069	 1.314	
Education/	Work	 -0.218	 -0.322	 -0.114	 0.804	 0.725	 0.892	 -0.215	 -0.319	 -0.112	 0.806	 0.727	 0.894	 -0.160	 -0.265	 -0.056	 0.852	 0.768	 0.945	
GP	Practice	 0.081	 -0.025	 0.187	 1.085	 0.975	 1.206	 0.035	 -0.072	 0.141	 1.035	 0.931	 1.152	 -0.061	 -0.168	 0.046	 0.941	 0.846	 1.047	
Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.567	 0.474	 0.661	 1.763	 1.606	 1.936	 0.636	 0.542	 0.730	 1.888	 1.719	 2.074	 0.572	 0.478	 0.666	 1.772	 1.613	 1.947	
2	Hours	 0.282	 0.183	 0.381	 1.326	 1.201	 1.464	 0.437	 0.338	 0.536	 1.548	 1.402	 1.709	 0.295	 0.196	 0.395	 1.344	 1.216	 1.484	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.130	 -0.217	 -0.044	 0.878	 0.805	 0.957	 -0.125	 -0.213	 -0.038	 0.882	 0.808	 0.963	 -0.189	 -0.277	 -0.102	 0.828	 0.758	 0.903	
Accuracy	
2	in	100	False	
Negative	 1.196	 1.135	 1.257	 3.307	 3.112	 3.514	 1.151	 1.090	 1.212	 3.161	 2.974	 3.361	 1.188	 1.127	 1.250	 3.282	 3.086	 3.489	
5	in	100	False	
Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	
Consultation	 0.171	 0.081	 0.262	 1.187	 1.085	 1.299	 0.182	 0.092	 0.273	 1.200	 1.096	 1.314	 0.226	 0.135	 0.317	 1.253	 1.144	 1.373	
Pharmacy	
Consultation	 0.154	 0.065	 0.244	 1.167	 1.067	 1.276	 0.190	 0.100	 0.279	 1.209	 1.105	 1.322	 0.098	 0.007	 0.188	 1.102	 1.007	 1.206	
		 317	




































GP	Consultation	 0.246	 0.157	 0.335	 1.279	 1.170	 1.398	 0.133	 0.043	 0.223	 1.142	 1.044	 1.250	 0.125	 0.035	 0.215	 1.133	 1.036	 1.240	
Sexual	Health	
Clinic	Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 0.001	 -0.085	 0.087	 1.001	 0.918	 1.091	 -0.104	 -0.190	 -0.017	 0.902	 0.827	 0.983	 -0.055	 -0.142	 0.031	 0.946	 0.868	 1.032	
Instant	Messenger	 0.102	 0.017	 0.188	 1.108	 1.017	 1.207	 -0.024	 -0.109	 0.062	 0.977	 0.897	 1.064	 0.001	 -0.085	 0.087	 1.001	 0.918	 1.091	
Email	 0.075	 -0.009	 0.160	 1.078	 0.991	 1.174	 0.037	 -0.048	 0.122	 1.038	 0.954	 1.130	 0.029	 -0.056	 0.115	 1.030	 0.945	 1.122	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
How	you	get	Antibiotics	
Post	to	Home	 -0.024	 -0.114	 0.066	 0.977	 0.893	 1.068	 0.010	 -0.081	 0.100	 1.010	 0.922	 1.106	 0.047	 -0.043	 0.137	 1.048	 0.957	 1.147	
Post	to	Collection	
Point	 0.010	 -0.078	 0.097	 1.010	 0.925	 1.102	 0.035	 -0.053	 0.123	 1.036	 0.948	 1.131	 0.046	 -0.042	 0.135	 1.047	 0.959	 1.144	
Collect	from	
Pharmacy	 0.039	 -0.054	 0.132	 1.039	 0.947	 1.141	 0.101	 0.008	 0.195	 1.106	 1.008	 1.215	 0.077	 -0.017	 0.171	 1.080	 0.983	 1.186	
Collect	from	Sexual	























Self-Test	 0.490	 0.396	 0.584	 1.632	 1.486	 1.792	 0.538	 0.434	 0.641	 1.712	 1.543	 1.899	
Post	 0.322	 0.227	 0.416	 1.380	 1.255	 1.516	 0.322	 0.218	 0.425	 1.380	 1.244	 1.530	
Pharmacy	 0.199	 0.115	 0.283	 1.220	 1.122	 1.327	 0.104	 0.011	 0.196	 1.109	 1.011	 1.217	
Education/	Work	 -0.162	 -0.247	 -0.077	 0.851	 0.781	 0.926	 -0.251	 -0.344	 -0.157	 0.778	 0.709	 0.854	
GP	Practice	 -0.006	 -0.093	 0.081	 0.994	 0.911	 1.085	 0.063	 -0.032	 0.159	 1.066	 0.969	 1.172	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.548	 0.471	 0.625	 1.730	 1.602	 1.867	 0.640	 0.556	 0.724	 1.896	 1.743	 2.062	
2	Hours	 0.271	 0.190	 0.352	 1.311	 1.209	 1.422	 0.416	 0.327	 0.505	 1.516	 1.387	 1.657	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.220	 -0.077	 0.862	 0.803	 0.926	 -0.149	 -0.227	 -0.071	 0.862	 0.797	 0.932	
Accuracy	
2	in	100	False	Negative	 1.186	 1.137	 1.236	 3.275	 3.116	 3.443	 1.196	 1.141	 1.250	 3.305	 3.129	 3.492	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.145	 0.071	 0.219	 1.156	 1.074	 1.245	 0.251	 0.169	 0.332	 1.285	 1.185	 1.394	
Pharmacy	Consultation	 0.108	 0.035	 0.182	 1.115	 1.036	 1.199	 0.203	 0.123	 0.284	 1.225	 1.130	 1.328	
GP	Consultation	 0.150	 0.077	 0.223	 1.162	 1.080	 1.250	 0.173	 0.092	 0.253	 1.189	 1.097	 1.288	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.059	 -0.130	 0.011	 0.942	 0.878	 1.011	 -0.077	 -0.155	 0.000	 0.926	 0.856	 1.000	
Instant	Messenger	 0.025	 -0.045	 0.095	 1.025	 0.956	 1.099	 -0.009	 -0.086	 0.068	 0.991	 0.918	 1.071	
Email	 0.066	 -0.003	 0.136	 1.069	 0.997	 1.145	 0.001	 -0.076	 0.077	 1.001	 0.927	 1.080	



















Post	to	Home	 -0.044	 -0.118	 0.030	 0.957	 0.889	 1.030	 0.053	 -0.028	 0.134	 1.055	 0.973	 1.144	
Post	to	Collection	Point	 -0.032	 -0.104	 0.040	 0.968	 0.901	 1.041	 0.070	 -0.009	 0.149	 1.072	 0.991	 1.160	
Collect	from	Pharmacy	 0.067	 -0.009	 0.143	 1.070	 0.991	 1.154	 0.055	 -0.029	 0.139	 1.056	 0.971	 1.149	
Collect	from	Sexual	Health	























Self-Test	 0.422	 0.305	 0.539	 1.524	 1.356	 1.714	 0.518	 0.434	 0.601	 1.678	 1.544	 1.824	
Post	 0.164	 0.047	 0.280	 1.178	 1.048	 1.323	 0.382	 0.298	 0.466	 1.465	 1.347	 1.594	
Pharmacy	 -0.056	 -0.160	 0.048	 0.945	 0.852	 1.049	 0.245	 0.170	 0.320	 1.277	 1.185	 1.377	
Education/	Work	 -0.273	 -0.377	 -0.168	 0.761	 0.686	 0.845	 -0.150	 -0.225	 -0.074	 0.861	 0.798	 0.928	
GP	Practice	 -0.122	 -0.229	 -0.014	 0.885	 0.795	 0.986	 0.097	 0.019	 0.174	 1.101	 1.019	 1.190	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.592	 0.498	 0.687	 1.808	 1.645	 1.988	 0.586	 0.518	 0.654	 1.797	 1.679	 1.923	
2	Hours	 0.305	 0.205	 0.406	 1.357	 1.227	 1.500	 0.353	 0.281	 0.425	 1.423	 1.325	 1.529	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.125	 -0.213	 -0.037	 0.882	 0.808	 0.963	 -0.156	 -0.219	 -0.093	 0.856	 0.803	 0.912	
Accuracy	
2	in	100	False	Negative	 1.099	 1.037	 1.160	 3.000	 2.820	 3.191	 1.248	 1.203	 1.292	 3.482	 3.331	 3.640	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.161	 0.069	 0.252	 1.174	 1.071	 1.287	 0.205	 0.140	 0.271	 1.228	 1.150	 1.311	
Pharmacy	Consultation	 0.094	 0.003	 0.184	 1.098	 1.003	 1.203	 0.168	 0.103	 0.233	 1.183	 1.108	 1.262	
GP	Consultation	 0.106	 0.015	 0.197	 1.112	 1.015	 1.217	 0.195	 0.130	 0.260	 1.215	 1.139	 1.297	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.054	 -0.142	 0.034	 0.947	 0.868	 1.034	 -0.048	 -0.110	 0.015	 0.953	 0.895	 1.015	
Instant	Messenger	 0.044	 -0.042	 0.131	 1.045	 0.958	 1.140	 0.025	 -0.037	 0.087	 1.025	 0.963	 1.091	
Email	 0.048	 -0.038	 0.134	 1.049	 0.962	 1.144	 0.053	 -0.009	 0.114	 1.054	 0.991	 1.121	



















Post	to	Home	 0.011	 -0.081	 0.102	 1.011	 0.922	 1.107	 0.020	 -0.046	 0.085	 1.020	 0.955	 1.089	
Post	to	Collection	Point	 0.034	 -0.056	 0.123	 1.034	 0.946	 1.131	 0.034	 -0.029	 0.098	 1.035	 0.971	 1.103	
Collect	from	Pharmacy	 0.083	 -0.012	 0.177	 1.086	 0.988	 1.194	 0.075	 0.008	 0.143	 1.078	 1.008	 1.153	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Table	6.30	-	Previous	STI	Testing	Subgroup	Analysis	Coefficients	and	Odds	Ratios,	including	Respective	95%	Confidence	Intervals
		 322	
		 Full	Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	 One	Partner	 Prev	Test	 No	Prev	Test	
n	 1,230	 607	 623	 415	 406	 409	 615	 512	 393	 790	
		 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	
How	you	Test	 		 		 		 		 		 		 		 		 		 		
Self-Test	 1.618	 1.549	 1.693	 1.664	 1.346	 1.895	 1.632	 1.712	 1.524	 1.678	
Post	 1.358	 1.308	 1.411	 1.477	 1.138	 1.487	 1.380	 1.380	 1.178	 1.465	
Pharmacy	 1.155	 1.131	 1.180	 1.270	 1.021	 1.185	 1.220	 1.109	 0.945	 1.277	
Education/	Work	 0.821	 0.919	 0.733	 0.804	 0.806	 0.852	 0.851	 0.778	 0.761	 0.861	
GP	Practice	 1.019	 1.049	 0.990	 1.085	 1.035	 0.941	 0.994	 1.066	 0.885	 1.101	
Sexual	Health	Clinic	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
Time	to	Result	 		 		 		 		 		 		 		 		 		 		
30	Mins	 1.806	 1.828	 1.786	 1.763	 1.888	 1.772	 1.730	 1.896	 1.808	 1.797	
2	Hours	 1.402	 1.365	 1.442	 1.326	 1.548	 1.344	 1.311	 1.516	 1.357	 1.423	
7	Days	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
14	Days	 0.862	 0.844	 0.881	 0.878	 0.882	 0.828	 0.862	 0.862	 0.882	 0.856	
Accuracy	 		 		 		 		 		 		 		 		 		 		
2	in	100	False	Negative	 3.242	 2.951	 3.570	 3.307	 3.161	 3.282	 3.275	 3.305	 3.000	 3.482	
5	in	100	False	Negative	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
Consultation	Method	 		 		 		 		 		 		 		 		 		
Online	Consultation	 1.212	 1.187	 1.239	 1.187	 1.200	 1.253	 1.156	 1.285	 1.174	 1.228	
Pharmacy	Consultation	 1.158	 1.106	 1.215	 1.167	 1.209	 1.102	 1.115	 1.225	 1.098	 1.183	
GP	Consultation	 1.183	 1.172	 1.194	 1.279	 1.142	 1.133	 1.162	 1.189	 1.112	 1.215	
Sexual	Health	Clinic	Consultation	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
Access	to	Healthcare	Professional	 		 		 		 		 		 		 		 		 		
Phone	 0.949	 0.937	 0.962	 1.001	 0.902	 0.946	 0.942	 0.926	 0.947	 0.953	
Instant	Messenger	 1.027	 0.994	 1.062	 1.108	 0.977	 1.001	 1.025	 0.991	 1.045	 1.025	
Email	 1.048	 1.034	 1.062	 1.078	 1.038	 1.030	 1.069	 1.001	 1.049	 1.054	
Face	to	Face	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
How	you	get	Antibiotics	 		 		 		 		 		 		 		 		 		
Post	to	Home	 1.011	 0.996	 1.028	 0.977	 1.010	 1.048	 0.957	 1.055	 1.011	 1.020	
Post	to	Collection	Point	 1.031	 1.082	 0.983	 1.010	 1.036	 1.047	 0.968	 1.072	 1.034	 1.035	
Collect	from	Pharmacy	 1.075	 1.064	 1.087	 1.039	 1.106	 1.080	 1.070	 1.056	 1.086	 1.078	







the	 potential	 uptake	 of	 new	 services	 (Ryan	 et	 al.	 2014).	 The	
probability	 that	 an	 individual	 takes	 up	 a	 given	 option	 (P1)	 is	 the	
exponential	of	the	utility	divided	by	the	sum	of	all	of	the	alternatives,	
this	is	represented	in	the	following	equation:	
	 !" = $%&= 1	$)	*) 	
	
Where	 j	 is	 the	alternative	and	J	 is	any	other	alternative	within	the	
choice	set	(Ryan	et	al.,	2014).		
	
Utilising	 the	 coefficients	 from	 the	 DCE	 results	 in	 table	 6.27,	 the	
probability	 of	 uptake	 has	 first	 been	 considered	 for	 the	 three	
pathways	within	the	eSTI2	exploratory	study:	the	sexual	health	clinic	
(the	reference	pathway	within	the	DCE),	 the	NCSP	 internet	testing	
pathway,	 and	 fully	 remote	 online	 pathway,	 and	 the	 ‘I	 would	 not	
test’	 option.	Recognising	 that	 test	 accuracy	has	been	 identified	as	
the	 attribute	 for	 which	 respondents	 expressed	 the	 strongest	
preference,	accuracy	has	been	assumed	to	be	the	same	for	the	fully	
remote	online	pathway	as	 for	 the	GUM	and	NCSP	 internet	 testing	
pathway	for	this	initial	analysis.	Table	6.33	summarises	the	make-up	
of	 the	 pathway	 attributes	 and	 levels	 and	 table	 6.34	 contains	 the	
sum	 of	 the	 coefficients	 for	 each	 of	 the	 pathway	 options	 and	 for	
each	of	 the	 sub-groups	within	 the	DCE	analysis.	 Table	6.35	 shows	








































		 Full	Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	 One	Partner	 Prev	Test	 No	Prev	Test	
Pathways	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	
Sexual	Health	Clinic	Pathway	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	
NCSP	Postal	Testing	Pathway	 0.377	 0.262	 0.495	 0.453	 0.294	 0.382	 0.349	 0.431	 0.214	 0.469	
Fully	Remote	Online	Pathway		 1.284	 1.209	 1.365	 1.288	 1.113	 1.459	 1.191	 1.406	 1.203	 1.336	












Pathways	 OR	 OR	 OR	 OR	 OR	 OR	 OR	 OR	 OR	 OR	
Sexual	Health	Clinic	Pathway	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
NCSP	Postal	Testing	Pathway	 1.458	 1.299	 1.641	 1.572	 1.342	 1.465	 1.418	 1.539	 1.239	 1.599	
Fully	Remote	Online	Pathway	(Pharmacy	
Collect)	 3.612	 3.350	 3.914	 3.624	 3.043	 4.301	 3.290	 4.078	 3.331	 3.806	
I	would	not	Test	 0.186	 0.205	 0.166	 0.267	 0.149	 0.153	 0.202	 0.134	 0.102	 0.233	
Table	6.34	-	Pathway	Odds	Ratios	
	





Sexual	health	clinic	 16%	 17%	 15%	 15%	 18%	 14%	 17%	 15%	 18%	 15%	
NCSP	Postal	Testing	 23%	 22%	 24%	 24%	 24%	 21%	 24%	 23%	 22%	 24%	
Fully	Remote	Online	Pathway	
(Pharm	Collect)	 58%	 57%	 58%	 56%	 55%	 62%	 56%	 60%	 59%	 57%	
I	would	not	test	 3%	 4%	 2%	 4%	 3%	 2%	 3%	 2%	 2%	 4%	






This	analysis	predicts	 that	 should	 the	 fully	 remote	online	pathway	
be	 introduced,	 a	 higher	 proportion	 of	 people	 choosing	 to	 test	
across	 all	 subgroups	 would	 choose	 this	 pathway	 to	 test	 and	 get	
treatment.	The	pathway	with	the	second	highest	uptake	would	be	
the	NCSP	 internet	 testing	pathway,	 followed	 closely	by	 the	 sexual	





is	 not	 misinterpreted	 when	 applying	 it	 to	 uptake.	 In	 framing	 the	
DCE	questionnaire,	the	introduction	to	the	survey	stated:	
“In	 completing	 the	 survey	 you	will	 be	presented	with	a	number	of	





The	 decision	 not	 to	 test	 is	 taken	 within	 the	 context	 of	 the	 two	
individual	 testing	 choices	 presented	 to	 the	 individual,	 having	 just	
been	presented	with	a	 summary	of	why	 it	 is	 important	 to	 test	 for	
chlamydia	 and	 the	 consequences	 of	 not	 testing.	 	 This	 cannot	 be	
interpreted	 in	 the	 same	way	 as	 an	 individual	 deciding	whether	 to	




Having	 considered	 the	 implementation	 of	 a	 fully	 remote	 online	
pathway	alongside	two	existing	pathways,	the	data	can	also	be	used	
to	 optimise	 the	 fully	 remote	 online	 pathway,	 assess	 the	 likely	
impact	 of	 integrating	 new	 technology	 and	 remote	 options	 into	




Although	 it	 is	 predicted	 that	 the	 envisaged	 fully	 remote	 online	
pathway	 would	 have	 a	 greater	 uptake	 than	 the	 existing	 sexual	
health	 clinic	 or	 NCSP	 internet	 testing	 pathways,	 the	 coefficients	
presented	in	tables	6.28	to	6.32	demonstrate	that	the	combination	




the	 levels	 with	 the	 strongest	 preference	 in	 the	 main	 dataset	 for	
each	 attribute	 leads	 to	 two	 changes	 being	 made	 to	 levels	 –	 to	
increase	 the	 accuracy	 of	 the	 test	 result	 to	 ‘two	 in	 100	 results	 are	
false	negatives’,	and	changing	access	to	a	healthcare	professional	to	
‘email	access’,	as	illustrated	in	table	6.36.	Creating	a	scenario	where	








































Pathways	 		 		 		 		 		 		 		 		 		 		
Concept	Fully	Remote	Online	
Pathway	 22%	 23%	 20%	 22%	 21%	 22%	 21%	 22%	 23%	 20%	
Optimum	Fully	Remote	Online	
Pathway		 77%	 75%	 79%	 77%	 78%	 78%	 78%	 78%	 76%	 78%	
Not	Test	 1%	 1%	 1%	 2%	 1%	 1%	 1%	 1%	 1%	 1%	







of	 the	equation,	 and	 focusing	 specifically	on	 the	element	of	 the	pathway	
relating	 to	 treatment,	 there	 are	 two	 attributes	 which	 warrant	 further	
exploration.	These	are	 ‘access	to	a	healthcare	professional’	and	 ‘how	you	
get	your	antibiotics’	because	the	results	indicated	no	statistically	significant	
difference	 in	preference	between	the	 levels	 in	the	majority	of	subgroups.	
This	 is	worthy	 of	 further	 consideration	 because	 it	 suggests	 that	 it	 would	
have	a	minimal	influence	over	people’s	decision	to	choose	an	option.	From	
a	 health	 service	 delivery	 perspective	 this	 may	 be	 an	 important	





you	 get	 your	 antibiotics’	 varied	 for	 each	of	 the	possible	 levels,	 and	 table	
6.39	 outlines	 the	 probability	 of	 uptake	 if	 each	 of	 the	 four	 options	 were	
available.	 This	 demonstrates	 very	 little	 difference	 in	 uptake	 between	 the	
four	pathways	(24-26%)	with	‘collect	from	pharmacy’	being	the	option	with	
the	 highest/	 joint	 highest	 probability	 of	 uptake	 in	 all	 subgroups,	 except	
males,	where	a	slightly	higher	preference	for	delivery	to	collection	point	is	
expressed.	Delivery	 to	 collection	point	was	 also	 as	 likely	 to	be	 chosen	 as	
collection	 from	pharmacy	 in	 the	 16-18	 age	 range	 and	 people	 in	 a	 sexual	
relationship	 with	 one	 partner.	 Whilst	 there	 are	 examples	 of	 delivery	 of	
drugs	for	chlamydia	within	private	sexual	healthcare	there	are	no	examples	
within	mainstream	sexual	health	services,	therefore	identifying	an	area	of	
further	 research	 in	 the	 development	 of	 remote	 sexual	 health	 pathways.
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Pathways	 		 		 		 		 		 		 		 		 		 		
Collect	from	pharmacy	 26%	 25%	 26%	 25%	 26%	 26%	 26%	 25%	 26%	 26%	
Deliver	to	home	 24%	 24%	 25%	 24%	 24%	 25%	 24%	 25%	 24%	 24%	
Deliver	to	collection	point	 25%	 26%	 24%	 25%	 25%	 25%	 24%	 25%	 25%	 25%	
Collect	from	sexual	health	clinic	 24%	 24%	 24%	 24%	 24%	 24%	 25%	 24%	 24%	 24%	
Not	Test	 1%	 2%	 1%	 2%	 1%	 1%	 2%	 1%	 1%	 2%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.39	-	Probability	of	Pathway	Uptake	(How	you	get	your	antibiotics	options)	
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Exploring	 access	 to	 a	 healthcare	 professional	 within	 the	 context	 a	 fully	
remote	online	pathway	is	also	an	important	consideration	when	optimising	
the	pathway	to	maximise	likely	uptake.	The	full	dataset	shows	a	statistically	
significant	 preference	 for	 not	 using	 the	 phone	 to	 access	 a	 healthcare	
professional	with	a	weaker	preference	for	this	than	the	comparator	(face-
to-face).	 The	 strongest	 preference	 within	 this	 attribute	 (although	 not	
statistically	significant)	is	email.		
	
Table	 6.40	 summarises	 the	 pathway	make	 up,	 and	 table	 6.41	 shows	 the	
probability	of	uptake	should	each	of	the	four	pathways	be	available.	Again,	
there	 is	 very	 little	 difference	 in	 likely	 uptake	between	 the	 four	pathways	
when	 the	 ‘access	 to	 healthcare	 professional’	 attribute	 is	 varied	 with	 the	
range	of	uptake	across	the	four	pathways	from	23%	to	26%.	Email	access	to	
a	healthcare	professional	 is	 the	most	consistently	preferred	option	across	
all	 subgroups	with	 the	 exception	of	 16-18	 year	 olds	who	would	be	more	
likely	 to	 choose	 the	pathway	with	access	 to	a	healthcare	professional	 via	
instant	 message	 (IM).	 Females,	 and	 those	 who	 have	 previously	 tested	
demonstrate	 no	 difference	 in	 likely	 uptake	 between	 email	 and	 IM,	 and	
people	in	a	sexual	relationship	with	one	partner	demonstrate	no	difference	
in	likely	uptake	between	IM,	email	and	face-to-face.	Again,	the	exploration	
of	 the	 acceptability	 of	 IM	 and	 email	 options	 to	 access	 a	 healthcare	



















































Pathways	 		 		 		 		 		 		 		 		 		 		
Phone	 23%	 23%	 23%	 23%	 23%	 24%	 23%	 23%	 23%	 23%	
IM	 25%	 25%	 26%	 26%	 25%	 25%	 25%	 25%	 26%	 25%	
Email	 26%	 26%	 26%	 25%	 26%	 26%	 26%	 25%	 26%	 26%	
Face	to	Face	 25%	 25%	 24%	 23%	 25%	 25%	 24%	 25%	 25%	 24%	
Not	Test	 1%	 1%	 1%	 2%	 1%	 1%	 1%	 1%	 1%	 1%	





Focusing	on	 the	delivery	of	 care	via	 sexual	health	clinics,	 the	data	
allow	a	similar	approach	 to	be	applied	 to	optimising	sexual	health	
clinic	 pathways	 in	 respect	 of	 the	 preferences	 expressed	 by	 young	
people	 in	 the	 DCE.	 Considering	 specifically	 the	 access	 to	 a	 health	
care	 professional	 attribute,	 as	 non-face-to-face	 consultation	






results,	 the	 probability	 of	 uptake,	 if	 the	 population	 are	 presented	
with	each	of	the	four	choices	are	broadly	similar.	This	demonstrates	
a	 marginally	 higher	 probability	 of	 uptake	 for	 non-face-to-face	
access	methods,	with	the	exception	of	the	‘in	a	sexual	relationship	
with	 one	 partner’	 subgroup	 where	 face-to-face	 has	 the	 same	
probability	 as	 email.	 Of	 interest,	 in	 all	 but	 one	 subgroup,	 the	
probability	of	 uptake	 is	 highest	 (or	 tied	 joint	highest)	 for	 email	 as	
the	 access	 option	 in	 all	 subgroups	 except	 16-18	 year	 olds	 who	
prefer	 the	 IM	 route.	 Of	 the	 preferred	 options,	 it	 is	 interesting	 to	
note	 that	 the	options	which	do	not	 involve	speaking	 to	a	HCP	are	



























































Pathways	 		 		 		 		 		 		 		 		 		 		
Face	to	Face	 24%	 24%	 24%	 22%	 25%	 24%	 24%	 25%	 24%	 23%	
Phone	 23%	 22%	 23%	 22%	 22%	 23%	 22%	 23%	 23%	 22%	
IM	 24%	 24%	 25%	 25%	 24%	 24%	 24%	 24%	 25%	 24%	
Email	 25%	 25%	 25%	 24%	 26%	 25%	 25%	 25%	 25%	 25%	
Not	Test	 4%	 5%	 4%	 6%	 4%	 4%	 5%	 3%	 2%	 5%	




sexual	 health	 clinic	 pathway	 (as	 opposed	 to	 the	 whole	 pathway),	
there	 is	a	notable	 impact	as	a	result	of	optimising	the	three	 levels	
relating	to	treatment	–	consultation	method,	access	to	a	healthcare	
professional	 and	 the	 route	 for	 obtaining	 antibiotics.	 Table	 6.44	
shows	 the	 make-up	 of	 a	 typical	 sexual	 health	 clinic	 pathway	
compared	 with	 the	 pathway	 with	 the	 highest	 strength	 of	
preference	for	the	three	treatment	levels.	Table	6.45	demonstrates	
that	 if	 both	 pathways	were	 available	 the	 uptake	of	 the	 optimised	
pathway	 would	 be	 54%	 compared	 with	 39%	 for	 the	 current	
pathway.	 There	 is	 a	 consistently	 higher	 probability	 across	 all	
subgroups	analysed.		
	
The	 significance	 of	 this	 finding	 is	 material	 within	 the	 context	 of	
delivering	sexual	health	clinic	services.	Of	all	of	the	service	options	
available,	the	sexual	health	clinic	is	the	most	comprehensive	owing	
to	 the	 range	 of	 tests	 it	 offers	 and	 diseases	 it	 treats,	 this	 cannot	







testing	 positive	 for	 genital	 chlamydia	 only.	 Data	 on	 co-infection	
rates	are	limited,	with	one	study	in	an	English	GUM	clinic	suggesting	
that	 28%	 of	 women	 testing	 positive	 for	 chlamydia	 had	 coexisting	
STIs	(Harindra	et	al.,	2002).	This	suggests	that	a	high	proportion	of	
those	 testing	 positive	 within	 a	 clinic	 setting	 test	 positive	 for	
chlamydia	 only	 and	 therefore	 could	 use	 the	 online	 consultation	








































Pathways	 		 		 		 		 		 		 		 		 		 		
Sexual	Health	Pathway	-	Current	 39%	 40%	 39%	 39%	 40%	 39%	 40%	 40%	 41%	 38%	
Sexual	Health	Pathway	-	
Optimised	Treatment	Element	 54%	 52%	 55%	 51%	 55%	 55%	 52%	 55%	 55%	 53%	
Not	Test	 7%	 8%	 6%	 10%	 6%	 6%	 8%	 5%	 4%	 9%	








to	 the	considerable	variation	 in	pathways	across	England,	 this	will	
be	explored	further	in	Chapter	7.	Focusing	on	two	of	the	treatment	





uptake	 than	 the	 other	 two	 options	 across	 the	 full	 dataset	 and	 all	
subgroups	analysed.	
	
Within	 the	 context	 of	 treatment	 uptake	 rates	 this	 finding	may	 be	
particularly	 significant	 for	 NCSP	 services	 where	 the	 last	 data	
published	 (2011-12)	 show	 significant	 variation	 in	 the	 range	 of	

























































Pathways	 		 		 		 		 		 		 		 		 		 		
NCSP	Internet	Testing	Pathway	-	
Pharmacy	 29%	 28%	 30%	 28%	 31%	 28%	 29%	 31%	 30%	 29%	
NCSP	Internet	Testing	Pathway	
GP	 30%	 30%	 30%	 31%	 29%	 29%	 30%	 30%	 30%	 30%	
NCSP	Internet	Testing	Pathway	
Optimised	 37%	 37%	 37%	 36%	 36%	 40%	 37%	 37%	 38%	 37%	
Not	Test	 4%	 4%	 3%	 5%	 3%	 3%	 4%	 3%	 2%	 4%	





Data	 from	 the	DCE	 can	also	be	used	 to	explore	 the	 impact	of	 the	
test	 parameters	 to	 inform	 the	 acceptability	 of	 new	 chlamydia	
testing	pathways.	Focusing	specifically	on	the	first	 three	attributes	
in	 the	pathway	–	how	you	 test,	how	 long	you	wait	 for	your	 result	
and	 test	 accuracy,	 analysis	 can	 be	 undertaken	 to	 understand	 the	
probability	of	uptake	and	trade-offs	between	attributes.		
	
As	 identified	 in	 section	6.5.3	accuracy	 is	 consistently	 the	attribute	
with	 the	 strongest	 preference	 across	 all	 subgroups.	 Looking	
specifically	 at	 the	 trade-off	 between	 accuracy	 and	 time	 to	 result,	


































Pathways	 		 		 		 		 		 		 		 		 		 		
5	in	100/	
30min	 38%	 40%	 35%	 36%	 39%	 38%	 36%	 39%	 40%	 36%	
2	in	100/	14	
days	 58%	 55%	 62%	 59%	 58%	 59%	 59%	 58%	 58%	 59%	
Not	Test	 4%	 5%	 3%	 5%	 3%	 3%	 4%	 3%	 2%	 5%	














preferences	 for	 new	 technologies	 in	 the	 testing	 and	 treatment	 of	
chlamydia.	 This	 method	 enables	 an	 understanding	 of	 the	 relative	
strength	 of	 preference	 between	 attributes	 and	 levels,	 and	 can	 be	
used	 by	 technology	 developers,	 policy	 makers,	 commissioners	 and	
service	 providers	 to	 give	 a	 first	 insight	 into	 preferences	 for	 new	
technologies	 which	 are	 currently	 in	 development	 and	 could	 be	
available	for	use	within	mainstream	services	within	the	next	three	to	
five	years	compared	with	features	of	existing	products	and	services.	
It	 highlights	 that	 accuracy	 is	 of	 critical	 importance	 in	 new	 test	
development	for	young	people,	with	time	to	result	second	to	this.	It	










of	 Coast	 and	 colleagues,	 which	 include	 ensuring	 attributes	 are	
“manipulable	 in	 policy”	 (Coast	 et	 al.,	 2012:739),	 the	 conduct	 of	
piloting,	 ensuring	 that	 ‘meaningful	 language’	 is	 used,	 clarity	 on	 the	




analysis	 and	 subsequent	 comparison	 between	 a	 number	 of	
subgroups	 including	gender,	age	range,	previous	 testing	history	and	
two	 relationship	 categories.	 Participants	 were	 drawn	 from	 the	
general	population	rather	than	via	health	care	settings	thus	enabling	
access	 to	 a	 population	 who	 had	 not	 previously	 tested	 for	 an	 STI	
before,	 setting	 it	 apart	 from	much	 of	 the	 previous	 research	 which	
focused	 on	 service	 users.	 This	 general	 population	 sample	 enables	
consideration	 of	 the	 preferences	 of	 those	 who	 have	 not	 used	 STI	




The	 use	 of	 an	 online	 panel	 provided	 analytics	 data	 to	 support	 the	
validity	 tests	 employed	 for	 the	 DCE.	 The	 accurate	 record	 of	 time	
taken	 to	 complete	 the	 survey	enabled	 validity	 checks,	which	would	
not	 have	 otherwise	 been	 possible	 with	 a	 written	 questionnaire	
response.	 However,	 the	 use	 of	 an	 online	 panel	 may	 limit	 the	




Given	 the	 breadth	 of	 sample	 achieved	 via	 the	 online	 panel	 as	
outlined	in	section	6.5.1	and	the	high	proportion	(97%)	of	15-24	year	
olds	 accessing	 the	 internet	 daily	 via	 a	 mobile	 device	 (ONS,	 2016a)	
and	owning	a	smartphone	(Ipsos	Media	CT,	2016)	this	demonstrates	




A	 number	 of	 limitations	 were	 identified	 whilst	 undertaking	 this	
research.	 The	 first	 relates	 to	 the	 selection	 of	 attributes	 and	 levels.	
Whilst	 it	 is	 identified	 that	 a	 strength	 of	 the	 process	 is	 the	 rigour	
employed	 in	 the	 selection	 process	 of	 attributes	 and	 levels,	 this	
cannot	 detract	 from	 the	 higher	 absolute	 number	 of	 attributes	 that	
are	involved	in	a	chlamydia	testing	and	treatment	pathway,	and	how	
these	 might	 impact	 on	 individual	 choices.	 To	 address	 this,	 where	
known	 attributes	 were	 excluded,	 as	 reported	 in	 section	 5.4.5,	
information	 was	 included	 in	 the	 background	 to	 minimise	 the	 risk	
associated	with	respondents	forming	their	own	views	on	the	impact	
of	these	attributes	on	the	pathway.	Range	of	STI	tests	was	identified	
as	 a	 significant	 factor	 by	 the	 focus	 groups	 during	 the	 research	 to	
select	 the	 attributes	 and	 levels	 included	 within	 the	 questionnaire.	
However,	 due	 to	practicalities	 in	 the	design	 and	 implementation	of	
the	DCE	it	was	not	possible	to	incorporate	this	attribute	into	the	final	
DCE	 without	 compromising	 the	 results.	 Key	 to	 this	 is	 what	 the	
respondent	 was	 considering	 at	 the	 time	 they	 complete	 the	
questionnaire,	 for	 example,	 which	 STI	 were	 they	 thinking	 of	 when	
completing	the	questionnaire.	The	focus	groups	touched	on	this	with	






feedback	 between	 the	 cognitive	 testing	 and	 final	DCE	 respondents.	
Whilst	 the	cognitive	 testing	did	not	 indicate	 that	participants	 found	
the	questionnaire	repetitive	during	the	testing	phase,	respondents	to	
the	 final	DCE	cited	this	 in	 their	qualitative	 feedback	to	 the	research	
company.	The	design	of	the	DCE	did	allow	for	a	number	of	options,	as	
outlined	 in	section	6.5.2.5,	which	may	mean	that	options	 for	 future	
research	 include	 blocking	 the	 design	 to	 three	 questionnaires	 to	
reduce	the	number	of	choice	sets	to	17	(16	plus	consistency	check).	
	
The	 final	 limitation	 identified	was	 the	model	 selected	 for	 analysing	
the	DCE	 results.	Methodological	 publications	 (Louviere	 et	 al.,	 2000,	
Ryan	et	al.,	2008,	Hauber	et	al.,	2016)	 indicate	a	number	of	models	
which	to	be	used	for	the	analysis	of	DCE	results	which	allow	for	both	
the	partial	and	 full	 relaxation	of	 the	 IIA.	Whilst	 it	 is	 recognised	 that	
the	 MNL	 model	 used	 is	 the	 ‘workhorse’	 for	 DCE	 analysis,	 it	 was	
beyond	 the	 scope	 of	 this	 research	 to	 explore	 the	 comparisons	 in	







investigation.	 However,	 this	 does	 not	 allow	 for	 the	 full	 extent	 of	
other	 modelling	 approaches	 such	 as	 latent	 class	 modelling	 which	





Of	 the	 other	 stated	 preference	 studies	 identified	 in	 the	 literature	
review	 in	 section	 4.2	 it	 is	 difficult	 to	 draw	 a	 direct	 comparison	 in	
respect	 of	 the	 findings	 because	 of	 the	 variance	 in	 study	 objectives	
relating	to	the	testing	and	treatment	of	STIs,	and	range	of	attributes	
and	levels	included.	Miners	and	colleagues	(2012),	and	Llewellyn	and	
colleagues	 (2013)	 have	 conducted	 the	 only	 other	 DCEs	 exploring	
preferences	 for	 sexual	health	 services	 in	England	however	 focus	on	
preferences	 within	 traditional	 service	 delivery	 models	 rather	 than	
considering	the	use	of	new	technologies.	These	DCEs	are	also	general	
in	respect	of	looking	at	preferences	for	sexual	health	services,	rather	
than	 focusing	 on	 one	 STI.	 It	 is	 not	 known	 when	 expressing	 their	
preferences	 how	 participants	 have	 been	 directed	 to	 consider	 what	
STI	 they	 may	 have.	 As	 identified	 in	 the	 focus	 groups	 with	 young	
people	 and	 expert	 groups	 the	 range	 of	 tests	 is	 an	 important	




In	 their	 exploration	 of	 the	 preferences	 for	 chlamydia	 screening	 in	
family	 planning	 clinics	 Watson	 and	 colleagues	 identified	 that	
screening	 at	 a	 family	 planning	 clinic	 increases	 the	 preference	 for	
screening	 whilst	 screening	 at	 home	 “is	 significant	 and	 negative,	
implying	 a	negative	effect	 on	 screening	preference”	 (Watson	et	 al.,	
2009:622).	 This	 is	 at	 odds	with	 the	 finding	within	 this	 study	which	
indicates	 significant	 positive	 preferences	 for	 both	 self-testing,	 and	
self-sampling	 and	 posting	 the	 result	 to	 a	 laboratory	 for	 analysis.	












clinic	 appointments	 (Miners	 et	 al.,	 2016).	 Miners	 and	 colleagues	
found	 that	 patients	 living	 with	 HIV	 had	 a	 stronger	 preference	 for	
shorter	waiting	times,	however	latent	class	modelling	demonstrated	
the	 two	 groups	 had	 differing	 preferences	 for	 HIV	 clinic	 and	 GP	
appointments	(Miners	et	al.,	2016).		
		
Considering	 the	 findings	 of	 this	 study	 within	 the	 context	 of	 the	
national	 policy	 direction	 of	 increasing	 digital	 access	 (NHS	 England,	
2014),	 and	 reducing	 face-to-face	 appointments	 (Department	 of	
Health,	 2011),	 it	 is	 interesting	 to	 note	 that	 whilst	 the	 lack	 of	 clear	
preference	 does	 not	 inform	 the	 redesign	 of	 pathways	 from	 the	
perspective	 of	 increasing	 uptake,	 the	 ambivalence	 suggests	 that	
alternative,	 more	 cost-efficient	 methods	 could	 be	 employed	 to	




health	 services,	 this	 DCE	 provides	 some	 evidence	 to	 support	 the	
policy	 direction	 of	 remote	 testing	 and	 treatment	 options.	 It	 offers	
commissioners	 insight	 into	 how	 young	 people	 may	 respond	 to	
changes	to	pathways	and	the	introduction	of	new	technologies.	This	
information	 will	 be	 beneficial	 in	 informing	 piloting	 of	 new	 service	
models.		However,	in	respect	of	the	fully	remote	online	pathway	it	is	
important	 to	note	 that	although	 the	 characteristics	of	 this	pathway	
demonstrate	 that	 should	 it	 exist	 the	probability	 of	 uptake	 is	 higher	




This	 suggests	 that	 whilst	 new	 technology	 has	 a	 role	 to	 play	 in	
increasing	 uptake,	 it	 is	 most	 likely	 as	 an	 additional	 rather	 than	
replacement	option.	
	
For	 technology	 developers	 the	 DCE	 highlights	 important	
considerations	 for	 test	 development,	 namely	 the	 strength	 of	
preference	 for	 test	 accuracy	 over	 other	 product	 characteristics	
included	 within	 the	 DCE.	 From	 the	 perspective	 of	 the	 delivery	 of	
online	 treatment	pathways	 it	 suggests	 that	consideration	should	be	
given	 to	 other	methods	 of	 contacting	 a	 healthcare	 professional	 for	
advice	if	necessary,	particularly	email	and	IM.		
	
There	 are	 a	 number	 of	 questions	 that	 the	 DCE	 does	 not	 answer,	
which	 are	 important	 considerations	 in	 the	 adoption	 of	 new	




other	 STIs	 to	 ensure	 that	 this	 is	 recognised	 in	 future	 service	
pathways.	 The	 complexities	 of	 options	 relating	 to	 testing	 and	
treatment,	 in	particular	what	can	be	delivered	safely	and	effectively	
remotely	mean	that	a	very	different	selection	of	attributes	and	levels	






made	 during	 the	 design	 phase	 of	 the	 research	 as	 it	 is	 a	 legal	
requirement	 that	 local	 authorities	 provide	 open	 access	 STI	 testing	
and	treatment	services,	therefore	under	current	legislation	users	will	
never	pay	a	 fee	 to	use	 the	 service.	However,	 the	 costs	 from	a	user	
perspective	 are	 notably	 different	 for	 different	 service	 options	 in	






of	 other	 STIs	 is	 one	 of	 a	 number	 of	 potential	 areas	 for	 future	
research.	 The	 DCE	 has	 also	 identified	 a	 number	 of	 other	
considerations	 for	 future	 research	 in	 respect	 of	 service	 delivery	
models,	 as	 well	 as	 some	 considerations	 for	 further	 research	 in	
respect	 of	 the	 DCE	 methodology.	 In	 respect	 of	 service	 delivery	
models,	 as	outlined	previously,	 two	of	 the	areas	warranting	 further	
exploration	are	 the	 routes	of	 access	 to	a	healthcare	professional	 in	
the	 delivery	 of	 treatment	 consultations,	 and	 the	 use	 of	 postal	
solutions	for	the	provision	of	drugs.		
	
In	 respect	 of	 methodological	 considerations,	 a	 number	 of	 issues	
where	 there	 is	 an	 absence	 of	 consensus	 on	 the	 most	 appropriate	
approach	 have	 been	 identified	 which	 may	 warrant	 further	
exploration	to	improve	consistency	in	the	application	of	the	method.	
Firstly,	 the	 number	 of	 choice	 sets	 included	 in	 the	 DCE.	 The	 online	
panel	 feedback	 indicated	 that	 participants	 found	 it	 repetitive,	
whereas	 this	 was	 not	 a	 theme	 identified	 at	 the	 cognitive	 testing	
stage.	 	 Understanding	 the	 extent	 of	 the	 impact	 of	 the	 number	 of	
choice	sets	within	the	questionnaire	in	respect	of	the	internal	validity	






be	 retained	 from	 and	 whether	 there	 is	 a	 threshold	 at	 which	





The	DCE	 has	 identified	 that	 the	 strongest	 attribute	 affecting	 young	
people’s	 preferences	 for	 chlamydia	 testing	 and	 treatment	was	 test	
accuracy,	 followed	 by	 time	 to	 result.	 The	 results	 demonstrated	 a	
general	 preference	 for	 remote	 pathway	 options,	 including	 self-
testing	 and	 self-sampling	 and	 posting	 the	 sample	 for	 analysis	 over	
attending	 a	 healthcare	 setting	 for	 testing.	 This	 is	 also	 reflected	 in	
treatment	 preferences,	 with	 participants	 indicating	 a	 general	
preference	for	online	consultation	to	consultation	via	GP,	pharmacy	
or	a	sexual	health	clinic.	Little	difference	was	observed	between	face-
to-face,	 telephone,	 email	 or	 instant	 messaging	 for	 accessing	 a	
healthcare	 professional.	 Interestingly	 the	 preference	 for	 remote	
options	did	not	hold	true	for	this	attribute,	with	face-to-face	contact	




Exploring	 the	 optimisation	 of	 pathways	 has	 demonstrated	 the	
potential	impact	of	levels	on	the	uptake	of	services,	both	in	terms	of	
new	pathways,	and	by	optimising	existing	pathways,	demonstrating	
the	 potential	 impact	 that	 substituting	 alternative	 options	 into	
existing	 pathways	 may	 have.	 The	 findings	 suggest	 that	 should	 an	
OCCP	 or	 fully	 remote	 online	 pathway	 be	 available	 a	 higher	




The	 next	 chapter,	 Chapter	 7,	 considers	 the	 costs	 and	 benefits	 of	
implementing	 eHealth	 clinics	 for	 the	 treatment	 of	 chlamydia	 and	
Chapter	8	builds	on	this,	taking	forward	the	work	of	Chapter	7	into	a	
preliminary	 economic	 evaluation	 of	 the	 OCCP	 and	 a	 fully	 remote	
online	 pathway	 and	 utilises	 the	 DCE	 coefficients	 identified	 in	 this	

















impact	 on	 costs	 of	 the	 introduction	 of	 the	 OCCP	 into	 mainstream	
sexual	health	services.	This	chapter	therefore	centres	on	the	eHealth	
clinic	 component	of	 the	pathway	only.	 In	 the	 following	 chapter	 the	
adoption	of	a	fully	remote	online	pathway	(Pathway	E,	figure	2.1)	will	
be	considered	in	a	decision	analytic	model.	Within	the	frameworks	of	
product	 development,	 HTA	 and	 economic	 evaluation	 outlined	 in	
table	3.5	the	OCCP	can	be	categorised	at	stage	2	in	its	development	–	
translational	research,	early	health	technology	assessment,	maturing	
innovation.	 This	 classification	 of	 the	 technology	 has	 been	 used	 to	











Figure	 7.1	 illustrates	 the	 scope	 of	 the	 pathways	 included	 in	 the	
costing	 study.	 This	 starts	 at	 results	 notification	 and	 concludes	
following	health	advisor	follow	up	(indicated	by	the	orange	shading).	
The	 three	 pathways	 included	 are	 GUM	 clinic	 and	 NCSP	 internet	
testing	pathways	(the	comparator	pathways)	and	the	OCCP.	For	this	
exploratory	 study,	 in	 the	 absence	 of	 a	 self-test,	 results	 notification	
was	undertaken	by	participants	logging	into	the	eHealth	clinic	to	get	

















This	 section	 builds	 on	 the	 high	 level	 introduction	 to	 the	methods	
adopted	 and	 the	 rationale	 for	 their	 selection	 in	 section	 3.5.1,	




Mogyorosy	&	 Smith	 identified	 in	 their	 literature	 review	 that	 the	
definition	 of	 the	 decision	 problem	 has	 an	 impact	 on	 all	
subsequent	 decisions	 in	 the	 evaluation	 (Mogyorosy	 &	 Smith,	





The	 decision	 problem	 within	 this	 study	 was	 framed	 within	 the	
context	of	eHTA:	to	quantify	the	likely	costs	and	outcomes	of	the	
OCCP	 in	 comparison	 with	 GUM	 and	 NCSP	 internet	 testing	
pathways.	 Drummond	 and	 colleagues	 identify	 a	 number	 of	
perspectives	that	can	be	applied	in	both	the	selection	of	costs	and	
consequences	 including	 the	 individual,	 healthcare	 providers,	
healthcare	purchasers	and	societal	(Drummond	et	al.,	2015).	They	
propose	that	the	perspective	taken	should	reflect	the	perspective	
of	 the	 audience	 intended	 to	 be	 informed	 by	 the	 economic	
evaluation	(ibid.).		It	was	determined	that	the	pathways	would	be	
costed	from	the	perspective	of	a	healthcare	provider	as	the	aim	of	
the	 research	 is	 to	 assess	 the	 impact	 on	 costs	 of	 the	 adoption	of	
the	 OCCP	 into	 mainstream	 sexual	 health	 services,	 this	 is	 in	 line	
with	the	MTEP	defined	approach	(NICE,	2011).	 	
		 355	
The	 consideration	 of	 the	 costs	 and	 consequences	 of	 the	
intervention	 for	 the	 immediate	 outcomes	 (process	 measures	
which	 reflect	 uptake	 of	 services)	 is	 beneficial	 to	 both	
commissioners	 and	 providers.	 Commissioners	 because	 the	
separation	 of	 commissioning	 responsibilities	 outlined	 in	 section	
2.4.2	 means	 that	 they	 are	 responsible	 for	 the	 testing	 and	
treatment	 services,	 and	 providers	 because	 similarly	 the	
organisation	 of	 services	 is	 such	 that	 the	 clinical	management	 of	






chlamydia	 and	 the	 elements	 of	 the	 pathway	 included	 in	 the	
costing	study.	The	section	of	the	pathway	to	be	costed	reflects	the	
elements	 provided	 by	 the	 OCCP.	 In	 their	 literature	 review,	
Mogyorosy	 and	 Smith	 summarise	 the	 key	 considerations	 for	





















































































As	 previously	 identified,	 the	 perspective	 for	 the	 analysis	 is	 the	
healthcare	 provider;	 this	 perspective	 informs	 the	 selection	 of	
costs	 to	 be	 considered	 within	 the	 analysis	 (Drummond	 et	 al.,	
2015).	 The	 second	 variable	 which	 influences	 the	 approach	 to	
identifying	resource	 items	 is	the	approach	taken	to	costing	(Gray	











Once	 determined,	 the	 level	 of	 precision	 is	 then	 relevant	 for	 the	
next	 two	 stages	 of	 costing	 (ibid.).	 Brouwer	 and	 colleagues	
recognise	 that	 in	 practice	 the	 majority	 of	 economic	 evaluations	









• Semi-structured	 interviews	with	 staff	 involved	 in	 the	 trial	
delivery.	
	
There	 was	 one	major	 adaption	made	 to	 the	 pathway	 to	 enable	
prescribing	 of	 azithromycin	 in	 the	 exploratory	 study.	 Owing	 to	
legal	 constraints	on	 the	use	of	 the	electronic	prescribing	 system,	
pre-pack	azithromycin	was	provided	to	community	pharmacies	to	
dispense.	 In	 order	 to	 provide	 a	 costing	 comparative	 to	 current	














This	approach	 is	 in	 line	with	 the	type	of	economic	evaluation	 for	
stage	 II	 of	 technology	 development	 identified	 by	 Sculpher	 and	
colleagues	 (Sculpher	et	al.,	 1997).	 They	 recognise	 that	 in	 respect	
of	the	identification	of	costs	there	is	greater	access	to	“individual	






interventions	 often	 have	 a	 large	 upfront	 non-recurrent	 cost	 that	
relate	to	the	development	of	the	technology	and	the	useful	life	of	
the	 intervention	 –	 how	 long	 it	 can	 exist	 without	 the	 need	 to	
update/	 upgrade	 (Tate	 et	 al.,	 2009).	 They	 clarify	 that	 sunk	 costs	
should	not	be	included	in	economic	evaluation	as	they	would	not	
recur	if	the	intervention	were	implemented	on	a	larger	scale,	and	
that	 future	costs	 for	updating	 the	 technology	should	be	 included	
(ibid).	In	addition,	they	address	the	issue	of	how	the	fixed	costs	of	
internet	 interventions	 (e.g.	 website	 hosting	 and	 maintenance)	
should	 be	 addressed.	 Their	 recommendation	 is	 that	 the	 likely	
uptake	of	 the	 internet	 intervention	 should	be	estimated	and	 the	
fixed	 cost	 converted	 to	 a	 per	 patient	 cost	 to	 enable	 comparison	





In	 order	 to	 enable	 the	 identification	 of	 resource	 items	 for	 the	
comparator	pathways,	a	literature	review	has	been	undertaken	to	
identify	 studies	 reporting	 the	 costs	 and	 cost-effectiveness	 of	
elements	of	 the	chlamydia	 testing	and	treatment	pathway	 in	 the	






To	 address	 this,	 a	 primary	 costing	 study	 was	 developed	 and	
undertaken	 to	 collect	 information	 on	 GUM	 and	 NCSP	 internet	
testing	pathways	 to	enable	establishment	of	 the	 reference	 cases	
for	 comparison	 with	 the	 OCCP.	 This	 included	 semi-structured	
interviews	with	 commissioners	 initially,	 and	 follow	up	 interviews	
with	service	providers.	The	objectives	of	the	study	were	to:	
• Map	 the	 GUM	 testing	 pathway	 –	 to	 gain	 a	 detailed	
understanding	of	and	 identify	resource	 items	and	units	of	




measure	 for	 the	 delivery	 of	 the	 chlamydia	 treatment	
pathway,	
• Identify	 the	 contractual	 arrangements	 surrounding	 this	 –	
to	 understand	 the	 contractual	 arrangements	 of	 the	
pathway,	for	example	whether	the	full	pathway	is	provided	
in	 house	 or	 elements	 are	 sub-contracted	 to	 other	
providers,	
• Identify	 performance	 data	 –	 to	 identify	 data	 for	 the	 key	





London	 and	 other	 parts	 of	 England,	 the	 study	 costed	 one	 GUM	
pathway	 (outside	 of	 London),	 and	 two	 NCSP	 internet	 testing	
pathways	 (one	 in	 London,	 one	 outside	 of	 London).	 A	 GUM	
pathway	 in	 London	 was	 not	 costed	 because	 access	 to	 study	
participants	 in	 London	 was	 challenging	 owing	 to	 a	 major	 re-
procurement	 exercise	 being	 undertaken	 by	 the	 London	 Local	
Authorities	in	2015-16.		
	
Interviews	 were	 selected	 over	 other	 methods	 such	 as	 postal	
surveys	 because	 a	 written	 questionnaire	 response	 would	 have	
been	laborious	for	participants	to	complete,	owing	to	the	number	
of	supplementary	questions	which	would	be	required	in	a	written	
questionnaire.	 These	 could	 be	 managed	 more	 effectively	 in	 an	
interview.		
	
Standard	 process	 mapping	 techniques	 endorsed	 by	 the	 NHS	
Institute	 for	 Innovation	 and	 Improvement	 (NHS	 Institute	 for	
Innovation	 and	 Improvement,	 2013)	 were	 used	 as	 the	 basis	 for	





“Ideally,	 resource	 utilisation	 measurement	 should	 be	
comprehensive,	 reliable,	valid	and	representative”	 (Mogyorosy	&	
Smith,	 2005:47).	 The	 scale	 of	 precision	 proposed	 by	 Drummond	
and	 colleagues	 is	 equally	 as	 applicable	 to	 resource	 unit	
measurement	as	it	 is	to	the	identification	of	costs	(Drummond	et	






the	 study,	 the	 requirements	 for	 representativeness	 and	






advantages	 and	 disadvantages	 in	 their	 literature	 review.	 These	
include	 time	 and	 motion	 studies,	 manager	 surveys,	 service	 use	
questionnaires	 and	 interviews,	 medical	 case	 record	 review,	
account	 classification,	 self-reported	 activity	 logs,	 postal	 surveys,	
self-reported	 questionnaires,	 cost	 diaries,	 relative	 value	 scale	



























align	 to	 the	micro	 costing	 end	of	 the	 spectrum	of	 precision.	 The	
benefits	 of	 the	 approach	 taken	 are	 that	 the	 data	 are	 easily	
accessible	and	provide	an	indicative	measure	of	resource	use	from	
people	with	a	high	degree	of	knowledge	about	how	the	service	is	






assign	monetary	values	 in	 the	UK.	These	 include	reference	costs,	














The	 decision	 to	 use	 these	 data	 sources	was	made	 based	 on	 the	
approach	 taken	 to	 costing,	 as	 using	 reference	 costs	 would	 not	
enable	 costing	with	 sufficient	 accuracy	 because	 the	 specification	
of	 the	 reference	 cost	 does	 not	 map	 onto	 to	 units	 in	 which	
elements	 of	 the	 pathway	 are	 costed.	 The	 activity	 was	 costed	 at	
2015	 prices	 (£GBP);	 where	 necessary	 the	 NHS	 Hospital	 and	
Community	Health	Services	 (HCHS)	pay	and	prices	 inflation	 index	




























clinical	 outcome	 measures	 it	 is	 important	 to	 note	 these	 are	 not	
health	outcome	measures,	they	are	process	measures.	As	outlined	
in	 section	 3.5.1	 these	 are	 also	 important	 considerations	 in	 the	
evaluation	 of	 complex	 interventions,	 and	 are	 defined	 within	 the	
NICE	MTEP	guidance	as	system	outcomes	“a	non-clinical	outcome,	
typically	 impacting	 on	 resource	 capacity,	 resulting	 from	 a	 clinical	
(patient-level)	treatment	episode”	(NICE,	2011:28).	
	
These	 outcomes	 are	 suitable	 for	 considering	 the	 short-term	









All	 of	 the	 intermediate	 (process)	 outcomes	 are	 important	 in	
considering	the	final	outcomes	for	chlamydia	treatment,	recognised	
primarily	as	health	complications	arising	from	untreated	chlamydia	
(also	 known	 as	 major	 outcomes).	 These	 include	 PID,	 ectopic	




The	 decision	 to	 use	 intermediate	 (process/system)	 outcomes	
alongside	 the	 costing	 study	 reflects	 that	 the	 consequences	 of	
untreated	 chlamydia	 can	 go	 undetected	 for	 a	 number	 of	 years,	
however	process-based	outcomes	offer	 insight	 into	the	 immediate	
impact	of	the	pathway	change.	This	also	aligns	to	Pietzsch	and	Paté-
Cornell’s	 view	 of	 the	 scope	 of	 eHTA,	 particularly	 the	 decision	
support	 function	 for	 developers	 to	 design	 and	
develop/manufacture	 the	 new	 technology	 (Pietzsch	 and	 Paté-
Cornell,	 2008).	 The	 intermediate	 outcomes	 centre	 on	 the	 direct	
changes	(both	positive	and	negative)	to	the	service	pathway.	
	
To	 identify	 the	 outcomes	 for	 patients	 participating	 in	 the	 OCCP	
exploratory	study,	the	system	was	designed	to	capture	information	
on	 the	 outcome	 measures	 listed	 in	 table	 7.4.	 To	 identify	 the	
outcome	 measures	 for	 the	 comparator	 pathways,	 two	 literature	
searches	 were	 undertaken,	 the	 first	 to	 identify	 studies	 published	
since	 2005	 which	 consider	 the	 costs	 or	 cost-effectiveness	 of	
chlamydia	 testing	 and	 treatment	 in	 the	 UK	 and	 the	 second	 to	
identify	published	studies	providing	data	on	outcomes.	The	search	







The	 objective	 of	 the	 literature	 review	was	 to	 identify	 and	 evaluate	
published	 studies	 exploring	 the	 costs	 and	 cost-effectiveness	 of	 the	
chlamydia	testing	and	treatment	in	the	UK	to:	
• Identify	 relevant	 resource	 items,	units	of	measure	and	 costs	
for	the	OCCP	costing	study,	







screening	 and	 chlamydia	 testing	 delivered	 in	 sexual	 health	
clinics	
• studies	 published	 between	 2005	 and	 2015.	 This	 date	 range	
was	selected	to	reflect	the	significant	changes	in	the	delivery	







• that	 do	 not	 relate	 to	 the	 costs	 or	 cost-effectiveness	 of	 an	






The	 following	 databases	 were	 searched	 on	 22	 February	 2015	 to	



















economic	 evaluation	 and	 systematic	 reviews	 of	 economic	
evaluation	 (Drummond	 et	 al.,	 2005,	Mistry,	 2011).	 Searches	were	
structured	in	the	databases	to	meet	the	search	requirements	of	the	
respective	database	and	terms	expanded	where	the	facility	existed	
to	 do	 this.	 The	 use	 of	 expanded	 terms,	 in	 particular	 “cost	 benefit	
analysis”	 and	 “costs	 and	 cost	 analysis”	 which	 include	 key	 terms	
such	 as:	 cost,	 cost	 analysis,	 cost	 comparison,	 cost	 measures	 and	



























removed.	 The	 titles	 and	 abstracts	 were	 reviewed	 and	 studies	
excluded	for	the	following	reasons:	








To	 assess	 the	 quality	 of	 retrieved	 articles,	 a	 number	 of	 checklists	
were	identified	including	that	by	Drummond	and	colleagues	(2005),	
the	Critical	Appraisal	Skills	Programme	(2013)	and	the	Consolidated	





CHEERS	 statement	 was	 selected	 as	 reporting	 checklists	 are	
designed	 to	 facilitate	 the	 reporting	 of	 full	 information	 about	 the	
study	in	articles,	whereas	appraisal	tools	are	designed	to	assess	the	
adequacy	 of	 methods	 (Altman,	 2013).	 For	 costing	 studies,	 no	
reporting	 checklist	 was	 identified;	 therefore	 the	 CHEERS	 checklist	




The	 initial	 search	 identified	 600	 records	 and	 59	 duplicates	 were	
removed	in	Endnote	leaving	541	for	initial	review.	The	re-run	of	the	
searches	to	identify	studies	published	in	2015	identified	71	records	
and	17	duplicates	were	removed,	 leaving	54	for	 initial	 review.	The	














































The	 data	 extraction	 form	 was	 designed	 to	 take	 into	 account	 the	
review	 question,	 adopting	 the	 approach	 outlined	 in	 section	 4.3.4.	




In	 total	 14	 studies	met	 the	 inclusion	 criteria;	 three	 studies	 had	 a	
focus	on	chlamydia	testing	(Hislop	et	al.,	2010,	Jackson	et	al.,	2015	
and	 Turner	 et	 al.,	 2014),	 four	 studies	 focused	 on	 partner	
notification	 (Althaus	 et	 al.,	 2014,	 Cassell	 et	 al.,	 2015,	 Low	 et	 al.,	
2006	 and	 Roberts	 et	 al.,	 2012),	 and	 seven	 studies	 took	 a	 broad	
overview	of	a	chlamydia	testing	and	treatment	pathway	(Adams	et	
al.,	2007,	Bracebridge	et	al.,	2012,	Kelly	et	al.,	2014,	Looker	et	al.,	




























1.	 Adams	et	al.	(2007)	 Opportunistic	Chlamydia	Screening	 CEA	 England	 Standalone	 No	
2.	 Althaus	et	al.	(2014)	 Partner	Notification	technologies	 CEA		 England	 HTA	containing	standalone	
economic	evaluation	
Yes	
3.	 Bracebridge	et	al.	(2012)	 Postal	Chlamydia	screening	and	treatment	 CCA	 England	 Integrated	 No	





Rapid	POCT	for	Chlamydia	testing	 CCA	&	CEA	 England	 HTA	containing	standalone	
economic	evaluation	
Yes	








8.	 Looker	et	al.	(2015)	 Chlamydia	Testing	 CEA	 Scotland	 Standalone	 No	
9.	 Low	et	al.	(2006)	 Partner	Notification	 CCA	 England	 Integrated	 No	
10.	 Low	et	al.	(2007)	 Proactive	Chlamydia	Screening	 CEA	 England	 HTA	containing	standalone	
economic	evaluation	
No	
11.	 Roberts	et	al.	(2012)	 Accelerated	Partner	Therapy	 CCA	 England	 Standalone	 Yes	
12.	 Robinson	et	al.	(2007)	 Proactive	Chlamydia	Screening	 Cost	Analysis	 England		 Standalone	 No	
13.	 Turner	et	al.	(2011)	
	
Chlamydia	Screening	&	Partner	Notification	 CEA	 England	 Standalone	 No	
14.	 Turner	et	al.,	(2014)	 Chlamydia	POCT		 CEA	 England	 Integrated	 Yes	
		 372	
Of	 the	 14	 included	 studies,	 three	 were	 cost	 analyses,	 seven	 cost	
effectiveness	 analyses	 and	 five	 cost	 consequence	 analyses	 (one	
study	 included	 both	 a	 cost	 effectiveness	 analysis	 and	 a	 cost	
consequence	analysis,	Hislop	et	al.,	2010)	as	identified	in	table	7.8.	
Six	 studies	 were	 standalone	 economic	 evaluations,	 four	 were	
integrated	 with	 a	 clinical,	 product	 or	 service	 evaluation	 and	 four	
were	 economic	 evaluations	 within	 HTA	 reports.	 Five	 studies	
introduced	 a	 new	 technology	 into	 their	 costing	 study/	 economic	
evaluation:	
• Three	 relating	 to	 partner	 notification	 (Althaus	 et	 al	 2014.,	
Cassell	et	al.,	2015	and	Roberts	et	al.,	2012),	
• Two	 relating	 to	 rapid	 point	 of	 care	 testing	 for	 chlamydia,	




The	 remaining	 nine	 studies	 were	 pathway	 related.	 Four	 studies	
















Each	 article	 was	 assessed	 against	 the	 relevant	 sections	 of	 the	
CHEERS	 checklist	 and	 evidence	 inputted	 into	 the	 data	 extraction	
sheet.	 The	 findings	 were	 then	 summarised	 to	 indicate	 whether	
there	 was	 evidence	 of	 full,	 partial	 or	 no	 achievement	 of	 the	
indicator,	or	whether	this	was	not	applicable	where	it	was	possible	
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The	 following	 sub-sections	 present	 the	 high-level	 findings	 of	 the	






2014,	 Low	 et	 al.,	 2006)	 the	 economic	 analysis	 was	 reported	
alongside	 a	 clinical	 or	 service	 evaluation.	 Similarly,	 where	
abstracts	 partially	met	 the	 checklist	 requirements,	 the	 economic	
analysis/	costing	study	was	reported	as	part	of	an	HTA,	or	as	part	
of	 another	 evaluation.	 The	 exception	 to	 this	 was	 the	 study	
published	by	Looker	and	colleagues	(2015)	whose	article	focused	
on	 the	 mathematical	 modelling	 component	 of	 the	 economic	
evaluation	rather	than	the	evaluation.	 In	this	study	the	reporting	




Key	 elements	 from	 the	 methods	 section	 of	 the	 checklist	 are	
summarised	 in	 table	 7.10	 at	 the	 end	 of	 this	 section.	 Almost	 all	
studies	were	 clear	 on	 their	 target	 population	 and	 subgroups	 for	
the	setting	of	the	study.	In	respect	of	the	study	perspective	for	the	
analysis,	 four	 of	 the	 fourteen	were	not	 clear	 (Bracebridge	 et	 al.,	
2012,	Kelly	et	al.,	2014,	Looker	et	al.,	2015,	and	Low	et	al.,	2007)	
and	a	further	seven	indicated	the	perspective	of	the	health	service	
or	NHS	 but	 did	 not	 state	whether	 this	was	 the	 commissioner	 or	










al.,	 2012:377)	 suggests	 a	 healthcare	 commissioner	 perspective,	
along	 with	 “an	 analysis	 of	 the	 cost	 of	 providing	 the	 service	 in	
primary	 care	 included	 the	 LES	 tariff”	 (Kelly	 et	 al.,	 2014:752),	
whereas	statements	such	as	“we	obtained	the	hourly	rates	of	pay	
(including	employer	 contributions)”	 (Low	et	 al.,	 2006:2)	 and	 “we	
measured	the	time	taken	to	complete	each	labour	dependent	step	
for	 the	 diagnostic	 tests”	 (Robinson	 et	 al.,	 2007:277)	 suggest	 a	
provider	 perspective.	 As	 highlighted	 by	 the	 NICE	 costing	 impact	
guidance	 (NICE,	 2011a)	 and	 Mogyorosy	 and	 Smith	 (2005),	 this	
distinction	 is	 important.	 They	 note	 that	 “there	 could	 be	 a	
difference	 in	 the	 unit	 cost	 depending	 on	 whether	 the	 cost	 to	




With	 the	 exception	 of	 Robinson	 and	 colleagues	 which	 was	 a	
costing	study	of	a	single	intervention,	all	other	studies	stated	the	
comparators	which	are	summarised	in	table	7.10.	These	include:	
• Theoretical	 modelling	 scenarios	 based	 on	 variance	 of	
parameters	 (Adams	 et	 al.,	 2014,	 Althaus	 et	 al.,	 2014,	











associated	 with	 the	 delivery	 of	 the	 service.	 Of	 those	 which	 did	
(Adams	et	al.,	2007,	Looker	et	al.,	2015	and	Low	et	al.,	2007)	were	
studies	 that	 included	 health	 outcomes	 beyond	 immediate	
treatment	and	partner	notification.	These	also	applied	a	discount	
rate	 because	 the	 time	 horizon	 extended	 beyond	 a	 one-year	
period.	Two	other	 studies	 included	a	 stated	 time	horizon	 (Hislop	
et	 al.,	 2010	and	Turner	 et	 al.,	 2014);	 however,	 these	were	 short	
term	time	horizons	of	under	a	month.	
	







• Treatment	Uptake	 (Bracebridge	et	 al.,	 2012,	Hislop	et	 al.,	
2010),	
• Partner	Notification	 Efficacy	 (Althaus	 et	 al.,	 2014,	 Low	 et	
al.,	2006,	Roberts	et	al.,	2012).	
	









All	 studies	 included	 information	 to	 varying	 degrees	 on	 the	
estimation	of	resources	and	costs.	The	costing	data	sources	cited	
are	summarised	in	table	7.10.	It	is	important	to	note	that	there	is	
some	 recycling	 of	 cost	 data	 between	 studies,	 in	 particular	 the	
ClaSS	study	data	(Low	et	al.,	2007)	 is	used	by	Cassell	et	al.,	2015	








range	 of	 costing	 precision	 from	highly	 detailed	 time	 and	motion	
studies	 (Robinson	 et	 al.,	 2007)	 and	 a	 pilot	 RCT	 (Roberts	 et	 al.,	
2012),	pathway	mapping	(Turner	et	al.,	2014)	and	semi-structured	




The	 review	of	 costing	 data	 sources	 in	 the	 published	 studies	was	













costs	 included	 in	 the	 analysis	 related	 to	 (Althaus	 et	 al.,	 2014,	
Looker	et	al.,	2015,	and	Turner	et	al.,	2014	do	not),	and	all	stated	
the	currency	as	British	Pounds.	The	date	 range	 for	 the	 literature	
review	 was	 studies	 published	 between	 2005	 and	 2015,	 and	 the	




of	 an	 economic	model	 (Adams	 et	 al.,	 2007,	 Althaus	 et	 al.,	 2014,	
Hislop	et	al.,	2010,	Looker	et	al.,	2015,	Low	et	al.,	2007,	Turner	et	
al.,	 2011	 and	 Turner	 et	 al.,	 2014).	 All	 cost-effectiveness	 studies	
provided	tables	detailing	the	model	parameters.	Where	details	of	
an	 economic	 model	 have	 been	 provided,	 three	 are	 dynamic	
(Adams	et	al.,	2007,	Looker	et	al.,	2015	and	Low	et	al.,	2007),	and	
four	are	static	(Althaus	et	al.,	2014,	Hislop	et	al.,	2010,	Turner	et	
al.,	 2011	 and	 Turner	 et	 al.,	 2014).	 The	 majority	 of	 studies	
contained	detail	of	the	assumptions	made	in	the	economic	models	
or	 costing;	 however,	 the	 quality	 of	 the	 way	 in	 which	 these	 are	
































































































































































All	 14	 studies	 contained	 a	 summary	 of	 the	 results	 identified,	
although	the	level	of	detail	varied	between	studies.	For	example,	
the	standalone	economic	evaluations	contained	more	detail	than	
the	 integrated	 studies	 where	 weight	 also	 had	 to	 be	 given	 to	
reporting	 the	clinical	 findings.	Only	 two	 (29%)	of	 the	 seven	cost-
effectiveness	analysis	 studies	 (Adams	et	al.,	2007	and	Low	et	al.,	
2007)	 included	 an	 incremental	 cost-effectiveness	 ratio	 (ICER).	 A	
summary	of	the	outcomes	reported	is	included	in	table	7.11.	Nine	
(64%)	 of	 the	 14	 studies	 explored	 uncertainty	 of	 model	 input	











One	 study	 (Roberts	 et	 al.,	 2012)	 reported	 that	 it	 was	 not	
appropriate	to	undertake	sensitivity	analysis	because	“the	results	



































































All	 of	 the	 included	 studies	 discussed	 the	 study	 findings	 and	 all	
except	 two	 discussed	 the	 limitations	 of	 the	 costing	 study/	
economic	evaluation.	The	two	which	did	not	were	studies	where	
the	 economic	 evaluation	was	 a	 component	 of	 a	 broader	 service	
evaluation	(Bracebridge	et	al.,	2012,	Kelly	et	al.,	2014).	Reporting	
of	 generalisability	 of	 findings	 and	 current	 knowledge,	 was	
generally	 reported	 more	 comprehensively	 in	 the	 standalone	
economic	evaluation	papers	 than	 the	papers	 reporting	economic	




Finally,	 all	 studies	 with	 the	 exception	 of	 Bracebridge	 and	





The	 objective	 of	 the	 literature	 review	 was	 to	 identify	 published	
studies	 exploring	 the	 costs	 and	 cost-effectiveness	 of	 chlamydia	
testing	 and	 treatment	 in	 the	 UK	 for	 the	 purposes	 of	 the	
identification	 of	 resource	 items,	 unit	 of	 measure	 and	 costs.	 The	
review	 identified	 only	 one	 study	 (Turner	 et	 al.,	 2014)	 containing	
recently	 mapped	 GUM	 clinic	 pathways	 in	 London	 and	 the	 South	
West	 with	 sufficient	 detail	 published	 on	 the	 pathway	 mapping	
separately	(Adams	et	al.,	2014)	to	be	used	in	this	study.		
		 387	
A	 refresh	of	 the	 literature	 search	was	undertaken	 to	 identify	 new	
studies	 published	 up	 to	December	 2016	 and	 identified	 no	 further	
studies	 for	 inclusion.	 From	 an	 NCSP	 pathway	 perspective	 it	 was	
noted	that	all	studies	using	NCSP	pathways	are	based	on	the	2008-
09	costing	initiative.	There	have	been	two	major	structural	changes	
within	 the	 NHS	 since	 this	 was	 undertaken,	 which	 may	 have	 an	
impact	on	resource	use	and	costs	–	the	dissolution	of	PCT	provider	
arms,	 the	 primary	 body	 coordinating	 and	 delivering	 the	 NCSP	 in	
2010,	 and	 the	 transfer	 of	 responsibility	 for	 public	 health	
commissioning	 to	 LAs	 in	 2013,	 which	 has	 led	 to	 a	 number	 of	
services	 being	 competitively	 tendered	 and	 subsequent	 changes	 to	
pathways.	 Alongside	 this,	 there	 has	 been	 a	 shift	 in	 patterns	 of	
access	 to	 chlamydia	 testing	 and	 treatment	 with	 an	 increase	 in	
internet	 testing	 from	 less	 than	 1%	 in	 2006	 to	 6%	 in	 2010,	with	 a	



























The	 majority	 of	 studies	 fall	 into	 two	 category	 groups	 –	 maturing	
innovation	 and	 moving	 into	 practice.	 The	 ‘moving	 into	 practice’	
category	 represent	 the	modelling	 studies	where	 data	 are	 used	 to	
generalise	results	to	other	settings	or	extrapolate	to	a	longer	term	
view	of	 the	 impact	 of	 the	 interventions.	 In	 all	 cases	 these	 studies	
relate	 to	 the	consideration	of	 chlamydia	 screening	programmes	 in	
their	entirety	and	their	impact	depends	on	variance	in	a	number	of	
parameters,	 for	 example,	 population	 screened.	 The	 ‘maturing	
innovation’	 category	 identifies	 studies	which	 explore	 pathways	 or	
technologies	 that	 are	 at	 a	 much	 earlier	 stage	 of	 development.	
These	 fall	 into	two	categories	–	studies	exploring	the	delivery	of	a	
service	 through	 an	 alternative	 pathway	 using	 existing	 technology	
(Bracebridge	et	al.,	2012,	Jackson	et	al.,	2012	and	Kelly	et	al.,	2014),	
and	 studies	 exploring	 the	 delivery	 of	 a	 service	 through	 the	
introduction	 of	 a	 new	 technology	 –	 accelerated	 partner	 therapy	
(Roberts	et	al.,	2012),	and	rapid	POCT	(Turner	et	al.,	2014).		
	




the	studies	 included	 in	 this	 literature	 review	 it	would	suggest	 that	
the	 economic	 evaluations	 selected	 are	 not	 always	 appropriate	 for	
the	stage	of	product	development.		
	
For	 example,	 Turner	 and	 colleagues’	 cost-effectiveness	 analysis	 of	
rapid	 POCT	 in	 a	 GUM	 clinic	 setting	 is	 an	 evaluation	 of	 a	 new	
technology	 in	 so	 far	 as	 it	 is	 not	 adopted	 yet	 within	 mainstream	
clinical	 services	 in	 England.	 However,	 the	 technology	 itself	 is	 fully	
developed	 with	 FDA	 approval.	 Therefore,	 Ijzerman	 and	 Steuten’s	
approach	would	class	this	as	stage	4	product	development	–	access	




None	 of	 the	 published	 studies	 consider	 the	 implementation	 an	
online	clinical	care	pathway	similar	to	OCCP,	although	two	explore	
remote	 pathways.	 Bracebridge	 and	 colleagues	 study	 explore	 an	
internet,	 postal	 and	 telephone	 based	 approach	 to	 delivering	
chlamydia	 testing	 and	 treatment	 (Bracebridge	 et	 al.,	 2012),	whilst	




Considering	 the	 delivery	 model	 for	 the	 NCSP	 internet	 testing	
pathway,	 none	 of	 the	 papers	 included	 which	 examined	 a	 full	
screening	pathway	costed	a	pathway	which	is	currently	reflective	of	
how	 the	 NCSP	 is	 delivered	 (a	 comparator	 pathway	 in	 the	 OCCP	
exploratory	 study).	 This	 is	 a	 reflection	 of	 the	 evolution	 of	 sexual	





Fourteen	 studies	 were	 identified	 for	 inclusion	 in	 this	 literature	
review	 exploring	 aspects	 of	 the	 chlamydia	 testing	 and	 treatment	
pathway	 ranging	 from	 highly	 theoretical	 modelling	 to	 determine	
cost-effectiveness	to	pragmatic	service	evaluations	and	early	stage	











Table	 7.4	 contains	 the	 outcome	 measures	 identified	 for	 the	 OCCP	





• any	 published	 study	 containing	 chlamydia	 trachomatis	
outcomes	data	for	GUM	or	NCSP	internet	testing	services	
• studies	 published	 between	 2005	 and	 September	 2016.	 As	
with	the	literature	review	which	identified	economic	analyses,	
this	date	range	was	selected	to	reflect	the	significant	changes	


























table	 7.13,	 the	 full	 Medline	 search	 is	 included	 in	 Appendix	 17.		
Search	 terms	 were	 identified	 from	 the	 definitions	 of	 the	 OCCP	
exploratory	 study	 outcomes.	 Searches	 were	 structured	 in	 the	
databases	 to	 meet	 the	 search	 requirements	 of	 the	 respective	
database	and	terms	exploded	where	the	facility	existed	to	do	this.	
Exploded	 search	 terms	 included	 ‘time	 to	 treatment’,	 ‘treatment	
outcome’	 and	 ‘contact	 tracing’.	 This	 extended	 the	 search	 terms	
covered	 to	 include,	 for	 example:	 clinical	 effectiveness,	 clinical	
























• Not	 primary	 research	 or	 systematic	 review	 e.g.	 study	
protocol.	
	
In	 addition	 to	 the	 database	 searches	 for	 published	 studies,	 the	
literature	 review	 was	 extended	 to	 include	 known	 primary	 data	
sources.	PHE	is	the	agency	responsible	for	the	collection	of	data	on	
STIs	 and	 sexual	 health	 services	 in	 England	 (and	 holds	 the	 data	
previously	published	by	the	NCSP).	A	review	of	the	studies	included	





The	 initial	 search	 identified	 372	 records	 and	 41	 duplicates	 were	
































































to	 the	OCCP	 primary	 and	 secondary	 outcomes.	 Four	were	 service	
evaluations	 (Brook	 et	 al.,	 2011,	 Fernando	 &	 Clutterbuck,	 2005,	
Forbes	&	Clutterbuck,	2009	and	Raval	&	Challenor,	2006),	two	were	
RCTs	-	one	a	pilot	(Estcourt	et	al.,	2015)	and	one	a	full	RCT	(Low	et	
al.,	 2007),	 and	 three	 were	 clinical	 audits	 (Challenor	 et	 al.,	 2005,	
McClean	 et	 al.,	 2006	 and	 McClean	 et	 al.,	 2008).	 Seven	 were	
conducted	in	a	GUM/	sexual	health	clinic	setting	(Brook	et	al.,	2011,	








Reviewing	 the	 PHE	 and	 BASHH	 websites	 identified	 three	 audits	
containing	comparable	outcomes:	partner	notification	in	chlamydia	
screening	 (PHE,	 2016),	 audit	 report	 on	 turnaround	 times	 (PHE,	
















Service	Evaluation	 2009/10	 466	 95%	 92-98%	 Monthly	results	reported	for	six	months	
Challenor	et	al.	(2005)	 Clinical	Audit	 2004	 1,670	 72%	 70.1-74.7%	 Percentage	of	index	treated	within	4	weeks	–	England		
Fernando	and	Clutterbuck	
(2005)	
Service	Evaluation		 2003	 83	 97.6%	 	 Single	result	reported	
BASHH	(2007)	 Clinical	Audit		 2007	 5,032	 99%	 97-100%	 Regional	Range	for	uncomplicated	infection	
Time	from	Index	Patient	Receiving	Diagnosis	to	Receiving	Appropriate	Treatment	
None	Identified	 	 	 	 	 	 	
Proportion	of	Sex	Partners	Treated	(Ratio	of	Partners	Treated	per	Index)	
Challenor	et	al.	(2005)	 Clinical	Audit	 2004	 1,670	 0.56	 0.54-0.59	 Proportion	of	sex	partners	treated	within	4	weeks	of	initial	PN	
interview	–	England.	Range	is	95%	CI	













Challenor	et	al.	(2005)	 Clinical	Audit	 2004	 1,670	 55%	 	 Percentage	of	partners	seen	(UK	value)	
Fernando	&	Clutterbuck	(2005)	 Service	Evaluation	 2003	 83	 90%	 	 Single	result	reported	
Low	et	al.	(2007)	 RCT	 2001-02	 64	 46.9%	 	 %	Partners	treated,	outcome	from	GUM	arm	
McClean	et	al.	(2006)	 Clinical	Audit	 2001	 661	 55%	 42-69%	 Percentage	of	partners	seen,	range	is	range	of	clinic	performance	
Time	from	Index	Patient	Receiving	Diagnosis	to	Partner	Receiving	Treatment	













Clinical	Audit	 2013	 3,909	 93.45%	 	 Percentage	of	chlamydia	positive	patients	in	audit	receiving	
treatment.		
Saunders	(2016)	 Clinical	Audit	 2013	 397	 88.9%	 	 Personal	communication	detailing	subset	of	PHE	clinical	audit	
(2014a)	for	NCSP	internet	testing	specifically	
Time	from	Index	Patient	Receiving	Diagnosis	to	Receiving	Appropriate	Treatment	















NCSP	(2012b)	 National	Dataset	 2011	 83,469	 0.5	 0.0-1.3	 Partner	treatment	rate.	Range	is	the	range	of	individual	PCT	
performance.	
Public	Health	England	(2016a)	 Clinical	Audit	 2015	 2,439	 0.53	 	 Partner	treatment	rate.		
Percentage	of	Sex	Partners	Identified	by	Index	Patients	Treated	
Estcourt	et	al.	(2015b)	 Pilot	RCT	 2011-13	 102	 46%	 	 Control	arm	partners	treated	
Low	et	al.	(2007)	 RCT	 2001-02	 119	 45%	 	 %	Partners	Treated,	outcome	from	practice	nurse	arm	
Public	Health	England	(2016a)	 Clinical	Audit	 2015	 2,886	 58%	 	 Partners	attending	a	service	following	notification	
Time	from	Index	Patient	Receiving	Diagnosis	to	Partner	Receiving	Treatment	











undertaken.	 It	 is	 important	 to	 note	 that	 the	 outcomes	 cover	 all	
testing	routes	within	the	NCSP	e.g.	tests	originating	at	GP	and	CaSH	
clinics	 as	 well	 as	 tests	 ordered	 online,	 with	 the	 exception	 of	
treatment	 uptake	 rate.	 The	 extent	 to	 which	 this	 is	 an	 issue	 is	
unknown,	 in	 respect	 of	 treatment	 and	 partner	 notification	
outcomes,	the	treatment	options	available	to	positive	patients	are	
the	same	regardless	of	the	testing	route.	The	national	datasets	and	
clinical	 audits	undertaken	by	PHE	and	BASHH	offer	 a	 considerably	
larger	sample	size	than	the	published	studies.		
	
A	 second	 point	 to	 note	 is	 the	 year	 in	 which	 the	 study	 was	
undertaken.	 As	 highlighted	 previously	 and	 summarised	 in	 section	
2.4.1,	there	were	significant	changes	to	STI	service	delivery	models	










The	 following	 sections	 outline	 the	 primary	 data	 collection	










• The	 OCCP	 exploratory	 study	 research	 health	 advisors	




















The	 initial	 interview	 took	 place	 with	 the	 service	 lead	 to	map	 the	








resource	 use	 in	 delivering	 elements	 of	 the	 NCSP	 internet	 testing	
pathway	 included	 in	 the	 study.	 A	 summary	 of	 the	 interview	
participants	is	included	in	table	7.18.	Participants	were	identified	by	
the	 commissioner	 or	 service	 lead	 who	 undertook	 the	 initial	
interview	 to	 map	 the	 pathway.	 A	 slightly	 different	 approach	 was	
taken	between	the	two	pathways,	in	pathway	one	the	service	lead	
was	 interviewed	 and	 undertook	 to	 provide	 the	 missing	 data	 by	
sourcing	 the	 information	 and	 providing	 it	 to	 the	 researcher,	
whereas	in	the	second	pathway,	the	service	lead	identified	the	staff	
that	 the	 research	 should	 contact	 and	 additional	 interviews	 with	













Data	on	 the	outcomes	of	 individual	patients	 completing	 the	OCCP	
pilot	 extracted	 as	 part	 of	 the	 exploratory	 study	 were	 utilised	









7.30.	 The	 following	 assumptions	 should	 be	 noted	 as	 per	 the	
methods	outlined	in	sections	7.2.1.3	to	7.2.1.5:	
• Staff	 costs	 were	 taken	 from	 PSSRU	 (PSSRU,	 2016).	 These	
costs	include	management,	non-staff	and	estate	overheads.	
It	 is	 therefore	 assumed	 that	 all	 non-specific	 service	
equipment	 required	 to	 deliver	 the	 service	 e.g.	 computers,	
servers,	 clinic	 room	 equipment	 etc	 and	 service	 overheads	
are	included	in	this	value		
• Training	costs	for	staff	specifically	involved	in	delivering	the	
OCCP	 were	 included	 based	 on	 the	 training	 required	 to	
deliver	the	exploratory	study	
• Using	 Tate	 and	 colleagues	 approach,	 development	 costs	
were	 excluded	 and	 web	 hosting	 and	 maintenance	 were	
included		(Tate	et	al.,	2009).	The	life	expectancy	of	the	OCCP	
is	 governed	by	 the	 clinical	pathway	and	whether	 there	are	
changes	 to	 the	 clinical	 pathway	 which	 result	 in	 the	 OCCP	
requiring	 significant	 redevelopment	 to	 incorporate	 these.	
The	 current	 clinical	 guidelines	 for	 the	 management	 of	
genital	 chlamydia	were	 introduced	 in	 2006	 (BASHH,	 2006),	
clinical	 opinion	 has	 not	 identified	 any	 likely	 change	 in	 the	
immediate	future	therefore	no	costs	were	included	relating	
to	the	 life	expectancy	of	 the	OCCP	 itself.	The	costs	relating	











Results	 SMS	 	0.03		 Item	 	1.00		 1	 	0.03		 		
Text	sent	to	all	patients	to	notify	results	
are	available	 Identified	through	pilot	costing	
Results	 Website	Hosting	 	0.10		 Item	 	1.00		 1	 	0.10		 		 Patients	log	in	to	get	result	 Cost	invoiced	to	pilot	







GUM	Clinic	A	 	5.41		 Item	 	1.00		 1	 	5.41		 		 		 GUM	Clinic	A	Costing	
Results	 Notification	via	NCSP	A		 	1.81		 Item	 	1.00		 1	 	1.81		 		 		 NCSP	A	Costing	
Results	 Notification	via	NCSP	B	 	1.27		 Item	 	1.00		 1	 	1.27		 		 		 NCSP	B	Costing	
Results	
Health	Advisor	(GUM	
Clinic	Data	Entry)	 	0.01		 Second	 	1.00		 600	 	7.50		 	AfC6		 GUM	Clinic	Positive	Patients	Only	
Estimate	from	pilot	researcher,	PSSRU	Band	6	
Hospital	Based	Nurse	Unit	Cost	2015	



















































for	Treatment	(GUM	A)	 	17.30		 Item	 	1.00		 1	 	17.30		 		 Calculation	from	GUM	A		 Service	lead	and	Directorate	Accountant	Interviews	
PN	
Included	in	Website	
Hosting	above	 	-				 Item	 	1.00		 1	 	-				 		 See	above	 		
















































Results	 SMS	 	0.03		 Item	 	1.00		 1	 	0.03		 		
Text	sent	to	all	patients	to	
notify	results	are	available	 Identified	through	pilot	costing	
Results	 Website	Hosting	 	0.10		 Item	 	1.00		 1	 	0.10		 		 Patients	log	in	to	get	result	 Cost	invoiced	to	pilot	








Clinic	B	 	13.63		 Item	 	1.00		 1	 	13.63		 		 		 GUM	Clinic	B	Calculations	
Results	 Notification	via	NCSP	A		 	1.81		 Item	 	1.00		 1	 	1.81		 		 		 NCSP	A	Costing	
Results	 Notification	via	NCSP	B	 	1.27		 Item	 	1.00		 1	 	1.27		 		 		 NCSP	B	Costing	
Results	
Health	Advisor	(GUM	Clinic	Data	





























































above	 	-				 Item	 	1.00		 1	 	-				 		 See	above	 		















































Res	-ve	 SMS	 	0.05		 Item	 	1.00		 1	 	0.05		 		 Negative	Result	 Interview	with	Service	Lead	
Res	-ve	
HCSW	Time	Results	System	
(AfC3)	 	0.42		 Minute	 	1.00		 5	 	2.08		 	AfC3		 Negative	Result	
PSSRU	2015	cost	for	Band	3	Hospital	based	
nurse	
Res	+ve	 SMS	 	0.05		 Item	 	1.00		 1	 	0.05		 		AfC6			 Positive	Result	 Interview	with	Service	Lead	
Res	+ve	 Nurse	Time	SMS	(AfC7)	 	0.90		 Minute	 	1.00		 3	 	2.70		 	AfC7		 Positive	Result	
Interview	with	Service	Lead.	PSSRU	cost	for	
band	7	hospital	based	nurse	2015	
Res	+ve	 Phone	Call	-	Admin	Time	(AfC2)	 	-				 Item	 	1.00		 2	 	-				 		 Positive	Result	
Admin	time	incorporated	in	PSSRU	estimate	
for	nursing	staff	
Res	+ve	 Nurse	Time	(AfC	7)	Phone	Call	 	0.90		 Minute	 	0.98		 3	 	2.65		 	AfC7		 Positive	Result	
Interview	with	Service	Lead.	PSSRU	cost	for	
band	7	hospital	based	nurse	2015	
Res	+ve	 Letter	Notification	 	0.65		 Item	 	0.02		 1	 	0.01		 		
Positive	Result.	Cost	of	2nd	class	post	
and	preparation	of	standard	letter	 Interview	with	Service	Lead	
Trt	 Admin	Time	(AfC	2)		 	0.38		 Minute	 	1.00		 2	 	0.77		 	AfC2		 		
Interview	with	Service	Lead.	PSSRU	cost	for	
band	2	hospital	based	nurse	2015	
Trt	 Nurse	Time	(AfC	7)	 	0.90		 Minute	 	1.00		 15	 	13.50		 	AfC7		 		
Interview	with	Service	Lead.	PSSRU	cost	for	
band	7	hospital	based	nurse	2015	
Trt	 Azithromycin	 	2.22		 Item	 	1.00		 1	 	2.22		 		 		 Interview	with	Directorate	Accountant	
Trt	 STI	Literature	 	0.06		 Item	 	3.00		 1	 	0.19		 		 Costs	not	identifiable	from	budget	
Adams	et	al.,	(2014),	Supp	info,	uplifted	
using	HCHS	inflation	to	2014/15	
Trt	 Male	Condom	 	0.06		 Item	 	10.00		 1	 	0.62		 		 Costs	not	identifiable	from	budget	
Adams	et	al.,	(2014),	Supp	info,	uplifted	
using	HCHS	inflation	to	2014/15	
PN	 PN	Slip	 	0.05		 Item	 	3.00		 1	 	0.16		 		 Costs	not	identifiable	from	budget	
Adams	et	al.,	(2014),	Supp	info,	uplifted	
using	HCHS	inflation	to	2014/15	

































Res	-ve	 Nurse		 	0.75		 Minute	 	1.00		 6	 	4.50		 	4.67		 AfC	5/6		 Negative	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.68		 	4.05		
Res	-ve	 Letter	Notification	 	0.58		 Item	 	0.02		 1	 	0.01		 	0.01		 		 Negative	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.58		 	0.01		
Res	-ve	 Phone	Call	 	0.07		 Minute	 	0.03		 1	 	0.00		 	0.00		 		 Negative	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.07		 	0.00		
Res	-ve	 SMS		 	0.10		 Item	 	0.95		 1	 	0.10		 	0.10		 		 Negative	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.10		 	0.10		
Res	+ve	 Nurse		 	1.10		 Minute	 	0.50		 15	 	8.25		 	8.56		 AfC	7/8		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.98		 	7.31		





Res	+ve	 Letter	Notification	 	0.58		 Item	 	0.05		 1	 	0.03		 	0.03		 		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.07		 	0.03		
Res	+ve	 Phone	Call	 	0.07		 Minute	 	0.05		 1	 	0.00		 	0.00		 		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.10		 	0.00		
Res	+ve	 SMS	 	0.10		 Item	 	0.90		 1	 	0.09		 	0.09		 		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.53		 	0.09		




































Trt	 KY	Lubricant	 	0.30		 Application	 	2.00		 1	 	0.60		 	0.62		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.30		 	0.62		
Trt	 STI	Literature	 	0.06		 Item	 	3.00		 1	 	0.18		 	0.19		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.06		 	0.19		
Trt	 Male	Condom	 	0.06		 Item	 	10.00		 1	 	0.60		 	0.62		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.06		 	0.62		
Trt	 Azithromycin	 	4.50		 Trt	Course	 	0.95		 1	 	4.28		 	4.44		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	4.50		 	4.44		
Trt	 Doxycycline	 	2.03		 Trt	Course	 	0.05		 1	 	0.10		 	0.11		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	2.03		 	0.11		





PN	 PN	Slip	 	0.05		 Item	 	3.00		 1	 	0.15		 	0.16		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.05		 	0.16		




























Results	 Central	Results	Admin	 	0.42		 Minute	 	1.00		 3	 	1.25		 	AfC3		
Text	sent	to	all	patients	to	
notify	results	are	available	 Identified	through	pilot	costing	










postage)	 	0.60		 Item	 	1.00		 1	 	0.60		 		 		 Estimate	of	print	cost	and	2nd	class	post	
Results	 Admin	time	(email	result)	 	0.42		 Minute	 	1.00		 6	 	2.50		 	AfC3		 		
Estimate	by	CSO	manager.	Cost	based	on	PSSRU	2015	AfC	Band	3	
Hospital-Based	Nurse	
Results	 Nurse	(phone	result)	 	0.73		 Minute	 	1.00		 6.5	 	4.77		 	AfC6		 Positive	patients	only	
Estimate	by	CSO	manager.	Cost	based	on	PSSRU	2015	Nurse	
Specialist	(Community)	






































Trt	 STI	Literature	 	0.06		 Item	 	3.00		 1	 	0.18		 		
CSO	manager	advised	given	
to	patients	at	CaSH	clinic	 Adams	et	al.,	(2014)	Sup	Info	
Trt	 Male	Condom	 	0.06		 Item	 	10.00		 1	 	0.60		 		
CSO	manager	advised	given	
to	patients	at	CaSH	clinic	 Adams	et	al.,	(2014)	Sup	Info	
PN		 PN	Contact	Slips	 	0.05		 Item	 	3.00		 1	 	0.15		 		 		 		
Trt	 GP		 	1.97		 Minute	 	1.00		 10	 	19.67		 		 		 PSSRU	2015	GP	Cost	
Trt	
Azithromycin	(Community	
Pharmacy)	 	1.81		 Item	 	1.00		 1	 	1.81		 		 		
http://www.drugtariff.nhsbsa.nhs.uk/#/00280039-
DC/DC00279526/Part%20VIIIA%20products%20A	Dec	2015	











Treatment	&	PN	 	36.16		 Item	 	1.00		 1	 	36.16		 		
Calculation	from	data	(Adams	
et	al.,	2014)	 Adams	et	al.,	(2014)	Sup	Info	








































Results	 Nurse	(positive)	 	0.87		 Minute	 	1.00		 17	 	14.73		 	AfC7		 Positive	patients	only	 Estimate	by	CSO	lead.	Cost	based	on	PSSRU	2015	Advanced	Nurse	(Community)	

















(Hospital	Pharmacy)	 	2.22		 Item	 	1.00		 1	 	2.22		 		
Drugs	sourced	via	hospital	
pharmacy	 Drug	cost	provided	by	provider	
Trt	 STI	Literature	 	0.06		 Item	 	3.00		 1	 	0.18		 		
Cost	unidentifiable	from	
budget	statements	 Adams	et	al.,	(2014)	Sup	Info	
Trt	 Male	Condom	 	0.06		 Item	 	10.00		 1	 	0.60		 		
Cost	unidentifiable	from	
budget	statements	 Adams	et	al.,	(2014)	Sup	Info	
PN	 PN	Contact	Slips	 	0.05		 Item	 	3.00		 1	 	0.15		 		
Cost	unidentifiable	from	
budget	statements	 Adams	et	al.,	(2014)	Sup	Info	

































































Results	Notification	(Negative)	 	2.13		 	4.78		 	1.81		 	0.05		
Results	Notification	(Positive)	 	5.41		 	16.70		 	1.81		 	14.73		
Average	Treatment	Cost		 	18.07		 	36.16		 	26.97		 	22.88		
Average	Positive	Patient	
Pathway	Cost	






Clinic	 B	 is	 more	 than	 double.	 On	 investigation	 into	 the	 possible	
causes	of	this	it	was	noted	that	it	is	not	possible	to	identify	how	the	
authors	 (Turner	 et	 al.,	 2014)	 derived	 the	 unit	 costs	 for	 staffing.	
Therefore,	 the	 cost	 per	 patient	 was	 recalculated	 using	 the	 2015	
Unit	of	Health	and	Social	Care	costs	(PSSRU,	2015)	for	staffing	costs	
to	make	it	directly	comparable.	The	revised	comparator	costings	are	










Results	Notification	(Negative)	 	2.13		 	4.16		 	1.81		 	0.05		
Results	Notification	(Positive)	 	5.41		 	13.63		 	1.81		 	14.73		
Average	Treatment	Cost		 	18.07		 	31.47		 	26.97		 	22.88		
Average	Positive	Patient	
Pathway	Cost	









• Results	 notification	 –	where	 a	 patient	 does	 not	 access	 the	
OCCP	to	obtain	results	within	seven	days	the	patient	reverts	
to	 the	 originating	 service,	 in	 costing	 terms	 there	 are	 four	
options	as	above,	
• GUM	Clinic	treatment	–	where	a	patient	does	not	complete	
the	 pathway	 online	 they	 are	 referred	 to	 a	 GUM	 clinic	 to	






















Results	Notification	(Negative)	 0.14	 	0.32		 	0.27		 n/a	 n/a	
Results	Notification	(Positive)	 0.14	 	2.02		 	0.23		 	1.10		 	2.60		
Table	7.33	-	Results	Notification	Costs	per	Patient	
This	 illustrates	 the	 impact	 of	 the	 variability	 of	 the	 cost	 in	
comparator	pathways	for	patients	who	choose	not	to	use	the	OCCP	
to	access	 their	 results.	 If	all	patients	accessed	 their	 result	 through	
the	 OCCP	 system,	 then	 compared	 to	 the	 comparator	 pathways	 it	
would	represent	the	lowest	cost	option	for	results	notification	in	all	
circumstances	 except	 when	 compared	 with	 NCSP	 B	 results	
notification	 for	 negative	 results	 where	 it	 is	 more	 expensive.	
However,	this	cost	of	results	notification	was	difficult	to	quantify	for	






















Online	Treatment	Only	 11.34	 11.34	 10.64	 10.64	





The	 difference	 in	 cost	 between	 NCSP	 and	 GUM	 online	 treatment	
only	 reflects	 the	costs	associated	with	 the	health	advisor	helpline.	
This	 was	 calculated	 by	 identifying	 the	 average	 (median)	 contact	
time	with	the	helpline	for	patients	originating	from	GUM	and	NCSP	
services	 and	 the	 percentage	 of	 participants	 who	 contacted	 the	
helpline	from	the	two	originating	service	categories.		
	
The	 full	 pathway	 identifies	 the	 costs	 associated	with	 the	 delivery,	
including	 the	 costs	 associated	with	 results	 notification	 and	 online	
treatment	 (excluding	 training	 costs	 and	 health	 advisor	 follow	 up).	
The	 variance	 in	 costs	 is	 driven	 by	 the	 impact	 of	 integrating	 the	
elements	 associated	 with	 existing	 services,	 in	 this	 case,	 results	
notification	 for	 patients	 not	 accessing	 their	 results	 through	 the	
OCCP	 system.	 The	 minor	 cost	 variance	 associated	 with	 helpline	
contact	 also	 accounts	 for	 the	 difference.	 A	 comparison	 of	 the	 full	
online	 pathway	 costs	 with	 the	 existing	 comparator	 pathways	 is	
summarised	in	table	7.35.	In	all	cases	where	treatment	is	provided	













Online	Treatment	Only	(OCCP)	 11.34	 11.34	 10.64	 10.64	
Treatment	Cost	Only	
(comparator	pathways)	 26.97	 22.88	 18.07	 36.16	
Full	Pathway	(online	only)	




28.78	 24.15	 23.48	 45.10	
Table	7.35	-	Comparison	of	OCCP	and	existing	GUM	and	NCSP	pathways.	
	
It	 is	 recognised	 however	 that	 not	 all	 patients	 commencing	 the	
online	 pathway	 for	 treatment	 will	 complete	 their	 treatment	
through	 this	 route.	 There	 can	 be	 a	 number	 of	 reasons	 for	 this	
including	symptoms,	allergies	or	medical	conditions	which	preclude	
online	care	being	delivered	safely	(Estcourt	and	Gibbs,	2016).	In	the	
exploratory	 study	 such	 patients	were	 directed	 to	 a	 GUM	 clinic	 to	
receive	 treatment.	 In	 considering	 the	 average	 cost	 per	 patient	 of	
the	online	service,	 factoring	 in	patients	who	are	diverted	from	the	






























The	 average	 positive	 patient	 pathway	 cost	 includes	 the	 cost	 of	













unsuitable	 to	 receive	 treatment	 via	 the	 online	 pathway.	 The	














































This	 shows	 the	 range	 of	 costs	 associated	 with	 treatment	 of	 all	
patients	commencing	the	OCCP	is	in	the	range	of	£15.03	to	£22.15,	
whereas	the	range	of	costs	associated	with	chlamydia	treatment	in	
the	 four	 existing	 services	 costed	 ranges	 from	 £23.48	 to	 £45.10.	
These	 differences	 in	 cost	 can	 in	 be	 explained	 by	 the	 significant	
variation	 identified	 in	 the	 delivery	 of	 care	 between	 the	 four	
pathways.	 Comparing	 the	differences	between	 the	delivery	of	 the	
GUM	Clinic	A	and	GUM	Clinic	B	services:	
• GUM	A	has	a	patient	group	direction	in	place	which	enables	
nurses	 to	 deliver	 the	 service	 for	 chlamydia	 treatment	
without	input	from	a	doctor.	The	results	notification	process	





undertaken	 by	 Adams	 et	 al	 (2014).	 The	 pathway	 costing	
used	 is	 designated	 that	 the	 primary	 purpose	 of	 the	 visit	 is	
chlamydia	treatment	only	(i.e.	there	is	no	secondary	reason	
for	 the	 visit	 e.g.	 further	 testing/	 a	 positive	 test	 result	 for	
another	 STI).	 Secondly	 the	 estimates	 of	 time	 to	 notify	
positive	 patients	 of	 results	 are	 significantly	 higher	 in	 this	
pathway	 costing	 than	 those	 identified	 in	 GUM	 Clinic	 A.	
Assuming	 the	 same	proportion	of	 positive	patients	 in	 both	
settings	leads	to	higher	costs	for	results	notification.	
• NCSP	A	offer	all	patients	a	choice	of	four	results	notification	
options	 and	 four	 choices	 of	 treatment.	 The	 service	 lead	





• NCSP	B	use	 text	notification	 for	all	 results,	with	all	positive	
patients	 being	 asked	 to	 contact	 the	 chlamydia	 screening	
office.	 During	 this	 call	 the	 nurse	 runs	 through	 questions	
which	 form	 the	 PGD	 to	 support	 the	 decision	 making	 on	
where	 the	 patient	 should	 attend	 for	 treatment,	 with	 the	
majority	 being	 encouraged	 to	 the	 pharmacy	 route.	 For	
patients	 receiving	 treatment	 via	 a	 community	 pharmacy	
consultation	 they	 are	 asked	 the	 same	 questions	 twice	 and	
effort	 is	duplicated	on	the	part	of	healthcare	professionals.	




• Both	 NCSP	 services	 include	 a	 follow	 up	 call	 by	 a	 health	
advisor	(or	nurse)	at	which	partner	notification	is	addressed	
if	 it	 hasn’t	 been	 taken	 up	 by	 the	 patient	 at	 the	 point	 of	
treatment.		
• Neither	GUM	service	indicated	any	health	advisor	follow	up.	
GUM	 A	 stated	 that	 patients	 were	 advised	 about	 the	
circumstances	under	which	they	would	need	to	contact	the	
clinic	 for	 further	 advice,	 GUM	 B	 pathway	 documentation	
provided	 no	 indication	 that	 this	 step	 had	 been	 costed.	
Whilst	this	is	consistent	in	comparing	the	costs	between	the	
two	comparator	options	this	has	been	included	in	the	OCCP	
as	 it	 is	 a	 recognised	 requirement	 of	 the	 guidelines	 for	 the	
management	of	chlamydia	(BASHH,	2006).	The	average	cost	







part	of	 the	primary	costing	study,	 the	 following	were	 identified	as	
the	key	variables	 impacting	on	cost	of	delivering	chlamydia	results	
notification	and	treatment	via	the	OCCP:	
• System	 costs	 associated	 with	 the	 OCCP	 eHealth	 clinic	 e.g.	
hosting	and	maintenance	










length	 lower	 quartile	 and	 upper	 quartile	 values	 for	 each	
stage	
• Online	 completion	 –	 percentage	 of	 people	 successfully	
completing	the	pathway	online	–	50%,	60%,	70%	and	80%	
• Helpline	 access	 –	 30%	 and	 100%	 of	 people	 access	 the	
helpline	at	the	results	and	treatment	stage	
• An	overall	 average	positive	patient	 pathway	 cost	was	 then	
























Comparing	 the	one-way	 sensitivity	analysis	 results	 for	 the	OCCP	 it	
can	 be	 seen	 that	 the	 range	 of	 average	 cost	 per	 patient	 for	 GUM	
patients	 is	 £16.15	 to	 £21.65	 and	 NCSP	 internet	 testing	 pathway	
patients	of	£16.18	to	£21.74.	 In	all	cases	this	 is	below	the	average	
cost	per	patient	 in	comparator	pathways	(GUM	clinic	average	cost	
per	 positive	 patient	 £34.29,	 range	 £23.48	 -	 £45.10,	NCSP	 internet	
testing	 pathway	 average	 cost	 per	 positive	 patient	 £26.46,	 range	
£24.15	 -	£28.78).	 Examining	 the	 impact	of	 the	 combination	of	 the	
lowest	 and	 highest	 cost	 options	 for	 the	 parameters	 from	 the	
sensitivity	 analysis,	 the	 highest	 cost	 options	 for	 both	 GUM	 and	
NCSP	 internet	 testing	 patients	 using	 the	 OCCP	 are	 below	 the	






However,	 if	 the	 highest	 cost	 options	 are	 combined	 (system	 costs	
double	 the	 base	 case,	 helpline	 cost	 upper	 quartile	 value,	 50%	 of	
people	 successfully	 completing	 the	 pathway	 online	 and	 100%	 of	
people	 completing	 the	 pathway	 online	 needing	 to	 contact	 the	
helpline)	then	the	average	cost	per	positive	patient	completing	the	
OCCP	 increases	 to	£25.29	and	£25.70	 for	GUM	and	NCSP	 internet	
testing	 patients	 respectively.	 This	 is	 higher	 than	 the	 lowest	 cost	




The	 OCCP	 exploratory	 study	 identified	 a	 number	 of	 primary	 and	
secondary	 outcomes,	 these	 are	 summarised	 in	 table	 7.40.	Of	 these	
outcomes,	 two	 are	 key	 parameters	 for	 the	 model	 presented	 in	














































The	 outcomes	 identified	 from	 the	 literature	 review	 detailed	 in	
section	7.4	are	summarised	in	tables	7.17	and	7.18,	along	with	their	
limitations.	 From	 the	 interviews	 with	 commissioners	 and	 service	
providers	as	part	of	the	primary	costing	study,	 limited	 information	
was	 available	 on	 the	 outcome	 measures	 which	 are	 directly	
comparable	to	the	OCCP.	Although	it	was	identified	that	these	data	
should	 be	 identifiable	 from	 routine	 datasets,	 interviews	 revealed	
that	it	is	not	possible	to	routinely	identify	this	information	from	the	
national	 data	 submissions,	 particularly	 following	 the	 decision	 to	
change	 the	 NCSP	 datasets	 in	 2013	 so	 that	 elements	 previously	
reported	 such	 as	 treatment	 uptake	 are	 no	 longer	 reported.	
Interviews	with	commissioners	revealed	that	their	monitoring	focus	




















































Meta-analysis	 of	 findings	 for	 comparator	 pathways	 from	 the	
literature	review	was	not	undertaken	as	the	reporting	of	studies	was	
not	 sufficiently	 clear.	 Therefore,	 the	 ‘base	 case’	 value	 identified	 in	
table	7.41	is	derived	from	the	study	with	the	largest	sample	size	and	
the	 range	 represents	 the	 lowest	 and	 highest	 average	 values	
identified	 from	 the	 studies	 included	 in	 the	 literature	 review.	





This	 is	 of	 particular	 significance	 in	 pathways	 such	 as	 sexual	 health	
services	 where	 the	 commissioners	 and	 providers	 are	 split	 across	
different	 element	 of	 the	 pathways.	 In	 the	 case	 of	 chlamydia	 for	
example,	the	focus	of	LA	commissioners	is	the	delivery	of	testing	and	
treatment	 services,	 whereas	 the	 focus	 of	 CCGs	 is	 the	 provision	 of	
services	 that	 manage	 the	 long-term	 consequences	 associated	 with	






and	 outcomes	 separately	 as	 a	 benefit,	 Mauskopf	 and	 colleagues	
point	 to	 it	 being	 a	 risk,	 in	 so	 far	 as	 “the	 weighting	 of	 the	 relative	
importance	 of	 different	 costs	 and	 benefits	 is	 left	 to	 each	 decision	
maker”	(Mauskopf	et	al.,	1998:282).	No	suggestion	is	offered	as	to	a	
resolution	 to	 this	 risk,	 and	 examples	 of	 how	weighting	 by	 decision	





The	 costing	 study	 has	 demonstrated	 that	 utilising	 the	 OCCP	 as	 a	
method	 for	 results	 notification,	 treatment	 and	 partner	 notification	
has	 the	 potential	 to	 deliver	 a	 service	 at	 a	 lower	 cost	 per	 positive	
patient	than	existing	pathways.	The	average	cost	per	patient	includes	
the	 cost	 of	 treatment	 via	 a	 GUM	 clinic	 for	 those	 patients	 who	 are	
unable	 to	 complete	 the	 online	 pathway.	 The	 outcomes	 deliver	 a	
mixed	 picture,	 with	 time	 from	 index	 diagnosis	 to	 treatment	 being	
considerably	 better	 than	 current	 pathways	 and	 the	 percentage	 of	
people	 receiving	 treatment	 being	 broadly	 similar.	 However,	 the	
percentage	 of	 partners	 treated	 is	 significantly	 lower	 than	 existing	
pathways.	The	partner	notification	results	should	be	interpreted	with	
caution	owing	to	the	 low	numbers	of	partners	who	were	registered	
on	 the	 system	by	 index	patients	 logging	on	 to	access	 treatment	via	







likely	 impact	 of	 the	 OCCP	 technology	 on	 the	 cost	 of	 delivery	 and	
outcomes	compared	with	existing	practice.		It	also	highlights	issues	to	
be	 taken	 into	 consideration	 in	 its	 future	 development	 and	 further	
research.	 It	 demonstrates	 that	 the	 OCCP	 is	 likely	 to	 be	 cost	 saving	
when	 implemented	 alongside	 existing	 pathways,	 however	 the	
proportion	 of	 patients	 requiring	 treatment	 via	 clinic	 demonstrates	
that	 its	 implementation	 could	 only	 be	 as	 an	 alternative	 treatment	
option	as	opposed	to	a	replacement	one.	Based	on	the	proportion	of	
patients	 completing	 treatment	online	or	 in	 a	GUM	clinic	within	 the	
pilot	study,	the	technology	offers	a	saving	of	£6.86	per	positive	NCSP	




A	 key	 strength	 of	 the	 study	 is	 that	 it	 uses	 comparator	 pathways	





There	are	a	number	of	 limitations	to	this	study,	firstly	 it	 is	a	costing	
study	 based	 on	 an	 exploratory	 study	 involving	 small	 number	 of	
patients	(the	exploratory	study	was	powered	for	non-inferiority).	The	
exploratory	 study	 focused	 specifically	 on	 the	 OCCP	 and	 did	 not	
collect	 any	 primary	 data	 on	 comparator	 pathways,	 specifically	 in	
terms	of	outcomes.	Participants	opted	 into	 the	study,	 there	was	no	
randomisation	 of	 participants	 between	 the	 OCCP	 and	 control	
(comparator)	pathways	therefore	there	is	the	potential	for	bias	in	the	
results.	No	information	is	known	about	the	individuals	who	chose	not	
to	 consent	other	 than	 they	met	 the	 inclusion	 criteria	 for	 the	 study.	
Whether	 there	 is	 anything	 significant	 about	 this	 cohort	 of	 patients	
which	 would	 impact	 on	 costs	 is	 unknown.	 This	 is	 significant	 in	 the	
context	 of	 costing	 the	 service	 as	 the	 rate	 of	 completion	 of	 the	
pathway	online	is	a	key	determinant	in	the	cost	of	the	service.		
	
Data	 for	 the	 costing	 study	 was	 collected	 primarily	 from	 the	 OCCP	
system,	literature	review	and	interviews	with	those	directly	involved	
in	the	commissioning	or	provision	of	services.	As	demonstrated	in	the	
results	 section,	 both	 cost	 and	 outcome	 parameters	 for	 comparator	
pathways	were	not	well	estimated	in	the	literature,	and	variability	in	
data	quality	is	a	recognised	weakness	of	a	cost	consequence	analysis	
approach	 (Mauskopf	 et	 al.,	 1998).	 As	 discussed	 in	 the	 methods	
section	 this	 impacts	 on	 the	 level	 of	 precision	 with	 the	 costing	






research	 and	 development.	 The	 study	 exposed	 issues	 with	 data	
collection	as	part	of	 the	exploratory	study,	 in	particular	 the	capture	
of	 data	 on	 access	 to	 the	 helpline	 was	 undertaken	 in	 an	 Excel	
spreadsheet	meaning	 that	 records	 of	 calls	 were	 not	 linked	 directly	
into	 the	 database	 capturing	 the	 patients’	 responses	 to	 the	 OCCP.	
Secondly	 it	 was	 not	 possible	 to	 disaggregate	 time	 spent	 by	 health	
advisors	 on	 research	 related	 activities	 e.g.	 service	 evaluation	
questions	at	the	end	of	the	health	advisor	follow	up	call	and	service	
delivery	 activities	 such	 as	 the	 follow	 up	 call	 itself.	 In	 considering	
future	 research	 in	 respect	 of	 the	 OCCP,	 it	 is	 accepted	 that	 a	
randomised	control	trial	is	the	next	step.	It	is	recommended	that	the	
‘back	 end’	 of	 the	 system	 is	 revised	 to	 enable	 the	 capture	 and	





not	 quantified,	 that	 the	 sexual	 health	 clinician	 leading	 the	 OCCP	




in	 the	course	of	 the	study.	However,	 there	were	a	small	number	of	








As	 part	 of	 the	 next	 phase	 of	 research	 it	 may	 also	 beneficial	 to	
consider	 patient	 costs.	 Whilst	 this	 is	 not	 a	 requirement	 for	
consideration	 in	 an	 economic	 evaluation	 for	 adoption	 into	
mainstream	services	 in	England	 it	 is	 recognised	that	uptake	 is	a	key	
consideration	 in	achieving	cost	effectiveness	(Tate	et	al.,	2009).	 It	 is	
recognised	 that	 the	majority	of	patients	 already	have	access	 to	 the	
base	 technology	 required	 (e.g.	 computer,	 smartphone,	 internet	
connection),	 and	 the	 qualitative	 research	 undertaken	 with	 people	
who	 completed	 the	 pathway	 indicated	 they	 believed	 it	 to	 be	more	
convenient	that	traditional	pathways	(Aicken	et	al.,	2016).	
	
Another	 key	 issue	 to	 consider	 in	 the	 next	 phase	 of	 the	 research	 is	
generalizability	 of	 the	 findings	 to	 mainstream	 practice.	 As	




compare	 with	 an	 optimised	 current	 pathway?	 A	 second	
consideration	 is	 the	 costs	 of	 running	 the	 OCCP	 compared	with	 the	






utilisation	 of	 the	 capacity.	 A	 final	 consideration	 for	 future	 research	
identified	 draws	 together	 the	 findings	 of	 the	 costing	 study	 and	 the	
stated	preference	study,	to	explore	the	impact	of	preferences	in	the	
design	 of	 the	 clinical	 care	 pathway.	 For	 example,	 considering	
variation	to	the	OCCP	to	provide	access	to	a	health	care	professional	
via	 instant	 messaging	 as	 the	 DCE	 indicated	 that	 there	 is	 no	
statistically	 significant	 difference	 in	 preference	 between	 instant	
messaging	and	face-to-face	contacts,	whereas	 it	suggests	that	there	
is	 a	 statistically	 significant	difference	 for	participants	 in	 the	DCE	 for	
face-to-face	contact	compared	with	phone	contact.	
	
Considering	 where	 this	 study	 sits	 within	 the	 context	 of	 other	
published	 studies,	 this	 is	 the	 first	 review	 of	 the	 costs	 and	
consequences	 of	 an	 OCCP	 for	 chlamydia	 which	 requires	 no	 input	
from	a	health	care	professional	to	prescribe	medication.	Bracebridge	
and	 colleagues	 explore	 the	 cost	 effectiveness	 of	 a	 fully	 remote	
chlamydia	 testing	 and	 treatment	 pathway	 with	 a	 doctor	 reviewing	
responses	 to	 an	 online	 questionnaire	 prior	 to	 prescribing	 the	
treatment	and	found	that	costs	per	positive	diagnosis	were	3.5	times	
higher	 than	 the	 NCSP	 average,	 however	 this	 includes	 the	 costs	 of	
testing	 and	 running	 the	 screening	 programme	 (Bracebridge	 et	 al.,	
2012).	A	 similar	 study	 to	 the	Bracebridge	and	 colleagues	 study	was	
identified	 in	California	which	centred	on	the	use	of	website	 for	 test	











This	 chapter	 offers	 valuable	 insight	 into	 the	 likely	 costs	 of	
implementation	 of	 a	 novel	 online	 clinical	 care	 pathway	 for	 the	
treatment	of	chlamydia.	The	preliminary	costing	analysis	shows	that	
it	 has	 the	 potential	 to	 be	 less	 expensive	 per	 patient	 than	 existing	







The	 pathway	mapping	 undertaken	 as	 part	 of	 the	 costing	 study	 has	
demonstrated	 that	 there	 is	 significant	 variance	 in	 the	 way	 that	
chlamydia	 treatment	 services	 are	 currently	 delivered	 which	 have	 a	
material	 impact	 on	 cost.	 This	 is	 an	 area	 which	 service	 providers	
would	 benefit	 from	 exploring	 further	 as	 it	 demonstrates	
opportunities	 for	 saving	 cost	 within	 existing	 delivery	 models.	 One	
other	important	finding	from	the	literature	review	and	costing	study	
is	 that	with	 the	 exception	 of	 Turner	 and	 colleagues	 (2014),	 current	
pathway	 delivery	 models	 are	 not	 reflected	 in	 previous	 published	
studies	 considering	 the	 cost-effectiveness	 of	 chlamydia	 testing	 and	
treatment.		
	
In	 the	 next	 chapter	 the	 broader	 impact	 of	 the	 adoption	 of	 a	 fully	
remote	online	pathway	for	chlamydia	will	be	considered	in	a	decision	














There	 are	 widely	 recognised	 benefits	 to	 using	 decision	 analytic	
modelling	 within	 stage	 II	 economic	 evaluation	 to	 inform	 the	 eHTA	
process.	In	particular,	it	has	a	key	role	to	play	in:	
















In	 Chapter	 7	 the	 costs	 and	 outcomes	 per	 average	 patient	 were	
identified	for	the	OCCP,	testing	the	concept	of	a	fully	remote	online	
pathway	 from	 results	 notification	 to	 health	 advisor	 follow	 up.	 This	
chapter	takes	forward	this	work	to:	




• Explore	 the	 uncertainty	 in	 model	 parameters	 through	
sensitivity	analyses	
• Apply	the	findings	from	the	DCE	to	 investigate	the	 impact	of	
uptake	of	testing	and	treatment	on	the	costs	and	outcomes	of	




the	 impact	 of	 the	 OCCP,	 taking	 forward	 the	 work	 presented	 in	
chapter	 7,	 and	 secondly	 exploring	 the	 potential	 impact	 of	 the	 full	
pathway	 compared	 to	 the	 GUM	 clinic	 pathway	 and	 NCSP	 internet	
testing	pathway.	The	self-test	 technology,	which	 is	being	developed	
by	 the	 eSTI2	 Consortium,	 is	 not	 yet	 ready	 for	 implementation	 into	
clinical	 practice	 or	 as	 a	 pilot	 (as	 of	 2016).	 Thus,	 this	work	 explores	
hypothetical	 scenarios	 to	 examine	 how	 the	 new	 test’s	 parameters	
and	associated	costs	would	impact	on	the	full	chlamydia	testing	and	
treatment	pathway.	As	a	result,	this	model	can	be	used	to	establish	




The	 analysis	 was	 undertaken	 to	 inform	 the	 future	 development	 of	
the	 OCCP,	 self-test	 technology	 and	 service	 pathways	 against	 a	
backdrop	 of	 increasing	 policy	 emphasis	 on	 the	 development	 and	
implementation	of	digital	 technology	within	 the	NHS	 in	England.	As	
outlined	 in	section	3.5.1,	a	decision	analytic	model	was	selected	for	
the	following	reasons:	
• This	 is	 an	 early	 stage	 evaluation	 of	 a	 new	 technology	 and	
therefore	 the	objective	 is	 to	demonstrate	 the	 likely	 impact	




• Data	 for	 parametrising	 a	model	 about	 the	 new	 technology	
are	somewhat	limited,	with	no	data	on	self-testing	(Stages	1	
and	 2	 in	 pathway	 E,	 figure	 2.1)	 and	only	 initial	 results	 and	
costings	 for	 the	 OCCP	 (Stages	 3	 to	 6	 in	 pathway	 E,	 figure	
2.1);	
• It	 is	 not	 yet	 known	 how	 the	 availability	 of	 self-tests	 may	
influence	sexual	behaviours,	risk	taking	and	testing	patterns,	
all	 of	 which	 would	 be	 material	 considerations	 within	 a	
dynamic	 model	 to	 inform	 parameters	 such	 as	 partner	
change	rate;	
• Whilst	 it	 is	recognised	that	dynamic	models	are	superior	to	
static	models	for	modelling	infectious	diseases	(Barton	et	al.,	





included	 the	 direct	 costs	 to	 the	 provider	 of	 delivering	 the	 service	
and	excluded	patient	related	costs.	This	is	in	line	with	the	approach	
outlined	 in	 the	 MTEP	 methods	 guide	 which	 states	 that	 “models	






defined	 as	 sexual	 health	 services	 commissioned	 by	 LAs	 to	 meet	
their	 statutory	 obligation	 to	 provide	 open	 access	 sexual	 health	





The	 disease	 focus	 of	 the	model	 was	Chlamydia	 Trachomatis.	 This	
was	 restricted	 to	 genital	 Chlamydia	 Trachomatis	 (excluding	
Chlamydia	 Trachomatis	 infections	 of	 other	 sites).	 The	 target	
population	 identified	 was	 defined	 as	 the	 general	 population,	
recognising	 that	 sexual	 health	 services	 are	 an	 open	 access	
diagnostic	service.	It	should	be	noted	that	whilst	the	age	range	for	
the	 NCSP	 is	 16-24	 year	 olds,	 within	 this	 analysis	 no	 assumptions	
were	 made	 regarding	 an	 upper	 age	 limit.	 Population	 subgroups	








The	 reasons	 for	 selecting	 these	 two	 options	 for	 comparison	were	
that	 they	 represent	 two	of	 the	main	pathways	of	established	care	
within	 mainstream	 sexual	 health	 services,	 and	 they	 reflect	 the	
pathways	 from	 which	 patients	 were	 sourced	 for	 the	 OCCP	








and	 treatment,	 and	 the	 mapping	 work	 to	 understand	 chlamydia	
testing	and	treatment	pathways	undertaken	as	part	of	 the	costing	
study.	 	 From	 the	 literature	 review	 presented	 in	 Chapter	 6,	 this	
included	static	models	presented	by	Hislop	et	al.,	(2010),	Turner	et	
al.,	 (2011)	 and	 Turner	 et	 al.,	 (2014).	 In	 addition,	 Roberts	 (2008),	
presented	 a	 summary	 of	 static	 structures	 used	 to	 evaluate	





















































primary	 data	 sources.	 The	 following	 sections	 outline	 the	
assumptions	in	respect	of	population,	disease,	uptake	of	treatment	




The	 model	 was	 created	 to	 start	 at	 decision	 to	 test.	 The	 model	
contains	three	parameters	(population	tested,	proportion	of	tests	
–	male	and	 female,	 and	pregnancy	 rate)	 that	 can	be	varied	with	
respect	 to	 the	 population,	 which	 are	 summarised	 in	 table	 8.1.	



























































The	 model	 created	 was	 a	 static	 model.	 Whilst	 it	 does	 not	






































































It	 is	 known	 that	 a	 proportion	 of	 chlamydia	 positive	 patients	
experience	 spontaneous	 resolution	 without	 requiring	 antibiotics	
to	 treat.	 A	 recent	 study	 estimates	 this	 to	 be	 approximately	 20%	
between	 screening	 and	 returning	 for	 treatment	 (Geisler	 et	 al.,	
2013).	Spontaneous	resolution	was	not	incorporated	in	the	model	
as	 current	 pathways	 do	 not	 undertake	 any	 retesting	 prior	 to	
treatment.		
	
It	 is	 also	 known	 that	 a	 high	 proportion	 of	 patients	 will	 be	
asymptomatic,	 as	 outlined	 in	 section	 2.4.3.	 The	management	 of	
patients	 attending	 clinics	 with	 symptoms	 will	 be	 different	 to	
asymptomatic	 patients.	 Therefore,	 the	GUM	pathway	within	 the	
model	represents	the	pathway	for	asymptomatic	patients	only.		
	
8.2.3.3 Health	 Outcomes	 –	 Complications	 Resulting	 from	 Untreated	
Chlamydia	
The	model	incorporated	outcome	measures	in	the	form	of	health	
complications	 (major	 outcomes)	 resulting	 from	 untreated	
chlamydia	 rather	 than	QALYs	 for	 the	 reasons	 outlined	 in	 section	
3.5.1.		
		 444	
This	builds	upon	 the	work	 in	Chapter	7	 to	 consider	 the	process/	
system	 outcomes	 defined	 by	 the	 OCCP	 exploratory	 study	 and	
enables	an	understanding	of	the	 impact	of	the	process	measures	
on	 health	 outcomes	 in	 the	 form	 of	 complications	 arising	 from	
untreated	chlamydia.		
	






















PID	 in	 women	 and	 epididymitis	 in	 men	 are	 recognised	
consequences	of	untreated	chlamydia	(WHO,	2007).	Of	the	2,072	
diagnoses	 of	 chlamydial	 PID	 and	 epididymitis	 made	 in	 2015	 in	
England,	 2,067	 of	 them	 were	 found	 to	 be	 chlamydial	 PID	 and	
epididymitis:	 1,511	 female	 and	560	male	 (Public	Health	 England,	





In	 their	 systematic	 review,	 Roberts	 and	 colleagues	 consider	
outcomes	as	short	term	e.g.	test	and	treat,	cost	per	case	detected	
or	longer	term	e.g.	major	outcome	averted	(Roberts	et	al.,	2012).	
Of	 the	 29	 screening	 papers	 and	 13	 diagnostic	 test	 papers	
considered	 by	 these	 authors,	 approximately	 one	 half	 considered	
short	 term	outcomes	only.	 Roberts	 and	 colleagues	believe	 these	
to	 be	 inferior	 to	 long	 term	 outcome	measures	 because	 they	 do	
not	provide	an	 indication	of	 the	overall	 success	of	 the	 screening	
programme	(ibid.).	The	outcomes	used	in	the	literature	review	of	




It	 can	 be	 seen	 that	 in	 terms	 of	 outcomes	 with	 respect	 to	
chlamydia	 testing	 and	 treatment,	 there	 are	 a	 number	 that	 have	
been	 adopted	 in	 previous	 cost	 effectiveness	 studies	 (see	 table	
7.11).	 For	 sequelae,	 a	 review	 of	 the	 literature	 was	 undertaken	
using	 the	 complications	 identified	 by	 the	WHO	 (set	 out	 in	 table	
8.4)	 to	 determine	 model	 parameters.	 This	 process	 reduced	 the	
































































































There	are	a	number	of	parameters	 in	 the	model	 (summarised	 in	
table	8.6),	which	relate	to	individual	choice.	Unlike	the	population,	


































































































As	 outlined	 in	 section	 8.2	 the	 technology	 was	 evaluated	 in	 two	
parts	-	the	OCCP	(from	results	notification	to	health	advisor	follow	
up)	and	the	fully	remote	online	pathway	(from	self-test	to	health	
advisor	 follow	 up).	 In	 the	 OCCP	 evaluation,	 the	 test	 parameters	
were	assumed	to	be	constant	across	all	three	pathways	(see	table	
8.7).	 For	 the	 fully	 remote	 online	 pathway,	 the	 test	 parameters	
chosen	were	the	parameters	for	the	test	in	use	at	one	of	the	OCCP	
exploratory	 study	 sites.	 As	 a	 result	 of	 the	 absence	 of	 a	 self-test	
developed	 by	 the	 eSTI2	 consortium,	 the	 test	 parameters	 used	 in	
the	 base	 case	 for	 the	 fully	 remote	 online	 pathway	 and	 the	
implications	 for	 a	 self-test	 were	 explored	 further	 in	 sensitivity	
analyses	presented	in	section	8.3.4.	
	



















































As	 in	 Chapter	 7,	 resource	 inputs	 were	 costed	 at	 2015	 prices	
(£GBP);	where	necessary,	 the	NHS	HCHS	pay	and	prices	 inflation	






positive	 patients	 only.	 This	 necessitated	 the	 comparison	 of	 the	
OCCP	 with	 the	 GUM	 clinic	 pathway	 and	 the	 comparison	 of	 the	
OCCP	 with	 the	 NCSP	 Internet	 Testing	 Pathway	 as	 the	 costs	
associated	with	delivery	are	different.	Within	the	GUM	clinic	there	
was	a	requirement	for	staff	to	enter	patient	details	onto	the	OCCP	


















































Within	 the	 fully	 remote	 online	 pathway	 the	 costs	 of	 results	
notification	onwards	 remain	 the	 same	as	 in	 the	OCCP.	However,	
the	 costs	 of	 testing	 are	 included	 in	 the	 evaluation.	 Data	 for	 the	
costs	of	testing	were	identified	from	literature	reviews.	A	number	
of	values	for	GUM	and	NCSP	internet	testing	were	identified.	The	
base	 case	 values	 outlined	 in	 table	 8.9	 have	 been	 taken	 from	





Within	 the	OCCP	 the	 costs	 of	 results	 notification	 are	 included	 in	
the	treatment	stage	as	this	is	where	the	OCCP	starts.	In	contrast,	
within	 the	 fully	 remote	 online	 pathway,	 the	 costs	 of	 results	
notification	 are	 included	 within	 the	 testing	 stage	 cost	 as	 this	 is	




















































the	 literature	 also	 identified	 variation	 in	 the	 costing	 of	 the	
treatment	of	sequelae.	To	understand	the	impact	of	this	issue	Ong	
and	 colleagues	 explored	 the	 impact	 of	 chlamydia	 sequelae	 cost	
estimates	 on	 economic	 evaluations	 of	 chlamydia	 screening	
programmes	 (Ong	 et	 al.,	 2016).	 Their	 findings	 demonstrated	 a	
considerable	 variation	 in	 the	 costs	 associated	 with	 the	




















average	 was	 taken	 from	 the	 UK	 studies	 included	 in	 Ong	 and	
colleagues.	Their	study	did	not	report	a	value	for	PROM.	A	search	
of	 the	 published	 literature	 failed	 to	 identify	 any	 published	 UK	
studies	on	costs	 for	the	management	of	PROM;	therefore,	a	cost	
was	taken	from	NICE	medical	technologies	guidance	on	the	use	of	
the	 Vision	 Amniotic	 Leak	 Detector	 (NICE,	 2013)	 and	 uplifted	 to	



































































The	 analysis	 was	 undertaken	 on	 a	 theoretical	 cohort	 of	 100,000	
people,	using	ONS	population	data	to	determine	the	split	between	
male	 and	 female	 (Office	 for	 National	 Statistics,	 2016c).	 The	 total	







in	 a	 measure	 of	 cost-effectiveness	 such	 as	 an	 incremental	 cost-
effectiveness	 ratio.	 This	 approach	 is	 adopted	 in	 cost	 consequence	
analysis,	 allowing	 the	opportunity	 for	 decision	makers	 to	 consider	
costs	 and	 outcomes	 separately	 (Drummond	 et	 al.,	 2005),	 a	 list	 of	








at	 a	 pathway	 level,	 the	 costs	 associated	 with	 service	 delivery	 for	
testing	and	treatment	of	chlamydia	are	the	same	for	both	sexes.		
	
Eddy	 and	 colleagues	 identify	 five	 types	 of	 model	 validation	 “face	
validity,	 verification	 (or	 internal	 validity),	 cross	 validity,	 external	
validity,	and	predictive	validity”	(Eddy	et	al.,	2012:843).			To	assure	
the	model,	the	following	checks	were	undertaken:	
• The	 face	 validity	 of	 the	model	was	 explored	with	 a	 sexual	
health	 clinician	 which	 included	 the	 model	 structure,	
parameter	inputs	and	results.	
• The	 model	 was	 constructed	 in	 Excel	 for	 Mac	 2011	 and	









• Other	 published	 studies	 exploring	 the	 costs	 and	 cost-
effectiveness	were	considered	to	determine	whether	cross-
validation	 was	 possible.	 Whilst	 no	 directly	 comparable	
studies	 were	 identified,	 the	 results	 of	 the	 model	 were	
compared	with	other	similar	studies	and	a	summary	of	 the	
findings	of	this	are	included	in	section	8.4.	
• External	 and	 predictive	 validation	 were	 not	 undertaken	 as	
this	 is	 an	 early	 economic	 evaluation	 and	 are	 recognised	 as	
not	essential	(Weinstein	et	al.,	2003).	
	
A	 key	 feature	 of	 early	 economic	 evaluation	 is	 that	 it	 is	 indicative	
rather	 than	definitive	and	significant	parameter	uncertainty	 is	one	
of	the	main	reasons	for	this	(Sculpher	et	al.,	1997).	The	aim	of	early	
economic	evaluation	 is	 to	provide	an	 indication	of	 the	 likely	 costs	
and	benefits	of	a	new	technology	and	to	 identify	areas	 for	 further	
consideration	 for	 technology	 developers.	 Therefore,	 sensitivity	
analysis	 has	 been	 undertaken.	 Reference	 was	 made	 to	 both	 the	
NICE	 MTEP	 methods	 guide	 (NICE,	 2011)	 and	 the	 ISPOR	 good	
research	practices	for	parameter	estimation	and	uncertainty	(Briggs	
et	 al.,	 2012)	 to	 inform	 the	 selection	 of	 the	 methods.	 One	 way	
sensitivity	analysis	was	selected	as	 the	method	so	 that	 the	 impact	
of	varying	individual	parameters	can	be	seen	on	the	key	outcomes	
to	provide	insight	into	the	impact	on	both	costs	and	outcomes.	Two	
way	 sensitivity	 analysis	 was	 not	 undertaken	 as	 there	 was	 no	
obvious	 correlation	 between	 parameters	 within	 the	 model	
therefore	this	may	offer	a	misleading	view.	Probabilistic	sensitivity	





















• Average	Cost	per	Positive	 (TP	&	FP)	 Index	Patient	 (excluding	
health	complications)	





are	 summarised	 in	 table	8.12.	 In	 respect	of	 the	 integration	of	 the	
OCCP	 into	 a	 GUM	 pathway	 compared	 with	 an	 existing	 GUM	
pathway,	 the	 results	 demonstrate	 that	 75	 fewer	 patients	 take	 up	
treatment	 via	 the	 OCCP	 (3,735	 GUM	 compared	with	 3,659	 GUM-





OCCP	 pathway	 translates	 into	 a	 corresponding	 increase	 in	 health	
complications	 arising	 from	 chlamydial	 infection,	 with	 nine	
additional	complications	occurring	at	an	additional	cost	of	£12,935.	
The	 similarity	 in	 uptake	 rate	 between	 the	 NCSP	 and	 NCSP-OCCP	
means	that	the	numbers	of	index	patients	taking	up	treatment	and	
health	 complications	 are	 the	 same,	 however	 the	 delivery	 of	 the	












Total	Index	Testing	Cost	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	
Total	Index	Patient	Uptake	(TP	&	FP)	 3,735	 3,659	 -75	 3,354	 3,358	 4	
Total	Index	Treatment	Cost	 £128,066	 £65,356	 -£62,710	 £88,774	 £59,966	 -£28,809	
Total	Health	Complications	–	Index	 47	 56	 9	 93	 93	 0	
Total	Cost	of	Health	Complications	–	Index	 £65,275	 £78,209	 £12,935	 £130,595	 £129,949	 -£647	
Total	Sex	Partners	Notified	(TP	&	FP)	 5,453	 11,161	 5,708	 3,957	 9,401	 5,444	
Total	Sex	Partners	Treated	 2,999	 4,241	 1,242	 2,293	 3,572	 1,280	
Total	Cost	of	Sex	Partner	Treatment	 £102,837	 £75,748	 -£27,090	 £60,690	 £63,804	 £3,114	
Total	Health	Complications	–	Sex	Partners	 199	 550	 352	 135	 464	 328	
Total	Cost	of	Health	Complications	–	Sex	
Partners	
£278,733	 £772,192	 £493,459	 £190,054	 £650,432	 £460,377	
Average	Cost	per	TP	index	Patient	excl	
Health	Complications	
£86.22	 £53.80	 -£32	 £62.18	 £51.43	 -£11	
Average	Cost	per	Positive	(TP&FP)	Patient	
excl	Health	Complications	







the	 sex	 partner	 notification	 and	 treatment	 stage.	 The	 index	
notification	 rate	 for	 partners	was	 significantly	 higher	 in	 the	OCCP	
(3.05	partners	per	index	patient	identified	by	GUM	patients	treated	
via	the	OCCP	and	2.8	partners	per	 index	for	NCSP	patients	treated	
via	 the	 OCCP)	 compared	 with	 the	 comparator	 pathways	 (1.46	
partners	per	index	via	a	GUM	clinic	and	1.18	partners	per	index	via	
the	NCSP).	This	increased	rate	of	partners	identified	per	index	was	a	
positive	 benefit	 of	 the	 OCCP	 compared	 with	 existing	 pathways.	
However,	 the	partner	 treatment	uptake	 rate	was	 lower,	with	38%	
of	 the	 partners	 identified	 by	 patients	 treated	 via	 the	 OCCP	 being	
treated	 compared	 with	 55%	 of	 GUM	 clinic	 partners	 and	 58%	 of	
NCSP	partners.	Although	results	in	table	8.12	demonstrated	a	larger	
number	 of	 partners	 treated	 via	 the	 OCCP	 owing	 to	 the	 larger	
number	 of	 partners	 identified	 (over	 1,200	 more	 than	 either	 the	
GUM	or	NCSP	 comparator	pathways),	 the	OCCP	 results	 in	 a	much	
higher	 number	 of	 sex	 partner	 health	 complications	 (352	 more	
complications	 for	 sex	 partners	 of	 index	 patients	 treated	 via	 the	
GUM-OCCP	rather	than	GUM	clinic	and	328	more	complications	for	
sex	 partners	 of	 index	 patients	 treated	 via	 the	 NCSP-OCCP	 rather	












There	 is	 high	 uncertainty	 within	 these	 as	 they	 are	 driven	 by	
personal	 choice	 and	 potentially	 could	 be	 improved	 upon	 with	
modifications	to	pathways.	The	values	considered	in	the	sensitivity	
analysis	were	based	on	 the	OCCP	achieving	 the	value	achieved	by	
the	 comparator	 pathway,	 and	 an	 incremental	 scale	 of	 values	 in	
between.	One-way	 sensitivity	analysis	on	 these	parameters	within	
























GUM	Base	Case	 99%	 	3,735		 	230,904		 	47		 	65,275		
GUM-OCCP	Base	
Case	 97%	 	3,659		 	141,104		 	56		 	78,209		
GUM-OCCP	
100%	Uptake	 100%	 	3,773		 	145,468		 	42		 	58,807		
GUM-OCCP	99%	
Uptake	 99%	 	3,735		 	144,013		 	47		 	65,275		
NCSP	Base	Case	 89%	 	3,354		 	88,774		 	93		 	130,595		
NCSP-OCCP	Base	
Case	 89%	 	3,358		 	59,966		 	93		 	129,949		
NCSP-OCCP	
100%	Uptake	 100%	 	3,773		 	139,067		 	42		 	58,807		
NCSP-OCCP	95%	
Uptake	 95%	 	3,584		 	132,114		 	65		 	91,144		
Table	8.13	–	Sensitivity	Analysis	-	Impact	of	Index	Treatment	Uptake	Rate	
Achieving	the	same	levels	of	uptake	as	the	GUM	clinic	in	the	GUM	
OCCP	would	 result	 in	 the	 same	 number	 of	major	 outcomes	 and	




Within	 the	NCSP	 internet	 testing	pathway	 the	uptake	 rates	were	
within	 0.01%	 of	 each	 other	 therefore	 both	 are	 comparable	 in	
respect	 of	 health	 complications.	However,	 the	 cost	 of	 treatment	
delivery	 via	 the	 OCCP	 is	 lower	 compared	 with	 the	 cost	 of	




Table	 8.14	 summarises	 the	 impact	 of	 sex	 partners	 identified	 per	
index	 patient.	 Recognising	 the	 OCCP	 achieved	 a	 notably	 higher	
number	of	sex	partners	identified	per	index	patient,	consideration	
was	 given	 to	 the	 impact	 of	 a	 lower	 level	 of	 identification	within	

























GUM	Base	Case	 	1.46		 	2,999		 	102,837		 	199		 	278,733		
GUM-OCCP	Base	
















	1.46		 	2,030		 	36,260		 	264		 	369,639		
NCSP	Base	Case	 	1.18		 	2,293		 	60,690		 	135		 	190,054		
NCSP-OCCP	Base	




















that	 the	 total	 number	 of	major	 outcomes	 for	 the	OCCP	 remains	
above	that	of	the	GUM	or	NCSP	comparator	pathways,	therefore	






Table	 8.15	 shows	 the	 impact	 of	 the	 percentage	 of	 sex	 partners	
taking	up	 treatment,	with	 the	 rate	of	 sex	partners	 identified	per	
index	as	per	 the	base	case.	The	values	were	selected	 to	 test	 the	
impact	of	achieving	an	 incremental	 improvement	 from	the	value	






















GUM	Base	Case	 55%	 	2,999		 102,837		 	199		 	278,733		
GUM-OCCP	Base	
Case	 38%	 	4,241		 	75,748		 	550		 	772,192		
GUM-OCCP	60%	
partner	uptake	 60%	 	6,697		 	119,602		 	364		 	511,207		
GUM-OCCP	55%	
partner	uptake	 55%	 	6,139		 	109,635		 	407		 	570,522		
GUM-OCCP	50%	
partner	uptake	 50%	 	5,581		 	99,668		 	449		 	629,836		
GUM-OCCP	45%	
partner	uptake	 45%	 	5,022		 	89,701		 	491		 	689,151		
GUM-OCCP	40%	
partner	uptake	 40%	 	4,464		 	79,734		 	534		 	748,466		
NCSP	Base	Case	 58%	 	2,293		 	60,690		 	135		 	190,054		
NCSP-OCCP	
Base	Case	 38%	 	3,572		 	63,804		 	464		 	650,432		
NCSP-OCCP	60%	
partner	uptake	 60%	 	5,641		 	100,743		 	307		 	430,599		
NCSP-OCCP	58%	
partner	uptake	 58%	 	5,453		 	97,385		 	321		 	450,584		
NCSP-OCCP	55%	
partner	uptake	 55%	 	5,171		 	92,347		 	343		 	480,561		
NCSP-OCCP	50%	
partner	uptake	 50%	 	4,701		 	83,952		 	378		 	530,523		
NCSP-OCCP	45%	
partner	uptake	 45%	 	4,231		 	75,557		 	414		 	580,485		
NCSP-OCCP	40%	






pathways,	 the	 total	 number	 of	 health	 complications	 remains	
higher	 within	 the	 OCCP	 pathways.	 This	 reflects	 the	
interdependency	between	both	sex	partner	identification	rate	and	






and	 sex	 partner	 treatment	 uptake	 rate,	 sensitivity	 analysis	 was	
undertaken	 on	 treatment	 uptake	 rate	 using	 the	 same	 value	 for	




















GUM	Base	Case	 55%	 	2,999		 	102,837		 	199		 	278,733		
GUM	-OCCP	
Base	Case	 38%	 	2,030		 	36,260		 	264		 	369,639		
GUM-OCCP	 60%	 	3,206		 	57,252		 	174		 	244,709		
GUM-OCCP	 55%	 	2,938		 	52,481		 	195		 	273,102		
GUM-OCCP	 50%	 	2,671		 	47,710		 	215		 	301,495		
GUM-OCCP	 45%	 	2,404		 	42,939		 	235		 	329,889		
GUM-OCCP	 40%	 	2,137		 	38,168		 	255		 	358,282		
NCSP	Base	Case	 58%	 	2,293		 	60,690		 	135		 	190,054		
NCSP-OCCP	
Base	Case	 38%	 	1,506		 	26,889		 	195		 	274,110		
NCSP-OCCP	 60%	 	2,377		 	42,456		 	129		 	181,467		
NCSP-OCCP	 58%	 	2,298		 	41,041		 	135		 	189,889		
NCSP-OCCP	 55%	 	2,179		 	38,918		 	144		 	202,522		
NCSP-OCCP	 50%	 	1,981		 	35,380		 	159		 	223,578		
NCSP-OCCP	 45%	 	1,783		 	31,842		 	174		 	244,633		





This	analysis	demonstrated	 that	where	 these	parameters	are	 the	
same	as	 the	comparator	pathway,	 the	parameter	 influencing	 the	







pathway	 from	 self-test	 to	 partner	 treatment	 and	 health	 advisor	
follow	 up.	 Table	 8.17	 outlines	 the	 results	 of	 the	 key	 outcome	
measures	 for	 a	 theoretical	 cohort	 of	 100,000	 people.	 Having	
evaluated	and	reported	on	the	base	case	parameters	and	sensitivity	
analysis	for	the	OCCP	in	the	previous	sections,	the	key	parameters	
where	variance	could	 impact	on	outcomes	and	cost	at	 the	 testing	
stage	are	test	cost	and	test	performance	characteristics	(sensitivity	
and	 specificity).	Within	 the	 base	 case,	 the	 test	 characteristics	 are	











Total	Index	Testing	Cost	 £12,900,000	 £2,269,000	 £2,129,000	 -£10,771,000	 -£140,000	
Total	Index	Patient	Treatment	Uptake	
(TP	&	FP)	
3,735	 3,354	 3,358	 -377	 4	
Total	Index	Treatment	Cost	 £92,511	 £83,610	 £56,709	 -£35,802	 -£26,901	
Total	Index	Testing	&	Treatment	Cost	 £13,066,797	 £2,409,768	 £2,246,047	 -£10,820,750	 -£163,721	
Total	Health	Complications	–	Index	 47	 93	 93	 46	 0	
Total	Cost	of	Health	Complications	–	
Index	
£62,275	 £130,595	 £129,949	 £64,674	 -£647	
Total	Sex	Partners	Notified	(TP	&	FP)	 5,453	 3,957	 9,401	 3,948	 5,444	
Total	Sex	Partners	Treated	 2,999	 2,293	 3,572	 573	 1,280	
Total	Cost	of	Sex	Partner	Treatment	 £74,286	 £57,159	 £60,338	 -£13,948	 £3,180	
Total	Health	Complications	–	Sex	
Partners	
199	 135	 464	 265	 328	
Total	Cost	of	Health	Complications	–	
Sex	Partners	
£278,733	 £190,054	 £650,432	 £371,698	 £460,377	
Average	Cost	per	TP	index	Patient	excl	
Health	Complications	
£1,771	 £1,002	 £933	 -£3,948	 -£69	
Average	Cost	per	Positive	(TP&FP)	
Patient	excl	Health	Complications	







with	 all	 GUM	 activity,	 and	 as	 highlighted	 in	 section	 2.4.4;	 the	
management	 of	 asymptomatic	 patients	 in	 GUM	 sees	 patients	




As	 noted	 in	 the	 previous	 section,	 the	 two	 parameters	 which	





test	performance	characteristics	were	adopted	as	 this	 is	 the	 test	
identified	 in	 operation	 at	 one	 of	 the	 sites	 within	 the	 OCCP	
exploratory	 study.	 Four	 tests	 are	 recognised	 within	 the	 BASHH	
testing	 guidelines	 for	 chlamydia	 as	 commonly	 used	 in	 clinical	

















94.97%	 99.17%	 2,718	 806	 96,332	 144	 77%	
Aptima	CT	Assay	




93.06%	 97.86%	 2,663	 2,079	 95,060	 199	 56%	
Xpert	CT/NG	






The	PPV	has	been	derived	using	 the	prevalence	 rate	used	 in	 the	





The	MTEP	methods	 guide	 highlights	 that	 a	 recommendation	 for	
adoption	 within	 the	 NHS	 is	 usually	 made	 when	 it	 is	 considered	
that:	
• “there	 is	sufficient	certainty	that	the	technology	produces	
at	 least	 equivalent	 clinical	 and/or	 health	 system	 benefits	
compared	 with	 current	 management	 options	 and	 with	 a	
net	reduction	in	resources	required;	or	
• there	 is	 sufficient	 certainty	 that	 the	 technology	 produces	
significantly	 greater	 clinical	 and/or	 healthcare	 system	




Hence,	 there	 is	 no	 basis	 to	 consider	 test	 performance	





note	 is	the	 increase	 in	the	 identification	of	true	positive	(53)	and	
reduction	in	the	number	of	false	positive	(651)	patients	diagnosed	
with	 chlamydia.	 This	 is	 particularly	 significant	 given	 the	 costs	












Number	of	True	Positive	Results	 2,704	 2,704	 2,757	 53	 53	
Number	of	False	Negative	Results	 157	 157	 104	 -53	 -53	
Number	of	True	Negative	Results	 96,070	 96,070	 96,721	 651	 651	
Number	of	False	Positive	Results	 1,069	 1,069	 418	 -651	 -651	
True	Positive	Index	Treatment	Uptake	 2,150	 1,643	 2,561	 411	 918	
Total	Index	Testing	Cost	 £12,900,000	 £2,269,000	 £2,129,000	 -£10,771,000	 -£140,000	
Total	Index	Patient	Treatment	Uptake	(TP	&	FP)	 3,735	 3,354	 2,825	 -909	 -528	
Total	Index	Treatment	Cost	 £92,511	 £83,610	 £47,721	 -£44,790	 -£35,888	
Total	Index	Testing	&	Treatment	Cost	 £13,066,797	 £2,409,768	 £2,227,497	 -£10,839,300	 -£182,271	
Total	Health	Complications	–	Index	 47	 93	 85	 38	 -8	
Total	Cost	of	Health	Complications	–	Index	 £62,275	 £130,595	 £118,680	 £53,400	 -£11,915	
Total	Sex	Partners	Notified	(TP	&	FP)	 5,453	 3,957	 7,911	 2,458	 3,954	
Total	Sex	Partners	Treated	 2,999	 2,293	 3006	 7	 713	
Total	Cost	of	Sex	Partner	Treatment	 £74,286	 £57,159	 £50,776	 -£23,511	 -£6,383	
Total	Health	Complications	–	Sex	Partners	 199	 135	 473	 274	 337	
Total	Cost	of	Health	Complications	–	Sex	Partners	 £278,733	 £190,054	 £663,165	 £384,432	 £473,111	
Average	Cost	per	TP	index	Patient	excl	Health	
Complications	
£4,881	 £1,002	 £908	 -£3,973	 -£95	
Average	Cost	per	Positive	(TP&FP)	Patient	excl	
Health	Complications	




As	outlined	 in	 section	8.3.3	 the	costs	associated	with	 testing	are	
notably	higher	in	the	GUM	clinic	than	the	NCSP	pathway.	This	is	in	
part	due	 to	 the	delivery	of	 testing	within	a	clinic	 setting	and	 the	
wider	 range	 of	 activities	 undertaken	 in	 a	 GUM	 setting	 beyond	
chlamydia	 testing.	 Adams	 and	 colleagues	 undertook	 pathway	
mapping	on	a	GUM	clinic	pathway	as	part	of	their	consideration	of	
the	 implementation	 of	 POCT	 NAATs	 within	 GUM	 clinics	 for	
chlamydia	and	gonorrhoea	(Adams	et	al.,	2014).	They	identified	a	
cost	of	£45.34	for	chlamydia	testing	only	within	GUM,	which	when	




online	 pathway,	 reducing	 the	 cost	 of	 GUM	 testing	 to	 the	 value	













Total	Index	Testing	Cost	 £4,575,000	 £2,269,000	 £2,129,000	 -£2,446,000	 -£140,000	
Total	Index	Patient	Treatment	Uptake	(TP	&	
FP)	
3,735	 3,354	 3,358	 -377	 4	
Total	Index	Treatment	Cost	 £92,511	 £83,610	 £56,709	 -£35,802	 -£26,901	
Total	Index	Testing	&	Treatment	Cost	 £4,741,797	 £2,409,768	 £2,246,047	 -£2,495,750	 -£163,721	
Total	Health	Complications	–	Index	 47	 93	 93	 46	 0	
Total	Cost	of	Health	Complications	–	Index	 £62,275	 £130,595	 £129,949	 £64,674	 -£647	
Total	Sex	Partners	Notified	(TP	&	FP)	 5,453	 3,957	 9,401	 3,948	 5,444	
Total	Sex	Partners	Treated	 2,999	 2,293	 3,572	 573	 1,280	
Total	Cost	of	Sex	Partner	Treatment	 £74,286	 £57,159	 £60,338	 -£13,948	 £3,180	
Total	Health	Complications	–	Sex	Partners	 199	 135	 464	 265	 328	
Total	Cost	of	Health	Complications	–	Sex	
Partners	
£278,733	 £190,054	 £650,432	 £371,698	 £460,377	
Average	Cost	per	TP	index	Patient	excl	
Health	Complications	
£1,771	 £1,002	 £933	 -£838	 -£69	
Average	Cost	per	Positive	(TP&FP)	Patient	
excl	Health	Complications	





The	 findings	 from	 the	DCE	presented	 in	Chapter	 6	 provide	 insight	
into	potential	uptake	of	chlamydia	testing	and	treatment	pathways.	
This	 section	 explores	 the	 application	 of	 this	 data	 within	 the	
economic	 model	 to	 assess	 the	 total	 costs	 and	 wider	 impact	 of	
implementing	the	OCCP	as	a	treatment	option	alongside	GUM	and	





NCSP	 internet	 testing),	 and	 the	 introduction	 of	 either	 OCCP	 (for	
treatment	 and	 partner	 notification),	 or	 the	 fully	 remote	 online	
pathway	(testing,	treatment	and	partner	notification)	alongside	the	
two	current	pathway	options	considered.	The	results,	based	on	the	




These	 results	 demonstrate	 that	 introducing	 the	 OCCP	 into	
mainstream	 practice	 alongside	 current	 pathways	 results	 in	 fewer	
index	patients	 treated	overall	but	more	sex	partners	 treated	 for	a	
lower	 cost.	 A	 similar	 results	 pattern	 is	 demonstrated	 for	 the	 fully	
remote	 online	 pathway.	 If	 the	 fully	 remote	 online	 pathway	 were	
optimised	to	achieve	higher	test	accuracy	and	a	comparable	level	of	
partner	 treatment	 uptake	 then	 fewer	 index	 patients	 are	 treated	
resulting	 from	 the	 reduction	 in	 false	 positives	 for	 less	 cost,	 and	 a	
significantly	 larger	 cohort	 of	 partners	 treated	 (with	 an	 associated	
increase	in	cost);	however,	there	are	still	a	larger	number	of	health	
complications	 arising	 for	 sex	 partners.	 This	 is	 due	 to	 the	






























Number	of	positive	index	patients	(TP	&	FP)	taking	up	treatment	 	3,525		 	87,615		 	3,465		 	76,611		 -61		 -11,004		
Total	health	complications	(index)	 	127		 	178,811		 	135		 	189,216		 	7		 	10,404		
Number	of	sex	partners	of	positive	index	patients	(TP	&	FP)	notified	 	4,630		 	-				 	6,321		 	-				 	1,690		 	-				
Number	of	sex	partners	(TP	&	FP)	taking	up	treatment	 	2,611		 	64,866		 	2,950		 	63,207		 	340		 -1,659		

























Total	Cost	of	Testing	 -	 6,627,710	 -	 3,885,960	 -	 -2,741,750	
Number	of	positive	index	patients	(TP	&	FP)	taking	up	treatment	 2,516	 62,544	 2,449	 49,380	 -67	 -13,164	
Total	health	complications	(index)	 74	 103,814	 85	 119,756	 11	 15,942	
Number	of	sex	partners	of	positive	index	patients	(TP	&	FP)	notified	 3,276	 -	 5,349	 -	 2,073	 -	
Number	of	sex	partners	(TP	&	FP)	taking	up	treatment	 1,850	 45,992	 2,275	 44,297	 424	 -1,695	




















Total	Cost	of	Testing	 -	 6,627,710	 -	 2,903,617	 -	 -3,724,093	
Number	of	positive	index	patients	(TP	&	FP)	taking	up	treatment	 2,516	 62,544	 2,425	 44,443	 -90	 -18,102	
Total	health	complications	(index)	 74	 103,814	 89	 125,451	 15	 21,637	
Number	of	sex	partners	of	positive	index	patients	(TP	&	FP)	notified	 3,276	 -	 8,562	 -	 5,286	 -	
Number	of	sex	partners	(TP	&	FP)	taking	up	treatment	 1,850	 45,992	 4,954	 87,243	 3,104	 41,251	








with	 existing	 pathways	 and	 also	 when	 integrated	 into	 a	 delivery	
model	alongside	mainstream	sexual	health	services.	The	exploratory	
study	 indicated	 that	 an	 OCCP	 is	 broadly	 comparable	 with	 existing	
pathways	for	treatment	uptake	and	far	exceeds	existing	pathways	in	
respect	 of	 the	 number	 of	 partners	 identified	 per	 index	 patient.	
However,	 is	 significantly	 below	 existing	 pathways	 in	 respect	 of	 the	
percentage	of	identified	partners	who	are	treated.	The	consequence	
of	 this	 is	 likely	 to	 be	 a	 significantly	 larger	 number	 of	 health	
complications	for	untreated	partners.	
	
Recognising	 the	 need	 to	 achieve	 parity	 with	 existing	 pathways	 in	
respect	 of	 clinical	 and/	 or	 system	 benefits	 to	 receive	 a	 positive	
endorsement	 by	 the	 NICE	 MTEP	 (NICE,	 2011)	 there	 are	 two	
important	 factors	which	 need	 to	 be	 considered.	 Firstly,	 the	 rate	 of	
sex	partners	identified	per	index.	The	data	for	this	has	been	gathered	




either	 a	 GUM	 clinic	 or	 via	 the	 NCSP	 internet	 testing	 pathway.	
Therefore,	 it	 is	 unlikely	 that	 their	 number	 of	 partners	 over	 the	





are	more	 honest	 in	 providing	 information	 via	 computer	 aided	 self-
interview	 (CASI)	 technology	 within	 sexual	 health	 services.	 For	
example,	 Richens	 and	 colleagues	 used	 CASI	 for	 history	 taking	 in	 a	
randomised	 control	 trial	 undertaken	 in	 sexual	 health	 clinics	 and	
found	that	it	“demonstrated	greater	capture	of	sensitive	information	
during	 computer	 assisted	 interviews	 and	 attributed	 this	 to	 a	
reduction	 in	 social	 desirability	 bias”	 (Richens	 et	 al.,	 2010:313),	 and	
Tideman	 and	 colleagues	 found	 in	 an	 RCT	 of	 CASI	 that	 “women	
undertaking	the	CASI	reported	a	significantly	higher	median	number	
of	 male	 partners	 for	 the	 preceding	 12	 months”	 (Tideman	 et	 al.,	
2007:52).		
	
This	 lends	 credence	 to	 the	 argument	 that	 the	 online	 nature	 of	 the	
OCCP	 has	 led	 to	 more	 honest	 responses	 from	 index	 patients	 than	
those	 in	 face-to-face	 situations.	 This	 would	 be	 viewed	 as	 a	 benefit	
from	 a	 public	 health	 perspective	 if	 the	 identification	 of	 additional	
partners	converts	 into	partner	treatment	and	reduced	transmission.	
This	 view	 is	 supported	 by	 Turner	 and	 colleagues	 who	 explored	
strategies	 to	 improve	 the	 cost-effectiveness	 of	 chlamydia	 screening	
and	 identified	 that	 “there	 is	 considerable	 scope	 to	 improve	partner	
notification	 outcomes.	 Furthermore,	 reallocation	 of	 resources	 to	
ensure	 provision	 and	monitoring	 of	 effective	 partner	 notification	 is	





Secondly,	 the	 number	 of	 health	 complications	 and	 associated	 costs	
arising	from	untreated	chlamydial	infection.	As	previously	outlined	in	
sections	3.5.1	and	8.2.3.3,	evidence	on	both	the	probability	of	health	
complications	 and	 their	 associated	 cost	 is	 limited.	 Price	 and	
colleagues	 highlight	 that	 the	 evidence	 base	 for	 the	 NCSP	 has	 been	
repeatedly	 called	 into	 question	 “with	 little	 consensus	 on	modelling	
assumptions,	 parameter	 values	 or	 evidence	 sources	 to	 be	 used	 in	
cost-effectiveness	 analyses”	 (Price	 et	 al.,	 2016:v)	 and	 Ong	 and	
colleagues	 acknowledge	 that	 “readers	 must	 be	 satisfied	 that	 the	
chlamydia-related	sequelae	considered,	and	 their	management	cost	




In	 considering	 the	 health	 complications	 included	 in	 the	model,	 the	
range	 of	 complications	 was	 limited	 to	 those	 where	 evidence	 was	




still	 a	 considerable	 range	 in	 the	 costs	 of	 treatment	 of	 health	
complications	 identified	 as	 outlined	 in	 table	 8.10.	Whilst	 sensitivity	





delivery	 of	 testing	 and	 treatment.	 This	 analysis	 has	 not	 been	





the	model	 parameters	which	 lead	 to	 an	 overall	 reduction	 in	 health	
complications	namely	index	treatment	uptake,	partner	identification	
per	 index	 and	partner	 treatment	uptake.	 The	DCE	data	 allowed	 for	
the	modelling	to	 incorporate	likely	patient	choice	and	the	impact	of	
that	on	costs	and	outcomes,	 in	particular,	 seeing	how	a	higher	 test	





to	 enable	 variation	 and	 further	 granularity	 in	 the	 pathway	 as	 the	
technology	develops.	It	has	demonstrated	that	it	can	provide	a	clear	






















the	 exploratory	 study.	 Process	measure	 data	was	 not	 collected	 for	
the	 comparator	 pathways	 alongside	 the	 OCCP	 therefore	 this	 data	
was	sourced	from	published	data.	 In	many	cases	the	published	data	
is	 based	on	 clinical	 audits	which	may	be	 subject	 to	bias	because	of	
the	 audit	 process.	 In	 the	 case	 of	 GUM	 in	 particular,	 data	 was	
published	 a	 number	 of	 years	 ago,	 meaning	 that	 it	 may	 not	 be	




test	 parameters	 for	 a	 NAAT	 self-test	 that	 can	 be	 entered	 into	 the	
model.	 The	 improved	 test	 parameters	 reported	 for	 the	 Cepheid	
GeneXpert	 test	 demonstrate	 the	 impact	 of	 a	 test	 with	 better	




The	model	 considered	 two	 comparator	 pathways	 from	mainstream	
practice	 but	 did	 not	 consider	 other	 types	 of	 technology	 currently	
under	development	which	may	be	available	to	the	health	service	at	
the	same	 time/	prior	 to	 the	availability	of	 the	OCCP	or	a	chlamydia	
NAAT	 self-test.	 This	 is	 an	 important	 factor	 for	 the	 technology	
developers	 more	 so	 than	 commissioners	 or	 providers	 of	 health	




Another	 relevant	 area	 of	 development	 is	 partner	 treatment	 with	
expedited	 partner	 therapy	 (EPT)	 and	 accelerated	 partner	 therapy	
(APT)	 demonstrating	 preliminary	 clinical	 effectiveness	 and	
acceptability	(Estcourt	et	al.,	2015b).	Given	the	lower	rates	of	partner	
uptake	within	 the	 current	OCCP	exploring	 such	 approaches	may	be	





it	 is	 acknowledged	 that	 the	 transmission	 dynamic	 elements	 of	
chlamydia	mean	that	there	may	be	benefits	resulting	from	reducing	
time	to	result	and	time	to	treatment	of	both	index	patients	and	their	





no	 other	 published	 studies	 exploring	 OCCP	 and	 self-testing	
technology	for	chlamydia.	Bracebridge	and	colleagues	have	explored	
the	 implementation	 of	 a	 postal	 testing	 pathway	 with	 treatment	
delivered	via	an	online	questionnaire	reviewed	by	a	GUM	doctor	who	
prescribed	treatment.	At	2008-09	prices	the	cost	of	screening	via	this	
pathway	 was	 £1,570	 per	 positive	 patient	 (excluding	 set	 up	 costs),	
compared	with	£506	per	positive	patient	 (Bracebridge	et	al.,	2012).	
This	compares	with	£669	per	positive	patient	tested	and	treated	via	





There	 are	 some	 notable	 differences	 in	 the	 pathways	 costed.	 For	
example,	 the	 Bracebridge	 remote	 pathway	 is	 a	 population	 based	
screening	pathway	so	incurs	the	costs	of	sending	kits	to	all	18-24	year	






(£384.01	 per	 positive	 patient	 tested	 and	 treated,	 compared	 with	
£567.70	 and	 £541.23)	 and	 more	 effective	 (Hislop	 et	 al.,	 2010).	
However,	 this	 research	 did	 not	 consider	 any	 variance	 between	








small	 increase	 in	 QALYs,	 reduction	 in	 health	 complications	 arising	
from	 untreated	 chlamydia	 and	 onward	 transmission	 (Turner	 et	 al.,	
2014).	 Finally,	 Turner	 and	 colleagues	 also	 undertook	 mathematical	
modelling	 to	 explore	 what	 changes	 to	 chlamydia	 screening	 might	
make	it	more	clinically	and	cost	effective.	Compared	to	the	2008-09	
screening	 cost	 of	 £506	 per	 infection	 treated,	 they	 identified	 that	
increased	uptake	of	partner	 treatment	 from	0.4	 to	0.8	partners	per	
index	 would	 reduce	 this	 to	 £449	 per	 infection	 treated	 whilst	
increasing	 male	 screening	 uptake	 from	 8%	 to	 24%	 would	 increase	





Generalisability	 of	 the	present	 research	 findings	 is	 limited	owing	 to	
variations	in	practice	at	local	level.	Such	variation	can	be	evidenced	in	
a	 number	 of	 sources	 including	 NCSP	 clinical	 audits	 (Public	 Health	
England,	2014a,	Public	Health	England,	2016a),	PHE	annual	STI	data	
(Public	 Health	 England,	 2016b)	 as	 well	 as	 the	 costing	 study	
undertaken	as	part	of	 this	 research.	 Local	variations	 in	delivery	and	
the	 impact	 on	 costs	 also	 featured	 in	 a	National	 Audit	Office	 report	
which	found	that	the	local	commissioning	approach	employed	by	the	
NCSP	 led	to	“duplication	of	effort	and	cost	 in	several	aspects	of	the	
programme	 which	 have	 been	 purchased	 in	 a	 fragmented	 way	 by	
multiple	local	commissioners”	(National	Audit	Office,	2009:9).	Whilst	










This	 research	 has	 also	 highlighted	 a	 number	 of	 other	 areas	 where	
further	 research	 would	 be	 beneficial	 prior	 to	 the	 adoption	 of	 an	
OCCP	 or	 fully	 remote	 online	 pathway.	 Firstly,	 research	 to	 explore	
how	the	new	technology	can	achieve	index	and	partner	uptake	rates	
comparable	with	existing	pathways.	Secondly,	further	exploration	of	
increased	 partner	 identification.	 Whilst	 potentially	 a	 significant	
benefit,	 consideration	 as	 to	 how	 to	manage	 the	 differential	 impact	
within	 the	 modelling	 is	 required.	 Within	 the	 model,	 only	 two	




Further	 research	would	be	beneficial	 to	understand	how	 these	 two	




recognised	 the	 limitations	 and	 gaps	 in	 knowledge	 from	 both	 a	
disease	and	cost	perspective	(ECDC,	2014).	Research	published	since	
then	 has	 addressed	 these	 gaps	 to	 some	 extent	 but	 still	 does	 not	
reach	 a	 conclusive	 position	 in	 respect	 of	 the	 incidence	 and	 cost	 of	
health	 complications	 arising	 from	 untreated	 chlamydia.	 Price	 and	
colleagues	 recently	 identified	 a	 set	 of	 parameters	 to	 be	 used	 in	
modelling	 some	 of	 the	 health	 complications	 but	 highlight	 the	 need	
for	 further	 research	 to	 validate	 their	 findings	 (Price	 et	 al.,	 2016).	
Similarly,	Ong	and	colleagues’	review	of	the	cost	estimates	of	health	
complications	 exposed	 the	 considerable	 differences	 in	 parameters	
within	the	UK	and	 internationally	when	 it	came	to	considering	both	
the	 cost	 of	 treating	 complications	 and	 the	 range	 of	 complications	
included	in	modelling	(Ong	et	al.,	2016).	Whilst	the	impact	of	changes	
in	 these	 parameters	 was	 not	 explored	 in	 sensitivity	 analysis	 in	 the	
current	research,	 it	 is	evident	that	the	variance	in	these	parameters	
has	a	material	effect	on	the	costs	associated	with	the	management	of	
chlamydia.	 Further	 research	 to	 determine	 a	 common	 set	 of	
complications,	their	 incidence	and	attributable	cost	in	the	UK	would	






performance	 characteristics.	 Recognising	 that	 test	 accuracy	 is	 the	
attribute	 most	 important	 to	 young	 people	 in	 choosing	 to	 test	 for	
chlamydia	and	the	importance	of	delivery	of	comparable	outcomes	in	
the	NICE	MTEP	approval	process	any	new	test	would	need	to	deliver	
a	 level	 of	 performance	 at	 least	 comparable	 to	 the	 existing	 tests.	
Notably,	in	table	8.18	a	PPV	of	below	90%	is	seen	for	all	tests	at	the	
general	 population	 prevalence	 rate	 identified	 in	 NATSAL-3	
(Sonnenberg	et	al.,	2013).	Given	the	desire	to	increase	uptake	across	
the	 general	 population,	 it	 is	 questionable	 whether	 clinic	 positivity	
rates	 are	 still	 the	 best	 measure	 to	 be	 used	 in	 assessing	 test	
performance.	A	better	measure	might	be	prevalence	estimates	in	the	




of	 perfect	 information	 (EVPI)	were	 not	 considered	 in	 this	 research.	
EVPI	 can	 be	 defined	 as	 the	 cost	 associated	 with	 removing	 all	
uncertainty	from	the	model,	thus	removing	the	possibility	of	making	
the	wrong	 decision	 (Briggs	 et	 al.,	 2006).	 The	 purpose	 of	 the	model	
was	 to	 demonstrate	 the	 likely	 impact	 on	 costs	 and	 outcomes,	
therefore	 it	 was	 considered	 not	 appropriate	 to	 undertake	 this	
analysis	 within	 the	 context	 of	 the	 current	 stage	 of	 technology	
development.	 Further	 research	 may	 be	 beneficial	 to	 explore	 the	







the	 impact	 of	 moving	 beyond	 the	 costs	 and	 outcomes	 associated	
with	 short-term	service	delivery	 to	 include	 the	consideration	of	 the	
impact	of	 the	 intermediate/	process	outcomes	on	 long	 term	health	
outcomes	 in	 the	 form	 of	 complications	 arising	 from	 untreated	
chlamydia.	 The	 results	 have	 shown	 that	 the	 parameters	 associated	
with	 number	 of	 partners	 notified	 per	 index,	 and	 partner	 treatment	




fully	 remote	 online	 pathway	 alongside	 existing	 pathways	 has	
demonstrated	that,	based	on	uptake	calculated	from	the	DCE	results,	
the	overall	mix	of	service	delivery	is	cost	saving	when	the	OCCP	and/	
or	 fully	 remote	 online	 pathway	 is	 introduced.	However,	 overall	 the	
number	 of	 complications	 and	 costs	 associated	 with	 untreated	










seven	 chapters	 and	 considers	 the	 learning	 in	 respect	 of	 the	













This	 thesis	 set	 out	 to	 explore	 the	 costs	 and	 benefits	 of	 integrating	
novel	digital	 technology	 for	 the	 testing	and	 treatment	of	 chlamydia	
into	 mainstream	 sexual	 health	 services	 in	 England.	 Two	 levels	 of	
integration	 of	 digital	 technology	 were	 considered.	 The	 most	
ambitious	was	a	fully	remote	online	pathway	incorporating	a	self-test	
and	 online	 treatment	 and	 partner	 notification;	 the	 second	 was	 a	
partial	 remote	 online	 pathway	 from	 results	 notification	 onwards	
(OCCP).	 The	 research	 findings	 illustrate	 several	 fundamental	 issues	
which	apply	to	this	and	potentially	other	evaluations	of	eHealth	and	
mHealth	initiatives,	particularly	those	which	aim	to	deliver	diagnosis	
and	 treatment,	 rather	 than	 interventions	 for	 behaviour	 change	 or	
long	 term	 condition	management.	 This	 chapter	 draws	 together	 the	
main	research	findings	from	Chapters	4	to	8,	reflects	on	the	research	





The	 literature	 reviews	 presented	 in	 Chapter	 4	 identified	 the	
research	 undertaken	 to	 date	 to	 understand	 which	 factors	 might	
influence	 individuals’	 decisions	 to	 access	 testing	 and	 treatment	
services	for	STIs	in	OECD	high	income	countries.	The	OCCP	and	fully	
remote	 online	 pathway	 technologies	 explored	 in	 this	 thesis	 have	







Chapter	 5	 supported	 this	 view.	 Time	 from	 test	 to	 result	 (time	 to	
result)	was	the	aspect	which	featured	most	frequently	in	the	focus	
group	discussions	with	a	general	 consensus	 in	all	 four	groups	 that	
quicker	 results	were	 preferred,	with	worry	 and	 anxiety	 about	 the	
outcome	of	the	test	being	the	main	reason	for	this	preference.	This	
was	 followed	 by	 test	 accuracy	 being	 drawn	 out	 by	 participants	
themselves	as	an	important	consideration.		
	
The	 questions	 raised	 by	 focus	 group	 participants	 demonstrated	 a	
general	 lack	 of	 understanding	 about	 the	 accuracy	 of	 currently	
available	tests	in	clinical	practice.	The	desire	for	a	broader	range	of	
tests,	 that	 is	 testing	 for	 multiple	 STIs,	 was	 another	 important	




The	 focus	 group	 findings	 were	 reflected	 in	 the	 DCE	 findings	
presented	 in	 Chapter	 6.	 The	 DCE	 results	 supported	 the	 view	 that	
test	 accuracy	 and	 time	 to	 result	 were	 the	 strongest	 attributes	
influencing	 young	 people’s	 preferences	 for	 chlamydia	 testing	 and	
treatment	pathways.	These	findings	suggest	that	any	new	self-tests	
coming	 into	 clinical	 practice	 would	 need	 to	 improve	 upon	 (or	 at	
least	equal)	the	current	laboratory	or	clinic-based	test	performance	
characteristics,	in	terms	of	both	accuracy	and	time	to	result.	Whilst	
not	 as	 stark	 in	 their	 strength	 of	 preference,	 the	 other	 attributes	
included	 within	 the	 study	 demonstrate	 a	 general	 preference	 for	
remote	 pathway	 options	 including	 self-testing	 and	 self-sampling	
and	 posting	 the	 sample	 for	 analysis	 over	 attending	 a	 healthcare	




This	 DCE	 research	 was	 recognised	 at	 The	 Lancet	 Public	 Health	






of	 any	 STI	 services,	 the	 costs	 and	 benefits	 of	 the	 introduction	 of	
digital	 technology	 must	 be	 considered	 by	 technology	 developers	
and	 commissioners.	 Chapter	 7	 explored	 the	 costs	 and	
consequences	 of	 introducing	 eHealth	 clinics	 (OCCP)	 for	
asymptomatic	 chlamydia	 treatment.	 The	 costing	 of	 this	 eHealth	
clinic	 was	 based	 on	 data	 drawn	 from	 the	 exploratory	 study	
undertaken	by	the	eSTI2	research	consortium.	The	analysis	showed	
the	OCCP	could	be	cost	saving	when	compared	with	GUM	and	NCSP	





savings	of	 the	 introduction	of	 an	eHealth	 clinic	 such	as	 the	OCCP.	
The	 outcome	 measures	 identified	 by	 the	 exploratory	 study	 to	
demonstrate	 the	 safety	 and	 feasibility	 of	 remote	 online	 care	
focused	 on	 process	 measures	 (such	 as	 uptake	 rates	 and	 time	 to	
treatment)	 rather	 than	 health-related	 outcomes.	 This	 approach	
demonstrated	non-inferiority	compared	with	existing	pathways	for	
all	 indicators	 other	 than	 partner	 treatment	 uptake.	 However,	 this	
needs	to	be	considered	within	the	context	of	recognised	issues	with	






costing	 study,	 the	 findings	 from	 the	 OCCP	 exploratory	 study	 and	
published	 data,	 demonstrated	 the	 links	 between	 the	 process	
measures	used	and	health	outcomes,	 i.e.	 the	health	complications	
arising	 from	 untreated	 chlamydia.	 This	 highlighted	 the	 impact	 of	
both	the	number	of	partners	identified	per	index	and	the	uptake	of	
partner	treatment.	Although	the	cost	per	case	detected	for	the	fully	
remote	 online	 pathway	 is	 lower	 than	 the	 comparator	 pathways	
(£38.56	 per	 positive	 patient	 compared	 with	 £61.82	 GUM,	 and	
£36.86	 per	 positive	 patient	 compared	 with	 £44.57	 NCSP	 internet	
testing	pathway),	and	process	measures/	health	outcomes	for	index	
patients	 (treatment	 uptake	 and	 complications	 arising	 from	
untreated	chlamydia)	are	broadly	similar,	adding	in	consideration	of	
partner	 outcomes	 demonstrated	 a	 significant	 difference	 in	 the	
number	of	health	complications	arising	 from	untreated	chlamydia.	
The	combined	costs	of	delivery	and	treatment	for	chlamydia	health	
complications	 are	 considerably	 higher	 for	 both	 the	OCCP	 and	 the	
fully	 remote	 online	 pathway	 than	 the	 comparator	 pathways.	
Presenting	costs	and	outcomes	separately	for	a	range	of	indicators	
highlights	 the	 parameters	 where	 further	 research	 is	 required	 to	
deliver	health-related	outcomes	(avoidance	of	complications	arising	
from	 untreated	 chlamydia)	 from	 the	 use	 of	 the	 new	 digital	
pathways	that	are	at	least	comparable	to	existing	pathways.	For	the	
OCCP	 the	 most	 significant	 parameter	 requiring	 further	 work	 is	
partner	 treatment	 uptake.	 Whilst	 there	 is	 no	 self-test	 currently	
available,	 this	 research	 suggests	 that	 the	 parameter	 of	 greatest	
importance	 for	 further	 work	 is	 test	 accuracy,	 both	 in	 terms	 of	





The	model	 established	 for	 the	 economic	 evaluation	 supports	 this	
further	 research	 through	 the	 ability	 to	 vary	 the	 parameters,	 for	
example,	 to	 enable	 test	 developers	 to	 understand	 the	 impact	 of	





The	 utilisation	 of	 qualitative	methods	with	 respondents	 to	 inform	
the	design	and	development	of	a	DCE	is	still	relatively	uncommon.	
Coast	and	colleagues	point	 to	 the	value	of	qualitative	work	 in	 the	
development	 of	 attribute	 and	 levels	 highlighting	 its	 worth	 in	 two	
stages	“conceptual	development	and	the	generation	of	meaningful	
language”	 (Coast	 et	 al.,	 2012:739).	 Whilst	 there	 are	 explicit	
recommendations	 regarding	 the	use	of	 qualitative	 research	 in	 the	
selection	 of	 attributes	 and	 levels	 for	 DCEs	 (Bridges	 et	 al.,	 2011),	
there	is	no	explicit	recommendation	that	this	qualitative	research	is	
undertaken	 with	 target	 respondents.	 The	 insight	 provided	 in	 the	
current	 research	by	 the	 focus	groups	with	young	people	 informed	
many	 aspects	 of	 the	 DCE	 including	 the	 attributes	 and	 levels	
selected,	 their	 phrasing	 and	 definition,	 and	 the	 explicit	
consideration	and	presentation	of	information	in	the	questionnaire	








The	 DCE	 did	 not	 address	 one	 of	 the	 most	 important	 attributes	
identified	by	young	people	in	the	focus	groups	which	is	the	range	of	
STIs	 for	 which	 they	 are	 tested.	 Currently	 the	 only	 national	 STI	
screening	 programme	 identified	 as	 cost-effective	 is	 chlamydia	
testing	 in	 the	16-25	population.	 It	 is	also	 recommended	men	who	
have	 sex	 with	 men	 should	 be	 tested	 annually	 for	 chlamydia,	
gonorrhoea,	syphilis,	HIV,	hepatitis	B	and	hepatitis	C	(BASHH,	2014).	
There	was	a	clear	and	justifiable	reason	for	excluding	this	from	the	
DCE	 design	 owing	 to	 the	 variance	 in	 the	 clinical	 management	 of	
different	 types	 of	 STIs	 and	 the	 scope	 for	 introduction	 of	 new	
technologies	into	those	pathways.		
	
Linked	 to	 this,	 the	 need	 to	 control	 a	 participant’s	 assumptions	
about	 which	 STI	 they	 were	 thinking	 about	 whilst	 completing	 the	
DCE	was	 another	 important	 consideration	 in	 limiting	 the	 scope	 to	
chlamydia,	 i.e.	 their	 choices	 may	 be	 different	 if	 thinking	 about	
testing	 and	 treatment	 for	 different	 STIs	 e.g.	 HIV	 or	 chlamydia.	
However,	the	impact	on	uptake	of	the	range	of	tests	is	an	important	




digital	 health	 interventions	 as	 being	 “is	 the	 digital	 health	
intervention	 likely	 to	 reach	 this	 population,	 and	 if	 so,	 is	 the	
population	likely	to	use	it?”	(Murray	et	al.,	2016:845).	A	key	benefit	
of	the	DCE	method	in	assessing	preferences	is	that	it	identifies	the	






The	 use	 of	 a	 mixed	 methods	 approach	 incorporating	 qualitative	
research	 with	 the	 respondent	 group,	 and	 evidence	 synthesis	
informed	by	published	literature	and	expert	opinion,	to	inform	the	
attribute	 selection	 and	 DCE	 design	 provided	 the	 opportunity	 to	
maximise	the	relevance	of	the	study	outcomes	to	inform	the	design	
of	 new	 technologies	 and	 new	 pathways	 for	 the	 testing	 and	
treatment	 of	 chlamydia.	 Although	 eHTA/	 HTA	 frameworks	
acknowledge	 acceptability	 and	 patient	 preferences	 within	 them,	
the	clinical	and	cost-effectiveness	of	 interventions	are	the	primary	
considerations	 in	 most,	 especially	 when	 HTA	 is	 undertaken	 for	
drugs	and	devices	where	uptake	is	driven	primarily	by	clinicians.	In	
public	health	interventions,	such	as	screening,	further	consideration	
is	 required	 of	 acceptability	 for	 evaluation	 of	 digital	 health	
interventions,	given	that	the	general	population	have	a	significantly	
greater	role	to	play	in	uptake	and	therefore	cost-effectiveness.	This	
is	 particularly	 relevant	 for	 digital	 health	 interventions	 for	 sexual	




On	 commencement	 of	 this	 research	 in	 2013	 there	 was	 little	
published	 in	 respect	of	 the	methods	 for	 the	evaluation	of	eHealth	
and	mHealth	 interventions,	 particularly	 in	 the	 early	 stage	 of	 their	
development	 and	 this	 remains	 the	 case	 in	 2016.	 Undertaking	 the	
economic	evaluation	within	an	eHTA	framework	provided	structure	
for	considering	 the	 likely	costs	and	benefits	of	 the	OCCP	or	a	 fully	
remote	 online	 pathway.	 However,	 these	 methods	 were	 primarily	
developed	 for	drugs	and	devices,	 and	are	not	optimal	 for	eHealth	
interventions	 owing	 to	 the	 pace	 of	 the	 base	 technology	





limiting	 factors	 for	 amassing	 an	 evidence	 base	 for	 eHealth	
interventions	 (Murray	 et	 al.,	 2016).	 This	 paper	 also	 identified	 a	
series	 of	 key	 research	 questions	 for	 evaluating	 a	 digital	 health	
intervention	which	 broadly	 align	 to	 the	 domains	 of	 HTA,	 drawing	
out	 specific	 issues	 for	 the	 evaluation	 of	 this	 type	 of	 technology	
(ibid.).		
	
However,	 this	 approach	 focuses	 on	 the	 use	 of	 digital	 health	
interventions	 for	 behaviour	 change,	 long-term	 condition	
management	 and	 non-drug	 based	 treatment.	 Whilst	 these	 are	 a	
helpful	reference	point,	there	are	specific	considerations	for	digital	
technologies	 when	 used	 for	 the	 testing	 and	 treatment	 of	 ‘acute’	
medical	 conditions.	 	 For	 self-testing	 this	 includes	 the	behaviour	of	
the	individual	following	a	test	result	(Ickenroth	et	al.,	2010)	and	for	
treatment	 this	 includes	 the	management	of	patients	who	need	 to	




There	 is	 still	 little	published	on	 the	methodological	 considerations	
for	the	costing	of	eHealth	interventions.	The	key	issues	identified	by	
Tate	and	colleagues	 in	2009	were	reflected	 in	a	recent	publication	
by	 McNamee	 and	 colleagues,	 but	 without	 any	 clear	
recommendations	 on	 a	 preferred	 approach	 (Tate	 et	 al.,	 2009,	
McNamee	 et	 al.,	 2016).	 Achieving	 consistency	 in	 key	 elements	 of	
the	 costing	 of	 digital	 interventions	 is	 important,	 particularly	 for	
enabling	 the	 comparison	 of	 costs	 between	 different	 initiatives.	
Similarly,	 there	 is	 currently	 no	 published	 guidance	 on	 how	 the	




This	 is	 not	 unique	 to	 eHealth	 and	 mHealth,	 similar	 issues	 and	
challenges	 were	 associated	 with	 the	 economic	 evaluation	 of	









of	 uptake	 when	 offered	 alongside	 the	 comparator	 options,	 it	 is	
unclear	whether	as	well	as	more	people	take	up	testing,	these	will	be	
the	 population	 at	 higher	 risk	 as	 opposed	 to	 the	 ‘worried	well’	 and	
whether	 there	 will	 be	 an	 increase	 in	 repeat	 testing.	 It	 is	 also	
uncertain	 whether	 increased	 availability	 and	 accessibility	 to	 online	
testing	 and	 treatment	 might	 lead	 to	 people	 taking	 more	 risks	 in	
respect	 of	 STIs	 negating	 the	 benefits	 of	 increased	 test	 uptake.	





As	 noted	 earlier,	 sexual	 health	 is	 an	 area	 which	 is	 already	
experiencing	 numerous	 simultaneous	 technological	 advances.	 For	
example,	the	extension	of	online	ordering	to	include	a	wider	range	of	
STI	 test	 kits	 for	 self-sampling	 (Wilson	 et	 al.,	 2016),	 further	
developments	to	POCT	to	include	low	cost	handheld	devices	(Mackay	
et	 al.,	 2015),	 and	 the	 exploration	 of	 APT	 for	 improving	 partner	
notification	and	treatment	uptake	(Althaus	et	al.	2014,	Roberts	et	al.,	
2012).	 All	 of	 these	 developments	 show	 promise	 for	 improving	 the	
clinical	 and/	 or	 cost-effectiveness	 of	 an	 aspect	 or	 all	 of	 an	
asymptomatic	chlamydia	screening	pathway.	There	is	an	opportunity	
for	 learning	 across	 these	 developments	 to	 further	 enhance	 the	
delivery	of	 care,	however	 there	 is	 a	 risk	 that	development	of	 these	
technologies	 in	 isolation	 will	 lead	 to	 fragmented	 solutions	 to	
individual	 aspects	 of	 the	 pathway.	 Both	 awareness	 of	 these	
developments	 and/	 or	 collaboration	 could	 contribute	 to	 the	
development	of	more	effective	products.		
	
Further	 research	 is	 also	 required	 to	understand	how	 these	areas	of	
development	 may	 impact	 on	 preferences	 for	 the	 use	 of	 new	
technologies	 for	 the	management	 of	 STIs	 other	 than	 chlamydia.	 In	
particular,	 given	 the	distinctions	drawn	out	 by	 young	people	 in	 the	
focus	 groups	 between	 thinking	 about	 differences	 in	 the	
consequences	of	disease,	for	example,	HIV	and	chlamydia,	it	is	likely	
that	 their	 preferences	 for	 attributes	 in	 respect	 of	 self-testing	 and	








Since	 the	 approach	 adopted	 for	 the	 early	 economic	 evaluation	
presented	 in	 this	 thesis	was	 based	 on	 the	NICE	MTEP	 (NICE,	 2011)	
methods,	 the	 costs	 incurred	 to	 the	NHS	were	 included	 and	 patient	
costs	were	excluded.	Recognising	the	intrinsic	link	between	uptake	of	
eHealth	 interventions	and	 their	 cost-effectiveness	 (McNamee	et	al.,	
2016)	 future	 research	 into	 the	 patient-borne	 costs	 (e.g.	 travel,	
internet	 access)	 associated	 with	 current	 screening	 pathways,	 the	







benefits.	 This	 has	 not	 been	 explored	 in	 the	 economic	 modelling	
undertaken	 in	 this	 thesis	 because	 it	 is	 not	 currently	 recognised	 as	







whilst	 there	 are	 a	 range	 of	 guidelines	 for	 health	 economic	
evaluations,	 little	consideration	has	been	given	 to	 their	applicability	
to	digital	health	interventions	(McNamee	et	al.,	2016).	Consideration	
would	also	need	to	be	given	to	the	acknowledged	 issues	associated	





One	 of	 the	 key	 issues	 is	 the	 pace	 of	 digital	 health	 technology	
development	 and	 therefore	 consideration	 should	 be	 given	 as	 to	
whether	the	existing	methods	used	in	HTA	are	appropriate	to	digital	
health	 interventions.	 Baker	 and	 colleagues	 have	 highlighted	 that	 it	
can	take	seven	years	from	the	submission	of	a	grant	proposal	to	the	
publication	of	the	research	(Baker	et	al.,	2014).	During	the	last	seven	
years	 (2010-2016),	 daily	 internet	 access	 has	 increased	 from	
approximately	60%	to	82%	(all	adults)	 (Office	for	National	Statistics,	
2016b),	 the	 functionality	 of	 smartphones,	 and	 smartphone	
consumables	 have	 increased	 significantly	 to	 include	 a	 range	 of	
devices	capable	of	monitoring	health	data	linked	to	the	smartphone,	
and	the	availability	of	apps	and	their	functionality	has	also	extended	
over	 time.	 Further	 work	 is	 required	 to	 establish	 appropriate	 rapid	








service	 configuration	 and	 delivery	within	mainstream	 sexual	 health	
services.	 Chapter	 2	 of	 this	 thesis	 set	 out	 the	 ‘best	 intentions’	 of	
government	 in	 respect	 of	 technology	 adoption	 within	 healthcare	
more	generally	and	sexual	health	services	specifically.	These	included	
using	online/	remote	consultation	(Department	of	Health,	2012),	and	
expanding	 internet	 testing	 services	 for	 STIs	 (Department	 of	 Health,	





The	 use	 of	 such	 technologies	 is	 still	 confined	 to	 isolated	 examples	
within	the	NHS,	reflecting	the	pattern	of	adoption	noted	by	the	WHO	
in	their	international	study	of	eHealth	and	mHealth	adoption	(WHO,	
2011a).	 Attempts	 to	 increase	 the	 pace	 and	 spread	 of	 digital	
technologies	through	approaches	such	as	the	NHS	apps	 library	have	




OCCP	 has	 highlighted	 the	 stark	 disconnect	 between	 the	 national	
policy	vision	 for	digital	health	and	the	reality	of	designing	an	online	
treatment	 eHealth	 intervention	 concluding	 that	 “much	 of	 the	
infrastructure	and	 legislation/	regulation	and	best	practice	guidance	




the	 national	 electronic	 prescribing	 system	 (EPS)	 being	 designed	 for	
the	 transmission	 of	 electronic	 prescriptions	 from	 GP	 practice	 to	





services	which	 involve	 the	prescribing	of	drugs	 for	 treatment	which	
will	 need	 to	 be	 addressed	 in	 future	 EPS	 upgrades.	 There	 are	
examples	of	accreditation	processes	for	telehealth	initiatives	such	as	
the	 European	 Code	 of	 Practice	 for	 Telehealth	 Services	 (TeleSCoPE,	
2014)	however	 this	 falls	 short	 of	 the	 requirements	of	 digital	 health	





In	 parallel	 to	 this,	 the	 commissioning	 of	 sexual	 health	 services	 in	
England	has	been	fragmented,	with	responsibility	split	between	local	
authorities,	CCGs	and	NHSE.	Whilst	conclusive	links	on	the	impact	of	
this	 split	have	not	 yet	been	drawn,	 concern	has	been	expressed	by	
both	 the	 House	 of	 Commons	 Health	 Select	 Committee	 and	
professional	 bodies	 including	 BASHH,	 and	 the	 Royal	 College	 of	
Physicians	 regarding	 the	 split	 between	HIV	 treatment	 and	 care	 and	
other	 sexual	 health	 services	 (BASHH,	 2013,	 House	 of	 Commons.		
Select	Committee	on	Health,	2011).	Examples	of	such	splits	are	now	
starting	to	emerge	including	the	example	of	sexual	health	services	in	
Cheshire	 West	 where	 HIV	 and	 sexual	 health	 services	 are	 now	
delivered	 by	 two	 different	 providers	 and	 therefore	 the	 HIV	 service	
can	no	longer	treat	other	STIs	(BMA,	2015).	This	has	led	to	a	call	from	
BASHH	 for	 “a	 strong	 national	 steer	 for	 co-commissioning	 of	 HIV,	






and	 	 estimates	of	 a	 reduction	of	 £3.3	billion	 in	 central	 government	
funding	 for	 local	 services	 were	 forecast	 by	 the	 Local	 Government	
Association	 (Local	 Government	 Association,	 2015)	 for	 2016-17	 (the	
first	year	without	ring	fencing	of	the	public	health	budget).		The	cost	
of	 testing	 and	 treatment	 for	 STIs	 is	 borne	 by	 the	 LA,	 however	 the	
benefits	 gained	 through	 the	 avoidance	 of	 long	 term	 complications	
such	as	PID	or	infertility	accrue	to	NHS	commissioning	organisations,	
primarily	 CCGs.	 Emerging	 tensions	 in	 STI	 commissioning	
responsibilities	have	recently	been	demonstrated	in	the	courts	with	a	
legal	 challenge	 brought	 against	NHS	 England	 in	 respect	 of	who	has	
the	 power	 to	 commission	 pre-exposure	 prophylaxis	 drugs	 for	 HIV	




Whilst	 local	 authorities	 generally	 adopt	 a	 similar	 approach	 to	 NHS	
organisations	 in	appraising	developments	 it	 is	unclear	whether	they	
will	consider	the	 implications	for	other	commissioning	organisations	
in	 their	 decision	 making.	 It	 is	 possible	 that	 a	 broader	 range	 of	
outcomes	might	be	considered,	drawing	out	links	to	potential	savings	
on	 other	 local	 authority	 controlled	 budgets	 and	 impacts	 on	 other	
areas	of	service	delivery	within	local	authority	control.	Although	this	
approach	 has	 been	 incorporated	 into	 public	 health	 guideline	
development	 (NICE,	 2014),	 it	 is	 not	 an	 approach	 usually	 taken	 in	
DAP/	 MTEP	 evaluations.	 This	 area	 warrants	 further	 research	 to	
understand	 how	 economic	 evaluations	 can	 incorporate	 a	 range	 of	
intermediate	and	final	outcome	measures	and	the	weight	that	should	
be	placed	on	 the	 impact	on	NHS	 versus	 local	 authority	opportunity	
costs.		
	
There	 has	 been	 a	 plethora	 of	 guidance	 on	 effective	 commissioning	
following	 the	 move	 to	 LA	 commissioning	 in	 April	 2013	 including	
model	contracts	and	service	specifications	issued	by	the	Department	
of	 Health	 (Department	 of	 Health,	 2013a,	 Department	 of	 Health,	
2013d),	 guidance	 from	 Public	 Health	 England	 on	 whole	 system	
commissioning	(Public	Health	England,	2014b)	and	from	the	NCSP	on	
the	 effective	 commissioning	 of	 chlamydia	 testing,	 treatment	 and	
partner	 notification	 (NCSP,	 2012a).	 However,	 despite	 this,	 and	 a	
number	 of	 sexual	 health	 services	 being	 reviewed	 and	 re-procured,	
achievement	 of	 the	 PHOF	 indicator	 for	 chlamydia	 diagnoses	 has	




No	 evaluation	 of	 the	 impact	 of	 the	 revised	 commissioning	






Considering	 both	 the	 general	 (Department	 of	 Health,	 2012)	 and	
sexual	health	(Department	of	Health,	2013)	policy	imperative	for	the	
adoption	of	 innovative	 technology	 into	mainstream	health	 services,	
the	 operational	 climate	 for	 the	 commissioning	 and	 implementation	
of	 new	 remote	 online	 pathways	 into	 sexual	 health	 services	 is	
positive.	 However,	 whilst	 reductions	 in	 LA	 commissioning	 budgets	









access	 treatment	 for	 chlamydia,	 and	 the	 relative	 strength	 of	
preference	 for	 those	 factors.	 This	 information	 should	 help	 inform	
both	 technology	 developers	 and	 commissioners,	 in	 shaping	 digital	
pathways	for	the	delivery	of	these	services.	The	economic	modelling	
has	also	contributed	new	knowledge	by	providing	an	insight	into	the	
likely	 costs	 and	 benefits	 of	 implementing	 a	 fully	 remote	 online	
pathway	or	 an	OCCP	 into	mainstream	 sexual	 health	 services.	 It	 has	
highlighted	 specific	 areas	 where	 further	 development	 of	 these	
pathways	is	required	to	maximise	the	likelihood	that	the	technology	
will	 be	 cost-effective.	 It	 has	 also	demonstrated	 that	both	 the	OCCP	
and	 a	 fully	 remote	 online	 pathway	 are	 likely	 to	 be	 used	 by	 young	
people	for	the	testing	and	treatment	of	chlamydia,	that	the	pathways	
are	likely	to	be	cost	saving	compared	with	current	practice,	although,	
further	 development	 is	 required	 to	 improve	 partner	 treatment	
uptake.	 The	 fully	 remote	 online	 pathway	 has	 the	 potential	 to	 be	 a	
viable	replacement	for	the	NCSP	internet	testing	pathway.	Although	
face-to-face	 services	 will	 still	 be	 required	 for	 the	 management	 of	
symptomatic	 patients	 and	 patients	 unsuitable	 for	 online	
management	 these	services	could	be	 rationalised	 leading	 to	 further	

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Formed	 from	 a	 collaboration	 of	 academic,	NHS	 and	 commercial	 partners	
the	 Electronic	 Self-Testing	 for	 Sexually	 Transmitted	 Infections	 (eSTI2)	
consortium	brings	together	point	of	care	(POC)	and	self-testing	diagnostic	
technologies	 for	 STIs	 with	 mobile	 technology	 to	 deliver	 rapid	 access	 to	
diagnosis	and	treatment.	The	stated	aim	of	the	eSTI2	programme	research	
is	to	“reduce	the	high	 impact	of	STIs,	a	national	priority	for	UK	health,	by	
building	 translational	 capacity	 to	 develop,	 improve,	 evaluate	 and	
implement	 simple	 to	 use,	 rapid,	 accurate,	 polymicrobial	 and	 affordable	
POC	 and	 non-POC	 micro-diagnostics	 that	 can	 be	 mobile-phone	
networked.”	 (eSTI2	 Consortium	 2010:1).	 The	 consortium	 supports	 a	
number	 of	 PhD	 fellowships	 focusing	 on	 different	 aspects	 of	 the	
programme.		
	
This	 doctoral	 research	 is	 focused	 on	 exploring	 the	 costs	 and	 benefits	 of	
introducing	 novel	 diagnostic	 and	 communication	 technologies	 for	 STI	
control	into	mainstream	NHS	practice	and	sits	within	work	stream	4	of	the	
eSTI2	 research	 programme.	 The	 eSTI2	 research	 programme	 to	 date	 is	



























via	 PC	 and	 mobile	 phone)	 for	 the	 treatment	 of	 chlamydia	 and	 partner	
notification	(July	2014	–	March	2015),	and	WS1,	WS2	and	WS3	are	aiming	





The	 range	 of	 pathogens	 which	 could	 fall	 within	 the	 scope	 of	 the	 eSTI2	
pathway	are	identified	in	the	original	eSTI2	research	proposal	as:	Neisseria	
Gonorrhoeae,	 Chlamydia	 trachomatis,	 Ureaplasma	 parvum,	 Mycoplasma	





The	 proposed	 approach	 to	 infectious	 disease	 diagnosis,	 treatment	 and	
surveillance,	 which	 will	 ultimately	 combine	 self-testing	 and	 mHealth,	 is	
revolutionary.	At	the	time	of	piloting,	the	clinical	care	pathway	(OCCP)	for	
the	 treatment	 of	 chlamydia	 will	 be	 the	 first	 pathway	 to	 prescribe	 a	







































































# Searches Results 
1 exp Sexually Transmitted Diseases/ or sexually transmitted.mp. 282485 
2 
(STI or STD).mp. [mp=title, abstract, original 
title, name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
12391 
3 sexual health.mp. or exp Reproductive Health/ 4915 
4 1 or 2 or 3 288603 
5 exp Patient Preference/ or exp Choice Behavior/ or stated preference.mp. 41766 
6 stated choice.mp. 29 
7 discrete choice.mp. 570 
8 DCE.mp. 2421 
9 conjoint analysis.mp. 336 
10 contingent valuation.mp. 390 
11 willingness to pay.mp. 2068 
12 WTP.mp. 773 
13 willingness to accept.mp. 358 
14 WTA.mp. 171 
15 visual analogue scale.mp. 11436 
16 VAS.mp. 25873 
17 rating scale.mp. 28065 
18 magnitude estimation.mp. 697 
19 standard gamble.mp. 635 
20 SG.mp. 5193 
21 time trade off.mp. 706 
22 TTO.mp. 558 
23 person trade off.mp. 43 
24 PTO.mp. 497 
25 functional measurement.mp. 125 
26 paired comparison*.mp. 1628 
27 pairwise choice*.mp. 16 
28 conjoint measurement.mp. 43 
29 
part worth util*.mp. [mp=title, abstract, 
original title, name of substance word, subject 
heading word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
7 
30 
conjoint stud*.mp. [mp=title, abstract, original 
title, name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare disease 
14 
		 549	
supplementary concept word, unique identifier] 
31 conjoint choice.mp. 7 
32 choice exercise*.mp. 11 
33 random paired scenario*.mp. 2 
34 payment card.mp. 29 
35 allocation of point*.mp. 6 
36 analytic hierarchy process.mp. 228 
37 measure of value.mp. 23 
38 
5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 
or 32 or 33 or 34 or 35 or 36 or 37 
115063 
39 4 and 38 908 


































































































































































































































































































































































ü	 ü	 p	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
1.3	–	What	is	the	rationale	for	using	conjoint	




ü	 ü	 û	 ü	 p	 ü	 ü	 û	 û	 ü	 p	 ü	
2.2	–	Was	attribute	selection	justified	and	





























































































































































ü	 û	 û	 û	 û	 p	 ü	 û	 û	 	p	 p	 ü	
3.2	–	Was	the	number	of	profiles	in	each	
conjoint	task	justified?	 p	 û	 û	 û	 û	 p	 ü	 û	 û	 p	 û	 ü	
3.3	–	Was	(should)	an	opt-out	or	status-quo	




û	 û	 û	 û	 û	 ü	 p	 ü	 û	 û	 p	 p	
4.2	–	Were	the	properties	of	the	experimental	
design	evaluated?	 û	 û	 û	 û	 p	 p	 ü	 p	 û	 û	 p	 p	
4.3	–	Was	the	number	of	conjoint	tasks	included	
in	the	data	collection	instrument	appropriate?	 û	 û	 û	 ü	 p	 ü	 ü	 ü	 û	 û	 û	 ü	
5.1	–	Was	there	sufficient	motivation	and	



























































































































































ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
6.2	–	Were	attributes	and	levels	defined,	and	




û	 p	 p	 û	 p	 û	 û	 û	 û	 û	 û	 p	
7.1	–	Was	the	sample	strategy	justified	(e.g.	






















































































































































û	 p	 p	 p	 p	 p	 p	 p	 û	 p	 p	 p	
8.1	–	Were	respondent	characteristics	examined	
and	tested?	 ü	 p	 p	 p	 ü	 ü	 ü	 ü	 ü	 p	 ü	 ü	
8.2	–	Was	the	quality	of	the	responses	












p	 ü	 p	 p	 ü	 ü	 p	 ü	 p	 ü	 ü	 p	
9.3	–	Were	study	limitations	and	generalizability	
















































































































































context	adequately	motivated?	 ü	 p	 p	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
10.2	–	Were	the	study	data-collection	
instrument	and	methods	described?	 p	 p	 p	 ü	 p	 p	 p	 p	 ü	 p	 p	 û	
10.3	–	Were	the	study	implications	clearly	









# Searches Results 
1 exp Reproductive Health/ 1255 
2 exp Sexually Transmitted Diseases/ or sexually transmitted*.mp. 300983 
3 
(STI or STD).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
13506 
4 1 or 2 or 3 305647 
5 test*.mp. 2882446 
6 treatment.mp. 3327476 
7 service.mp. 248426 
8 Patient Preference/ 3912 
9 
acceptab*.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
108974 
10 exp Choice Behavior/ or choice.mp. 224059 
11 uptake.mp. 278539 
12 access*.mp. 330379 
13 5 or 6 or 7 5886436 
14 8 or 9 or 10 or 11 or 12 918715 
15 4 and 13 and 14 11413 
16 limit 15 to (english language and humans) 10491 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Good	 evening,	 my	 name’s	 Sue,	 I’m	 a	 PhD	 student	 at	 the	 University	 of	
Warwick	and	I	work	on	a	project	which	is	developing	new	tests	and	ways	to	
get	treated	for	sexually	transmitted	infections.	Firstly	I	want	to	say	a	huge	
thank	 you	 for	 giving	 up	 your	 time	 this	 evening	 to	 talk	 to	 me	 this,	 your	
feedback	on	how	to	develop	sexual	health	services	 is	really	 important	 for	
my	 research	 and	 hopefully	 through	 this	 will	 inform	 how	 services	 are	
developed	in	the	future.		
	
What	 I’m	 here	 to	 talk	 to	 you	 about	 is	 ways	 of	 testing	 and	 accessing	





you	get	 the	result	 in	 the	same	visit	e.g.	at	a	clinic	or	pharmacy.	Self-tests	
are	 when	 you	 can	 undertake	 the	 test	 and	 find	 out	 the	 result	 yourself	
without	 needing	 to	 attend	 a	 clinic,	 like	 how	 a	 pregnancy	 test	works.	 For	
some	 STIs	 smartphone	 apps	 and	 e-health	 clinics	 are	 being	 developed	 so	
that	 if	 you	have	a	positive	 test	 result	 you	can	complete	an	online	clinical	




ways	 of	 testing	 and	 accessing	 treatment	 are	 acceptable	 to	 people,	 there	




Your	 participation	 will	 help	 us	 understand	 how	 people	 want	 to	 access	







What	 you’ll	 be	 doing	 is	 listening	 to	 some	 scenarios	 and	 answering	
questions	about	what	you	think	about	them,	and	then	we’re	going	to	do	a	










3. The	 nature	 of	 the	 topic	 means	 that	 you	 may	 find	 as	 discussions	
progress	you	feel	uncomfortable	and	don’t	want	to	continue,	if	you	
feel	you	want	to	 leave	at	any	point	please	do	so.	 I	can	assure	you	
that	 the	 questions	 and	 focus	 of	 the	 group	 is	 on	 the	 services	
themselves,	 I	 will	 not	 be	 asking	 any	 questions	 about	 your	
experiences	of	sex	or	using	sexual	health	services	
4. As	 explained	 in	 the	 information	 leaflet	 the	 discussion	 is	 being	
recorded	so	I	don’t	miss	anything	you’ve	got	to	say,	but	everything	
will	be	anonymous	and	kept	confidential.	To	help	me	when	I	listen	














I	would	 like	you	 to	keep	 in	mind	 three	 scenarios	 for	 the	next	part	of	 the	
focus	group,	don’t	worry	about	making	notes	because	there’s	a	summary	
of	 the	 key	points	 for	 you	 to	 look	 at	 in	 front	of	 you.	 To	break	 it	 up	 a	bit,	




The	 first	 two	are	examples	of	 the	 sort	 of	 thing	people	have	 to	do	at	 the	






online,	 or	 walk	 into	 the	 sexual	 health	 clinic	 which	 is	 one	 of	 the	 local	
services	where	you	can	be	tested	for	STIs.	Clinics	are	normally	open	during	
the	 day	 in	 the	 week	 and	 then	 some	 evenings	 and	 for	 a	 few	 hours	 on	 a	
Saturday.	You	register	with	the	receptionist	on	arrival	and	sit	in	the	waiting	
room.	Whilst	you’re	sat	waiting	you	fill	 in	a	number	of	forms	that	provide	
information	 on	 who	 you	 are,	 your	 risks	 and	 symptoms.	 You	 get	 called	
through	 to	 see	either	 a	nurse	or	 a	doctor	 and	 they	ask	 you	a	number	of	
questions	 including	whether	 you’ve	 got	 any	 symptoms	 and	 details	 about	
your	 health	 e.g.	 any	 medication	 you	 take.	 They	 will	 also	 ask	 you	 about	
whether	you’ve	had	an	STI	before	and	a	bit	about	your	recent	sex	partners.			
	
Depending	 on	 whether	 you	 report	 symptoms	 you	 may	 have	 an	
examination.	For	men	you’ll	then	have	a	blood	and	urine	test	and/	or	swab.	
For	 women	 it	 will	 be	 blood	 and	 a	 vaginal	 swab.	 Everyone	 is	 tested	 for	
chlamydia,	 gonorrhoea,	 HIV	 and	 syphilis,	 some	 people	 will	 be	 tested	 for	
other	STIs	depending	on	their	risk.	If	you	have	swabs	you’ll	wait	for	them	to	
be	analysed	and	get	provisional	results,	normally	in	about	15-30minutes.	If	






treated	 then	 the	 clinic	 will	 contact	 you	 to	 arrange	 a	 time	 to	 return	 for	
treatment.	When	 you	 go	 back	 to	 the	 clinic	 you	will	 be	 seen	 by	 a	 health	
advisor	and	a	senior	nurse	or	a	doctor.	The	health	advisor	will	talk	to	you	
about	 the	 infection	 you’ve	 got	 and	 telling	 your	 partners.	 You	 will	 be	
encouraged	to	notify	your	partners	directly	yourself	but	if	you	don’t	want	
to	the	clinic	will	do	this	for	you.	When	you	see	the	senior	nurse	or	doctor	










clinic	 is	 and	 book	 an	 appointment,	 travel	 to	 and	 from	 the	 clinic,	 twice	 if	
your	 results	are	positive,	 spend	 time	 in	 the	clinic.	Although	 the	 service	 is	







1. Can	 you	 think	 of	 the	 things	 in	 the	 example	 that	 might	 make	 a	
difference	 to	whether	 you	 decided	 to	 use	 this	 service?	What	 you	
particularly	like	or	don’t	like?	
	







You	 access	 the	 local	 chlamydia	 screening	website	 and	 input	 your	 details	
and	a	test	is	sent	to	you	at	home	in	the	post.	The	test	you	are	sent	will	test	
you	 for	 chlamydia	and	gonorrhoea	only.	You	 take	your	 sample	yourself	–	
either	 a	 urine	 sample	 or	 swab,	 complete	 the	 form	 that	 comes	 with	 it,	




have	 a	 number	 of	 options	 to	 get	 treatment.	 Firstly	 you	 go	 back	 to	 the	
screening	website	and	put	in	your	postcode	and	it	brings	up	the	list	of	the	
nearest	 places	 you	 can	 go	 for	 treatment.	 If	 your	 result	 is	 positive	 for	
chlamydia	only	this	will	include	options	like	GPs,	pharmacies	or	community	
sexual	 health	 clinics.	 	When	 you	 see	 the	 health	 professional	 you	 will	 be	







If	 your	 result	 is	 positive	 for	 gonorrhoea	 you	 will	 need	 to	 make	 an	
appointment	at	a	community	sexual	health	or	GUM	clinic	to	get	treatment.	
You’ll	 see	a	doctor	or	nurse	who	will	 explain	about	 the	 infection	and	 the	
treatment.	They	will	also	talk	to	you	about	telling	your	partners.		
	
Whichever	 route	 you	 choose	 for	 treatment	 you’ll	 be	 followed	 up	 by	 a	
health	 advisor	 two	 weeks	 later	 to	 make	 sure	 there’s	 been	 no	 problems	
with	your	treatment,	and	that	your	partners	have	been	notified.		
	
So,	 that’s	 the	 second	example,	again	 I’d	 like	you	 to	 think	about	 is	what’s	
involved	in	that	example	for	you	–	you	have	to	order	a	test	online	if	your	
results	are	positive	you	have	to	find	out	how	to	get	treated	and	travel	 to	
the	GP,	 pharmacy	 or	 clinic	 in	 order	 to	 get	 your	 treatment.	 Although	 the	






2. Can	 you	 think	 of	 the	 things	 in	 the	 example	 that	 might	 make	 a	





















within	 the	 app	 or	 on	 the	 website,	 similar	 to	 those	 asked	 in	 clinic.	 For	
		 597	
example	whether	you’ve	got	any	symptoms	and	details	about	your	health	
e.g.	 any	medication	 you	 take.	 It	will	 also	 ask	whether	 you’ve	 had	 an	 STI	







partners	 so	 that	 they	 can	 access	 the	 app	 or	 website	 to	 get	 more	
information.		
	
There	will	 be	 a	 helpline,	 staffed	by	 trained	health	 advisors,	who	 you	 can	
contact	 if	 you’ve	 got	 any	problems	or	 concerns,	 they	will	 help	 you	 if	 the	
app	 can’t	 let	 you	 choose	 a	 pharmacy	 to	 get	 your	 treatment	 from.	Again,	















3. Can	 you	 think	 of	 the	 things	 in	 the	 example	 that	 might	 make	 a	










In	 talking	 about	 the	 individual	 examples	 you’ve	 picked	 some	 of	 the	 key	
		 598	
things	that	you	may	want	to	make	a	decision	based	on.	Thinking	about	all	
of	 the	 examples	 together	 now,	 and	 there’s	 a	 summary	 of	 the	 key	
similarities	 and	 differences	 for	 you,	 you	 can	 now	 think	 about	 comparing	
them,	 there	 may	 be	 one	 particular	 thing	 about	 an	 option	 that	 makes	 it	






4. Would	 anyone	 like	 to	 kick	 off	with	what	 they	 think	would	 be	 the	
most	 important	 thing	 to	 them	 in	 making	 a	 choice	 about	 which	
service	to	use	to	get	tested	for	an	STI	and	why?	What	I’m	going	to	









5. Can	you	 think	of	any	other	 factors	about	a	 service	 that	we’ve	not	
talked	 about	 so	 far	 that	 would	 be	 important	 to	 you	 in	 deciding	








6. There’s	 a	 few	 things	 that	 other	 people	 have	 identified	 as	 being	






you	 rather	have	 the	option	 to	 test	at	home	and	 it	was	a	 little	 less	
accurate	 than	 the	 test	 you	 would	 have	 if	 you	 went	 to	 a	 clinic,	
whether	 you	 see	 a	 healthcare	 professional	 if	 your	 results	 are	
		 599	
positive,	confidentiality,	other	options	on	location	of	services,	we’ve	
talked	 about	 a	 little	 about	 sexual	 health	 clinics,	 GPs,	 pharmacies	









winner	–	what	 the	group	thinks	 is	 the	most	 important	 factor	 in	accessing	
sexual	health	services.	I’m	going	to	keep	this	moving	along	just	like	Dermot	




















Ok,	 thank	you	again	 for	your	help,	 if	 you	would	 like	 to	 see	a	 copy	of	 the	


























































































































































































































































































































































































































# Searches Results 
1 "cost effective*".mp. 72679 
2 "cost benefit".mp. or exp Cost-Benefit Analysis/ 64741 
3 "cost utility*".mp. 2367 
4 "cost minimi*".mp. 861 
5 "cost consequence".mp. 112 
6 
(CEA or CBA or CMA or CUA or CCA).mp. [mp=title, 
abstract, original title, name of substance word, 
subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
48258 
7 "economic analys*".mp. 2826 
8 "economic evaluation".mp. 4937 
9 "economic model*".mp. or exp Models, Economic/ 11324 
10 "cost analys*".mp. or exp "Costs and Cost Analysis"/ 185476 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 282194 
12 exp Chlamydia/ or exp Chlamydia trachomatis/ 12737 
13 11 and 12 352 






# Searches Results 
1 exp Chlamydia/ or exp Chlamydia trachomatis/ 13674 
2 exp Genital Diseases, Male/ or exp Genital Diseases, Female/ 629036 
3 1 and 2 9889 
4 exp Time-to-Treatment/ 2211 
5 "loss to follow*".mp. 2209 
6 "appropriate clinical management".mp. 296 
7 exp Treatment Outcome/ 788680 
8 diagnosis to treatment.mp. 372 
9 exp Contact Tracing/ 3650 
10 4 or 5 or 6 or 7 or 8 or 9 795965 
11 3 and 10 335 
12 limit 11 to (english language and humans) 296 
	
	
